No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3uytA, 1.0000, 0.00, 1.000, 287, 287, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
2, 4hnfB, 0.9821, 0.85, 1.000, 290, 287, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
3, 3uzpA, 0.9816, 0.86, 1.000, 292, 287, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
4, 5w4wA, 0.9769, 0.89, 1.000, 291, 286, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
5, 5w4wB, 0.9756, 0.92, 1.000, 291, 286, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
6, 5w4wD, 0.9749, 0.86, 1.000, 287, 285, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
7, 4kbkB, 0.9734, 0.81, 1.000, 289, 284, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
8, 5oktC, 0.9729, 0.82, 1.000, 285, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
9, 4kb8B, 0.9707, 0.79, 1.000, 285, 283, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
10, 3uysD, 0.9705, 0.80, 1.000, 284, 283, CRYSTAL STRUCTURE OF APO HUMAN CK1D
11, 5fqdF, 0.9700, 1.15, 0.767, 294, 287, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
12, 4kbaB, 0.9696, 0.82, 1.000, 285, 283, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
13, 5fqdC, 0.9694, 1.16, 0.767, 294, 287, STRUCTURAL BASIS OF LENALIDOMIDE INDUCED CK1A DEGRADATION BY THE CRL4CRBN UBIQUITIN LIGASE
14, 4hnfA, 0.9686, 1.17, 1.000, 289, 287, CRYSTAL STRUCTURE OF CK1D IN COMPLEX WITH PF4800567
15, 3uysC, 0.9677, 0.78, 1.000, 286, 282, CRYSTAL STRUCTURE OF APO HUMAN CK1D
16, 4twcB, 0.9665, 1.14, 0.993, 292, 284, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
17, 5mqvC, 0.9660, 1.07, 0.996, 288, 285, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
18, 1ckjB, 0.9658, 1.13, 1.000, 293, 286, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
19, 4kbkA, 0.9639, 0.79, 1.000, 283, 281, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
20, 1eh4B, 0.9639, 1.19, 0.573, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
21, 5oktA, 0.9633, 0.80, 0.996, 285, 281, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
22, 4twcA, 0.9631, 1.34, 0.990, 293, 286, 2-BENZAMIDO-N-(1H-BENZO[D]IMIDAZOL-2-YL)THIAZOLE-4- CARBOXAMIDE DERIVATIVES AS POTENT INHIBITORS OF CK1D/E
23, 1ckjA, 0.9627, 1.36, 1.000, 296, 287, CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317 COMPLEX WITH BOUND TUNGSTATE
24, 4xhgA, 0.9616, 1.35, 0.672, 357, 287, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
25, 6groA, 0.9608, 1.31, 0.598, 293, 286, HUMAN CSNK1G3 BOUND TO SB-223133 
26, 5x17A, 0.9603, 1.20, 1.000, 290, 285, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
27, 1eh4A, 0.9603, 1.25, 0.566, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
28, 4hgtA, 0.9600, 1.13, 0.996, 283, 283, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
29, 5mqvA, 0.9596, 1.07, 1.000, 286, 283, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
30, 3sv0A, 0.9596, 1.34, 0.787, 294, 287, CRYSTAL STRUCTURE OF CASEIN KINASE-1 LIKE PROTEIN IN PLANT
31, 4tn6A, 0.9595, 1.31, 1.000, 292, 286, CK1D IN COMPLEX WITH INHIBITOR
32, 4kbcA, 0.9595, 0.99, 1.000, 288, 282, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
33, 5mqvB, 0.9590, 1.15, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
34, 5x17B, 0.9584, 1.24, 1.000, 289, 285, CRYSTAL STRUCTURE OF MURINE CK1D IN COMPLEX WITH ADP
35, 5mqvF, 0.9582, 1.10, 0.993, 286, 283, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
36, 5oktD, 0.9580, 0.94, 0.996, 282, 280, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
37, 5w4wC, 0.9570, 0.88, 1.000, 284, 280, IDENTIFICATION AND PROFILING OF A SELECTIVE AND BRAIN PENETRANT RADIOLIGAND FOR IN VIVO TARGET OCCUPANCY MEASUREMENT OF CASEIN KINASE 1 (CK1) INHIBITORS
38, 4tw9A, 0.9564, 1.28, 0.989, 290, 283, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
39, 3uysA, 0.9561, 0.90, 1.000, 281, 280, CRYSTAL STRUCTURE OF APO HUMAN CK1D
40, 4tw9B, 0.9560, 1.15, 0.989, 289, 281, DIFLUORO-DIOXOLO-BENZOIMIDAZOL-BENZAMIDES AS POTENT INHIBITORS OF CK1DELTA AND EPSILON WITH NANOMOLAR INHIBITORY ACTIVITY ON CANCER CELL PROLIFERATION
41, 4kbkD, 0.9551, 0.84, 1.000, 281, 279, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
42, 2izuA, 0.9547, 1.30, 0.592, 297, 284, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
43, 2csnA, 0.9544, 1.42, 0.577, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 WITH CKI7
44, 3uytB, 0.9533, 1.34, 1.000, 286, 286, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
45, 5mqvD, 0.9528, 1.31, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
46, 3uytC, 0.9528, 1.11, 1.000, 286, 282, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
47, 4nt4A, 0.9526, 1.47, 0.582, 300, 285, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF GILGAMESH ISOFORM I FROM DROSOPHILA MELANOGASTER
48, 1csnA, 0.9526, 1.45, 0.573, 293, 286, BINARY COMPLEX OF CASEIN KINASE-1 WITH MGATP
49, 4g17A, 0.9522, 1.69, 0.598, 302, 286, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-TERT-BUTYLPHENYL)AMINO]-1H- BENZIMIDAZOLE-6-CARBONITRILE
50, 4xh0A, 0.9519, 1.14, 0.667, 350, 282, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (SO4 CONDITION)
51, 4hokI, 0.9518, 1.30, 0.972, 291, 284, CRYSTAL STRUCTURE OF APO CK1E
52, 2iztA, 0.9516, 1.34, 0.595, 296, 284, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
53, 5mqvE, 0.9515, 1.33, 1.000, 287, 284, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH 4-(2 5-DIMETHOXYPHENYL)-N-(4-(5-(4-FLUORPHENYL)-2-(METHYLTHIO)-1H- IMIDAZOL-4-YL)-PYRIDIN-2-YL)-1-METHYL-1H-PYRROLE-2-CARBOXAMIDE
54, 4xhhA, 0.9513, 1.16, 0.667, 358, 282, STRUCTURE OF C. GLABRATA HRR25 APO STATE
55, 4hokM, 0.9511, 1.54, 0.972, 291, 287, CRYSTAL STRUCTURE OF APO CK1E
56, 2chlA, 0.9509, 1.52, 0.594, 298, 286, STRUCTURE OF CASEIN KINASE 1 GAMMA 3
57, 4hgsA, 0.9507, 1.71, 0.598, 302, 286, CRYSTAL STRUCTURE OF CK1GS WITH COMPOUND 13
58, 4tn6B, 0.9506, 1.44, 0.979, 285, 282, CK1D IN COMPLEX WITH INHIBITOR
59, 3uysB, 0.9504, 0.87, 1.000, 279, 278, CRYSTAL STRUCTURE OF APO HUMAN CK1D
60, 5ih5A, 0.9502, 1.05, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A
61, 4hglA, 0.9501, 1.72, 0.598, 302, 286, CRYSTAL STRUCTURE OF CK1G3 WITH COMPOUND 1
62, 4g16A, 0.9496, 1.74, 0.594, 302, 286, CRYSTAL STRUCTURE OF CK1G3 WITH 2-[(4-{[3-(TRIFLUOROMETHYL)PYRIDIN2- YL]OXY}PHENYL)AMINO]-1H-BENZIMIDAZOLE-6-CARBONITRILE
63, 5ih4A, 0.9491, 1.08, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA APO (KINASE DOMAIN)
64, 5oktB, 0.9488, 0.83, 0.993, 281, 277, CRYSTAL STRUCTURE OF HUMAN CASEIN KINASE I DELTA IN COMPLEX WITH IWP-2 
65, 5ih6A, 0.9488, 1.09, 1.000, 286, 280, HUMAN CASEIN KINASE 1 ISOFORM DELTA (KINASE DOMAIN) IN COMPLEX WITH EPIBLASTIN A DERIVATIVE
66, 5x18A, 0.9487, 1.58, 0.538, 294, 286, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
67, 4hokO, 0.9480, 1.30, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
68, 4hokU, 0.9476, 1.22, 0.972, 289, 282, CRYSTAL STRUCTURE OF APO CK1E
69, 2izrA, 0.9471, 1.71, 0.593, 298, 285, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
70, 4jjrA, 0.9468, 0.87, 0.996, 284, 277, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
71, 4hokE, 0.9468, 1.42, 0.972, 291, 284, CRYSTAL STRUCTURE OF APO CK1E
72, 4kbkC, 0.9467, 0.79, 1.000, 280, 276, CK1D IN COMPLEX WITH (3S)-3-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H- PYRAZOL-4-YL]PYRIDIN-2-YL}MORPHOLINE INHIBITOR
73, 1ckiA, 0.9466, 1.16, 1.000, 292, 280, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
74, 2izsA, 0.9459, 1.80, 0.591, 298, 286, STRUCTURE OF CASEIN KINASE GAMMA 3 IN COMPLEX WITH INHIBITOR
75, 2c47D, 0.9456, 1.26, 0.582, 290, 280, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
76, 4hokW, 0.9455, 1.36, 0.972, 289, 283, CRYSTAL STRUCTURE OF APO CK1E
77, 4hokS, 0.9450, 1.29, 0.972, 286, 282, CRYSTAL STRUCTURE OF APO CK1E
78, 4xhlA, 0.9443, 1.35, 0.652, 330, 282, STRUCTURE OF S. CEREVISIAE HRR25 1-394 (K38R MUTANT)
79, 4hniA, 0.9435, 1.33, 0.972, 284, 282, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
80, 1ckiB, 0.9434, 1.11, 1.000, 286, 279, RECOMBINANT CASEIN KINASE I DELTA TRUNCATION MUTANT CONTAINING RESIDUES 1-317
81, 4hokA, 0.9427, 1.40, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
82, 2c47B, 0.9422, 1.24, 0.581, 289, 279, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
83, 4hokQ, 0.9411, 1.43, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
84, 4hokK, 0.9410, 1.45, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
85, 4hokG, 0.9408, 1.43, 0.972, 290, 283, CRYSTAL STRUCTURE OF APO CK1E
86, 4kb8D, 0.9404, 1.06, 0.993, 278, 276, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
87, 4kb8C, 0.9396, 0.80, 1.000, 277, 274, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
88, 3uzpB, 0.9395, 1.44, 0.996, 284, 282, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P21 CRYSTAL FORM
89, 4hokC, 0.9391, 1.45, 0.972, 289, 283, CRYSTAL STRUCTURE OF APO CK1E
90, 2c47A, 0.9391, 1.23, 0.579, 288, 278, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
91, 4kbaC, 0.9379, 0.84, 1.000, 277, 274, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
92, 5x18B, 0.9355, 1.81, 0.542, 294, 286, CRYSTAL STRUCTURE OF CASEIN KINASE I HOMOLOG 1
93, 4hniB, 0.9347, 1.37, 0.968, 284, 280, CRYSTAL STRUCTURE OF CK1E IN COMPLEX WITH PF4800567
94, 4jjrB, 0.9325, 1.12, 0.993, 283, 276, A P21 CRYSTAL FORM OF MAMMALIAN CASEIN KINASE 1 DELTA
95, 4kbaD, 0.9316, 0.83, 1.000, 274, 272, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
96, 4hgtB, 0.9309, 1.28, 0.971, 280, 277, CRYSTAL STRUCTURE OF CK1D WITH COMPOUND 13
97, 2cmwA, 0.9306, 1.59, 0.568, 294, 280, STRUCTURE OF HUMAN CASEIN KINASE 1 GAMMA-1 IN COMPLEX WITH 2-(2-HYDROXYETHYLAMINO)-6-(3-CHLOROANILINO)-9- ISOPROPYLPURINE (CASP TARGET)
98, 4kbcB, 0.9298, 1.60, 0.978, 277, 276, CK1D IN COMPLEX WITH {4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDIN-2- YL}METHANOL INHIBITOR
99, 2c47C, 0.9295, 1.21, 0.578, 282, 275, STRUCTURE OF CASEIN KINASE 1 GAMMA 2
100, 5cyzA, 0.9224, 1.37, 0.641, 353, 276, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 1
101, 4nfmA, 0.9161, 1.80, 0.375, 293, 280, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
102, 5czoB, 0.9157, 1.48, 0.652, 365, 276, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
103, 5czoA, 0.9137, 1.83, 0.650, 365, 280, STRUCTURE OF S. CEREVISIAE HRR25:MAM1 COMPLEX FORM 2
104, 4nfnA, 0.9099, 1.90, 0.375, 293, 280, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
105, 4btjA, 0.9089, 1.73, 0.378, 292, 278, TTBK1 IN COMPLEX WITH ATP
106, 4btmA, 0.9088, 1.74, 0.378, 292, 278, TTBK1 IN COMPLEX WITH INHIBITOR
107, 4btmB, 0.9078, 1.80, 0.384, 293, 279, TTBK1 IN COMPLEX WITH INHIBITOR
108, 4btjB, 0.9074, 1.82, 0.380, 293, 279, TTBK1 IN COMPLEX WITH ATP
109, 4btkA, 0.9057, 1.53, 0.376, 287, 274, TTBK1 IN COMPLEX WITH INHIBITOR
110, 3uytD, 0.8985, 0.97, 1.000, 268, 264, CRYSTAL STRUCTURE OF CK1D WITH PF670462 FROM P1 CRYSTAL FORM
111, 4kb8A, 0.8933, 0.74, 1.000, 265, 260, CK1D IN COMPLEX WITH 1-{4-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4- YL]PYRIDIN-2-YL}-N-METHYLMETHANAMINE LIGAND
112, 4kbaA, 0.8851, 0.78, 1.000, 263, 258, CK1D IN COMPLEX WITH 9-[3-(4-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-4-YL]- 2345-TETRAHYDROPYRIDO[23-F][14]OXAZEPINE INHIBITOR
113, 6cqhB, 0.8704, 2.21, 0.302, 316, 275, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
114, 6dd4B, 0.8638, 2.18, 0.298, 309, 272, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
115, 6cswB, 0.8618, 2.23, 0.298, 308, 272, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
116, 6bu6B, 0.8603, 2.09, 0.293, 307, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
117, 6bu6D, 0.8600, 2.18, 0.290, 318, 272, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
118, 6cmmB, 0.8582, 2.14, 0.300, 310, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
119, 6bp0B, 0.8578, 2.01, 0.295, 304, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
120, 5ukfA, 0.8573, 2.28, 0.289, 322, 273, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
121, 6bu6A, 0.8572, 2.28, 0.289, 322, 273, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
122, 6cmmD, 0.8571, 2.19, 0.299, 315, 271, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
123, 6bruA, 0.8565, 2.37, 0.292, 322, 274, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
124, 6dd4D, 0.8561, 2.23, 0.299, 311, 271, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
125, 6cqhD, 0.8560, 2.16, 0.296, 315, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
126, 3op5A, 0.8556, 2.31, 0.286, 320, 273, HUMAN VACCINIA-RELATED KINASE 1
127, 6cnxB, 0.8548, 2.13, 0.301, 311, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
128, 6cnxA, 0.8547, 2.37, 0.289, 322, 273, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
129, 6cswD, 0.8543, 2.27, 0.299, 312, 271, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
130, 5uvfC, 0.8531, 2.02, 0.303, 301, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
131, 6cmmA, 0.8529, 2.32, 0.287, 318, 272, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
132, 6cnxD, 0.8520, 2.18, 0.294, 312, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
133, 6cfmD, 0.8517, 2.26, 0.300, 313, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
134, 3op5B, 0.8514, 2.25, 0.277, 319, 271, HUMAN VACCINIA-RELATED KINASE 1
135, 6bruD, 0.8511, 2.21, 0.297, 311, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
136, 6bp0D, 0.8506, 2.24, 0.297, 311, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
137, 3op5C, 0.8502, 2.08, 0.292, 308, 267, HUMAN VACCINIA-RELATED KINASE 1
138, 6bruB, 0.8501, 2.00, 0.297, 301, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
139, 6cqhA, 0.8496, 2.28, 0.289, 316, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
140, 6btwB, 0.8477, 2.04, 0.297, 301, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
141, 5ukfC, 0.8471, 2.23, 0.279, 317, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
142, 3op5D, 0.8469, 2.04, 0.297, 302, 266, HUMAN VACCINIA-RELATED KINASE 1
143, 5tkxA, 0.8464, 2.38, 0.295, 315, 271, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
144, 6btwD, 0.8461, 2.20, 0.300, 307, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
145, 5uu1A, 0.8455, 2.44, 0.320, 315, 272, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
146, 5uvfA, 0.8454, 2.32, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
147, 6bp0A, 0.8452, 2.31, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
148, 6btwA, 0.8449, 2.31, 0.293, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
149, 6cswC, 0.8446, 2.38, 0.277, 319, 271, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
150, 6cfmA, 0.8443, 2.27, 0.286, 316, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
151, 5uvfB, 0.8438, 2.22, 0.280, 316, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
152, 6dd4A, 0.8437, 2.28, 0.290, 317, 269, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
153, 6cmmC, 0.8432, 2.23, 0.280, 316, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
154, 6dd4C, 0.8420, 2.34, 0.289, 317, 270, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
155, 6bruC, 0.8408, 2.22, 0.281, 315, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
156, 6bu6C, 0.8404, 2.23, 0.281, 315, 267, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
157, 6cfmC, 0.8399, 2.27, 0.280, 316, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
158, 6bp0C, 0.8396, 2.28, 0.287, 315, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
159, 6cswA, 0.8394, 2.30, 0.291, 316, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
160, 5uvfD, 0.8391, 2.09, 0.299, 296, 264, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
161, 6btwC, 0.8384, 2.31, 0.287, 315, 268, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
162, 2jiiB, 0.8380, 2.60, 0.230, 326, 274, STRUCTURE OF VACCINIA RELATED KINASE 3
163, 6cnxC, 0.8379, 2.19, 0.289, 311, 266, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
164, 2jiiA, 0.8358, 2.54, 0.232, 321, 272, STRUCTURE OF VACCINIA RELATED KINASE 3
165, 6cfmB, 0.8347, 2.12, 0.298, 297, 262, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
166, 6cqhC, 0.8313, 2.15, 0.293, 308, 263, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
167, 2lavA, 0.8250, 2.82, 0.285, 361, 274, NMR SOLUTION STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 1
168, 2kulA, 0.8237, 2.79, 0.272, 360, 276, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE 1(VRK1)
169, 2v62B, 0.8223, 2.59, 0.300, 310, 267, STRUCTURE OF VACCINIA-RELATED KINASE 2
170, 2rsvA, 0.8208, 3.10, 0.275, 403, 276, SOLUTION STRUCTURE OF HUMAN FULL-LENGTH VACCINIA RELATED KINASE 1 (VRK1)
171, 2v62A, 0.8197, 2.55, 0.297, 309, 266, STRUCTURE OF VACCINIA-RELATED KINASE 2
172, 2ktyA, 0.8132, 2.95, 0.279, 360, 276, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE-1
173, 5xs2A, 0.8057, 3.30, 0.145, 366, 275, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
174, 4bcpA, 0.8040, 2.58, 0.192, 298, 260, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
175, 4bcoA, 0.8038, 2.58, 0.192, 298, 260, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
176, 3thbA, 0.8022, 2.74, 0.183, 287, 263, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
177, 1oiyC, 0.8020, 2.47, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
178, 4eonA, 0.8018, 2.57, 0.188, 299, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
179, 4eosC, 0.8015, 2.48, 0.186, 296, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
180, 4w8eA, 0.8013, 2.70, 0.218, 290, 262, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
181, 4eonC, 0.8013, 2.55, 0.185, 298, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
182, 2iw8A, 0.8013, 2.53, 0.181, 297, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
183, 5cyiC, 0.8012, 2.48, 0.190, 296, 258, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
184, 2g9xA, 0.8012, 2.61, 0.192, 298, 260, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
185, 4a4lA, 0.8010, 2.75, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
186, 4eoiC, 0.8007, 2.48, 0.190, 296, 258, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
187, 4ec8A, 0.8006, 2.99, 0.179, 325, 268, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
188, 4cfxC, 0.8006, 2.64, 0.188, 298, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
189, 3dogA, 0.8006, 2.63, 0.188, 297, 260, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
190, 5lmkA, 0.8005, 2.62, 0.192, 296, 260, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
191, 5cyiA, 0.8005, 2.55, 0.189, 298, 259, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
192, 1h1sC, 0.8004, 2.50, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
193, 4eorA, 0.8003, 2.55, 0.189, 293, 259, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
194, 4a4oA, 0.8002, 2.77, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
195, 4eolA, 0.7999, 2.57, 0.189, 294, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
196, 4eolC, 0.7997, 2.55, 0.189, 299, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
197, 3eocA, 0.7997, 2.59, 0.193, 295, 259, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
198, 5nevA, 0.7996, 2.45, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
199, 5lqeC, 0.7996, 2.50, 0.194, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
200, 4eokC, 0.7995, 2.56, 0.197, 299, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
201, 3ddqA, 0.7994, 2.65, 0.188, 296, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
202, 2yacA, 0.7994, 2.76, 0.183, 290, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
203, 4eokA, 0.7993, 2.57, 0.193, 293, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
204, 1oiuA, 0.7992, 2.56, 0.189, 296, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
205, 1h1qC, 0.7992, 2.52, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
206, 4ogrI, 0.7991, 2.91, 0.184, 318, 266, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
207, 2iw9A, 0.7991, 2.56, 0.189, 293, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
208, 1h1sA, 0.7989, 2.51, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
209, 4eopC, 0.7988, 2.51, 0.190, 296, 258, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
210, 1oguA, 0.7988, 2.57, 0.189, 296, 259, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
211, 4cfmA, 0.7987, 2.52, 0.190, 296, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
212, 3ddpA, 0.7986, 2.58, 0.185, 297, 259, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
213, 3kb7A, 0.7985, 2.78, 0.183, 289, 263, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
214, 1oi9A, 0.7985, 2.52, 0.190, 295, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
215, 5nevC, 0.7984, 2.52, 0.194, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
216, 2g9xC, 0.7984, 2.68, 0.192, 274, 260, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
217, 4u8zA, 0.7982, 2.70, 0.206, 289, 262, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
218, 5lqeA, 0.7981, 2.48, 0.191, 295, 257, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
219, 2owbA, 0.7981, 2.73, 0.183, 294, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
220, 4imyE, 0.7980, 2.76, 0.186, 313, 263, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
221, 3ddpC, 0.7980, 2.64, 0.188, 298, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
222, 3bhuA, 0.7980, 2.67, 0.188, 297, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
223, 3fc2A, 0.7979, 2.78, 0.183, 293, 263, PLK1 IN COMPLEX WITH BI6727
224, 1h1qA, 0.7979, 2.53, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
225, 4cfxA, 0.7978, 2.73, 0.188, 298, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
226, 1oiyA, 0.7978, 2.52, 0.190, 293, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
227, 4j53A, 0.7977, 2.79, 0.183, 293, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
228, 4eopA, 0.7976, 2.58, 0.189, 297, 259, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
229, 4cfwC, 0.7975, 2.54, 0.190, 297, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
230, 2cchC, 0.7975, 2.54, 0.186, 296, 258, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
231, 2biyA, 0.7975, 2.72, 0.193, 287, 259, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
232, 1oi9C, 0.7974, 2.52, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
233, 1h1rA, 0.7974, 2.55, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
234, 3bhtA, 0.7971, 2.68, 0.188, 297, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
235, 3miaA, 0.7970, 3.05, 0.184, 324, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
236, 4w8dA, 0.7969, 2.73, 0.206, 289, 262, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
237, 4qmqA, 0.7969, 2.63, 0.212, 289, 260, MST3 IN COMPLEX WITH CP-673451
238, 4cfnA, 0.7969, 2.59, 0.189, 296, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
239, 2iw6C, 0.7969, 2.50, 0.187, 295, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
240, 4qmmA, 0.7968, 2.70, 0.211, 288, 261, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
241, 2rkuA, 0.7968, 2.79, 0.183, 294, 263, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
242, 4j52A, 0.7967, 2.79, 0.183, 293, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
243, 4bcoC, 0.7967, 2.55, 0.190, 269, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
244, 4or5F, 0.7966, 3.08, 0.180, 324, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
245, 3qhrC, 0.7966, 2.55, 0.190, 297, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
246, 5ta6A, 0.7965, 2.80, 0.183, 294, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
247, 3qhrA, 0.7965, 2.55, 0.190, 297, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
248, 4eoiA, 0.7964, 2.59, 0.189, 294, 259, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
249, 3qhwC, 0.7964, 2.55, 0.186, 297, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
250, 3qhwA, 0.7962, 2.55, 0.186, 297, 258, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
251, 3mi9A, 0.7962, 3.13, 0.179, 328, 268, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
252, 2iw6A, 0.7962, 2.51, 0.191, 292, 257, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
253, 4eosA, 0.7960, 2.60, 0.185, 296, 259, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
254, 2uzlC, 0.7960, 2.51, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
255, 2cchA, 0.7960, 2.56, 0.190, 296, 258, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
256, 1oguC, 0.7960, 2.57, 0.190, 272, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
257, 1h1rC, 0.7960, 2.57, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
258, 2c6tA, 0.7958, 2.53, 0.191, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
259, 4ogrA, 0.7957, 3.03, 0.190, 314, 269, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
260, 4rqvA, 0.7956, 2.73, 0.189, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
261, 4pniA, 0.7956, 2.87, 0.198, 492, 262, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
262, 4eooC, 0.7956, 2.57, 0.190, 297, 258, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
263, 4b6lA, 0.7955, 2.78, 0.214, 281, 262, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
264, 3my5A, 0.7954, 2.70, 0.192, 296, 260, CDK2/CYCLINA IN COMPLEX WITH DRB
265, 2uzlA, 0.7954, 2.52, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
266, 2hy81, 0.7954, 2.87, 0.217, 293, 263, PAK1 COMPLEX WITH ST2001
267, 5lvlA, 0.7953, 2.71, 0.189, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
268, 4cfvA, 0.7952, 2.71, 0.192, 300, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
269, 3bhvA, 0.7952, 2.70, 0.192, 297, 260, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
270, 1pkdA, 0.7952, 2.57, 0.190, 296, 258, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
271, 1fvvA, 0.7952, 2.67, 0.193, 298, 259, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
272, 4bcnA, 0.7951, 2.63, 0.189, 296, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
273, 3a7iA, 0.7951, 2.76, 0.210, 286, 262, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
274, 2uzeA, 0.7951, 2.52, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
275, 1p5eA, 0.7951, 2.57, 0.190, 296, 258, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
276, 4qmyA, 0.7950, 2.77, 0.210, 287, 262, MST3 IN COMPLEX WITH STAUROSPORINE
277, 4qmxA, 0.7950, 2.76, 0.210, 287, 262, MST3 IN COMPLEX WITH SARACATINIB
278, 4xx9A, 0.7949, 2.74, 0.189, 288, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
279, 4eojA, 0.7949, 2.70, 0.196, 295, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
280, 2wmbA, 0.7949, 2.58, 0.186, 296, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
281, 2uzdA, 0.7949, 2.54, 0.187, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
282, 1h26A, 0.7949, 2.56, 0.186, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
283, 4qmoA, 0.7946, 2.75, 0.206, 288, 262, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
284, 3bhuC, 0.7946, 2.59, 0.190, 271, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
285, 2bkzA, 0.7946, 2.70, 0.188, 302, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
286, 4qmvA, 0.7945, 2.66, 0.212, 288, 260, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
287, 2bkzC, 0.7945, 2.71, 0.188, 298, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
288, 4wboA, 0.7944, 3.04, 0.197, 497, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
289, 4cfuA, 0.7944, 2.72, 0.192, 299, 260, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
290, 3nynB, 0.7944, 2.72, 0.177, 553, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
291, 4qmzA, 0.7943, 2.77, 0.210, 286, 262, MST3 IN COMPLEX WITH SUNITINIB
292, 4ct2A, 0.7943, 2.73, 0.197, 277, 259, HUMAN PDK1-PKCZETA KINASE CHIMERA
293, 4bcmA, 0.7943, 2.58, 0.190, 295, 258, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
294, 4nw5A, 0.7942, 2.62, 0.182, 302, 258, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
295, 1h1pA, 0.7941, 2.59, 0.194, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
296, 4qmpA, 0.7940, 2.73, 0.211, 289, 261, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
297, 4nw6A, 0.7940, 2.72, 0.178, 302, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
298, 2uzeC, 0.7940, 2.54, 0.191, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
299, 4eoqA, 0.7938, 2.63, 0.189, 295, 259, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
300, 4eomA, 0.7938, 2.64, 0.189, 296, 259, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
301, 4ct1A, 0.7938, 2.73, 0.197, 283, 259, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
302, 1vywA, 0.7938, 2.72, 0.192, 302, 260, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
303, 4dc2A, 0.7937, 2.88, 0.167, 328, 263, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
304, 3rcjA, 0.7937, 2.69, 0.190, 281, 258, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
305, 5mrdA, 0.7936, 2.73, 0.193, 283, 259, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
306, 4rrvA, 0.7936, 2.74, 0.193, 283, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
307, 4rqkA, 0.7936, 2.76, 0.189, 285, 259, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
308, 4qmuA, 0.7936, 2.78, 0.210, 286, 262, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
309, 2wxvA, 0.7936, 2.74, 0.192, 302, 260, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
310, 3orxC, 0.7935, 2.68, 0.198, 283, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
311, 2c5oA, 0.7935, 2.61, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
312, 4wboD, 0.7934, 3.07, 0.197, 491, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
313, 4qnaA, 0.7934, 2.79, 0.210, 284, 262, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
314, 4or5A, 0.7934, 3.15, 0.180, 319, 267, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
315, 4bckA, 0.7934, 2.65, 0.189, 298, 259, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
316, 3orxD, 0.7934, 2.69, 0.198, 282, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
317, 3nyoB, 0.7934, 2.71, 0.177, 553, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
318, 4fx3C, 0.7933, 2.69, 0.193, 298, 259, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
319, 1h27A, 0.7933, 2.58, 0.190, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
320, 1gy3A, 0.7933, 2.55, 0.191, 295, 257, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
321, 5lvnA, 0.7932, 2.76, 0.189, 283, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
322, 4eomC, 0.7932, 2.61, 0.190, 275, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
323, 3orxA, 0.7932, 2.69, 0.198, 283, 258, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
324, 3ej1A, 0.7932, 2.68, 0.189, 295, 259, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
325, 4cfwA, 0.7931, 2.67, 0.189, 299, 259, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
326, 6b3eA, 0.7930, 3.06, 0.223, 309, 264, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
327, 3hrfA, 0.7930, 2.76, 0.189, 284, 259, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
328, 3eocC, 0.7930, 2.60, 0.194, 293, 258, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
329, 3d5uA, 0.7930, 2.79, 0.198, 288, 262, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
330, 1h1pC, 0.7930, 2.60, 0.190, 296, 258, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
331, 5lvmA, 0.7929, 2.73, 0.189, 283, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
332, 4wboC, 0.7929, 2.99, 0.202, 481, 263, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
333, 3iw4C, 0.7929, 2.74, 0.177, 332, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
334, 2wxvC, 0.7929, 2.73, 0.192, 299, 260, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
335, 2ou7A, 0.7929, 2.80, 0.183, 292, 262, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
336, 2c4gC, 0.7929, 2.75, 0.196, 300, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
337, 4imyA, 0.7928, 3.15, 0.184, 314, 266, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
338, 3nynA, 0.7928, 2.84, 0.176, 553, 261, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
339, 5ta8A, 0.7927, 2.84, 0.183, 294, 263, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
340, 4qmwA, 0.7927, 2.79, 0.202, 286, 262, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
341, 4eooA, 0.7927, 2.65, 0.189, 294, 259, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
342, 3d5wA, 0.7927, 2.70, 0.208, 284, 260, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
343, 3a8xA, 0.7927, 2.76, 0.165, 334, 260, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
344, 2wevA, 0.7927, 2.61, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
345, 2xikA, 0.7926, 2.77, 0.218, 288, 262, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
346, 2v5qB, 0.7925, 2.81, 0.183, 285, 262, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
347, 1gy3C, 0.7925, 2.57, 0.191, 295, 257, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
348, 4o27B, 0.7924, 2.80, 0.209, 281, 263, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
349, 1e9hC, 0.7924, 2.60, 0.190, 296, 258, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
350, 5ackA, 0.7923, 2.73, 0.189, 286, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
351, 3a8xB, 0.7923, 2.72, 0.166, 329, 259, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
352, 2x1nA, 0.7923, 2.62, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
353, 1h28C, 0.7923, 2.63, 0.190, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
354, 3bhtC, 0.7922, 2.55, 0.187, 270, 257, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
355, 5lvoA, 0.7921, 2.73, 0.189, 285, 259, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
356, 5if1A, 0.7921, 2.71, 0.193, 298, 259, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
357, 3tnwA, 0.7921, 2.67, 0.189, 295, 259, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
358, 1jstC, 0.7921, 2.64, 0.190, 297, 258, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
359, 4a06A, 0.7920, 2.74, 0.190, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
360, 3t8oA, 0.7920, 3.01, 0.197, 493, 264, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
361, 2bpmA, 0.7920, 2.75, 0.192, 302, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
362, 2wpaA, 0.7919, 2.76, 0.188, 302, 260, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
363, 2v22A, 0.7919, 2.62, 0.194, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
364, 2cciA, 0.7919, 2.60, 0.190, 296, 258, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
365, 4qmsA, 0.7917, 2.80, 0.206, 283, 262, MST3 IN COMPLEX WITH DASATINIB
366, 4eoqC, 0.7917, 2.61, 0.190, 275, 258, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
367, 4bcgA, 0.7917, 2.93, 0.186, 312, 263, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
368, 2wmaA, 0.7917, 2.62, 0.186, 296, 258, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
369, 2uueA, 0.7917, 2.62, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
370, 4eojC, 0.7916, 2.61, 0.194, 282, 258, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
371, 1q8zB, 0.7916, 2.89, 0.219, 364, 260, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
372, 2whbA, 0.7915, 2.63, 0.194, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
373, 1qmzC, 0.7915, 2.61, 0.190, 296, 258, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
374, 2uzbA, 0.7914, 2.57, 0.198, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
375, 1urcA, 0.7914, 2.63, 0.186, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
376, 4i6hA, 0.7913, 2.87, 0.163, 285, 263, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
377, 3dbeA, 0.7912, 2.73, 0.204, 284, 260, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
378, 1qmzA, 0.7912, 2.61, 0.190, 296, 258, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
379, 4wnkA, 0.7910, 2.83, 0.195, 499, 261, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
380, 4bcnC, 0.7910, 2.55, 0.187, 295, 256, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
381, 3nyoA, 0.7909, 2.75, 0.177, 553, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
382, 3c50A, 0.7909, 2.99, 0.202, 499, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
383, 2wihA, 0.7909, 2.77, 0.192, 302, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
384, 2c5oC, 0.7909, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
385, 3iw4B, 0.7908, 2.71, 0.178, 325, 259, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
386, 2x1nC, 0.7908, 2.64, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
387, 2c5vC, 0.7908, 2.65, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
388, 2c5vA, 0.7908, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
389, 1vywC, 0.7908, 2.76, 0.192, 299, 260, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
390, 4wboB, 0.7907, 3.09, 0.201, 495, 264, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
391, 4fx3A, 0.7907, 2.75, 0.189, 298, 259, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
392, 6b3eC, 0.7906, 3.10, 0.223, 307, 264, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
393, 3my1A, 0.7906, 2.94, 0.183, 314, 263, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
394, 2wpaC, 0.7906, 2.76, 0.192, 299, 260, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
395, 2v5qA, 0.7906, 2.85, 0.183, 285, 262, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
396, 2c5xA, 0.7906, 2.63, 0.186, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
397, 1urcC, 0.7906, 2.65, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
398, 1p5eC, 0.7906, 2.63, 0.190, 296, 258, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
399, 4i5pA, 0.7905, 2.77, 0.172, 284, 261, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
400, 3zh8A, 0.7905, 2.99, 0.170, 318, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
401, 2c5nA, 0.7905, 2.64, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
402, 5otfA, 0.7904, 3.05, 0.167, 411, 264, MRCK BETA IN COMPLEX WITH BDP-00009066
403, 4ii5A, 0.7904, 2.61, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
404, 3orxB, 0.7904, 2.68, 0.195, 280, 257, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
405, 3iw4A, 0.7904, 2.77, 0.177, 330, 260, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
406, 2cciC, 0.7904, 2.64, 0.186, 296, 258, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
407, 4ii5C, 0.7903, 2.61, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
408, 3c4wA, 0.7903, 2.99, 0.194, 494, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
409, 1finA, 0.7903, 2.74, 0.193, 298, 259, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
410, 4cfnC, 0.7902, 2.54, 0.187, 296, 256, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
411, 3zh8B, 0.7902, 3.00, 0.174, 317, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
412, 3ckxA, 0.7902, 2.79, 0.206, 276, 262, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
413, 3bhvC, 0.7902, 2.64, 0.190, 271, 258, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
414, 2c4gA, 0.7902, 2.79, 0.192, 301, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
415, 4i3zA, 0.7901, 2.62, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
416, 4cfuC, 0.7901, 2.64, 0.190, 272, 258, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
417, 2uzbC, 0.7901, 2.60, 0.198, 292, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
418, 2c6tC, 0.7901, 2.59, 0.195, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
419, 1h28A, 0.7901, 2.63, 0.190, 296, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
420, 4qmtA, 0.7900, 2.82, 0.210, 284, 262, MST3 IN COMPLEX WITH HESPERADIN
421, 2wmbC, 0.7900, 2.56, 0.191, 266, 256, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
422, 1pkdC, 0.7900, 2.64, 0.190, 296, 258, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
423, 4qmnA, 0.7899, 2.84, 0.214, 283, 262, MST3 IN COMPLEX WITH BOSUTINIB
424, 3c4wB, 0.7899, 2.91, 0.198, 518, 262, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
425, 1ol1C, 0.7899, 2.67, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
426, 4i3zC, 0.7898, 2.63, 0.191, 295, 257, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
427, 3c51A, 0.7898, 3.02, 0.198, 487, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
428, 2whbC, 0.7896, 2.65, 0.194, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
429, 1ol1A, 0.7896, 2.64, 0.186, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
430, 4i6fA, 0.7895, 2.84, 0.164, 285, 262, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
431, 4bcmC, 0.7895, 2.57, 0.187, 294, 256, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
432, 4i6bA, 0.7893, 2.79, 0.172, 285, 261, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
433, 3c4xA, 0.7893, 3.00, 0.194, 496, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
434, 2bpmC, 0.7893, 2.78, 0.192, 299, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
435, 2acxA, 0.7893, 2.84, 0.184, 495, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
436, 1ol2A, 0.7892, 2.66, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
437, 1e9hA, 0.7892, 2.61, 0.191, 295, 257, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
438, 3tkuA, 0.7891, 3.17, 0.166, 395, 265, MRCK BETA IN COMPLEX WITH FASUDIL
439, 1h27C, 0.7891, 2.63, 0.190, 291, 258, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
440, 4imyC, 0.7890, 2.93, 0.179, 310, 262, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
441, 4eorC, 0.7890, 2.58, 0.191, 270, 256, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
442, 2jedA, 0.7890, 2.81, 0.205, 324, 259, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
443, 2iw9C, 0.7890, 2.58, 0.191, 268, 256, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
444, 1q99B, 0.7890, 2.91, 0.219, 364, 260, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
445, 3tkuB, 0.7889, 3.17, 0.170, 395, 265, MRCK BETA IN COMPLEX WITH FASUDIL
446, 2jd5B, 0.7889, 2.91, 0.219, 360, 260, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
447, 1uv5A, 0.7888, 3.00, 0.192, 348, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
448, 3f5xA, 0.7887, 2.75, 0.193, 297, 259, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
449, 3dogC, 0.7887, 2.52, 0.188, 267, 255, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
450, 6aywB, 0.7886, 2.90, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
451, 5if1C, 0.7886, 2.65, 0.194, 296, 258, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
452, 4a07A, 0.7886, 2.74, 0.190, 282, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
453, 4aw0A, 0.7885, 2.75, 0.194, 283, 258, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
454, 3rwqA, 0.7885, 2.65, 0.196, 283, 255, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
455, 2wihC, 0.7885, 2.78, 0.192, 299, 260, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
456, 5izjA, 0.7884, 2.82, 0.207, 328, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
457, 3f5xC, 0.7884, 2.75, 0.193, 298, 259, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
458, 1fvvC, 0.7884, 2.75, 0.193, 298, 259, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
459, 1okwA, 0.7882, 2.66, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
460, 1h1wA, 0.7882, 2.66, 0.192, 284, 255, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
461, 5lmkC, 0.7881, 2.55, 0.192, 265, 255, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
462, 3lq5A, 0.7881, 2.65, 0.163, 307, 258, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
463, 3ddqC, 0.7881, 2.52, 0.188, 266, 255, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
464, 2v22C, 0.7881, 2.68, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
465, 5veeA, 0.7880, 2.85, 0.184, 289, 261, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
466, 3zdiA, 0.7880, 3.01, 0.196, 348, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
467, 3a7jA, 0.7879, 2.84, 0.210, 286, 262, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
468, 2jedB, 0.7879, 2.79, 0.201, 320, 259, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
469, 2uueC, 0.7878, 2.69, 0.190, 296, 258, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
470, 4bchA, 0.7877, 2.75, 0.193, 308, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
471, 3eidA, 0.7877, 2.68, 0.195, 292, 257, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
472, 1zrzA, 0.7876, 2.78, 0.163, 310, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
473, 1uvrA, 0.7876, 2.68, 0.196, 284, 255, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
474, 1stcE, 0.7876, 2.75, 0.215, 334, 256, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
475, 1h25A, 0.7876, 2.54, 0.188, 293, 255, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
476, 4bcpC, 0.7875, 2.53, 0.188, 267, 255, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
477, 3zrkB, 0.7875, 3.12, 0.195, 348, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
478, 3v8sD, 0.7875, 3.15, 0.196, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
479, 3c50B, 0.7875, 2.94, 0.206, 496, 262, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
480, 2acxB, 0.7875, 2.78, 0.178, 492, 259, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
481, 2uzdC, 0.7874, 2.64, 0.195, 295, 257, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
482, 2c5nC, 0.7873, 2.70, 0.190, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
483, 3q53A, 0.7872, 2.89, 0.219, 291, 260, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
484, 3db6A, 0.7872, 2.87, 0.198, 287, 262, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
485, 3c4xB, 0.7872, 3.01, 0.194, 475, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
486, 3a8wA, 0.7872, 2.68, 0.167, 326, 257, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
487, 2i40A, 0.7872, 2.65, 0.195, 291, 256, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
488, 4l6qB, 0.7871, 3.22, 0.191, 388, 267, ROCK2 IN COMPLEX WITH BENZOXABOROLE
489, 3v8sB, 0.7871, 3.18, 0.192, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
490, 3qc9C, 0.7871, 3.03, 0.202, 482, 263, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
491, 1q4lB, 0.7871, 3.03, 0.195, 337, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
492, 1q4lA, 0.7871, 3.02, 0.195, 342, 261, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
493, 1jstA, 0.7871, 2.70, 0.190, 297, 258, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
494, 5vloB, 0.7870, 2.92, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
495, 3qc9D, 0.7870, 3.03, 0.202, 486, 263, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
496, 3qc9B, 0.7870, 3.03, 0.202, 481, 263, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
497, 3qc9A, 0.7870, 3.03, 0.202, 486, 263, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
498, 2i40C, 0.7870, 2.72, 0.194, 296, 258, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
499, 5wngD, 0.7869, 3.16, 0.192, 396, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
500, 4yhjB, 0.7869, 2.92, 0.176, 490, 262, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
501, 4uakA, 0.7869, 3.08, 0.167, 404, 264, MRCK BETA IN COMPLEX WITH ADP
502, 2wfyA, 0.7869, 2.63, 0.191, 295, 257, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
503, 2iw8C, 0.7868, 2.57, 0.188, 265, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
504, 1q97B, 0.7868, 2.85, 0.220, 361, 259, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
505, 3zrlB, 0.7867, 3.14, 0.202, 347, 262, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
506, 3c4zA, 0.7867, 3.03, 0.198, 493, 263, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
507, 1oiuC, 0.7867, 2.57, 0.192, 265, 255, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
508, 4cfmC, 0.7866, 2.54, 0.193, 266, 254, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
509, 4o0tA, 0.7865, 2.91, 0.217, 292, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
510, 5u7qC, 0.7864, 3.14, 0.196, 390, 265, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
511, 4l6qA, 0.7864, 3.14, 0.196, 388, 265, ROCK2 IN COMPLEX WITH BENZOXABOROLE
512, 3ej1C, 0.7864, 2.75, 0.193, 294, 259, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
513, 2wevC, 0.7864, 2.72, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
514, 1h26C, 0.7864, 2.61, 0.191, 267, 256, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
515, 5oteA, 0.7863, 3.12, 0.166, 407, 265, MRCK BETA IN COMPLEX WITH BDP-00008900
516, 5dh3B, 0.7863, 2.96, 0.186, 283, 264, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
517, 3tv7D, 0.7863, 3.16, 0.192, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
518, 5wneD, 0.7861, 3.16, 0.192, 396, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
519, 3qfvB, 0.7860, 3.20, 0.166, 396, 265, MRCK BETA IN COMPLEX WITH TPCA-1
520, 5li1A, 0.7859, 2.69, 0.163, 331, 257, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
521, 3a7gB, 0.7859, 2.86, 0.210, 290, 262, HUMAN MST3 KINASE
522, 2wfyC, 0.7859, 2.69, 0.190, 296, 258, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
523, 4nu1A, 0.7858, 3.13, 0.195, 356, 262, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
524, 3qfvA, 0.7858, 3.13, 0.166, 395, 265, MRCK BETA IN COMPLEX WITH TPCA-1
525, 3pfqA, 0.7858, 2.99, 0.169, 520, 261, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
526, 1j1bA, 0.7858, 3.05, 0.195, 354, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
527, 3zrmB, 0.7857, 3.06, 0.195, 347, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
528, 3tv7B, 0.7856, 3.18, 0.192, 397, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
529, 4dawA, 0.7855, 2.98, 0.214, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
530, 2vd5A, 0.7855, 2.99, 0.179, 390, 262, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
531, 2gcdA, 0.7855, 2.75, 0.212, 308, 260, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
532, 5u7rA, 0.7854, 3.18, 0.192, 387, 266, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
533, 5l1zA, 0.7852, 3.07, 0.162, 310, 266, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
534, 4ogrE, 0.7852, 3.13, 0.169, 310, 267, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
535, 4o0xA, 0.7852, 2.96, 0.186, 290, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
536, 2gcdB, 0.7852, 2.75, 0.212, 308, 260, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
537, 1okwC, 0.7851, 2.71, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
538, 3zh8C, 0.7850, 2.92, 0.172, 312, 261, A NOVEL SMALL MOLECULE APKC INHIBITOR
539, 1q41B, 0.7850, 3.05, 0.195, 343, 261, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
540, 3my5C, 0.7849, 2.57, 0.192, 266, 255, CDK2/CYCLINA IN COMPLEX WITH DRB
541, 1pyxB, 0.7849, 3.06, 0.195, 338, 261, GSK-3 BETA COMPLEXED WITH AMP-PNP
542, 5f94A, 0.7848, 3.14, 0.191, 346, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
543, 5deyA, 0.7848, 3.00, 0.213, 295, 263, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
544, 4nm0A, 0.7847, 3.07, 0.195, 356, 261, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
545, 1q5kA, 0.7847, 3.04, 0.192, 345, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
546, 1h24A, 0.7847, 2.58, 0.192, 293, 255, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
547, 5lcuA, 0.7846, 2.79, 0.203, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
548, 5dfpA, 0.7846, 3.02, 0.214, 292, 262, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
549, 4nstA, 0.7846, 3.12, 0.221, 322, 263, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
550, 4l9iB, 0.7846, 3.05, 0.202, 493, 263, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
551, 2o5kA, 0.7846, 3.06, 0.195, 350, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
552, 2c5xC, 0.7845, 2.72, 0.194, 296, 258, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
553, 1q8zA, 0.7845, 2.61, 0.236, 354, 254, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
554, 6aywA, 0.7844, 2.93, 0.196, 293, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
555, 5u7rB, 0.7844, 2.95, 0.202, 387, 262, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
556, 5lctA, 0.7844, 2.81, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
557, 5lcpA, 0.7844, 2.79, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
558, 5izjB, 0.7844, 2.86, 0.203, 325, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
559, 4ualA, 0.7843, 2.99, 0.169, 403, 261, MRCK BETA IN COMPLEX WITH BDP00005290
560, 4aw2A, 0.7843, 3.11, 0.163, 398, 264, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
561, 6gn1B, 0.7842, 3.05, 0.196, 339, 260, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
562, 5vedA, 0.7842, 2.92, 0.187, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
563, 3i4bB, 0.7842, 3.06, 0.195, 347, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
564, 2wtkC, 0.7842, 2.85, 0.174, 285, 258, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
565, 1q3wB, 0.7842, 3.06, 0.195, 341, 261, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
566, 4b7tA, 0.7841, 3.08, 0.195, 350, 261, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
567, 3ndmD, 0.7841, 3.20, 0.195, 396, 266, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
568, 3hrcA, 0.7841, 2.71, 0.192, 279, 255, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
569, 1j1bB, 0.7841, 3.06, 0.192, 364, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
570, 5lcqA, 0.7840, 2.79, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
571, 4yhjA, 0.7840, 2.94, 0.172, 501, 262, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
572, 4figA, 0.7840, 2.82, 0.192, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
573, 4bcjA, 0.7840, 2.86, 0.193, 309, 259, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
574, 3sayB, 0.7840, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
575, 1j1cA, 0.7840, 3.06, 0.195, 354, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
576, 1bx6A, 0.7840, 2.80, 0.211, 337, 256, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
577, 6babD, 0.7839, 2.96, 0.196, 291, 260, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
578, 5hvuA, 0.7839, 3.15, 0.189, 394, 265, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
579, 5f94B, 0.7839, 3.16, 0.191, 349, 262, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
580, 4qmlA, 0.7839, 2.90, 0.210, 280, 262, MST3 IN COMPLEX WITH AMP-PNP
581, 4figB, 0.7839, 2.82, 0.192, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4
582, 3m1sB, 0.7839, 3.06, 0.195, 349, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
583, 5m71A, 0.7838, 2.80, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
584, 5m0bA, 0.7838, 2.80, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
585, 5lcrA, 0.7838, 2.83, 0.211, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
586, 4eqcA, 0.7838, 3.01, 0.214, 296, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
587, 3sayA, 0.7838, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
588, 2cjmC, 0.7838, 2.63, 0.195, 294, 256, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
589, 1okyA, 0.7838, 2.61, 0.194, 281, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
590, 6gn1A, 0.7837, 3.05, 0.196, 339, 260, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
591, 4xbrA, 0.7837, 2.85, 0.195, 315, 261, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
592, 4bcqC, 0.7837, 2.57, 0.189, 292, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
593, 3tnwC, 0.7837, 2.51, 0.186, 291, 253, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
594, 5dewA, 0.7836, 3.06, 0.213, 295, 263, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
595, 4fieB, 0.7836, 2.84, 0.192, 300, 261, FULL-LENGTH HUMAN PAK4
596, 4fieA, 0.7836, 2.84, 0.192, 300, 261, FULL-LENGTH HUMAN PAK4
597, 3ndmB, 0.7836, 3.15, 0.200, 396, 265, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
598, 5m6yA, 0.7835, 2.82, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
599, 5wnhD, 0.7834, 3.21, 0.192, 397, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
600, 5li9A, 0.7834, 2.72, 0.168, 329, 256, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
601, 5kksA, 0.7834, 3.19, 0.184, 395, 266, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
602, 5dh3A, 0.7834, 2.99, 0.186, 287, 264, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
603, 4q9zB, 0.7834, 3.04, 0.195, 308, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
604, 4ekkA, 0.7834, 2.82, 0.213, 318, 258, AKT1 WITH AMP-PNP
605, 1ol2C, 0.7834, 2.75, 0.194, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
606, 4bckC, 0.7833, 2.56, 0.189, 293, 254, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
607, 3du8A, 0.7833, 3.08, 0.195, 336, 261, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
608, 4ec9A, 0.7832, 2.94, 0.165, 306, 260, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
609, 4bciA, 0.7832, 2.77, 0.198, 308, 257, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
610, 3v8sA, 0.7832, 3.22, 0.189, 395, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
611, 3pvwA, 0.7832, 2.97, 0.214, 613, 262, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
612, 3ocbA, 0.7832, 2.85, 0.213, 315, 258, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
613, 2i0eA, 0.7832, 2.70, 0.171, 326, 257, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
614, 1pyxA, 0.7832, 3.07, 0.192, 343, 261, GSK-3 BETA COMPLEXED WITH AMP-PNP
615, 1h8fB, 0.7832, 3.07, 0.195, 350, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
616, 5m6vA, 0.7831, 2.82, 0.211, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
617, 5dzcA, 0.7831, 2.84, 0.209, 816, 258, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
618, 4j71B, 0.7831, 3.05, 0.196, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
619, 2f2uA, 0.7831, 3.20, 0.189, 386, 264, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
620, 1yhwA, 0.7831, 3.02, 0.218, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
621, 1yhvA, 0.7831, 3.02, 0.218, 293, 262, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
622, 1o9uA, 0.7831, 3.05, 0.196, 349, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
623, 5m75A, 0.7830, 2.82, 0.207, 350, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
624, 4bcfA, 0.7830, 2.72, 0.195, 307, 257, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
625, 3v8sC, 0.7830, 3.23, 0.189, 395, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
626, 1unlB, 0.7830, 2.54, 0.175, 292, 252, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
627, 1h8fA, 0.7830, 3.08, 0.195, 352, 261, GLYCOGEN SYNTHASE KINASE 3 BETA.
628, 5uzjA, 0.7829, 3.05, 0.193, 387, 264, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
629, 4j71A, 0.7829, 3.06, 0.196, 347, 260, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
630, 1q99A, 0.7829, 2.62, 0.232, 354, 254, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
631, 5kpkA, 0.7828, 3.06, 0.196, 346, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
632, 3q3bB, 0.7828, 3.10, 0.195, 341, 261, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
633, 5f9eB, 0.7827, 2.91, 0.196, 293, 260, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
634, 3l1sB, 0.7827, 3.06, 0.195, 330, 261, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
635, 5l2wA, 0.7826, 2.54, 0.190, 297, 252, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
636, 5kpkB, 0.7826, 3.07, 0.196, 344, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
637, 4yvcA, 0.7826, 3.12, 0.193, 388, 264, ROCK 1 BOUND TO THIAZOLE INHIBITOR
638, 1q41A, 0.7826, 3.07, 0.192, 339, 261, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
639, 1j1cB, 0.7826, 3.08, 0.192, 364, 261, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
640, 5xqxA, 0.7825, 3.11, 0.144, 340, 263, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
641, 4pteB, 0.7825, 3.10, 0.192, 347, 261, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
642, 3zrmA, 0.7825, 3.09, 0.204, 344, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
643, 3d9vA, 0.7825, 3.06, 0.193, 400, 264, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
644, 1rekA, 0.7825, 2.75, 0.215, 336, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
645, 5kpmA, 0.7824, 3.07, 0.204, 344, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
646, 5f0aA, 0.7824, 2.86, 0.209, 811, 258, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
647, 4cxaA, 0.7824, 3.16, 0.224, 329, 263, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
648, 2f2uB, 0.7824, 3.30, 0.189, 383, 265, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
649, 1okvA, 0.7824, 2.67, 0.187, 295, 257, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
650, 1i09B, 0.7824, 3.08, 0.195, 341, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
651, 5kktA, 0.7823, 3.18, 0.189, 389, 264, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
652, 5acbC, 0.7823, 2.96, 0.222, 324, 261, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
653, 4ra4A, 0.7823, 2.86, 0.181, 317, 259, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
654, 3m1sA, 0.7823, 3.08, 0.192, 348, 261, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
655, 3i4bA, 0.7823, 3.08, 0.192, 359, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
656, 1u5qA, 0.7823, 2.80, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
657, 5wnfD, 0.7822, 3.21, 0.188, 396, 266, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
658, 5idpA, 0.7822, 3.31, 0.146, 342, 267, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
659, 5bmlA, 0.7822, 3.02, 0.194, 393, 263, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
660, 3zrkA, 0.7822, 3.11, 0.192, 345, 261, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
661, 2jgzA, 0.7822, 2.39, 0.192, 288, 250, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
662, 4afjB, 0.7821, 3.05, 0.197, 346, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
663, 4achB, 0.7821, 3.10, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
664, 3q3bA, 0.7821, 3.10, 0.192, 344, 261, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
665, 1howA, 0.7821, 2.69, 0.217, 346, 254, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
666, 5efqA, 0.7820, 3.11, 0.210, 321, 262, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
667, 4o0vA, 0.7820, 3.00, 0.183, 290, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
668, 4fr4D, 0.7820, 3.07, 0.202, 346, 263, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
669, 4fifB, 0.7820, 2.88, 0.192, 292, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
670, 4fifA, 0.7820, 2.88, 0.192, 293, 261, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
671, 3a7fA, 0.7820, 2.66, 0.207, 283, 256, HUMAN MST3 KINASE
672, 2x39A, 0.7820, 2.97, 0.212, 316, 259, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
673, 1rejA, 0.7820, 2.79, 0.211, 333, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
674, 4fr4F, 0.7819, 3.07, 0.202, 346, 263, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
675, 4wotC, 0.7818, 3.13, 0.189, 392, 264, ROCK2 IN COMPLEX WITH 1426382-07-1
676, 4nstC, 0.7818, 3.13, 0.221, 317, 262, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
677, 4achA, 0.7818, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
678, 2jldB, 0.7818, 3.09, 0.195, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
679, 5ok3A, 0.7817, 2.79, 0.200, 349, 255, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
680, 5hlpB, 0.7817, 2.99, 0.205, 335, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
681, 5ukfD, 0.7816, 1.97, 0.299, 268, 244, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
682, 5hlnB, 0.7816, 3.03, 0.196, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
683, 2etrA, 0.7816, 3.17, 0.192, 400, 265, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
684, 1svhA, 0.7816, 2.81, 0.211, 335, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
685, 1bkxA, 0.7816, 2.81, 0.207, 337, 256, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
686, 5vibA, 0.7815, 2.75, 0.208, 308, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
687, 5n1dA, 0.7815, 2.84, 0.207, 348, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
688, 5hlpA, 0.7815, 3.02, 0.205, 337, 259, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
689, 4pteA, 0.7815, 3.05, 0.192, 341, 260, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
690, 4nm5A, 0.7815, 3.14, 0.195, 361, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
691, 3zrlA, 0.7815, 3.06, 0.204, 345, 260, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
692, 2wipC, 0.7815, 2.61, 0.189, 292, 254, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
693, 2q0nA, 0.7815, 2.98, 0.190, 293, 263, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
694, 1xh8A, 0.7815, 2.82, 0.211, 337, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
695, 5f95A, 0.7814, 3.10, 0.195, 345, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
696, 5airA, 0.7814, 3.08, 0.195, 353, 261, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
697, 3a7hB, 0.7814, 2.93, 0.210, 290, 262, HUMAN MST3 KINASE IN COMPLEX WITH ATP
698, 5o0eA, 0.7813, 2.80, 0.204, 349, 255, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
699, 5dykA, 0.7813, 2.76, 0.211, 809, 256, CRYSTAL STRUCTURE OF PF3D7_1436600
700, 4o0yA, 0.7813, 3.02, 0.190, 290, 263, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
701, 4nusA, 0.7813, 3.03, 0.185, 301, 259, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
702, 4nm3A, 0.7813, 3.13, 0.195, 357, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
703, 4c35A, 0.7813, 2.81, 0.196, 337, 255, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
704, 3q52A, 0.7813, 3.05, 0.210, 292, 262, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
705, 2ow3B, 0.7813, 3.08, 0.204, 351, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
706, 2etkA, 0.7813, 3.09, 0.193, 400, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
707, 1u5qB, 0.7812, 2.80, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
708, 1h24C, 0.7812, 2.64, 0.196, 293, 255, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
709, 1finC, 0.7812, 2.87, 0.193, 298, 259, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
710, 5xvfA, 0.7811, 2.88, 0.188, 289, 261, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
711, 5uplA, 0.7811, 2.90, 0.188, 290, 261, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
712, 4yveA, 0.7811, 3.20, 0.186, 390, 264, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
713, 4ptcB, 0.7811, 3.17, 0.191, 347, 262, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
714, 4fr4A, 0.7811, 3.11, 0.202, 350, 262, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
715, 3sd0B, 0.7811, 3.12, 0.195, 349, 261, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
716, 3o7lD, 0.7811, 2.89, 0.207, 333, 256, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
717, 3l9mA, 0.7811, 2.74, 0.208, 338, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
718, 3gb2A, 0.7811, 3.07, 0.192, 340, 260, GSK3BETA INHIBITOR COMPLEX
719, 2v55A, 0.7811, 3.23, 0.192, 393, 265, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
720, 2gniA, 0.7811, 2.78, 0.219, 338, 256, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
721, 1q5kB, 0.7811, 3.09, 0.192, 344, 261, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
722, 5upkB, 0.7810, 2.93, 0.195, 288, 261, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
723, 5u7qA, 0.7810, 3.28, 0.192, 388, 265, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
724, 5kpmB, 0.7810, 3.07, 0.204, 345, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
725, 5hlnA, 0.7810, 3.06, 0.200, 346, 260, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
726, 4iq6B, 0.7810, 3.12, 0.195, 332, 261, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
727, 3pupA, 0.7810, 3.10, 0.192, 346, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
728, 2vd5B, 0.7810, 2.89, 0.181, 380, 259, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
729, 2gnjA, 0.7810, 2.80, 0.215, 335, 256, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
730, 5u7rC, 0.7809, 3.12, 0.193, 387, 264, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
731, 2v55C, 0.7809, 3.24, 0.192, 396, 265, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
732, 1szmA, 0.7809, 2.72, 0.201, 317, 254, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
733, 1q3wA, 0.7809, 3.11, 0.192, 344, 261, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
734, 5k5nB, 0.7808, 2.84, 0.199, 334, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
735, 4q9zA, 0.7808, 3.00, 0.204, 331, 260, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
736, 4acdA, 0.7808, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
737, 3pupB, 0.7808, 3.10, 0.192, 347, 261, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
738, 3l9lA, 0.7808, 2.85, 0.211, 338, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
739, 3krwA, 0.7808, 3.05, 0.206, 618, 262, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
740, 1q8yB, 0.7808, 2.81, 0.219, 357, 256, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
741, 5ezrA, 0.7807, 2.85, 0.209, 803, 258, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
742, 4fr4E, 0.7807, 3.09, 0.202, 342, 263, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
743, 4acgA, 0.7807, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
744, 1uu7A, 0.7807, 2.72, 0.198, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
745, 4un0C, 0.7806, 3.07, 0.221, 308, 262, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
746, 3du8B, 0.7806, 3.10, 0.192, 339, 261, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
747, 5ho7A, 0.7805, 2.58, 0.195, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
748, 5f95B, 0.7805, 3.13, 0.192, 338, 261, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
749, 4ptcA, 0.7805, 3.11, 0.195, 342, 261, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
750, 4acgB, 0.7805, 3.11, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
751, 1q3dB, 0.7805, 3.10, 0.195, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
752, 5airB, 0.7804, 3.10, 0.192, 361, 261, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
753, 4nm7A, 0.7804, 3.16, 0.195, 355, 261, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
754, 3l9mB, 0.7804, 2.85, 0.207, 336, 256, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
755, 2esmA, 0.7804, 3.11, 0.190, 400, 263, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
756, 5kktB, 0.7803, 3.18, 0.189, 394, 265, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
757, 5efqC, 0.7803, 3.13, 0.210, 325, 262, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
758, 4u45A, 0.7803, 2.81, 0.195, 289, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
759, 3fxzA, 0.7803, 3.03, 0.218, 292, 261, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
760, 3f7zB, 0.7803, 3.11, 0.196, 339, 260, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
761, 2wipA, 0.7803, 2.70, 0.188, 297, 255, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
762, 4u44A, 0.7802, 2.88, 0.198, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
763, 4nttB, 0.7802, 2.83, 0.203, 339, 256, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
764, 3mv5A, 0.7802, 2.89, 0.217, 315, 258, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
765, 5wneA, 0.7801, 3.29, 0.189, 384, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
766, 5uuuA, 0.7801, 2.97, 0.211, 414, 261, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
767, 5lihA, 0.7801, 2.96, 0.176, 324, 261, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
768, 4ptgB, 0.7801, 3.12, 0.192, 332, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
769, 3mvhA, 0.7801, 2.99, 0.212, 311, 259, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
770, 2ow3A, 0.7801, 3.13, 0.204, 346, 260, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
771, 1okvC, 0.7801, 2.78, 0.190, 296, 258, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
772, 5nw8A, 0.7800, 2.83, 0.208, 337, 255, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
773, 4j1rC, 0.7800, 3.00, 0.205, 344, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
774, 2uw9A, 0.7800, 2.99, 0.208, 316, 259, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
775, 2i0eB, 0.7800, 2.74, 0.171, 300, 257, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
776, 2gfcA, 0.7800, 2.80, 0.215, 335, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
777, 2etkB, 0.7800, 3.24, 0.188, 398, 266, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
778, 4w7pB, 0.7799, 3.22, 0.189, 387, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
779, 4ptgA, 0.7799, 3.13, 0.192, 333, 261, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
780, 4j1rB, 0.7799, 3.00, 0.205, 346, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
781, 4accA, 0.7799, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
782, 3pwyA, 0.7799, 2.65, 0.198, 281, 252, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
783, 3f7zA, 0.7799, 3.03, 0.197, 339, 259, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
784, 3d9vB, 0.7799, 3.15, 0.192, 398, 265, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
785, 3cqwA, 0.7799, 2.81, 0.214, 318, 257, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
786, 2jldA, 0.7798, 3.11, 0.192, 349, 261, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
787, 2jdoA, 0.7798, 2.81, 0.214, 314, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
788, 1u5rA, 0.7798, 2.82, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
789, 4fijA, 0.7797, 3.00, 0.186, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4
790, 4acdB, 0.7797, 3.12, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
791, 2jdvA, 0.7797, 2.80, 0.199, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
792, 5u7qB, 0.7796, 3.28, 0.192, 385, 265, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
793, 5oy4B, 0.7796, 3.11, 0.200, 353, 260, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
794, 4c34A, 0.7796, 2.90, 0.199, 336, 256, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
795, 3tn8A, 0.7796, 2.72, 0.195, 304, 256, CDK9/CYCLIN T IN COMPLEX WITH CAN508
796, 3sc1A, 0.7796, 2.59, 0.195, 278, 251, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
797, 3nx8A, 0.7796, 2.84, 0.211, 333, 256, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
798, 1xh5A, 0.7796, 2.85, 0.211, 335, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
799, 5wngA, 0.7795, 3.19, 0.192, 395, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
800, 5hbjA, 0.7795, 3.11, 0.156, 342, 262, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
801, 2ojfE, 0.7795, 2.85, 0.214, 336, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
802, 1r0eB, 0.7795, 3.12, 0.195, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
803, 6c0tA, 0.7794, 2.95, 0.189, 334, 259, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
804, 4wotB, 0.7794, 3.14, 0.197, 394, 264, ROCK2 IN COMPLEX WITH 1426382-07-1
805, 3tv7A, 0.7794, 3.30, 0.185, 394, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
806, 3ocbB, 0.7794, 2.90, 0.213, 319, 258, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
807, 1xh9A, 0.7794, 2.80, 0.211, 336, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
808, 5vloA, 0.7793, 2.87, 0.191, 290, 257, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
809, 4ra5B, 0.7793, 3.10, 0.195, 310, 261, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
810, 4jdiA, 0.7793, 3.01, 0.191, 289, 262, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
811, 4fr4C, 0.7793, 3.01, 0.195, 344, 261, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
812, 3juhA, 0.7793, 2.90, 0.178, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
813, 1xhaA, 0.7793, 2.85, 0.211, 348, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
814, 5ceiA, 0.7792, 3.30, 0.147, 345, 266, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
815, 4z84A, 0.7792, 2.84, 0.207, 335, 256, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
816, 3l9lB, 0.7792, 2.85, 0.211, 337, 256, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
817, 1smhA, 0.7792, 2.83, 0.207, 348, 256, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
818, 1r0eA, 0.7792, 3.12, 0.195, 344, 261, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
819, 2jd5A, 0.7791, 2.63, 0.237, 353, 253, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
820, 1u5rB, 0.7791, 2.81, 0.212, 308, 260, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
821, 1q8wA, 0.7791, 2.83, 0.204, 334, 255, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
822, 4tnbA, 0.7790, 2.93, 0.207, 529, 261, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
823, 4j1rA, 0.7790, 3.01, 0.205, 343, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
824, 4fiiA, 0.7790, 3.01, 0.179, 291, 263, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
825, 4ekkB, 0.7790, 2.87, 0.217, 318, 258, AKT1 WITH AMP-PNP
826, 2xchA, 0.7790, 2.61, 0.195, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
827, 2uzuE, 0.7790, 2.86, 0.214, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
828, 2oh0E, 0.7790, 2.86, 0.214, 336, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
829, 2jdtA, 0.7790, 2.85, 0.207, 334, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
830, 2f7eE, 0.7790, 2.85, 0.214, 336, 257, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
831, 6b8jA, 0.7789, 3.06, 0.197, 344, 259, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
832, 4j1rD, 0.7789, 3.01, 0.205, 345, 259, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
833, 3tv7C, 0.7789, 3.31, 0.185, 394, 265, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
834, 6c9dB, 0.7788, 2.98, 0.213, 422, 258, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
835, 4w7pC, 0.7788, 3.26, 0.193, 383, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
836, 4fr4B, 0.7788, 3.02, 0.195, 350, 261, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
837, 2f7xE, 0.7788, 2.86, 0.214, 336, 257, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
838, 1q3dA, 0.7788, 3.14, 0.195, 339, 261, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
839, 5vefA, 0.7787, 2.99, 0.179, 289, 262, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
840, 3krxA, 0.7787, 2.99, 0.211, 618, 261, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
841, 3a8wB, 0.7787, 2.69, 0.169, 327, 254, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
842, 2uzwE, 0.7787, 2.89, 0.210, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
843, 5wnfA, 0.7786, 3.19, 0.189, 395, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
844, 5uvcA, 0.7786, 3.02, 0.202, 457, 262, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
845, 5oy4A, 0.7786, 3.15, 0.200, 349, 260, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
846, 5f9eA, 0.7786, 2.92, 0.201, 334, 259, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
847, 4qo9B, 0.7786, 3.00, 0.202, 285, 262, MST3 IN COMPLEX WITH DANUSERTIB
848, 3pvuA, 0.7786, 3.03, 0.214, 609, 262, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
849, 3otuA, 0.7786, 2.67, 0.194, 276, 253, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
850, 1jbpE, 0.7786, 2.83, 0.207, 339, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
851, 5ntjA, 0.7785, 2.88, 0.208, 346, 255, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
852, 2uw7A, 0.7785, 2.86, 0.207, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
853, 2etrB, 0.7785, 3.26, 0.188, 398, 266, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
854, 5t31B, 0.7784, 3.13, 0.208, 333, 260, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
855, 5kksB, 0.7784, 3.27, 0.188, 395, 266, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
856, 4l9iA, 0.7784, 3.08, 0.202, 504, 262, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
857, 5i0bA, 0.7783, 2.97, 0.187, 288, 262, STRUCTURE OF PAK4
858, 4l67A, 0.7783, 3.02, 0.175, 289, 263, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
859, 4afjA, 0.7783, 3.09, 0.197, 342, 259, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
860, 3nayB, 0.7783, 2.63, 0.195, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
861, 2c1bA, 0.7783, 2.85, 0.211, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
862, 1unlA, 0.7783, 2.58, 0.175, 292, 252, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
863, 5nqcA, 0.7781, 2.87, 0.171, 331, 257, CK2ALPHA IN COMPLEX WITH NMR154
864, 5hngA, 0.7781, 2.63, 0.195, 280, 251, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
865, 5hnbA, 0.7781, 3.33, 0.147, 342, 266, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
866, 3tnhA, 0.7781, 2.68, 0.184, 288, 255, CDK9/CYCLIN T IN COMPLEX WITH CAN508
867, 3sd0A, 0.7781, 3.21, 0.195, 350, 262, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
868, 3p0mA, 0.7781, 2.84, 0.211, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
869, 5ukfB, 0.7780, 1.85, 0.311, 265, 241, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
870, 5kplA, 0.7780, 3.14, 0.204, 339, 260, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
871, 4gv1A, 0.7780, 2.93, 0.213, 329, 258, PKB ALPHA IN COMPLEX WITH AZD5363
872, 2gnfA, 0.7780, 2.85, 0.215, 339, 256, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
873, 4xbuA, 0.7779, 3.03, 0.186, 292, 263, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
874, 4ra5A, 0.7779, 2.95, 0.197, 332, 259, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
875, 4cfvC, 0.7779, 2.60, 0.190, 264, 253, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
876, 2gnhA, 0.7779, 2.84, 0.215, 338, 256, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
877, 2gngA, 0.7779, 2.86, 0.215, 338, 256, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
878, 1ydrE, 0.7779, 2.85, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
879, 4ie9A, 0.7778, 2.86, 0.211, 335, 256, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
880, 4accB, 0.7778, 3.14, 0.195, 350, 261, GSK3B IN COMPLEX WITH INHIBITOR
881, 3twjA, 0.7778, 3.23, 0.192, 396, 265, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
882, 3mfuA, 0.7778, 3.13, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
883, 3dndA, 0.7778, 2.86, 0.211, 334, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
884, 2wmaC, 0.7778, 2.70, 0.188, 265, 255, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
885, 2c1aA, 0.7778, 2.86, 0.211, 335, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
886, 1fmoE, 0.7778, 2.79, 0.199, 336, 256, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
887, 5wneC, 0.7777, 2.99, 0.199, 384, 261, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
888, 3nayA, 0.7777, 2.64, 0.195, 278, 251, PDK1 IN COMPLEX WITH INHIBITOR MP6
889, 2vn9B, 0.7777, 3.03, 0.192, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
890, 5uq2A, 0.7776, 2.85, 0.190, 296, 258, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
891, 5bmsA, 0.7776, 3.01, 0.191, 290, 262, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
892, 4uj2A, 0.7776, 2.87, 0.211, 335, 256, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
893, 4ij9A, 0.7776, 2.86, 0.211, 335, 256, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
894, 4fihA, 0.7776, 3.01, 0.176, 291, 262, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
895, 3l1sA, 0.7776, 3.01, 0.193, 336, 259, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
896, 3f88A, 0.7776, 3.03, 0.197, 340, 259, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
897, 4z83E, 0.7775, 2.88, 0.207, 335, 256, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
898, 4axaA, 0.7775, 2.87, 0.207, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
899, 3mfsA, 0.7775, 3.05, 0.205, 303, 259, CASK-4M CAM KINASE DOMAIN AMPPNP
900, 3blrA, 0.7775, 2.70, 0.191, 300, 256, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
901, 2uztA, 0.7775, 2.90, 0.210, 336, 257, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
902, 2uvxA, 0.7775, 2.85, 0.207, 335, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
903, 1ydsE, 0.7775, 2.86, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
904, 1vebA, 0.7775, 2.85, 0.211, 338, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
905, 6g4yB, 0.7774, 3.29, 0.178, 328, 269, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
906, 4ujbA, 0.7774, 2.87, 0.211, 344, 256, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
907, 4otdA, 0.7774, 2.88, 0.202, 334, 258, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
908, 4ks7A, 0.7774, 3.00, 0.191, 286, 262, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
909, 4jdhA, 0.7774, 3.07, 0.183, 289, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
910, 4f7sA, 0.7774, 3.34, 0.154, 339, 266, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
911, 4crlA, 0.7774, 3.23, 0.148, 339, 264, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
912, 2erzE, 0.7774, 2.86, 0.211, 334, 256, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
913, 5wnhC, 0.7773, 3.00, 0.199, 388, 261, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
914, 4yu2A, 0.7773, 2.63, 0.235, 348, 251, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
915, 4o0rA, 0.7773, 3.02, 0.198, 293, 262, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
916, 2uzvA, 0.7773, 2.87, 0.214, 336, 257, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
917, 1sveA, 0.7773, 2.86, 0.211, 341, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
918, 4yuqA, 0.7772, 2.99, 0.233, 462, 258, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
919, 4jdkA, 0.7772, 3.06, 0.179, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
920, 3cquA, 0.7772, 2.99, 0.212, 318, 259, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
921, 3blhA, 0.7772, 2.65, 0.197, 291, 254, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
922, 3agmA, 0.7772, 2.84, 0.215, 337, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
923, 2vo7A, 0.7772, 2.86, 0.207, 335, 256, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
924, 2vo0A, 0.7772, 2.85, 0.203, 340, 256, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
925, 5t31A, 0.7771, 3.04, 0.208, 334, 259, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
926, 5he2A, 0.7771, 3.00, 0.211, 628, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
927, 5hbeA, 0.7771, 3.29, 0.151, 344, 265, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
928, 3lijA, 0.7771, 2.89, 0.227, 465, 256, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
929, 1q61A, 0.7771, 2.86, 0.207, 335, 256, PKA TRIPLE MUTANT MODEL OF PKB
930, 1cmkE, 0.7771, 2.92, 0.207, 348, 256, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
931, 5u7rD, 0.7770, 2.97, 0.204, 382, 260, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
932, 5kplB, 0.7770, 3.07, 0.197, 339, 259, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
933, 4yxsA, 0.7770, 2.84, 0.215, 335, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
934, 4yveB, 0.7770, 3.28, 0.188, 393, 266, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
935, 4c0tA, 0.7770, 3.34, 0.186, 290, 263, CANDIDA ALBICANS PKH KINASE DOMAIN
936, 2vn9A, 0.7770, 3.03, 0.192, 301, 260, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
937, 2eu9A, 0.7770, 3.03, 0.175, 345, 257, CRYSTAL STRUCTURE OF CLK3
938, 2esmB, 0.7770, 3.27, 0.188, 398, 266, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
939, 5wngC, 0.7769, 3.02, 0.199, 387, 261, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
940, 3ow4A, 0.7769, 2.86, 0.214, 317, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
941, 1svgA, 0.7769, 2.86, 0.211, 338, 256, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
942, 1re8A, 0.7769, 2.83, 0.215, 337, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
943, 1i09A, 0.7769, 3.08, 0.196, 338, 260, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
944, 5t8oB, 0.7768, 3.27, 0.186, 328, 269, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
945, 5dmzA, 0.7768, 2.88, 0.178, 339, 258, STRUCTURE OF HUMAN BUB1 KINASE DOMAIN PHOSPHORYLATED AT SER969
946, 4qpmA, 0.7768, 2.91, 0.181, 329, 259, STRUCTURE OF BUB1 KINASE DOMAIN
947, 4eklA, 0.7768, 2.82, 0.218, 329, 257, AKT1 WITH GDC0068
948, 3oogA, 0.7768, 2.87, 0.211, 333, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
949, 6c0uA, 0.7767, 2.88, 0.211, 338, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
950, 3anqA, 0.7767, 2.47, 0.241, 342, 249, HUMAN DYRK1A/INHIBITOR COMPLEX
951, 1ydtE, 0.7767, 2.87, 0.211, 334, 256, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
952, 5bx6A, 0.7766, 2.88, 0.211, 343, 256, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
953, 5bmlB, 0.7766, 3.30, 0.188, 395, 266, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
954, 4tndA, 0.7766, 2.98, 0.207, 529, 261, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
955, 4c57A, 0.7766, 3.02, 0.179, 310, 263, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
956, 3zo4A, 0.7766, 2.88, 0.211, 335, 256, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
957, 3dneA, 0.7766, 2.86, 0.215, 336, 256, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
958, 2gu8A, 0.7766, 2.86, 0.211, 335, 256, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
959, 6fyrA, 0.7765, 3.03, 0.175, 355, 257, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
960, 5m0cA, 0.7765, 2.87, 0.211, 336, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
961, 5dmzB, 0.7765, 2.89, 0.178, 339, 258, STRUCTURE OF HUMAN BUB1 KINASE DOMAIN PHOSPHORYLATED AT SER969
962, 3pooA, 0.7765, 2.86, 0.211, 331, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
963, 3eidC, 0.7765, 2.75, 0.195, 290, 256, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
964, 3anrA, 0.7765, 2.52, 0.240, 342, 250, HUMAN DYRK1A/HARMINE COMPLEX
965, 2xh5A, 0.7765, 2.98, 0.213, 316, 258, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
966, 2f7zE, 0.7765, 2.91, 0.210, 336, 257, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
967, 1atpE, 0.7765, 2.83, 0.195, 334, 256, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
968, 4yuqB, 0.7764, 2.97, 0.230, 462, 257, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
969, 4w7pD, 0.7764, 3.25, 0.189, 387, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
970, 4uj1A, 0.7764, 2.89, 0.211, 335, 256, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
971, 3aglB, 0.7764, 2.86, 0.215, 335, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
972, 2gnlA, 0.7764, 2.87, 0.215, 338, 256, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
973, 1jluE, 0.7764, 2.86, 0.211, 337, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
974, 5uzkA, 0.7763, 2.89, 0.211, 335, 256, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
975, 4ujaA, 0.7763, 2.88, 0.211, 336, 256, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
976, 3h30A, 0.7763, 2.90, 0.171, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
977, 3f88B, 0.7763, 3.15, 0.196, 340, 260, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
978, 2vo3A, 0.7763, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
979, 2vnyA, 0.7763, 2.84, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
980, 2vnwA, 0.7763, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
981, 2cjmA, 0.7763, 2.57, 0.190, 285, 252, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
982, 1o6kA, 0.7763, 3.00, 0.201, 317, 259, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
983, 4jdjA, 0.7762, 3.08, 0.179, 288, 263, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
984, 4crsA, 0.7762, 2.87, 0.195, 331, 257, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
985, 3juhB, 0.7762, 2.98, 0.178, 334, 258, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
986, 3anqB, 0.7762, 2.56, 0.244, 343, 250, HUMAN DYRK1A/INHIBITOR COMPLEX
987, 2uw4A, 0.7762, 2.81, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
988, 2jdrA, 0.7762, 2.83, 0.218, 316, 257, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
989, 1o6lA, 0.7762, 3.01, 0.201, 316, 259, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
990, 1ctpE, 0.7762, 2.94, 0.203, 332, 256, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
991, 5wnhA, 0.7761, 3.22, 0.189, 394, 265, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
992, 5wnfC, 0.7761, 3.03, 0.199, 386, 261, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
993, 4iw0A, 0.7761, 3.38, 0.165, 647, 266, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
994, 3mftA, 0.7761, 3.15, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN MN2+
995, 3e8cF, 0.7761, 2.88, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
996, 3e8cD, 0.7761, 2.88, 0.211, 344, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
997, 3e8cB, 0.7761, 2.88, 0.211, 344, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
998, 3blqA, 0.7761, 2.54, 0.187, 295, 252, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
999, 2xckA, 0.7761, 2.65, 0.195, 275, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
1000, 1h25C, 0.7761, 2.63, 0.190, 278, 253, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1001, 4yvcB, 0.7760, 3.30, 0.192, 392, 266, ROCK 1 BOUND TO THIAZOLE INHIBITOR
1002, 4krcA, 0.7760, 2.69, 0.183, 297, 252, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
1003, 3zo2A, 0.7760, 2.85, 0.204, 340, 255, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
1004, 3e8cC, 0.7760, 2.88, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1005, 3e8cA, 0.7760, 2.89, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1006, 1xh6A, 0.7760, 2.85, 0.215, 331, 256, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1007, 1q8tA, 0.7760, 2.88, 0.211, 338, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
1008, 5k5nA, 0.7759, 2.91, 0.199, 331, 256, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
1009, 4yu2B, 0.7759, 2.59, 0.236, 347, 250, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1010, 4yljD, 0.7759, 2.59, 0.236, 347, 250, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1011, 4o22A, 0.7759, 2.85, 0.208, 336, 255, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
1012, 4ae6A, 0.7759, 2.96, 0.210, 319, 257, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
1013, 3o0gA, 0.7759, 2.48, 0.176, 289, 250, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1014, 3h30B, 0.7759, 2.90, 0.171, 333, 257, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1015, 3e8cE, 0.7759, 2.88, 0.211, 336, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1016, 1xh4A, 0.7759, 2.85, 0.208, 334, 255, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1017, 5bx7A, 0.7758, 2.88, 0.211, 343, 256, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
1018, 4yu2D, 0.7758, 2.58, 0.236, 346, 250, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1019, 4mq1B, 0.7758, 2.47, 0.237, 340, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1020, 3vqhA, 0.7758, 2.88, 0.211, 344, 256, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
1021, 3iopA, 0.7758, 2.58, 0.196, 275, 250, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
1022, 3bhhB, 0.7758, 2.96, 0.183, 289, 257, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1023, 2v7oA, 0.7758, 3.02, 0.185, 305, 259, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
1024, 2uw3A, 0.7758, 2.82, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
1025, 1q8uA, 0.7758, 2.88, 0.211, 341, 256, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
1026, 4uj9A, 0.7757, 2.86, 0.215, 339, 256, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
1027, 4otgA, 0.7757, 2.99, 0.197, 322, 259, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1028, 4mq1A, 0.7757, 2.50, 0.233, 345, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1029, 4bcqA, 0.7757, 2.58, 0.187, 292, 252, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1030, 3zo3A, 0.7757, 2.85, 0.208, 337, 255, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
1031, 3rwpA, 0.7757, 2.61, 0.200, 277, 250, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
1032, 3pscA, 0.7757, 2.97, 0.170, 614, 259, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1033, 3owpA, 0.7757, 2.88, 0.211, 334, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1034, 3ovvA, 0.7757, 2.88, 0.207, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1035, 3nuuA, 0.7757, 2.56, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
1036, 3h9oA, 0.7757, 2.54, 0.192, 275, 250, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
1037, 2qurA, 0.7757, 2.86, 0.211, 338, 256, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1038, 5lihB, 0.7756, 2.77, 0.168, 318, 256, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
1039, 4xw4A, 0.7756, 2.85, 0.208, 334, 255, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
1040, 4ks8A, 0.7756, 2.95, 0.192, 286, 260, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
1041, 3mfrA, 0.7756, 3.16, 0.204, 302, 260, CASK-4M CAM KINASE DOMAIN NATIVE
1042, 5vhbA, 0.7755, 2.79, 0.209, 325, 254, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
1043, 5icpA, 0.7755, 3.34, 0.147, 343, 266, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
1044, 5i5zA, 0.7755, 3.24, 0.152, 345, 264, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
1045, 3nczD, 0.7755, 3.16, 0.194, 397, 263, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1046, 3eb0A, 0.7755, 2.89, 0.231, 311, 255, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
1047, 3e8eI, 0.7755, 2.89, 0.211, 345, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1048, 5he1A, 0.7754, 3.04, 0.207, 618, 261, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1049, 5dylA, 0.7754, 2.81, 0.212, 802, 255, CRYSTAL STRUCTURE OF PVX_084705
1050, 4yu2C, 0.7754, 2.58, 0.236, 346, 250, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1051, 4hptE, 0.7754, 2.88, 0.211, 335, 256, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
1052, 4aw1A, 0.7754, 2.63, 0.190, 283, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
1053, 3nczA, 0.7754, 3.12, 0.198, 399, 262, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1054, 3anrB, 0.7754, 2.55, 0.240, 342, 250, HUMAN DYRK1A/HARMINE COMPLEX
1055, 1xh7A, 0.7754, 2.85, 0.204, 337, 255, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
1056, 5xvaA, 0.7753, 3.08, 0.186, 292, 263, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH216
1057, 5u7qD, 0.7753, 3.23, 0.190, 383, 263, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
1058, 4nttA, 0.7753, 2.88, 0.199, 339, 256, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1059, 3ambA, 0.7753, 2.89, 0.211, 340, 256, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
1060, 4yxrA, 0.7752, 2.86, 0.215, 334, 256, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
1061, 3orxE, 0.7752, 2.61, 0.204, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1062, 1apmE, 0.7752, 2.82, 0.195, 338, 256, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
1063, 4w7pA, 0.7751, 3.27, 0.189, 388, 264, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
1064, 3orzB, 0.7751, 2.66, 0.199, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1065, 3l9nA, 0.7751, 2.85, 0.204, 332, 255, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
1066, 3c0hB, 0.7751, 3.32, 0.179, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1067, 2uw0A, 0.7751, 2.86, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
1068, 5ho8A, 0.7750, 2.57, 0.201, 278, 249, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1069, 4yljB, 0.7750, 2.60, 0.236, 347, 250, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1070, 4rz7A, 0.7750, 2.87, 0.207, 801, 256, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
1071, 3x2uA, 0.7750, 2.85, 0.208, 336, 255, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
1072, 3orzD, 0.7750, 2.66, 0.199, 278, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1073, 3fy0A, 0.7750, 3.07, 0.218, 292, 261, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
1074, 3e8eP, 0.7750, 2.90, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1075, 3c4yA, 0.7750, 3.13, 0.195, 478, 262, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1076, 3ag9B, 0.7750, 2.90, 0.203, 317, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
1077, 5ax9C, 0.7749, 2.75, 0.197, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1078, 4r8qA, 0.7749, 2.94, 0.178, 332, 259, STRUCTURE AND SUBSTRATE RECRUITMENT OF THE HUMAN SPINDLE CHECKPOINT KINASE BUB1
1079, 2vx3A, 0.7749, 2.63, 0.236, 346, 250, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1080, 2uw6A, 0.7749, 2.85, 0.200, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1081, 2uvyA, 0.7749, 2.86, 0.200, 333, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
1082, 6c9dA, 0.7748, 3.04, 0.213, 425, 258, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1083, 4c57B, 0.7748, 3.08, 0.174, 308, 264, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
1084, 3c0iA, 0.7748, 3.08, 0.197, 298, 259, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
1085, 2f57B, 0.7748, 3.04, 0.188, 299, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1086, 1q62A, 0.7748, 2.88, 0.207, 336, 256, PKA DOUBLE MUTANT MODEL OF PKB
1087, 1q24A, 0.7748, 2.84, 0.195, 335, 256, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
1088, 4iq6A, 0.7747, 3.12, 0.193, 324, 259, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1089, 4dh5A, 0.7747, 2.84, 0.208, 333, 255, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
1090, 4c38A, 0.7747, 2.85, 0.200, 334, 255, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
1091, 5o5mA, 0.7746, 2.90, 0.208, 336, 255, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
1092, 5he0A, 0.7746, 3.03, 0.215, 621, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1093, 4yljC, 0.7746, 2.61, 0.236, 346, 250, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1094, 4mq2A, 0.7746, 2.62, 0.232, 343, 250, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1095, 4g6lA, 0.7746, 3.18, 0.145, 336, 262, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
1096, 3c0gA, 0.7746, 3.31, 0.183, 309, 263, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1097, 2h9vA, 0.7746, 3.25, 0.193, 383, 264, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
1098, 5m0lA, 0.7745, 2.88, 0.211, 338, 256, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
1099, 4yljA, 0.7745, 2.61, 0.236, 346, 250, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1100, 4pnkA, 0.7745, 3.06, 0.192, 625, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1101, 4njdA, 0.7745, 3.07, 0.186, 290, 263, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
1102, 4idvA, 0.7745, 3.28, 0.183, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1103, 3zo1A, 0.7745, 2.86, 0.208, 339, 255, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
1104, 3amaA, 0.7745, 2.88, 0.211, 342, 256, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
1105, 5l2qB, 0.7744, 2.69, 0.154, 282, 254, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
1106, 2vo6A, 0.7744, 2.86, 0.204, 335, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
1107, 1okzA, 0.7744, 2.58, 0.197, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
1108, 5uzjB, 0.7743, 3.23, 0.193, 386, 264, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
1109, 4wotA, 0.7743, 3.16, 0.198, 389, 262, ROCK2 IN COMPLEX WITH 1426382-07-1
1110, 3kkvA, 0.7743, 2.87, 0.208, 335, 255, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
1111, 3d5xA, 0.7743, 2.76, 0.200, 279, 255, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
1112, 5lvpD, 0.7742, 2.65, 0.196, 276, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
1113, 5l2qA, 0.7742, 2.72, 0.153, 293, 255, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
1114, 5izfA, 0.7742, 2.91, 0.211, 336, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
1115, 3nuyA, 0.7742, 2.59, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
1116, 2xuuA, 0.7742, 3.09, 0.188, 301, 260, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
1117, 4k18A, 0.7741, 2.81, 0.196, 277, 255, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
1118, 2uw8A, 0.7741, 2.88, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
1119, 1xjdA, 0.7741, 2.72, 0.206, 280, 252, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
1120, 5m0uA, 0.7740, 2.77, 0.202, 346, 252, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
1121, 3qklA, 0.7740, 3.07, 0.212, 317, 259, SPIROCHROMANE AKT INHIBITORS
1122, 3idbA, 0.7740, 2.89, 0.211, 341, 256, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1123, 2jdsA, 0.7740, 2.86, 0.208, 334, 255, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
1124, 5j5xA, 0.7739, 2.92, 0.211, 340, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
1125, 4g3dA, 0.7739, 3.29, 0.190, 324, 268, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
1126, 4c37A, 0.7739, 2.87, 0.200, 335, 255, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
1127, 3c0hA, 0.7739, 3.30, 0.179, 300, 263, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
1128, 1q97A, 0.7739, 2.68, 0.226, 351, 252, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
1129, 5t8qB, 0.7738, 3.33, 0.178, 328, 269, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
1130, 5a4qB, 0.7738, 2.54, 0.241, 335, 249, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1131, 4wotD, 0.7738, 3.22, 0.194, 389, 263, ROCK2 IN COMPLEX WITH 1426382-07-1
1132, 3x2wA, 0.7738, 2.84, 0.212, 336, 255, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1133, 6fd3A, 0.7737, 3.09, 0.218, 296, 262, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
1134, 5l2qD, 0.7737, 2.73, 0.157, 294, 255, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
1135, 4mq2B, 0.7737, 2.52, 0.233, 338, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1136, 3nusA, 0.7737, 2.60, 0.197, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
1137, 3fwqB, 0.7737, 2.98, 0.171, 334, 258, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1138, 2vx3D, 0.7737, 2.58, 0.237, 342, 249, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1139, 2uw5A, 0.7737, 2.85, 0.208, 333, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
1140, 4krdA, 0.7736, 2.62, 0.184, 294, 250, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
1141, 3ow4B, 0.7736, 2.90, 0.214, 317, 257, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1142, 3orxG, 0.7736, 2.60, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1143, 3e87B, 0.7736, 3.04, 0.201, 321, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1144, 3e87A, 0.7736, 3.04, 0.201, 321, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1145, 4c33A, 0.7735, 2.88, 0.200, 335, 255, PKA-S6K1 CHIMERA APO
1146, 3mvjE, 0.7735, 2.92, 0.211, 334, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1147, 3e8eE, 0.7735, 2.92, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1148, 2uvzA, 0.7735, 2.86, 0.204, 334, 255, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
1149, 2r7bA, 0.7735, 2.60, 0.197, 274, 249, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
1150, 1q8yA, 0.7735, 2.67, 0.226, 351, 252, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
1151, 6ft7B, 0.7734, 3.02, 0.179, 356, 257, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1152, 4ntsB, 0.7734, 2.97, 0.207, 341, 256, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1153, 4e7wA, 0.7734, 3.18, 0.174, 359, 259, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
1154, 3e8eB, 0.7734, 2.92, 0.211, 337, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1155, 6babA, 0.7733, 3.11, 0.188, 290, 261, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1156, 5fetA, 0.7733, 2.79, 0.209, 802, 254, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
1157, 4yzbA, 0.7733, 2.99, 0.238, 466, 256, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1158, 4qpmB, 0.7733, 2.91, 0.182, 328, 258, STRUCTURE OF BUB1 KINASE DOMAIN
1159, 4qo9A, 0.7733, 3.05, 0.203, 280, 261, MST3 IN COMPLEX WITH DANUSERTIB
1160, 3ionA, 0.7733, 2.61, 0.197, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
1161, 2cdzA, 0.7733, 3.01, 0.192, 289, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
1162, 5a4qA, 0.7732, 2.51, 0.245, 341, 249, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1163, 5a4eA, 0.7732, 2.50, 0.241, 341, 249, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1164, 4zy4A, 0.7732, 3.16, 0.202, 288, 262, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1165, 4xw5A, 0.7732, 2.87, 0.208, 334, 255, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
1166, 4idvC, 0.7732, 3.34, 0.178, 335, 269, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1167, 4ib3A, 0.7732, 2.86, 0.208, 336, 255, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
1168, 4dfzE, 0.7732, 2.88, 0.208, 347, 255, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
1169, 3e8eA, 0.7732, 2.92, 0.211, 341, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1170, 4idtB, 0.7731, 3.09, 0.202, 335, 263, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1171, 4iafA, 0.7731, 2.86, 0.208, 333, 255, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1172, 3qamE, 0.7731, 2.90, 0.211, 348, 256, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1173, 2x4zA, 0.7731, 3.03, 0.184, 290, 261, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
1174, 2eufB, 0.7731, 2.71, 0.187, 282, 252, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1175, 4mq1D, 0.7730, 2.53, 0.237, 336, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1176, 3fjqE, 0.7730, 2.85, 0.199, 334, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
1177, 3d0eB, 0.7730, 3.03, 0.201, 322, 259, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1178, 3a7gA, 0.7730, 3.04, 0.218, 289, 262, HUMAN MST3 KINASE
1179, 1cdkB, 0.7730, 2.85, 0.195, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1180, 6ccyA, 0.7729, 2.94, 0.218, 325, 257, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
1181, 5a54A, 0.7729, 2.50, 0.241, 341, 249, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1182, 5a4lB, 0.7729, 2.56, 0.241, 339, 249, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1183, 4j7bA, 0.7729, 2.71, 0.206, 284, 253, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1184, 3q9wA, 0.7729, 2.81, 0.175, 328, 252, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1185, 3d0eA, 0.7729, 3.03, 0.201, 322, 259, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
1186, 3anqC, 0.7729, 2.53, 0.241, 340, 249, HUMAN DYRK1A/INHIBITOR COMPLEX
1187, 5t8pB, 0.7728, 3.45, 0.192, 328, 271, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
1188, 5n3rA, 0.7728, 2.87, 0.212, 336, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
1189, 5kbqA, 0.7728, 3.08, 0.198, 289, 262, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
1190, 4dg2E, 0.7728, 2.89, 0.208, 347, 255, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
1191, 3x2vA, 0.7728, 2.84, 0.212, 331, 255, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1192, 3orzC, 0.7728, 2.65, 0.200, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1193, 3cikA, 0.7728, 3.05, 0.196, 619, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1194, 3c13A, 0.7728, 2.87, 0.178, 328, 253, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1195, 1uu3A, 0.7728, 2.62, 0.201, 276, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
1196, 5oniA, 0.7727, 3.16, 0.171, 334, 258, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1197, 5lvpC, 0.7727, 2.62, 0.196, 275, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
1198, 5lvpB, 0.7727, 2.55, 0.197, 276, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
1199, 5a4lA, 0.7727, 2.51, 0.245, 341, 249, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1200, 4mq2D, 0.7727, 2.59, 0.237, 329, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1201, 4j7bD, 0.7727, 2.66, 0.206, 281, 252, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
1202, 4c36A, 0.7727, 2.87, 0.200, 335, 255, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
1203, 3orxF, 0.7727, 2.61, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1204, 3bqcA, 0.7727, 2.88, 0.178, 328, 253, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1205, 1ym7C, 0.7727, 3.09, 0.173, 607, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1206, 1w98A, 0.7727, 2.69, 0.194, 297, 252, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
1207, 5cspA, 0.7726, 2.76, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1208, 5a54B, 0.7726, 2.55, 0.245, 339, 249, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1209, 3qcxA, 0.7726, 2.54, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
1210, 3orxH, 0.7726, 2.61, 0.205, 274, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
1211, 2bcjA, 0.7726, 3.01, 0.170, 624, 259, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1212, 1rdqE, 0.7726, 2.91, 0.207, 340, 256, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
1213, 4idtA, 0.7725, 3.09, 0.190, 334, 263, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
1214, 3ow3A, 0.7725, 2.92, 0.211, 334, 256, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1215, 3mvjA, 0.7725, 2.88, 0.195, 334, 256, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1216, 3e8eL, 0.7725, 2.92, 0.211, 336, 256, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1217, 2cpkE, 0.7725, 2.87, 0.208, 333, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
1218, 1omwA, 0.7725, 3.00, 0.178, 614, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1219, 5bnjA, 0.7724, 3.18, 0.153, 343, 262, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
1220, 5a4tB, 0.7724, 2.54, 0.245, 339, 249, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1221, 4xw6A, 0.7724, 2.86, 0.208, 334, 255, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
1222, 4appA, 0.7724, 3.03, 0.183, 291, 262, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
1223, 3orzA, 0.7724, 2.66, 0.200, 276, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
1224, 3c0gB, 0.7724, 3.31, 0.176, 320, 262, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
1225, 2wo6A, 0.7724, 2.59, 0.232, 344, 250, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
1226, 2pe0A, 0.7724, 2.62, 0.201, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
1227, 1uu8A, 0.7724, 2.62, 0.197, 277, 249, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
1228, 1j3hB, 0.7724, 2.91, 0.208, 327, 255, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1229, 5n1fA, 0.7723, 2.90, 0.208, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
1230, 5n1hA, 0.7722, 2.87, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
1231, 5csvA, 0.7722, 2.78, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
1232, 4o21A, 0.7722, 2.88, 0.208, 333, 255, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
1233, 5acbD, 0.7721, 2.98, 0.225, 319, 258, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1234, 3qalE, 0.7721, 2.89, 0.195, 339, 256, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
1235, 3e88B, 0.7721, 3.04, 0.201, 319, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1236, 3e88A, 0.7721, 3.04, 0.201, 319, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1237, 2vx3B, 0.7721, 2.59, 0.237, 340, 249, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1238, 2pe2A, 0.7721, 2.55, 0.193, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
1239, 6ft7A, 0.7720, 3.02, 0.179, 356, 257, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
1240, 5n3pA, 0.7720, 2.87, 0.212, 336, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
1241, 4ib5A, 0.7720, 3.07, 0.178, 331, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1242, 4iayA, 0.7720, 2.89, 0.208, 333, 255, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1243, 4iacA, 0.7720, 2.88, 0.208, 333, 255, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
1244, 4dh8A, 0.7720, 2.82, 0.188, 333, 255, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
1245, 3qkkA, 0.7720, 2.91, 0.214, 326, 257, SPIROCHROMANE AKT INHIBITORS
1246, 3qcsA, 0.7720, 2.55, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
1247, 3nunA, 0.7720, 2.56, 0.193, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
1248, 5n3qA, 0.7719, 2.87, 0.212, 336, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
1249, 5n3gA, 0.7719, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
1250, 5n1gA, 0.7719, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
1251, 5a3xB, 0.7719, 2.55, 0.241, 340, 249, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1252, 4x6rA, 0.7719, 2.87, 0.208, 347, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1253, 4wbbB, 0.7719, 2.91, 0.208, 334, 255, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
1254, 4idvB, 0.7719, 3.35, 0.182, 335, 269, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1255, 4iakA, 0.7719, 2.88, 0.208, 334, 255, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1256, 5ukmA, 0.7718, 3.08, 0.204, 621, 260, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1257, 5n3nA, 0.7718, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
1258, 5n23A, 0.7718, 2.89, 0.208, 333, 255, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
1259, 5h9bA, 0.7718, 2.92, 0.201, 269, 254, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
1260, 3qcyA, 0.7718, 2.57, 0.202, 275, 248, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
1261, 3mb6A, 0.7718, 2.89, 0.182, 329, 253, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1262, 3anrC, 0.7718, 2.52, 0.241, 337, 249, HUMAN DYRK1A/HARMINE COMPLEX
1263, 1z5mA, 0.7718, 2.63, 0.197, 275, 249, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
1264, 6g4zB, 0.7717, 3.38, 0.183, 325, 268, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
1265, 5aikB, 0.7717, 2.62, 0.240, 342, 250, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1266, 5a4tA, 0.7717, 2.53, 0.241, 341, 249, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1267, 4iazA, 0.7717, 2.89, 0.208, 334, 255, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1268, 3qcqA, 0.7717, 2.55, 0.193, 276, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
1269, 2wo6B, 0.7717, 2.61, 0.237, 339, 249, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
1270, 2pe1A, 0.7717, 2.57, 0.193, 275, 249, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
1271, 5xvgA, 0.7716, 3.13, 0.186, 292, 263, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH226
1272, 5n3tA, 0.7716, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
1273, 5jr7C, 0.7716, 2.88, 0.208, 335, 255, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
1274, 4mq2C, 0.7716, 2.60, 0.237, 339, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1275, 5myvB, 0.7715, 2.85, 0.204, 349, 255, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1276, 4zk5A, 0.7715, 3.04, 0.198, 286, 258, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
1277, 4obpA, 0.7715, 3.06, 0.198, 285, 258, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
1278, 4nctA, 0.7715, 2.56, 0.241, 341, 249, HUMAN DYRK1A IN COMPLEX WITH PKC412
1279, 4md7E, 0.7715, 3.01, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1280, 3qd3A, 0.7715, 2.57, 0.193, 278, 249, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
1281, 3pvbA, 0.7715, 2.87, 0.208, 341, 255, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1282, 1xqzA, 0.7715, 2.85, 0.196, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
1283, 6fyvA, 0.7714, 2.92, 0.201, 329, 254, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1284, 1ym7D, 0.7714, 3.06, 0.177, 599, 260, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1285, 5n3jA, 0.7713, 2.89, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
1286, 4wb5A, 0.7713, 2.89, 0.208, 335, 255, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1287, 4mk0A, 0.7713, 3.12, 0.196, 631, 260, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
1288, 4md7G, 0.7713, 3.02, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1289, 4ae9A, 0.7713, 2.90, 0.208, 321, 255, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
1290, 3eb0C, 0.7713, 2.82, 0.221, 310, 253, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
1291, 2x7fB, 0.7713, 2.81, 0.192, 288, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1292, 5ooiA, 0.7712, 2.95, 0.176, 329, 255, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1293, 5n3kA, 0.7712, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
1294, 4b4lA, 0.7712, 3.16, 0.188, 299, 261, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
1295, 3fhiA, 0.7712, 2.92, 0.211, 336, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
1296, 2wtkE, 0.7712, 3.16, 0.152, 308, 264, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1297, 1zltA, 0.7712, 2.98, 0.215, 272, 256, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
1298, 5mxxA, 0.7711, 3.07, 0.190, 361, 258, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1299, 4mq1C, 0.7711, 2.55, 0.237, 328, 249, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1300, 3owlA, 0.7711, 2.89, 0.185, 330, 254, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1301, 5n3lA, 0.7710, 2.88, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
1302, 5jr7A, 0.7710, 2.90, 0.208, 335, 255, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
1303, 4md8E, 0.7710, 3.01, 0.172, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1304, 3bhhA, 0.7710, 3.07, 0.183, 289, 257, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
1305, 2vx3C, 0.7710, 2.63, 0.237, 338, 249, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1306, 4e4mB, 0.7709, 3.24, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1307, 3e8dB, 0.7709, 3.06, 0.201, 317, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1308, 3e8dA, 0.7709, 3.06, 0.201, 315, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
1309, 1ym7A, 0.7709, 3.09, 0.192, 608, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1310, 6c2yA, 0.7708, 3.01, 0.212, 617, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
1311, 5n3oA, 0.7708, 2.91, 0.208, 335, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
1312, 5n3hA, 0.7708, 2.89, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
1313, 4ysmB, 0.7708, 3.16, 0.236, 475, 259, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1314, 4md7F, 0.7708, 3.01, 0.176, 332, 255, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1315, 4e4mD, 0.7708, 3.23, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1316, 4dh1A, 0.7708, 2.89, 0.208, 333, 255, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
1317, 3soaA, 0.7708, 3.00, 0.186, 436, 258, FULL-LENGTH HUMAN CAMKII
1318, 1ym7B, 0.7708, 3.09, 0.192, 608, 261, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1319, 1gngB, 0.7708, 3.34, 0.201, 355, 264, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
1320, 5n3iA, 0.7707, 2.90, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
1321, 5aikA, 0.7707, 2.62, 0.240, 344, 250, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1322, 4rllA, 0.7706, 2.92, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1323, 4nctD, 0.7706, 2.60, 0.241, 331, 249, HUMAN DYRK1A IN COMPLEX WITH PKC412
1324, 4md8G, 0.7706, 3.01, 0.172, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1325, 4ib1A, 0.7706, 2.89, 0.208, 335, 255, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1326, 1gngA, 0.7706, 3.21, 0.200, 348, 260, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
1327, 5n3sA, 0.7705, 2.89, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
1328, 5motA, 0.7705, 2.81, 0.179, 328, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
1329, 5hbhA, 0.7705, 3.03, 0.151, 336, 259, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
1330, 5d7aC, 0.7705, 2.86, 0.188, 286, 255, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1331, 4jqeA, 0.7705, 2.94, 0.153, 369, 255, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1332, 4giiA, 0.7705, 3.17, 0.213, 289, 263, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
1333, 4dh3A, 0.7705, 2.90, 0.208, 333, 255, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
1334, 5omyA, 0.7704, 3.01, 0.172, 332, 256, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1335, 5myvC, 0.7704, 2.86, 0.204, 348, 255, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1336, 5e8uA, 0.7704, 3.23, 0.198, 306, 262, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
1337, 5aikC, 0.7704, 2.65, 0.240, 342, 250, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1338, 5a3xA, 0.7704, 2.61, 0.244, 342, 250, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1339, 3c4yB, 0.7704, 2.89, 0.184, 466, 255, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1340, 5mohA, 0.7703, 2.72, 0.179, 326, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
1341, 4gmyA, 0.7703, 3.26, 0.193, 298, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
1342, 4g3cB, 0.7703, 3.51, 0.181, 327, 271, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
1343, 3tnpF, 0.7703, 2.90, 0.208, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1344, 3tnpC, 0.7703, 2.90, 0.208, 334, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1345, 3q9yA, 0.7703, 2.84, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
1346, 6fykB, 0.7702, 3.04, 0.180, 349, 255, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1347, 5n3mA, 0.7702, 2.89, 0.212, 337, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
1348, 4ysmA, 0.7702, 3.19, 0.236, 475, 259, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1349, 3qc4A, 0.7702, 2.78, 0.194, 276, 252, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
1350, 3ofmA, 0.7702, 2.98, 0.180, 325, 255, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
1351, 3anqD, 0.7702, 2.57, 0.241, 334, 249, HUMAN DYRK1A/INHIBITOR COMPLEX
1352, 1cdkA, 0.7702, 2.87, 0.195, 342, 256, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
1353, 5d7aA, 0.7701, 2.91, 0.184, 289, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1354, 3a7hA, 0.7701, 3.07, 0.218, 289, 262, HUMAN MST3 KINASE IN COMPLEX WITH ATP
1355, 2pvrA, 0.7701, 2.84, 0.178, 328, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
1356, 2ckeD, 0.7701, 3.20, 0.188, 300, 261, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1357, 1na7A, 0.7701, 2.86, 0.178, 326, 253, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
1358, 5x8iB, 0.7700, 2.93, 0.197, 327, 254, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1359, 4dfxE, 0.7700, 2.91, 0.208, 347, 255, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
1360, 3j4rE, 0.7700, 3.09, 0.206, 325, 257, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
1361, 3j4rD, 0.7700, 3.09, 0.206, 325, 257, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
1362, 3j4qE, 0.7700, 3.09, 0.206, 325, 257, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
1363, 3j4qD, 0.7700, 3.09, 0.206, 325, 257, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
1364, 2a2aD, 0.7700, 3.16, 0.192, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1365, 5ugbA, 0.7699, 3.36, 0.177, 307, 265, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
1366, 4gihA, 0.7699, 3.12, 0.215, 288, 261, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
1367, 4e4mA, 0.7699, 3.29, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1368, 4azeB, 0.7699, 2.61, 0.233, 345, 249, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1369, 3q9xB, 0.7699, 2.93, 0.173, 330, 254, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1370, 3q6wA, 0.7699, 3.15, 0.173, 297, 260, STRUCTURE OF DUALLY-PHOSPHORYLATED MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG WITH SPECIFICITY FOR THE ACTIVATED RECEPTOR
1371, 3begA, 0.7699, 2.92, 0.149, 348, 255, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1372, 2wtkB, 0.7699, 3.12, 0.133, 311, 263, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
1373, 2j0iA, 0.7699, 3.15, 0.186, 289, 263, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
1374, 5t8pA, 0.7698, 3.37, 0.179, 327, 268, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO BENZOXEPIN COMPOUND 2
1375, 5ax9A, 0.7698, 2.79, 0.197, 282, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1376, 4wb7A, 0.7698, 2.85, 0.196, 402, 255, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1377, 4g3eB, 0.7698, 3.32, 0.180, 325, 267, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
1378, 4e4mE, 0.7698, 3.29, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
1379, 3v5wA, 0.7698, 3.10, 0.200, 623, 260, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
1380, 1l3rE, 0.7698, 2.88, 0.212, 338, 255, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1381, 5a3xD, 0.7697, 2.59, 0.241, 331, 249, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1382, 4tl0A, 0.7697, 3.16, 0.180, 300, 261, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
1383, 4idvD, 0.7697, 3.35, 0.179, 335, 268, CRYSTAL STRUCTURE OF NIK WITH COMPOUND 4-{3-[2-AMINO-5-(2- METHOXYETHOXY)PYRIMIDIN-4-YL]-1H-INDOL-5-YL}-2-METHYLBUT-3-YN-2-OL (13V)
1384, 4ib0A, 0.7697, 2.90, 0.208, 334, 255, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1385, 4dh7A, 0.7697, 2.91, 0.208, 333, 255, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
1386, 4dg0E, 0.7697, 2.91, 0.208, 338, 255, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
1387, 4azeA, 0.7697, 2.61, 0.233, 348, 249, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1388, 5x8iA, 0.7696, 2.93, 0.197, 328, 254, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1389, 4azeC, 0.7696, 2.61, 0.233, 348, 249, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1390, 4x6qC, 0.7695, 2.90, 0.208, 334, 255, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
1391, 4md8H, 0.7695, 3.03, 0.172, 331, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1392, 3q9zB, 0.7695, 3.16, 0.174, 332, 259, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1393, 6fypA, 0.7694, 3.06, 0.179, 348, 257, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
1394, 5oulA, 0.7694, 2.86, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
1395, 5ooiB, 0.7694, 2.93, 0.177, 325, 254, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1396, 5lvpA, 0.7694, 2.74, 0.195, 275, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
1397, 5aikD, 0.7694, 2.60, 0.241, 342, 249, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
1398, 4md8F, 0.7694, 3.05, 0.176, 332, 256, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1399, 4md7H, 0.7694, 3.19, 0.178, 330, 259, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1400, 3rpsA, 0.7694, 3.14, 0.171, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1401, 5os8A, 0.7693, 2.86, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
1402, 5m4cA, 0.7693, 2.98, 0.173, 329, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1403, 5a4eD, 0.7693, 2.58, 0.241, 331, 249, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1404, 4wb8A, 0.7693, 2.91, 0.208, 334, 255, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
1405, 4tksA, 0.7693, 3.35, 0.177, 307, 265, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
1406, 3twjC, 0.7693, 3.35, 0.192, 396, 265, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
1407, 3qkmA, 0.7693, 2.93, 0.214, 329, 257, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1408, 2qcsA, 0.7693, 2.91, 0.208, 335, 255, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
1409, 5n7pA, 0.7692, 2.96, 0.207, 350, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
1410, 5e8xA, 0.7692, 3.21, 0.207, 304, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
1411, 3tnqB, 0.7692, 2.94, 0.208, 331, 255, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
1412, 3owjA, 0.7692, 2.97, 0.177, 328, 254, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
1413, 2vz6A, 0.7692, 3.15, 0.188, 291, 260, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1414, 2ckeC, 0.7692, 3.17, 0.188, 300, 260, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1415, 1uu9A, 0.7692, 2.63, 0.198, 276, 248, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
1416, 5h8bA, 0.7691, 3.00, 0.176, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1417, 5cvfA, 0.7691, 2.87, 0.178, 325, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1418, 4jiaA, 0.7691, 3.27, 0.193, 298, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
1419, 3o7lB, 0.7691, 2.86, 0.194, 326, 253, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1420, 2a2aC, 0.7691, 3.17, 0.188, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1421, 5uq1C, 0.7690, 2.66, 0.187, 289, 251, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
1422, 5otzA, 0.7690, 2.85, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
1423, 4iaiA, 0.7690, 2.91, 0.208, 333, 255, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1424, 2w4kA, 0.7690, 3.15, 0.188, 301, 260, X-RAY STRUCTURE OF A DAP-KINASE 2-302
1425, 1pjkA, 0.7690, 2.87, 0.178, 331, 253, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1426, 1j91B, 0.7690, 3.04, 0.169, 327, 255, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1427, 5hkmA, 0.7689, 2.62, 0.198, 272, 248, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
1428, 5a4tD, 0.7689, 2.60, 0.241, 332, 249, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1429, 5a4qD, 0.7689, 2.59, 0.241, 334, 249, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1430, 4wihA, 0.7689, 2.90, 0.195, 350, 256, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
1431, 4iadA, 0.7689, 2.91, 0.208, 334, 255, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
1432, 4wb7B, 0.7688, 2.89, 0.212, 402, 255, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1433, 4nctB, 0.7688, 2.56, 0.242, 333, 248, HUMAN DYRK1A IN COMPLEX WITH PKC412
1434, 4iwdA, 0.7688, 3.18, 0.169, 299, 261, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
1435, 4gl9B, 0.7688, 3.06, 0.205, 280, 259, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1436, 5he3A, 0.7687, 3.11, 0.211, 623, 261, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
1437, 4ythA, 0.7687, 3.18, 0.206, 287, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
1438, 4gj2A, 0.7687, 3.13, 0.215, 288, 261, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1439, 3nczC, 0.7687, 3.31, 0.194, 389, 263, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
1440, 3lxpA, 0.7687, 3.15, 0.225, 285, 262, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
1441, 5n7uA, 0.7686, 2.95, 0.191, 350, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
1442, 5n1vA, 0.7686, 2.98, 0.176, 331, 255, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1443, 4nh1B, 0.7686, 3.03, 0.176, 332, 255, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1444, 3oxtA, 0.7686, 2.93, 0.195, 335, 256, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
1445, 3idcA, 0.7686, 2.89, 0.199, 341, 256, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
1446, 1ds5B, 0.7686, 3.05, 0.169, 328, 255, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1447, 4wb6B, 0.7685, 2.93, 0.191, 340, 256, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1448, 3pe1A, 0.7685, 2.86, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1449, 3anrD, 0.7685, 2.58, 0.245, 340, 249, HUMAN DYRK1A/HARMINE COMPLEX
1450, 5otrA, 0.7684, 2.87, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1451, 5n1eA, 0.7684, 2.97, 0.207, 347, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
1452, 4nh1A, 0.7684, 3.03, 0.176, 330, 255, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1453, 3ndmA, 0.7684, 3.03, 0.205, 383, 258, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
1454, 2oxyA, 0.7684, 3.02, 0.169, 327, 255, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1455, 4md9P, 0.7683, 2.93, 0.173, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1456, 3q04A, 0.7683, 2.91, 0.173, 328, 254, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1457, 3pe2A, 0.7683, 2.88, 0.178, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1458, 3ngaB, 0.7683, 3.01, 0.176, 331, 255, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1459, 2ckeA, 0.7683, 3.21, 0.192, 301, 261, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1460, 5uklA, 0.7681, 3.13, 0.200, 630, 260, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
1461, 5cf5A, 0.7681, 3.23, 0.202, 287, 263, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1462, 4x2gA, 0.7681, 3.31, 0.210, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1463, 4hpuE, 0.7681, 2.93, 0.208, 336, 255, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
1464, 2ckeB, 0.7681, 3.30, 0.191, 300, 262, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
1465, 5a4qC, 0.7680, 2.59, 0.245, 332, 249, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1466, 2x7fC, 0.7680, 2.74, 0.186, 285, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
1467, 5n37A, 0.7679, 2.94, 0.204, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
1468, 5jebA, 0.7679, 3.38, 0.173, 299, 266, CRYSTAL STRUCTURE OF EGFR TYROSINE KINASE DOMAIN WITH NOVEL INHIBITOR OF ACTIVE STATE OF HER2
1469, 5h8eA, 0.7679, 3.02, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1470, 3tniA, 0.7679, 2.53, 0.189, 297, 249, STRUCTURE OF CDK9/CYCLIN T F241L
1471, 2oxyB, 0.7679, 3.02, 0.169, 327, 255, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1472, 2bilB, 0.7679, 2.81, 0.198, 274, 253, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
1473, 5n1vB, 0.7678, 3.00, 0.173, 331, 255, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1474, 5a4eB, 0.7678, 2.57, 0.242, 322, 248, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1475, 4x2fA, 0.7678, 3.31, 0.206, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1476, 4dg3E, 0.7678, 2.94, 0.208, 335, 255, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
1477, 3fwqA, 0.7678, 3.14, 0.178, 334, 258, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1478, 2qvsE, 0.7678, 3.08, 0.207, 323, 256, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
1479, 5t8oA, 0.7677, 3.25, 0.189, 324, 265, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
1480, 5e8wA, 0.7676, 3.23, 0.211, 303, 261, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
1481, 5d7aB, 0.7676, 2.93, 0.184, 286, 256, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
1482, 3qa0B, 0.7676, 2.95, 0.173, 330, 254, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1483, 5oorA, 0.7675, 2.90, 0.209, 273, 254, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
1484, 4x2nA, 0.7675, 3.19, 0.208, 303, 260, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1485, 4gl9D, 0.7675, 3.09, 0.205, 282, 259, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1486, 4dinA, 0.7675, 2.96, 0.211, 340, 256, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
1487, 3r0tA, 0.7675, 2.89, 0.174, 327, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1488, 3nszA, 0.7675, 2.78, 0.179, 327, 252, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
1489, 3bwjA, 0.7675, 2.96, 0.208, 338, 255, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
1490, 2yabA, 0.7675, 3.14, 0.196, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1491, 2yaaA, 0.7675, 3.23, 0.195, 300, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1492, 5a3xC, 0.7674, 2.65, 0.244, 333, 250, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
1493, 4md9L, 0.7674, 2.97, 0.177, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1494, 4ll5A, 0.7674, 2.75, 0.198, 268, 252, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
1495, 4gj3A, 0.7674, 3.18, 0.214, 288, 262, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
1496, 3wikA, 0.7674, 3.00, 0.173, 334, 254, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1497, 2a2aA, 0.7674, 3.19, 0.188, 304, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1498, 5oniB, 0.7673, 3.24, 0.172, 334, 261, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1499, 5ctpB, 0.7673, 2.79, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1500, 5cf5B, 0.7673, 3.34, 0.196, 294, 265, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1501, 4x2kA, 0.7673, 3.32, 0.210, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1502, 4x2jA, 0.7673, 3.32, 0.210, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1503, 4rerA, 0.7673, 2.64, 0.209, 458, 249, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
1504, 3r7oA, 0.7673, 3.19, 0.173, 299, 260, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
1505, 2oi4X, 0.7673, 2.78, 0.194, 275, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
1506, 2gs6A, 0.7673, 3.35, 0.174, 311, 265, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
1507, 5ot5A, 0.7672, 2.78, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1508, 5n1kA, 0.7672, 2.96, 0.208, 341, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
1509, 5idnA, 0.7672, 3.01, 0.156, 336, 257, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
1510, 5cu4A, 0.7672, 2.87, 0.178, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1511, 5ct0A, 0.7672, 2.80, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1512, 5a54C, 0.7672, 2.59, 0.245, 332, 249, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1513, 4md9M, 0.7672, 3.07, 0.176, 331, 256, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1514, 4hyiA, 0.7672, 2.95, 0.216, 269, 255, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
1515, 2ydiA, 0.7672, 3.06, 0.211, 279, 256, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
1516, 2bujA, 0.7672, 2.70, 0.183, 291, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
1517, 1z9xB, 0.7672, 3.23, 0.192, 303, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
1518, 1fotA, 0.7672, 2.97, 0.185, 299, 254, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
1519, 5owhA, 0.7671, 3.15, 0.171, 334, 257, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1520, 5mmfA, 0.7671, 2.79, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1521, 5cx9A, 0.7671, 2.79, 0.179, 328, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1522, 5cquA, 0.7671, 2.88, 0.182, 328, 253, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1523, 5a4lD, 0.7671, 2.61, 0.245, 334, 249, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1524, 4fbxA, 0.7671, 3.17, 0.171, 333, 257, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1525, 5otyA, 0.7670, 2.88, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1526, 5oslA, 0.7670, 2.88, 0.182, 328, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
1527, 5cu6A, 0.7670, 2.88, 0.178, 327, 253, CRYSTAL STRUCTURE OF CK2ALPHA
1528, 5unpB, 0.7669, 2.93, 0.182, 347, 253, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1529, 5unpA, 0.7669, 2.93, 0.182, 347, 253, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1530, 5t1hA, 0.7669, 3.03, 0.176, 331, 255, CRYSTAL STRUCTURE OF CK2
1531, 5ax9B, 0.7669, 2.63, 0.200, 274, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
1532, 4uv0A, 0.7669, 3.08, 0.188, 300, 260, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
1533, 4qteA, 0.7669, 2.67, 0.216, 348, 250, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
1534, 4aqcA, 0.7669, 3.34, 0.201, 289, 264, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
1535, 2j2iB, 0.7669, 2.75, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
1536, 1z9xA, 0.7669, 3.21, 0.184, 303, 261, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
1537, 1m17A, 0.7669, 3.36, 0.174, 312, 264, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
1538, 6fyoA, 0.7668, 2.96, 0.189, 331, 254, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1539, 5xgnA, 0.7668, 3.25, 0.192, 302, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
1540, 5n9kA, 0.7668, 2.97, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1541, 5mmrA, 0.7668, 2.81, 0.179, 326, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1542, 5kwhA, 0.7668, 3.03, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2
1543, 5ig1A, 0.7668, 3.16, 0.201, 300, 259, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
1544, 4jx3A, 0.7668, 2.88, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE
1545, 3qa0A, 0.7668, 3.01, 0.176, 330, 255, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1546, 3lltA, 0.7668, 2.70, 0.240, 341, 250, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1547, 2yabB, 0.7668, 3.22, 0.195, 299, 261, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
1548, 2a2aB, 0.7668, 3.21, 0.188, 303, 260, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
1549, 1lr4A, 0.7668, 3.06, 0.169, 327, 255, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1550, 5xdkA, 0.7667, 3.47, 0.185, 307, 265, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
1551, 5cu0A, 0.7667, 2.82, 0.179, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1552, 4wb6A, 0.7667, 2.92, 0.188, 336, 255, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
1553, 4nctC, 0.7667, 2.58, 0.238, 339, 248, HUMAN DYRK1A IN COMPLEX WITH PKC412
1554, 3qd4A, 0.7667, 2.62, 0.198, 276, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
1555, 3f3zA, 0.7667, 2.93, 0.211, 271, 256, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
1556, 1ia8A, 0.7667, 3.06, 0.219, 272, 256, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
1557, 5lxdB, 0.7666, 2.93, 0.219, 385, 251, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
1558, 5kgkA, 0.7666, 2.76, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
1559, 5clpB, 0.7666, 2.78, 0.175, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1560, 5a54D, 0.7666, 2.61, 0.245, 334, 249, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1561, 4md9G, 0.7666, 2.98, 0.181, 329, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1562, 2w1iB, 0.7666, 3.23, 0.198, 284, 263, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1563, 1xwsA, 0.7666, 2.75, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
1564, 5lxdA, 0.7665, 2.93, 0.219, 385, 251, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
1565, 2yaaB, 0.7665, 3.20, 0.192, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
1566, 2y0aA, 0.7665, 3.19, 0.188, 300, 260, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
1567, 2x2kA, 0.7665, 3.05, 0.167, 289, 257, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
1568, 4cxaC, 0.7664, 3.03, 0.223, 330, 256, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
1569, 2bzhB, 0.7664, 2.87, 0.197, 275, 254, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
1570, 6ehkA, 0.7663, 2.89, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
1571, 5n32A, 0.7663, 2.95, 0.196, 345, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
1572, 5cqwA, 0.7663, 3.01, 0.176, 331, 255, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1573, 4md9E, 0.7663, 2.98, 0.177, 329, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1574, 3rvgA, 0.7663, 3.06, 0.205, 285, 259, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
1575, 2w1iA, 0.7663, 3.23, 0.198, 284, 263, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
1576, 1j91A, 0.7663, 3.01, 0.169, 327, 254, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1577, 5v61A, 0.7662, 2.74, 0.220, 348, 250, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
1578, 5l3aA, 0.7662, 3.31, 0.197, 290, 264, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
1579, 4ivaA, 0.7662, 3.29, 0.193, 290, 264, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
1580, 4ib5C, 0.7662, 3.30, 0.181, 332, 260, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1581, 4f7nA, 0.7662, 3.04, 0.152, 334, 256, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
1582, 6b8yA, 0.7661, 3.33, 0.206, 304, 262, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
1583, 5u6iA, 0.7661, 2.73, 0.216, 339, 250, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
1584, 5otlB, 0.7661, 2.80, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1585, 5mhiA, 0.7661, 2.98, 0.191, 348, 256, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
1586, 5fg8A, 0.7661, 3.09, 0.195, 269, 256, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
1587, 4md9K, 0.7661, 2.93, 0.177, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1588, 4ditA, 0.7661, 3.17, 0.195, 328, 257, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1589, 4as0A, 0.7661, 2.79, 0.194, 273, 252, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
1590, 3zuvC, 0.7661, 2.71, 0.220, 357, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1591, 1ds5C, 0.7661, 3.20, 0.162, 328, 259, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1592, 6fykA, 0.7660, 3.01, 0.185, 349, 254, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1593, 5x3fB, 0.7660, 2.89, 0.186, 348, 253, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
1594, 4g3dB, 0.7660, 3.28, 0.192, 318, 265, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
1595, 3tacA, 0.7660, 3.27, 0.192, 324, 261, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
1596, 3f2aA, 0.7660, 2.97, 0.184, 276, 255, CRYSTAL STRUCTURE OF HUMAN PIM-1 IN COMPLEX WITH DAPPA
1597, 3c4eA, 0.7660, 2.75, 0.194, 273, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1598, 5mp8A, 0.7659, 2.73, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1599, 5movA, 0.7659, 2.79, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1600, 4fv7A, 0.7659, 2.66, 0.217, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
1601, 2x8dA, 0.7659, 3.07, 0.211, 279, 256, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
1602, 2wu6A, 0.7659, 3.11, 0.179, 350, 257, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1603, 2gdoA, 0.7659, 2.99, 0.208, 269, 255, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
1604, 1yxsA, 0.7659, 2.90, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
1605, 1lp4A, 0.7659, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1606, 1j3hA, 0.7659, 2.98, 0.197, 329, 254, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1607, 1dawA, 0.7659, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1608, 6g4zA, 0.7658, 3.24, 0.190, 322, 263, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
1609, 5oquA, 0.7658, 2.78, 0.183, 324, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1610, 5n3aA, 0.7658, 2.96, 0.204, 349, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
1611, 5m56A, 0.7658, 2.98, 0.177, 331, 254, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1612, 5m4fA, 0.7658, 3.11, 0.176, 330, 255, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1613, 3c4eB, 0.7658, 2.75, 0.194, 273, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1614, 2x7gA, 0.7658, 2.91, 0.165, 344, 254, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1615, 1fq1B, 0.7658, 2.92, 0.191, 295, 256, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1616, 5wg4A, 0.7657, 3.11, 0.201, 621, 259, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
1617, 5n3cA, 0.7657, 2.97, 0.204, 348, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
1618, 5n3bA, 0.7657, 2.97, 0.204, 342, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
1619, 4ntsA, 0.7657, 2.98, 0.185, 341, 254, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1620, 2bikB, 0.7657, 2.77, 0.187, 272, 252, HUMAN PIM1 PHOSPHORYLATED ON SER261
1621, 1xo2B, 0.7657, 2.69, 0.187, 289, 251, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1622, 5oueA, 0.7656, 2.81, 0.179, 328, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1623, 4u6rA, 0.7656, 3.15, 0.169, 403, 260, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
1624, 5w5qA, 0.7655, 3.05, 0.194, 291, 258, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
1625, 5n1lA, 0.7655, 2.96, 0.204, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
1626, 5mo8A, 0.7655, 2.82, 0.179, 325, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1627, 4ysjB, 0.7655, 3.06, 0.227, 462, 256, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
1628, 4md9H, 0.7655, 2.96, 0.181, 328, 254, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1629, 4f6wA, 0.7655, 2.94, 0.153, 330, 255, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
1630, 3qd0A, 0.7655, 2.55, 0.194, 274, 247, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
1631, 3q32A, 0.7655, 3.25, 0.202, 291, 263, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
1632, 3ngaA, 0.7655, 3.21, 0.181, 331, 259, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1633, 3axwA, 0.7655, 3.01, 0.177, 329, 254, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1634, 1jwhA, 0.7655, 2.93, 0.174, 336, 253, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1635, 6fykC, 0.7654, 3.04, 0.181, 349, 254, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1636, 5orkA, 0.7654, 2.75, 0.179, 324, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1637, 5nhvA, 0.7654, 2.69, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1638, 5n3eA, 0.7654, 2.97, 0.204, 348, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
1639, 5n36A, 0.7654, 2.97, 0.204, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
1640, 4qtbB, 0.7654, 2.68, 0.216, 348, 250, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
1641, 4lrmA, 0.7654, 3.52, 0.169, 307, 267, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
1642, 4e1zA, 0.7654, 3.17, 0.215, 288, 260, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
1643, 2f57A, 0.7654, 3.05, 0.178, 297, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
1644, 1ds5A, 0.7654, 3.16, 0.163, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1645, 6babB, 0.7653, 2.94, 0.194, 285, 253, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
1646, 6aydA, 0.7653, 2.79, 0.198, 272, 252, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
1647, 5hg5A, 0.7653, 3.44, 0.180, 302, 266, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
1648, 4grbA, 0.7653, 2.87, 0.179, 327, 252, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
1649, 3kxhA, 0.7653, 3.03, 0.165, 326, 254, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1650, 3aglA, 0.7653, 2.98, 0.215, 338, 256, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
1651, 5moeA, 0.7652, 2.80, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1652, 5h8eB, 0.7652, 3.05, 0.173, 331, 255, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1653, 1ql6A, 0.7652, 2.72, 0.168, 281, 250, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
1654, 5othA, 0.7651, 2.81, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1655, 5nhhA, 0.7651, 2.77, 0.215, 348, 251, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1656, 5mo6A, 0.7651, 2.76, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1657, 5ke0A, 0.7651, 2.71, 0.216, 340, 250, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
1658, 5hvuB, 0.7651, 3.29, 0.191, 394, 262, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
1659, 5cu0B, 0.7651, 2.79, 0.179, 325, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1660, 5aepA, 0.7651, 3.24, 0.198, 287, 263, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
1661, 5a4tC, 0.7651, 2.64, 0.241, 332, 249, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1662, 3q5iA, 0.7651, 3.05, 0.220, 470, 254, CRYSTAL STRUCTURE OF PBANKA_031420
1663, 1ywvA, 0.7651, 2.83, 0.194, 274, 253, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
1664, 6gmdB, 0.7650, 2.83, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1665, 5v62A, 0.7650, 2.78, 0.220, 349, 250, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
1666, 5os7A, 0.7650, 2.83, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1667, 5n1nA, 0.7650, 2.97, 0.204, 348, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
1668, 5n1mA, 0.7650, 2.97, 0.204, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
1669, 5dgzA, 0.7650, 2.87, 0.194, 273, 253, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
1670, 4qygB, 0.7650, 2.96, 0.213, 264, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1671, 3at2A, 0.7650, 3.07, 0.176, 334, 255, CRYSTAL STRUCTURE OF CK2ALPHA
1672, 2vz6B, 0.7650, 3.27, 0.191, 294, 262, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
1673, 2cgxA, 0.7650, 2.90, 0.217, 265, 254, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1674, 1zysA, 0.7650, 3.04, 0.212, 271, 255, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
1675, 1lpuA, 0.7650, 3.17, 0.163, 327, 258, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1676, 6ft8A, 0.7649, 3.18, 0.195, 338, 256, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1677, 5v82A, 0.7649, 2.93, 0.193, 273, 254, PIM1 KINASE IN COMPLEX WITH CPD17 (1-(6-(44-DIFLUOROPIPERIDIN-3-YL) PYRIDIN-2-YL)-6-(6-METHYLPYRAZIN-2-YL)-1H-PYRAZOLO[43-C]PYRIDINE)
1678, 5ndtA, 0.7649, 2.87, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
1679, 5n39A, 0.7649, 2.97, 0.204, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
1680, 5kgiA, 0.7649, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
1681, 4lfiA, 0.7649, 3.13, 0.151, 370, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1682, 3q9zA, 0.7649, 3.21, 0.178, 332, 259, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1683, 3naxA, 0.7649, 2.81, 0.174, 278, 253, PDK1 IN COMPLEX WITH INHIBITOR MP7
1684, 5isoC, 0.7648, 2.81, 0.216, 429, 250, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
1685, 5a4lC, 0.7648, 2.64, 0.245, 332, 249, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1686, 4yzbB, 0.7648, 2.80, 0.243, 464, 251, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1687, 4lfiB, 0.7648, 3.13, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1688, 4a7cA, 0.7648, 2.79, 0.187, 273, 252, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
1689, 3wowA, 0.7648, 3.05, 0.176, 334, 255, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1690, 2xj0A, 0.7648, 2.87, 0.194, 274, 253, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1691, 2ivsA, 0.7648, 3.04, 0.167, 284, 257, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1692, 1ds5D, 0.7648, 3.17, 0.163, 328, 258, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1693, 5mpjA, 0.7647, 2.84, 0.175, 326, 252, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1694, 5imeA, 0.7647, 2.99, 0.203, 280, 256, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
1695, 4yllA, 0.7647, 2.70, 0.236, 340, 250, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
1696, 4qygA, 0.7647, 2.83, 0.218, 264, 252, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
1697, 3q32B, 0.7647, 3.43, 0.195, 294, 266, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
1698, 3e63A, 0.7647, 3.29, 0.208, 290, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1699, 3e3bX, 0.7647, 2.99, 0.181, 334, 254, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1700, 2zoqB, 0.7647, 2.71, 0.216, 351, 250, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
1701, 5vioD, 0.7646, 2.96, 0.218, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1702, 5nhoA, 0.7646, 2.71, 0.216, 343, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1703, 5n4nA, 0.7646, 2.78, 0.198, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
1704, 4zimB, 0.7646, 3.35, 0.193, 294, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1705, 4x0mA, 0.7646, 3.34, 0.206, 303, 262, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
1706, 4rpvA, 0.7646, 2.79, 0.194, 273, 252, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
1707, 2bdwB, 0.7646, 3.14, 0.201, 309, 259, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
1708, 1z57A, 0.7646, 3.09, 0.196, 333, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1709, 1vjyA, 0.7646, 3.20, 0.208, 299, 260, CRYSTAL STRUCTURE OF A NAPHTHYRIDINE INHIBITOR OF HUMAN TGF- BETA TYPE I RECEPTOR
1710, 5vi9A, 0.7645, 2.95, 0.206, 306, 252, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
1711, 5n4rA, 0.7645, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
1712, 5kgdA, 0.7645, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
1713, 5b0xA, 0.7645, 3.02, 0.177, 329, 254, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
1714, 4mbiA, 0.7645, 2.90, 0.197, 274, 254, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
1715, 4kwpA, 0.7645, 3.09, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1716, 4jx7A, 0.7645, 2.91, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR 2-[(TRANS- 4-AMINOCYCLOHEXYL)AMINO]-4-{[3-(TRIFLUOROMETHYL) PHENYL]AMINO}PYRIDO[43-D]PYRIMIDIN-5(6H)-ONE
1717, 3w2qA, 0.7645, 3.44, 0.174, 307, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
1718, 3c4eC, 0.7645, 2.77, 0.194, 272, 252, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1719, 5telA, 0.7644, 2.93, 0.193, 273, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1720, 5n33A, 0.7644, 2.97, 0.208, 347, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
1721, 5mo7B, 0.7644, 2.78, 0.175, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1722, 5flfD, 0.7644, 3.06, 0.205, 290, 259, DISEASE LINKED MUTATION IN FGFR
1723, 5cx9B, 0.7644, 2.78, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1724, 4n6yA, 0.7644, 2.81, 0.183, 273, 252, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
1725, 4fzaB, 0.7644, 3.12, 0.198, 281, 257, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
1726, 3owkA, 0.7644, 3.09, 0.183, 330, 257, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1727, 2ya9A, 0.7644, 3.15, 0.181, 299, 260, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1728, 2gs2A, 0.7644, 3.49, 0.177, 305, 266, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
1729, 5opuA, 0.7643, 2.79, 0.211, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
1730, 5n4zA, 0.7643, 2.79, 0.194, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
1731, 5c1qB, 0.7643, 2.78, 0.194, 273, 252, SERINE/THREONINE-PROTEIN KINASE PIM-1
1732, 4ylkA, 0.7643, 2.70, 0.236, 341, 250, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
1733, 4i23A, 0.7643, 3.39, 0.171, 304, 263, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
1734, 4ckiA, 0.7643, 3.03, 0.168, 293, 256, CRYSTAL STRUCTURE OF ONCOGENIC RET TYROSINE KINASE M918T BOUND TO ADENOSINE
1735, 3u9cA, 0.7643, 3.16, 0.178, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1736, 2o3pA, 0.7643, 2.93, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETIN
1737, 5v60A, 0.7642, 2.76, 0.220, 347, 250, PHOSPHO-ERK2 BOUND TO AMP-PCP
1738, 5n4xA, 0.7642, 2.89, 0.194, 272, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
1739, 5n4uA, 0.7642, 2.81, 0.194, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
1740, 5mowA, 0.7642, 2.71, 0.184, 328, 250, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1741, 5mo5B, 0.7642, 2.79, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1742, 5kgeA, 0.7642, 2.90, 0.194, 273, 253, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
1743, 5dhjA, 0.7642, 2.88, 0.194, 273, 253, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
1744, 4rewA, 0.7642, 2.80, 0.212, 411, 250, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
1745, 4k1bA, 0.7642, 2.89, 0.194, 273, 253, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
1746, 3u87A, 0.7642, 3.10, 0.183, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1747, 3rpsB, 0.7642, 3.20, 0.171, 334, 257, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1748, 3kxnA, 0.7642, 3.15, 0.163, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1749, 3e62A, 0.7642, 3.29, 0.205, 291, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
1750, 3cxwA, 0.7642, 2.94, 0.193, 272, 254, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
1751, 5vioA, 0.7641, 2.98, 0.226, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1752, 5mmrB, 0.7641, 2.78, 0.183, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1753, 5m56B, 0.7641, 3.17, 0.176, 328, 256, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1754, 5j1wA, 0.7641, 3.07, 0.196, 338, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1755, 5fgkA, 0.7641, 2.95, 0.145, 331, 255, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
1756, 5cf6B, 0.7641, 3.37, 0.197, 290, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1757, 4qyeA, 0.7641, 2.98, 0.217, 271, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
1758, 4f08A, 0.7641, 3.30, 0.209, 288, 263, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1759, 4d0xA, 0.7641, 3.29, 0.205, 291, 264, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
1760, 2xiyA, 0.7641, 2.98, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-2 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1761, 2wotA, 0.7641, 3.23, 0.208, 303, 260, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
1762, 2o64A, 0.7641, 2.93, 0.193, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
1763, 1yxuC, 0.7641, 2.79, 0.194, 272, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1764, 5orjA, 0.7640, 2.80, 0.179, 325, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1765, 5n50A, 0.7640, 2.79, 0.198, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
1766, 5mmfB, 0.7640, 2.78, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1767, 5lxcB, 0.7640, 2.91, 0.211, 385, 251, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1768, 5cf4B, 0.7640, 3.35, 0.197, 291, 264, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1769, 4ytiA, 0.7640, 3.23, 0.198, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
1770, 4mblA, 0.7640, 2.83, 0.198, 274, 253, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
1771, 4gvjA, 0.7640, 3.23, 0.214, 290, 262, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
1772, 4f08B, 0.7640, 3.29, 0.205, 288, 263, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1773, 4cfhA, 0.7640, 2.70, 0.209, 401, 249, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
1774, 3zuvA, 0.7640, 2.74, 0.220, 357, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
1775, 3u9cB, 0.7640, 3.17, 0.178, 331, 258, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1776, 5t8qA, 0.7639, 3.27, 0.182, 323, 264, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO ARYL PYRROLE FRAGMENT 17
1777, 5oumA, 0.7639, 2.83, 0.179, 326, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1778, 5oueB, 0.7639, 2.79, 0.183, 326, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1779, 5hg8A, 0.7639, 3.44, 0.185, 300, 265, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
1780, 5flfB, 0.7639, 3.11, 0.204, 292, 260, DISEASE LINKED MUTATION IN FGFR
1781, 4ubaB, 0.7639, 3.11, 0.172, 333, 256, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1782, 4li5A, 0.7639, 3.46, 0.175, 306, 263, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
1783, 4alvA, 0.7639, 2.96, 0.193, 274, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
1784, 3vc4A, 0.7639, 2.89, 0.194, 274, 253, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
1785, 2o63A, 0.7639, 2.92, 0.197, 274, 254, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
1786, 2hxqA, 0.7639, 2.98, 0.216, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
1787, 2erkA, 0.7639, 2.74, 0.220, 351, 250, PHOSPHORYLATED MAP KINASE ERK2
1788, 2bzjA, 0.7639, 2.79, 0.198, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
1789, 2a27A, 0.7639, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1790, 1yxuB, 0.7639, 2.79, 0.194, 273, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1791, 5wg3A, 0.7638, 3.02, 0.195, 618, 256, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
1792, 5v80A, 0.7638, 2.89, 0.198, 273, 253, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
1793, 5n3dA, 0.7638, 2.99, 0.204, 346, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
1794, 5cu2A, 0.7638, 2.95, 0.180, 328, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1795, 3qc4B, 0.7638, 2.84, 0.195, 278, 251, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
1796, 3mb7A, 0.7638, 3.20, 0.182, 330, 258, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1797, 2welA, 0.7638, 2.97, 0.196, 304, 255, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
1798, 2a27C, 0.7638, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1799, 1yxvA, 0.7638, 2.95, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
1800, 5n4vA, 0.7637, 2.90, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
1801, 5hd7A, 0.7637, 2.71, 0.212, 347, 250, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
1802, 5cxhA, 0.7637, 3.09, 0.186, 277, 258, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
1803, 4wsyA, 0.7637, 2.89, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
1804, 4py1A, 0.7637, 3.17, 0.215, 289, 261, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
1805, 3r01A, 0.7637, 2.88, 0.194, 274, 253, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1806, 1xr1A, 0.7637, 3.06, 0.196, 277, 255, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
1807, 6g4yA, 0.7636, 3.25, 0.194, 322, 263, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 1A 
1808, 5n4yA, 0.7636, 2.83, 0.198, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
1809, 4medA, 0.7636, 2.89, 0.186, 272, 253, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
1810, 4k0yA, 0.7636, 2.95, 0.193, 274, 254, STRUCTURE OF PIM-1 KINASE BOUND TO N-(4-FLUOROPHENYL)-7-HYDROXY-5- (PIPERIDIN-4-YL)PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
1811, 4gfmA, 0.7636, 3.27, 0.202, 289, 263, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
1812, 3mvjB, 0.7636, 2.95, 0.185, 320, 254, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
1813, 2o65A, 0.7636, 2.84, 0.198, 274, 253, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
1814, 2a27F, 0.7636, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1815, 5texA, 0.7635, 2.94, 0.193, 274, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1816, 5op5A, 0.7635, 2.76, 0.212, 259, 250, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
1817, 5nhlA, 0.7635, 2.72, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1818, 5e90A, 0.7635, 3.30, 0.204, 303, 260, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
1819, 4xh6A, 0.7635, 2.90, 0.198, 273, 253, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
1820, 4wrsA, 0.7635, 2.89, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
1821, 4ji9A, 0.7635, 3.20, 0.203, 284, 261, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
1822, 4gw8A, 0.7635, 2.82, 0.194, 273, 252, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
1823, 3rawA, 0.7635, 3.12, 0.179, 351, 257, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1824, 3jyaA, 0.7635, 2.87, 0.194, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
1825, 2a27G, 0.7635, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1826, 1yxxA, 0.7635, 2.95, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH (3E)-3-[(4- HYDROXYPHENYL)IMINO]-1H-INDOL-2(3H)-ONE
1827, 1m2qA, 0.7635, 3.17, 0.167, 327, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1828, 6fylA, 0.7634, 3.01, 0.185, 340, 254, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
1829, 5n5mA, 0.7634, 2.83, 0.183, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
1830, 5mo8B, 0.7634, 2.79, 0.179, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1831, 5cvhA, 0.7634, 2.79, 0.179, 327, 251, CRYSTAL STRUCTURE OF CK2ALPHA
1832, 4i5mA, 0.7634, 2.76, 0.179, 273, 251, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
1833, 4f6uA, 0.7634, 3.14, 0.156, 334, 257, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
1834, 2a27H, 0.7634, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1835, 2a27D, 0.7634, 3.17, 0.177, 304, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1836, 5ouuB, 0.7633, 2.79, 0.183, 325, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1837, 5orhB, 0.7633, 2.90, 0.181, 325, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1838, 4hyhA, 0.7633, 2.95, 0.209, 263, 254, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
1839, 4fzfB, 0.7633, 3.07, 0.191, 279, 256, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
1840, 4ewhA, 0.7633, 2.98, 0.215, 274, 256, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
1841, 4dgoA, 0.7633, 3.17, 0.163, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1842, 2xixA, 0.7633, 3.00, 0.181, 272, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-1 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1843, 1yxuA, 0.7633, 2.80, 0.194, 273, 252, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1844, 5nhjA, 0.7632, 2.73, 0.216, 345, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1845, 4rvkA, 0.7632, 3.00, 0.209, 264, 254, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
1846, 3fl5A, 0.7632, 3.14, 0.163, 324, 257, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1847, 3eyhA, 0.7632, 3.23, 0.208, 285, 260, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
1848, 2a27E, 0.7632, 3.18, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1849, 5vioC, 0.7631, 2.98, 0.218, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
1850, 5t5tA, 0.7631, 2.73, 0.214, 368, 248, AMPK BOUND TO ALLOSTERIC ACTIVATOR
1851, 5oumB, 0.7631, 2.80, 0.183, 326, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1852, 5j1vB, 0.7631, 3.12, 0.192, 337, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1853, 4rlkA, 0.7631, 3.19, 0.163, 327, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1854, 3r00A, 0.7631, 2.97, 0.193, 274, 254, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
1855, 2ya9B, 0.7631, 3.15, 0.193, 299, 259, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
1856, 2xzsA, 0.7631, 3.19, 0.188, 301, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
1857, 2cgvA, 0.7631, 2.88, 0.217, 264, 253, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
1858, 6g33C, 0.7630, 3.12, 0.196, 336, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1859, 6bskA, 0.7630, 2.92, 0.194, 273, 253, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
1860, 6b16A, 0.7630, 3.28, 0.215, 285, 261, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
1861, 5oopA, 0.7630, 2.87, 0.218, 261, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
1862, 5nhpA, 0.7630, 2.72, 0.216, 338, 250, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
1863, 5dwrA, 0.7630, 2.90, 0.182, 273, 253, IDENTIFICATION OF N-(4-((1R3S5S)-3-AMINO-5-METHYLCYCLOHEXYL)PYRIDIN- 3-YL)-6-(26-DIFLUOROPHENYL)-5-FLUOROPICOLINAMIDE (PIM447) A POTENT AND SELECTIVE PROVIRAL INSERTION SITE OF MOLONEY MURINE LEUKEMIA (PIM) 12 AND 3 KINASE INHIBITOR IN CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES
1864, 4qyhB, 0.7630, 2.99, 0.209, 264, 254, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
1865, 4jq8A, 0.7630, 3.25, 0.185, 303, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
1866, 4gl9C, 0.7630, 3.14, 0.205, 282, 259, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
1867, 4dgmA, 0.7630, 3.17, 0.163, 326, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1868, 4anmA, 0.7630, 3.16, 0.163, 328, 258, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1869, 3nlbA, 0.7630, 2.88, 0.210, 261, 252, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
1870, 3jpvA, 0.7630, 2.91, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
1871, 2zoqA, 0.7630, 2.73, 0.216, 351, 250, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
1872, 2j5eA, 0.7630, 3.47, 0.185, 309, 265, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
1873, 5modB, 0.7629, 2.80, 0.183, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1874, 5j1wB, 0.7629, 3.02, 0.201, 337, 254, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1875, 5h8bB, 0.7629, 3.18, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1876, 4qyyA, 0.7629, 2.72, 0.220, 337, 250, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
1877, 4n70A, 0.7629, 2.91, 0.182, 274, 253, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
1878, 4fi1A, 0.7629, 3.15, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1879, 4asxA, 0.7629, 2.93, 0.195, 310, 256, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
1880, 3nr9A, 0.7629, 3.15, 0.184, 341, 255, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1881, 3jxwA, 0.7629, 2.89, 0.194, 274, 253, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
1882, 2brbA, 0.7629, 3.01, 0.216, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1883, 2br1A, 0.7629, 2.99, 0.216, 272, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1884, 5n5lA, 0.7628, 2.84, 0.183, 271, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
1885, 5mowB, 0.7628, 2.81, 0.183, 324, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1886, 4mwhA, 0.7628, 3.15, 0.151, 371, 258, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1887, 4kikB, 0.7628, 3.24, 0.192, 648, 261, HUMAN IKB KINASE BETA
1888, 4iaaA, 0.7628, 2.83, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
1889, 4f09A, 0.7628, 3.35, 0.193, 288, 264, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
1890, 2brnA, 0.7628, 3.01, 0.212, 268, 255, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1891, 1phkA, 0.7628, 2.82, 0.171, 277, 251, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
1892, 6g97A, 0.7627, 2.76, 0.216, 344, 250, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1893, 5kwhB, 0.7627, 3.18, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
1894, 4wt6A, 0.7627, 2.81, 0.194, 273, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
1895, 2a27B, 0.7627, 3.17, 0.177, 303, 260, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
1896, 5otoA, 0.7626, 2.96, 0.180, 327, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1897, 5ot6A, 0.7626, 2.88, 0.179, 327, 252, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1898, 5cf6A, 0.7626, 3.23, 0.203, 285, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1899, 4riyD, 0.7626, 3.42, 0.179, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
1900, 4r3pA, 0.7626, 3.43, 0.178, 310, 264, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
1901, 4ftiA, 0.7626, 2.96, 0.221, 270, 253, CRYSTAL STRUCTURE OF THE CHK1
1902, 4aluA, 0.7626, 2.98, 0.189, 274, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
1903, 6fyiA, 0.7625, 3.02, 0.185, 336, 254, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
1904, 5toeA, 0.7625, 2.96, 0.197, 272, 254, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
1905, 5cf8A, 0.7625, 3.23, 0.203, 285, 261, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
1906, 3q9xA, 0.7625, 3.16, 0.178, 330, 258, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1907, 3nr9C, 0.7625, 2.98, 0.182, 347, 253, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1908, 2broA, 0.7625, 3.11, 0.215, 272, 256, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1909, 5n1oA, 0.7624, 3.00, 0.200, 335, 255, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
1910, 5modA, 0.7624, 2.96, 0.180, 327, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1911, 5j1vA, 0.7624, 3.10, 0.196, 338, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1912, 4dtkA, 0.7624, 2.92, 0.194, 273, 253, NOVEL AND SELECTIVE PAN-PIM KINASE INHIBITOR
1913, 3u87B, 0.7624, 3.10, 0.175, 329, 257, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1914, 3qf9A, 0.7624, 2.83, 0.194, 274, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
1915, 2jiuA, 0.7624, 3.37, 0.183, 303, 263, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
1916, 2ivtA, 0.7624, 3.05, 0.168, 288, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
1917, 1ungA, 0.7624, 2.62, 0.169, 288, 248, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1918, 1dayA, 0.7624, 3.25, 0.162, 327, 259, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1919, 5oq5A, 0.7623, 2.88, 0.230, 265, 252, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
1920, 4zy5A, 0.7623, 3.19, 0.197, 283, 259, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1921, 4rc4A, 0.7623, 2.85, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1922, 4qfgA, 0.7623, 2.73, 0.213, 365, 249, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
1923, 4j96B, 0.7623, 3.16, 0.173, 305, 260, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
1924, 3bgpA, 0.7623, 2.94, 0.182, 272, 253, HUMAN PIM-1 COMPLEXED WITH A BENZOISOXAZOLE INHIBITOR VX1
1925, 2wu7A, 0.7623, 3.13, 0.179, 348, 257, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1926, 2bziB, 0.7623, 2.91, 0.186, 272, 253, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
1927, 6b1uA, 0.7622, 2.71, 0.218, 441, 248, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
1928, 5xvuB, 0.7622, 2.87, 0.190, 321, 252, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1929, 5owlB, 0.7622, 3.18, 0.174, 332, 259, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1930, 5os7B, 0.7622, 2.82, 0.183, 325, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1931, 5orhA, 0.7622, 2.92, 0.181, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1932, 5cqwB, 0.7622, 3.23, 0.181, 331, 259, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1933, 4dglC, 0.7622, 3.04, 0.177, 334, 254, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1934, 3w8lA, 0.7622, 2.93, 0.178, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1935, 3c4eD, 0.7622, 2.92, 0.194, 273, 253, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
1936, 2xizA, 0.7622, 3.00, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-3 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
1937, 2hxlA, 0.7622, 3.01, 0.220, 272, 255, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
1938, 5n9nA, 0.7621, 3.12, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1939, 5n9lA, 0.7621, 3.12, 0.179, 329, 257, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1940, 5lxcA, 0.7621, 2.74, 0.205, 383, 249, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
1941, 5em8A, 0.7621, 3.30, 0.176, 303, 262, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
1942, 4xhkB, 0.7621, 2.85, 0.183, 269, 252, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
1943, 4ubaA, 0.7621, 3.25, 0.181, 333, 259, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1944, 2hogA, 0.7621, 3.04, 0.217, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
1945, 6gmdA, 0.7620, 2.82, 0.183, 325, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1946, 5vilD, 0.7620, 2.97, 0.214, 271, 252, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1947, 5j79A, 0.7620, 3.10, 0.170, 283, 259, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
1948, 4i41A, 0.7620, 2.86, 0.183, 272, 252, CRYSTAL STRUCTURE OF HUMAN SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE
1949, 4gubA, 0.7620, 3.00, 0.182, 329, 253, CASEIN KINASE II BOUND TO INHIBITOR
1950, 2xj2A, 0.7620, 3.00, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1951, 5otdA, 0.7619, 2.96, 0.180, 327, 255, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1952, 5ku8A, 0.7619, 3.05, 0.173, 328, 254, CRYSTAL STRUCTURE OF CK2
1953, 5kggA, 0.7619, 2.86, 0.194, 273, 252, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-(5-CHLORANYL-1~{H}-INDOL- 3-YL)ETHANAMINE
1954, 5iisA, 0.7619, 2.86, 0.183, 273, 252, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
1955, 4rblA, 0.7619, 2.80, 0.183, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
1956, 4ianA, 0.7619, 2.65, 0.177, 321, 249, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1957, 3kxmA, 0.7619, 3.17, 0.163, 326, 258, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1958, 2objA, 0.7619, 2.87, 0.183, 272, 252, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH INHIBITOR
1959, 1yxuD, 0.7619, 2.93, 0.194, 273, 253, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
1960, 1m2pA, 0.7619, 3.20, 0.163, 325, 258, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1961, 6gdqA, 0.7618, 2.69, 0.217, 339, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1962, 6g93A, 0.7618, 2.70, 0.217, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
1963, 5wg5A, 0.7618, 3.07, 0.213, 617, 258, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
1964, 5mo5A, 0.7618, 2.91, 0.181, 326, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1965, 3we8A, 0.7618, 2.82, 0.198, 273, 252, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
1966, 3krrA, 0.7618, 3.34, 0.205, 291, 264, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
1967, 5walA, 0.7617, 3.26, 0.214, 286, 262, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
1968, 5usqA, 0.7617, 3.19, 0.213, 299, 258, ALK-5 KINASE INHIBITOR COMPLEX
1969, 5kcxA, 0.7617, 2.91, 0.198, 272, 253, PIM-1 KINASE IN COMPLEX WITH A SELECTIVE N-SUBSTITUTED 7-AZAINDOLE INHIBITOR
1970, 4zimA, 0.7617, 3.32, 0.195, 285, 262, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
1971, 4ysjA, 0.7617, 3.13, 0.235, 459, 255, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
1972, 4fsnA, 0.7617, 3.03, 0.205, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
1973, 4cfeC, 0.7617, 2.75, 0.217, 403, 249, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
1974, 3gniB, 0.7617, 3.02, 0.152, 304, 257, STRUCTURE OF STRAD AND MO25
1975, 3b2tA, 0.7617, 3.27, 0.172, 288, 261, STRUCTURE OF PHOSPHOTRANSFERASE
1976, 5vilC, 0.7616, 3.05, 0.213, 271, 253, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1977, 5ipjA, 0.7616, 2.94, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A QUINAZOLINONE-PYRROLOPYRROLONE INHIBITOR.
1978, 5eolA, 0.7616, 2.95, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A MACROCYCLIC QUINOXALINE-PYRROLODIHYDROPIPERIDINONE INHIBITOR
1979, 4zhxA, 0.7616, 2.75, 0.217, 408, 249, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
1980, 4ty1A, 0.7616, 2.92, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AMINOOXADIAZOLE-INDOLE INHIBITOR.
1981, 4jrvA, 0.7616, 3.30, 0.180, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
1982, 5vilA, 0.7615, 2.96, 0.223, 271, 251, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
1983, 5ot6B, 0.7615, 2.93, 0.181, 326, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1984, 4rvtA, 0.7615, 3.06, 0.196, 281, 255, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
1985, 4md9F, 0.7615, 3.14, 0.183, 327, 257, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1986, 4bbeC, 0.7615, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
1987, 3rawB, 0.7615, 3.14, 0.179, 349, 257, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1988, 2brmA, 0.7615, 2.97, 0.209, 263, 254, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
1989, 1wbpA, 0.7615, 2.99, 0.154, 350, 254, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1990, 1nvqA, 0.7615, 3.06, 0.209, 264, 254, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
1991, 6ft9A, 0.7614, 3.12, 0.196, 336, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1992, 6e4uA, 0.7614, 2.75, 0.214, 365, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
1993, 5t1hB, 0.7614, 3.20, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
1994, 5otiA, 0.7614, 3.06, 0.180, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
1995, 3wilA, 0.7614, 3.13, 0.183, 331, 257, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1996, 3warA, 0.7614, 3.27, 0.178, 334, 259, CRYSTAL STRUCTURE OF HUMAN CK2A
1997, 3utoB, 0.7614, 3.49, 0.183, 566, 262, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
1998, 3tkiA, 0.7614, 2.98, 0.225, 272, 253, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
1999, 3cy3A, 0.7614, 2.86, 0.183, 270, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND THE JNK INHIBITOR V
2000, 3bwfA, 0.7614, 2.84, 0.194, 273, 252, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
2001, 1om1A, 0.7614, 3.18, 0.163, 325, 258, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
2002, 5uq1A, 0.7613, 2.75, 0.188, 288, 250, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
2003, 5ot5B, 0.7613, 2.92, 0.181, 325, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
2004, 5mo6B, 0.7613, 2.93, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2005, 5ku8B, 0.7613, 3.21, 0.178, 331, 258, CRYSTAL STRUCTURE OF CK2
2006, 5cu3A, 0.7613, 2.82, 0.179, 325, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2007, 5cu2B, 0.7613, 2.93, 0.185, 325, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
2008, 5ctpA, 0.7613, 2.92, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
2009, 4bbfA, 0.7613, 3.32, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2010, 4bbeD, 0.7613, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2011, 4bbeA, 0.7613, 3.29, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2012, 3nz0A, 0.7613, 3.25, 0.223, 285, 260, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
2013, 3ikaA, 0.7613, 3.32, 0.192, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
2014, 2x7fA, 0.7613, 2.74, 0.203, 276, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2015, 1zohA, 0.7613, 3.19, 0.163, 326, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2016, 5orkB, 0.7612, 2.76, 0.180, 323, 250, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
2017, 5oquB, 0.7612, 2.93, 0.185, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
2018, 5flfA, 0.7612, 3.09, 0.205, 296, 258, DISEASE LINKED MUTATION IN FGFR
2019, 5f1zA, 0.7612, 3.14, 0.232, 281, 259, STRUCTURE OF TYK2 WITH INHIBITOR 16: 3-AZANYL-5-[(2~{S})-3- METHYLBUTAN-2-YL]-7-[1-METHYL-5-(2-OXIDANYLPROPAN-2-YL)PYRAZOL-3-YL]- 1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
2020, 5e8sA, 0.7612, 3.29, 0.208, 301, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
2021, 4rixD, 0.7612, 3.36, 0.176, 297, 261, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2022, 3kckA, 0.7612, 3.23, 0.203, 285, 261, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
2023, 1jwhB, 0.7612, 3.08, 0.176, 335, 255, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
2024, 5tq8A, 0.7611, 3.55, 0.203, 291, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2025, 5cf4A, 0.7611, 3.21, 0.204, 283, 260, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2026, 4rc2A, 0.7611, 2.87, 0.183, 272, 252, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2027, 4gl9A, 0.7611, 3.15, 0.205, 282, 259, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
2028, 4bbfD, 0.7611, 3.31, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2029, 3w2oA, 0.7611, 3.46, 0.181, 305, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
2030, 3r04A, 0.7611, 2.81, 0.195, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2031, 2b7aA, 0.7611, 3.25, 0.203, 284, 261, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
2032, 1jamA, 0.7611, 3.19, 0.163, 327, 258, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
2033, 5turA, 0.7610, 2.95, 0.194, 270, 253, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
2034, 5j1wC, 0.7610, 3.10, 0.188, 316, 255, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
2035, 5ct0B, 0.7610, 2.94, 0.181, 326, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
2036, 4qyhA, 0.7610, 2.88, 0.218, 264, 252, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
2037, 4ifcA, 0.7610, 2.66, 0.173, 327, 249, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
2038, 4cffC, 0.7610, 2.76, 0.213, 422, 249, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2039, 4bbeB, 0.7610, 3.30, 0.195, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2040, 2xj1A, 0.7610, 3.02, 0.181, 273, 254, PROTEIN KINASE PIM-1 IN COMPLEX WITH SMALL MOLECULE INIBITOR
2041, 1zoeA, 0.7610, 3.18, 0.163, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
2042, 6e4tA, 0.7609, 2.71, 0.214, 361, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2043, 5u8lA, 0.7609, 3.39, 0.190, 289, 263, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
2044, 5opvA, 0.7609, 2.92, 0.211, 261, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2045, 5mo7A, 0.7609, 2.99, 0.180, 327, 255, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2046, 5hd4A, 0.7609, 2.75, 0.220, 347, 250, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
2047, 5e8zA, 0.7609, 3.20, 0.213, 303, 258, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
2048, 4rvmA, 0.7609, 2.95, 0.209, 264, 253, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
2049, 4f7jA, 0.7609, 3.02, 0.157, 326, 254, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
2050, 3u4uA, 0.7609, 3.00, 0.184, 327, 255, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
2051, 3socB, 0.7609, 2.93, 0.196, 309, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2052, 4qyfA, 0.7608, 2.95, 0.209, 269, 253, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
2053, 4ewhB, 0.7608, 2.98, 0.216, 273, 255, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
2054, 4bbfB, 0.7608, 3.29, 0.198, 288, 262, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2055, 3tjcA, 0.7608, 3.27, 0.199, 284, 261, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
2056, 3bgzA, 0.7608, 2.88, 0.183, 267, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH DIPHENYL INDOLE INHIBITOR VX3
2057, 1wmkC, 0.7608, 3.18, 0.189, 303, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2058, 6e4wA, 0.7607, 2.72, 0.214, 361, 248, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2059, 5othB, 0.7607, 2.93, 0.181, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
2060, 5n3fA, 0.7607, 2.95, 0.194, 318, 253, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
2061, 5mpjB, 0.7607, 2.95, 0.185, 324, 254, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
2062, 4ib5B, 0.7607, 3.25, 0.182, 329, 258, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
2063, 4ftuA, 0.7607, 3.06, 0.205, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
2064, 3lxnA, 0.7607, 3.13, 0.216, 287, 259, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2065, 2oxdA, 0.7607, 3.12, 0.163, 325, 257, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
2066, 2hy0A, 0.7607, 3.03, 0.217, 272, 254, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
2067, 1wmkD, 0.7607, 3.18, 0.189, 314, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2068, 1wmkB, 0.7607, 3.18, 0.189, 314, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2069, 5ztnB, 0.7606, 2.76, 0.217, 395, 249, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
2070, 4u42A, 0.7606, 3.09, 0.196, 282, 255, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2071, 3vbyA, 0.7606, 2.81, 0.195, 267, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2072, 3pvgA, 0.7606, 3.18, 0.163, 326, 257, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
2073, 3kvwA, 0.7606, 2.81, 0.209, 403, 249, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
2074, 3iecB, 0.7606, 2.71, 0.217, 313, 249, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2075, 3be9A, 0.7606, 3.17, 0.163, 327, 257, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
2076, 2cgwA, 0.7606, 2.89, 0.222, 262, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2077, 1wmkF, 0.7606, 3.18, 0.189, 303, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2078, 1wmkE, 0.7606, 3.18, 0.189, 313, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2079, 5ig1B, 0.7605, 3.30, 0.211, 304, 261, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2080, 4qfrA, 0.7605, 2.72, 0.214, 361, 248, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2081, 3dcvA, 0.7605, 2.94, 0.182, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM1 KINASE COMPLEXED WITH 4-(4- HYDROXY-3-METHYL-PHENYL)-6-PHENYLPYRIMIDIN-2(1H)-ONE
2082, 3cy2A, 0.7605, 2.88, 0.194, 271, 252, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND II
2083, 1wmkH, 0.7605, 3.18, 0.189, 304, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2084, 5ztnA, 0.7604, 2.77, 0.217, 395, 249, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
2085, 5usyB, 0.7604, 3.21, 0.196, 287, 260, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2086, 5ufuA, 0.7604, 2.87, 0.213, 368, 249, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2087, 5orjB, 0.7604, 2.95, 0.185, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
2088, 5op7A, 0.7604, 2.88, 0.210, 261, 252, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
2089, 5h8gA, 0.7604, 2.91, 0.179, 324, 251, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
2090, 5cvgA, 0.7604, 2.81, 0.181, 326, 249, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
2091, 3t9iA, 0.7604, 2.91, 0.175, 273, 252, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
2092, 2xzsB, 0.7604, 3.27, 0.188, 293, 260, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
2093, 1yi4A, 0.7604, 2.82, 0.183, 267, 251, STRUCTURE OF PIM-1 BOUND TO ADENOSINE
2094, 6g9aA, 0.7603, 2.73, 0.217, 341, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2095, 5moeB, 0.7603, 2.88, 0.182, 323, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
2096, 5ezvA, 0.7603, 2.74, 0.218, 441, 248, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2097, 5diaA, 0.7603, 2.96, 0.194, 273, 253, PIM1 IN COMPLEX WITH CPD36 ((1S3S)-N1-(6-(5-(PYRIDIN-3-YL)-1H- PYRAZOLO[34-C]PYRIDIN-3-YL)PYRIDIN-2-YL)CYCLOHEXANE-13-DIAMINE)
2098, 5cshA, 0.7603, 2.93, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2099, 4hgeA, 0.7603, 3.28, 0.202, 284, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
2100, 2zjwA, 0.7603, 3.06, 0.181, 332, 254, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
2101, 1wmkG, 0.7603, 3.18, 0.189, 313, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2102, 1wmkA, 0.7603, 3.18, 0.189, 303, 259, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
2103, 1f0qA, 0.7603, 3.22, 0.163, 329, 258, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
2104, 6ehuA, 0.7602, 2.98, 0.178, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2105, 5xvuC, 0.7602, 2.95, 0.190, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2106, 5tq3B, 0.7602, 3.40, 0.198, 285, 262, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2107, 5cf8B, 0.7602, 3.32, 0.198, 288, 262, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
2108, 4qp1B, 0.7602, 2.72, 0.221, 343, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2109, 3vbtA, 0.7602, 2.81, 0.195, 267, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2110, 3r02A, 0.7602, 2.83, 0.195, 271, 251, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
2111, 2qc6A, 0.7602, 3.09, 0.165, 326, 254, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
2112, 2pvnA, 0.7602, 3.17, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2113, 1u59A, 0.7602, 3.40, 0.172, 282, 262, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2114, 5ts8A, 0.7601, 3.16, 0.167, 332, 257, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
2115, 5czhA, 0.7601, 3.52, 0.177, 311, 265, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
2116, 4rc3A, 0.7601, 2.83, 0.187, 271, 251, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH MITOXANTRONE DERIVATIVES
2117, 4mtaA, 0.7601, 2.95, 0.194, 273, 253, CRYSTAL STRUCTURE OF PIM-1 KINASE DOMAIN IN COMPLEX WITH 2-METHYL-5- PHENYLFURAN-3-CARBOXYLIC ACID
2118, 4ckjA, 0.7601, 3.12, 0.167, 292, 257, CRYSTAL STRUCTURE OF RET TYROSINE KINASE DOMAIN BOUND TO ADENOSINE
2119, 4aqcB, 0.7601, 3.35, 0.198, 295, 263, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
2120, 3e64A, 0.7601, 3.34, 0.201, 291, 264, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
2121, 2oxxA, 0.7601, 3.20, 0.163, 325, 258, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
2122, 5isoA, 0.7600, 2.77, 0.217, 453, 249, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2123, 5e8tA, 0.7600, 3.25, 0.208, 302, 259, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
2124, 3utoA, 0.7600, 3.55, 0.183, 559, 262, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
2125, 3q4zA, 0.7600, 3.08, 0.171, 282, 257, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2126, 2cguA, 0.7600, 2.88, 0.218, 263, 252, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
2127, 1sykB, 0.7600, 3.06, 0.189, 323, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2128, 5xvuA, 0.7599, 2.93, 0.190, 321, 253, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
2129, 5cvhB, 0.7599, 2.95, 0.185, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA
2130, 4yc3A, 0.7599, 2.88, 0.200, 295, 250, CDK1/CYCLINB1/CKS2 APO
2131, 4e6qA, 0.7599, 3.36, 0.197, 296, 264, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2132, 4bbfC, 0.7599, 3.35, 0.198, 288, 263, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
2133, 3nr9B, 0.7599, 3.02, 0.186, 347, 253, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
2134, 1zogA, 0.7599, 3.21, 0.163, 325, 258, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
2135, 1nvsA, 0.7599, 3.09, 0.209, 264, 254, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
2136, 5otdB, 0.7598, 2.93, 0.181, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
2137, 5kq5A, 0.7598, 2.72, 0.214, 362, 248, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2138, 2ivuA, 0.7598, 3.10, 0.172, 288, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474
2139, 1yhsA, 0.7598, 2.83, 0.183, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO STAUROSPORINE
2140, 1sykA, 0.7598, 3.04, 0.189, 348, 254, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2141, 1h4lB, 0.7598, 2.40, 0.181, 278, 243, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2142, 6g33B, 0.7597, 3.15, 0.192, 337, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
2143, 6eiiB, 0.7597, 2.80, 0.179, 326, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
2144, 5otoB, 0.7597, 2.94, 0.181, 324, 254, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
2145, 5op2A, 0.7597, 2.96, 0.209, 263, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2146, 5ootA, 0.7597, 2.87, 0.211, 260, 251, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2147, 5hvyA, 0.7597, 3.42, 0.158, 335, 259, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
2148, 4qfsA, 0.7597, 2.73, 0.214, 361, 248, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2149, 4ifcB, 0.7597, 2.69, 0.169, 329, 249, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
2150, 3pzhA, 0.7597, 3.18, 0.163, 327, 257, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
2151, 2j6mA, 0.7597, 3.29, 0.181, 306, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
2152, 1h4lA, 0.7597, 2.46, 0.180, 278, 244, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
2153, 5ui0B, 0.7596, 3.17, 0.170, 304, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2154, 5g1xA, 0.7596, 2.65, 0.193, 262, 249, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
2155, 5cziA, 0.7596, 3.37, 0.175, 310, 263, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
2156, 4azfA, 0.7596, 2.75, 0.209, 404, 249, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
2157, 3kxgA, 0.7596, 3.17, 0.163, 326, 257, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
2158, 3at4A, 0.7596, 3.14, 0.183, 331, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
2159, 1nvrA, 0.7596, 3.00, 0.209, 264, 253, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
2160, 1m14A, 0.7596, 3.27, 0.185, 307, 260, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
2161, 5j95A, 0.7595, 3.15, 0.195, 284, 256, MAP4K4 IN COMPLEX WITH INHIBITOR
2162, 4lm5A, 0.7595, 2.79, 0.200, 264, 250, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH 2-{4-[(3-AMINOPROPYL) AMINO]QUINAZOLIN-2-YL}PHENOL (RESULTING FROM DISPLACEMENT OF SKF86002)
2163, 4ft7A, 0.7595, 3.07, 0.209, 270, 254, CRYSTAL STRUCTURE OF THE CHK1
2164, 4f7lA, 0.7595, 2.94, 0.154, 328, 253, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
2165, 3w2pA, 0.7595, 3.49, 0.177, 308, 265, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
2166, 3vbxA, 0.7595, 2.83, 0.195, 268, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2167, 1wakA, 0.7595, 3.02, 0.154, 353, 254, X-RAY STRUCTURE OF SRPK1
2168, 6ft9B, 0.7594, 3.05, 0.201, 337, 254, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
2169, 5myvA, 0.7594, 2.98, 0.166, 352, 253, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
2170, 5lxmA, 0.7594, 2.76, 0.200, 266, 250, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
2171, 4ji9B, 0.7594, 3.40, 0.198, 288, 263, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
2172, 4dgnA, 0.7594, 3.18, 0.163, 325, 257, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
2173, 2pvmA, 0.7594, 3.19, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2174, 5vioB, 0.7593, 2.86, 0.225, 271, 249, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
2175, 5ui0A, 0.7593, 3.16, 0.170, 301, 259, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
2176, 5n4oA, 0.7593, 2.79, 0.196, 271, 250, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
2177, 3pwdA, 0.7593, 3.21, 0.163, 327, 258, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
2178, 3hx4A, 0.7593, 3.31, 0.209, 467, 258, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2179, 3dfcB, 0.7593, 3.08, 0.193, 280, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2180, 2c3lA, 0.7593, 2.97, 0.226, 265, 252, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2181, 5vjaB, 0.7592, 3.05, 0.192, 266, 255, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2182, 5o13A, 0.7592, 2.93, 0.183, 270, 252, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2183, 5d9kB, 0.7592, 2.78, 0.181, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2184, 4riwD, 0.7592, 3.44, 0.179, 297, 262, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2185, 4e6qB, 0.7592, 3.38, 0.193, 296, 264, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
2186, 4dn5B, 0.7592, 3.06, 0.205, 330, 259, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2187, 4d0wA, 0.7592, 3.28, 0.206, 289, 262, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2188, 3vbvA, 0.7592, 2.84, 0.195, 268, 251, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2189, 3eqrA, 0.7592, 3.11, 0.230, 270, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2190, 3e5aA, 0.7592, 2.86, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
2191, 3bgqA, 0.7592, 2.89, 0.179, 272, 252, HUMAN PIM-1 KINASE IN COMPLEX WITH AN TRIAZOLO PYRIDAZINE INHIBITOR VX2
2192, 2f2cB, 0.7592, 2.73, 0.181, 280, 248, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
2193, 4lrmB, 0.7591, 3.33, 0.180, 293, 261, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
2194, 4jr3A, 0.7591, 3.35, 0.184, 303, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
2195, 4cffA, 0.7591, 2.76, 0.218, 424, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2196, 4bzoA, 0.7591, 2.91, 0.183, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO- PYRAZINONE INHIBITOR
2197, 3gu8A, 0.7591, 3.04, 0.193, 278, 254, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
2198, 3at3A, 0.7591, 3.14, 0.183, 332, 257, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
2199, 5oq8A, 0.7590, 2.94, 0.214, 261, 252, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2200, 4wuaA, 0.7590, 3.02, 0.154, 344, 254, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
2201, 4fzdB, 0.7590, 3.09, 0.204, 275, 255, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
2202, 6ft9C, 0.7589, 3.13, 0.188, 337, 255, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
2203, 5tq5A, 0.7589, 3.60, 0.203, 291, 266, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2204, 3k2lA, 0.7589, 2.87, 0.205, 402, 249, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
2205, 1zwsD, 0.7589, 3.16, 0.187, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2206, 5oyfA, 0.7588, 2.95, 0.174, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
2207, 5cwzA, 0.7588, 2.96, 0.194, 284, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2208, 4alwA, 0.7588, 3.06, 0.193, 273, 254, BENZOFUROPYRIMIDINONE INHIBITORS OF PIM-1
2209, 3jy9A, 0.7588, 3.23, 0.192, 282, 260, JANUS KINASE 2 INHIBITORS
2210, 6drwA, 0.7587, 3.21, 0.189, 289, 259, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
2211, 4cfeA, 0.7587, 2.75, 0.218, 425, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2212, 3fupA, 0.7587, 3.29, 0.199, 284, 261, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2213, 3eygA, 0.7587, 3.21, 0.209, 280, 258, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2214, 2y7jA, 0.7587, 2.77, 0.193, 284, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2215, 1yi3A, 0.7587, 2.86, 0.183, 267, 251, CRYSTAL STRUCTURE OF PIM-1 BOUND TO LY294002
2216, 4zy6A, 0.7586, 3.33, 0.208, 284, 260, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2217, 4ytfA, 0.7586, 3.28, 0.195, 283, 261, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
2218, 4iebA, 0.7586, 3.17, 0.207, 472, 256, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2219, 4ft9A, 0.7586, 3.03, 0.206, 270, 253, CRYSTAL STRUCTURE OF THE CHK1
2220, 3w8lB, 0.7586, 3.02, 0.178, 326, 253, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
2221, 2x2mA, 0.7586, 3.01, 0.161, 286, 254, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2222, 2itpA, 0.7586, 3.29, 0.177, 305, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
2223, 2eb2A, 0.7586, 3.35, 0.169, 305, 261, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
2224, 5flfC, 0.7585, 3.20, 0.204, 283, 260, DISEASE LINKED MUTATION IN FGFR
2225, 5cy3A, 0.7585, 3.14, 0.187, 276, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT AND ORALLY BIOAVAILABLE BENZISOTHIAZOLE INHIBITOR
2226, 4ytcA, 0.7585, 3.30, 0.191, 284, 262, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
2227, 3ag9A, 0.7585, 3.07, 0.181, 323, 254, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2228, 6b2eA, 0.7584, 2.76, 0.218, 442, 248, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
2229, 5hu3A, 0.7584, 3.06, 0.194, 266, 253, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2230, 4n6zA, 0.7584, 2.90, 0.183, 272, 252, PIM1 COMPLEXED WITH A PYRIDYLCARBOXAMIDE
2231, 3kxxB, 0.7584, 3.24, 0.203, 305, 261, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
2232, 2pvhA, 0.7584, 3.20, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2233, 2ojgA, 0.7584, 2.75, 0.220, 337, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2234, 1yxtA, 0.7584, 3.05, 0.193, 274, 254, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMPPNP
2235, 4qtbA, 0.7583, 2.92, 0.209, 351, 254, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
2236, 4ianB, 0.7583, 2.69, 0.173, 319, 249, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
2237, 4ae6B, 0.7583, 3.04, 0.190, 321, 253, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2238, 1yrpB, 0.7583, 2.98, 0.190, 275, 252, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2239, 1yrpA, 0.7583, 2.98, 0.190, 275, 252, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
2240, 6b1uC, 0.7582, 2.71, 0.219, 459, 247, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
2241, 5xv7A, 0.7582, 3.10, 0.153, 350, 255, SRPK1 IN COMPLEX WITH ALECTINIB
2242, 5usyA, 0.7582, 3.26, 0.196, 287, 260, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
2243, 5cs6A, 0.7582, 2.96, 0.175, 327, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
2244, 4ft3A, 0.7582, 2.96, 0.214, 269, 252, CRYSTAL STRUCTURE OF THE CHK1
2245, 3gu4A, 0.7582, 3.09, 0.193, 280, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
2246, 6eiiA, 0.7581, 2.86, 0.179, 326, 251, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
2247, 5wevA, 0.7581, 3.24, 0.189, 293, 259, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
2248, 4jq7A, 0.7581, 3.24, 0.181, 303, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
2249, 4j98B, 0.7581, 3.13, 0.174, 304, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2250, 6gihA, 0.7580, 3.00, 0.182, 324, 253, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
2251, 6g8xA, 0.7580, 2.73, 0.221, 338, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2252, 5tq3A, 0.7580, 3.33, 0.200, 282, 260, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2253, 5eg3A, 0.7580, 3.34, 0.172, 301, 261, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
2254, 4ijpB, 0.7580, 2.70, 0.173, 333, 249, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
2255, 4hgeB, 0.7580, 3.34, 0.202, 288, 262, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 8
2256, 4fv3A, 0.7580, 2.74, 0.221, 346, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
2257, 2ojjA, 0.7580, 2.77, 0.220, 344, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2258, 1zwsF, 0.7580, 3.17, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2259, 6gl9A, 0.7579, 3.36, 0.205, 292, 264, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
2260, 6ehuB, 0.7579, 3.10, 0.180, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
2261, 5d9kA, 0.7579, 2.83, 0.181, 280, 248, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2262, 4fsrA, 0.7579, 2.98, 0.214, 269, 252, CRYSTAL STRUCTURE OF THE CHK1
2263, 3vbqA, 0.7579, 2.95, 0.194, 271, 252, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2264, 3tjcB, 0.7579, 3.36, 0.198, 287, 262, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
2265, 3kxxA, 0.7579, 3.26, 0.199, 305, 261, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
2266, 2xa4B, 0.7579, 3.23, 0.205, 275, 258, INHIBITORS OF JAK2 KINASE DOMAIN
2267, 2itqA, 0.7579, 3.21, 0.178, 300, 259, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
2268, 4u43A, 0.7578, 3.12, 0.195, 287, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
2269, 4c2vA, 0.7578, 2.74, 0.187, 270, 251, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2270, 4bznA, 0.7578, 2.92, 0.183, 272, 252, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH A PYRROLO(12-A) PYRAZINONE INHIBITOR
2271, 1oecA, 0.7578, 3.07, 0.176, 280, 256, FGFR2 KINASE DOMAIN
2272, 1jkkA, 0.7578, 3.10, 0.193, 277, 254, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2273, 5vjaA, 0.7577, 3.05, 0.193, 266, 254, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2274, 5nguA, 0.7577, 2.75, 0.217, 339, 249, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2275, 1zwsG, 0.7577, 3.17, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2276, 1yvjA, 0.7577, 3.21, 0.232, 288, 259, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
2277, 5y86A, 0.7576, 3.02, 0.214, 391, 252, CRYSTAL STRUCTURE OF KINASE 
2278, 5u6yL, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2279, 5u6yK, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2280, 5u6yJ, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2281, 5u6yI, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2282, 5u6yH, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2283, 5u6yG, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2284, 5u6yF, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2285, 5u6yE, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2286, 5u6yD, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2287, 5u6yC, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2288, 5u6yB, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2289, 5u6yA, 0.7576, 3.26, 0.193, 459, 259, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
2290, 5kziA, 0.7576, 2.99, 0.194, 273, 253, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN IMIDAZOPYRIDAZINE INHIBITOR.
2291, 5ebzC, 0.7576, 3.66, 0.188, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
2292, 4euuB, 0.7576, 3.08, 0.164, 307, 256, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2293, 4asxB, 0.7576, 3.16, 0.191, 307, 256, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
2294, 3eqrB, 0.7576, 2.88, 0.217, 271, 253, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
2295, 6bkuA, 0.7575, 2.69, 0.206, 267, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
2296, 4wd5A, 0.7575, 3.36, 0.192, 307, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
2297, 4j96A, 0.7575, 3.18, 0.174, 302, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
2298, 1f5qA, 0.7575, 3.09, 0.177, 296, 254, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
2299, 3iecD, 0.7574, 2.66, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2300, 3iecC, 0.7574, 2.68, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2301, 3gubA, 0.7574, 3.00, 0.190, 278, 252, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
2302, 3erkA, 0.7574, 2.85, 0.216, 350, 250, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
2303, 5vilB, 0.7573, 2.88, 0.229, 271, 249, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
2304, 4wnpC, 0.7573, 2.92, 0.236, 271, 250, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2305, 4lrmC, 0.7573, 3.33, 0.180, 293, 261, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
2306, 4euuA, 0.7573, 3.08, 0.164, 307, 256, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2307, 4e6dA, 0.7573, 3.25, 0.204, 286, 260, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
2308, 3bceB, 0.7573, 3.40, 0.170, 286, 259, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2309, 5otqA, 0.7572, 2.97, 0.174, 327, 253, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
2310, 5di1A, 0.7572, 2.99, 0.194, 285, 253, MAP4K4 IN COMPLEX WITH AN INHIBITOR
2311, 3q4tB, 0.7572, 2.93, 0.197, 308, 254, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2312, 3iokA, 0.7572, 3.26, 0.203, 285, 261, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2313, 3fupB, 0.7572, 3.38, 0.195, 287, 262, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
2314, 3ehaA, 0.7572, 3.06, 0.194, 279, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2315, 2yexA, 0.7572, 2.94, 0.210, 269, 252, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2316, 1wvxA, 0.7572, 2.97, 0.190, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2317, 5ezvC, 0.7571, 2.76, 0.218, 440, 248, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
2318, 4l3lA, 0.7571, 3.03, 0.190, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
2319, 3lpbB, 0.7571, 3.17, 0.202, 284, 258, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
2320, 3gu5A, 0.7571, 3.11, 0.193, 280, 254, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
2321, 2yakA, 0.7571, 3.08, 0.192, 277, 255, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
2322, 2c3kA, 0.7571, 2.92, 0.215, 262, 251, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2323, 6gl9B, 0.7570, 3.35, 0.221, 291, 263, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
2324, 4ijpA, 0.7570, 2.78, 0.172, 330, 250, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
2325, 3kk8A, 0.7570, 3.19, 0.198, 283, 258, CAMKII SUBSTRATE COMPLEX A
2326, 3gu7A, 0.7570, 3.11, 0.193, 280, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
2327, 1ig1A, 0.7570, 3.11, 0.193, 280, 254, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
2328, 6g9hA, 0.7569, 2.77, 0.221, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2329, 5ebzJ, 0.7569, 3.51, 0.196, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
2330, 5cavA, 0.7569, 3.19, 0.181, 306, 259, EGFR KINASE DOMAIN WITH COMPOUND 41A
2331, 3tjdA, 0.7569, 3.32, 0.181, 284, 260, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
2332, 3jy0A, 0.7569, 3.16, 0.193, 275, 254, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
2333, 6cd6D, 0.7568, 2.71, 0.206, 267, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2334, 5opbA, 0.7568, 2.96, 0.213, 262, 253, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH INDAZOLE LRRK2 INHIBITOR
2335, 4dn5A, 0.7568, 3.10, 0.193, 331, 259, CRYSTAL STRUCTURE OF NF-KB-INDUCING KINASE (NIK)
2336, 2pwlB, 0.7568, 3.06, 0.191, 286, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2337, 2pvkA, 0.7568, 3.21, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2338, 2ojiA, 0.7568, 2.80, 0.220, 344, 250, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
2339, 5m4iA, 0.7567, 3.31, 0.172, 331, 256, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2340, 2y7jC, 0.7567, 2.77, 0.193, 284, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2341, 2b7aB, 0.7567, 3.38, 0.198, 287, 262, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
2342, 1zwsB, 0.7567, 3.16, 0.195, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2343, 4zhxC, 0.7566, 2.78, 0.222, 452, 248, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2344, 4xrlA, 0.7566, 2.76, 0.221, 337, 249, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2345, 4txcA, 0.7566, 3.01, 0.193, 276, 254, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2346, 3pp0B, 0.7566, 3.38, 0.169, 296, 261, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2347, 2pvjA, 0.7566, 3.22, 0.163, 326, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2348, 5opsA, 0.7565, 2.78, 0.214, 258, 248, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
2349, 4r3rA, 0.7565, 3.52, 0.178, 309, 264, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
2350, 4p7eA, 0.7565, 3.37, 0.203, 281, 261, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
2351, 3iecA, 0.7565, 2.69, 0.219, 311, 247, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
2352, 1zwsH, 0.7565, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2353, 1zwsA, 0.7565, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2354, 5vjaC, 0.7564, 2.96, 0.191, 265, 251, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2355, 5ouuA, 0.7564, 2.81, 0.181, 324, 249, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
2356, 4u40A, 0.7564, 3.13, 0.194, 295, 258, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
2357, 4fv2A, 0.7564, 2.77, 0.221, 344, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
2358, 6babC, 0.7563, 3.15, 0.180, 284, 256, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2359, 5uyjA, 0.7563, 2.75, 0.206, 281, 248, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2360, 5friA, 0.7563, 3.34, 0.208, 301, 259, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
2361, 5ebzL, 0.7563, 3.55, 0.192, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
2362, 4zzoA, 0.7563, 2.75, 0.217, 339, 249, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
2363, 4j95B, 0.7563, 3.10, 0.175, 282, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2364, 1jksA, 0.7563, 3.12, 0.193, 280, 254, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2365, 6cd6B, 0.7562, 2.72, 0.211, 266, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2366, 5u6bB, 0.7562, 2.99, 0.176, 291, 255, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2367, 5m4uA, 0.7562, 3.19, 0.180, 332, 256, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
2368, 5lwnA, 0.7562, 3.42, 0.200, 290, 265, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
2369, 4j99B, 0.7562, 3.10, 0.175, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2370, 2pmlX, 0.7562, 3.24, 0.189, 340, 259, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
2371, 5nhfA, 0.7561, 2.78, 0.221, 339, 249, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
2372, 5mp8B, 0.7561, 2.91, 0.187, 323, 252, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
2373, 5lwmA, 0.7561, 3.42, 0.200, 290, 265, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
2374, 4hvgA, 0.7561, 3.27, 0.223, 281, 260, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
2375, 4fszA, 0.7561, 3.03, 0.210, 268, 252, CRYSTAL STRUCTURE OF THE CHK1
2376, 4dglD, 0.7561, 3.17, 0.179, 328, 257, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
2377, 2pmnX, 0.7561, 3.23, 0.189, 340, 259, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2378, 6fekA, 0.7560, 2.99, 0.170, 294, 253, ONCOGENIC POINT MUTATION OF RET RECEPTOR TYROSINE KINASE
2379, 5vuaB, 0.7560, 2.86, 0.196, 270, 250, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2380, 4wnpA, 0.7560, 2.92, 0.231, 273, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2381, 5my8A, 0.7559, 3.13, 0.153, 355, 255, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
2382, 3gu6A, 0.7559, 3.13, 0.193, 280, 254, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
2383, 1jklA, 0.7559, 3.13, 0.193, 280, 254, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
2384, 6glbA, 0.7558, 3.29, 0.206, 288, 262, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
2385, 5u6bD, 0.7558, 3.00, 0.176, 291, 255, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
2386, 5tq4A, 0.7558, 3.56, 0.194, 290, 263, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
2387, 5hibA, 0.7558, 3.50, 0.163, 314, 263, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2388, 5ebzA, 0.7558, 3.57, 0.192, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
2389, 4e6dB, 0.7558, 3.32, 0.203, 286, 261, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 7
2390, 2y7jB, 0.7558, 2.80, 0.193, 281, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2391, 2x0gA, 0.7558, 3.30, 0.185, 318, 260, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2392, 2gphA, 0.7558, 2.84, 0.220, 345, 250, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
2393, 1z9xC, 0.7558, 3.15, 0.187, 303, 257, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
2394, 5myvD, 0.7557, 3.02, 0.166, 351, 253, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
2395, 5ar5A, 0.7557, 3.18, 0.170, 284, 259, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2396, 3bkbA, 0.7557, 3.11, 0.207, 373, 256, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
2397, 1gjoA, 0.7557, 3.09, 0.176, 280, 256, THE FGFR2 TYROSINE KINASE DOMAIN
2398, 6glaA, 0.7556, 3.30, 0.206, 288, 262, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
2399, 6cd6C, 0.7556, 2.70, 0.206, 265, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2400, 3dgkA, 0.7556, 3.14, 0.193, 278, 254, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
2401, 2x7oA, 0.7556, 3.35, 0.211, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
2402, 1iasB, 0.7556, 3.33, 0.212, 324, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2403, 5ugxA, 0.7555, 3.08, 0.175, 297, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
2404, 5cu3B, 0.7555, 2.99, 0.181, 324, 254, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
2405, 4xneA, 0.7555, 2.76, 0.221, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2406, 2pvlA, 0.7555, 3.22, 0.163, 327, 257, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
2407, 2phkA, 0.7555, 3.08, 0.179, 277, 252, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
2408, 4lmuA, 0.7554, 2.80, 0.201, 265, 249, CRYSTAL STRUCTURE OF PIM1 IN COMPLEX WITH THE INHIBITOR QUERCETIN (RESULTING FROM DISPLACEMENT OF SKF86002)
2409, 3io7A, 0.7554, 3.25, 0.196, 282, 260, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
2410, 3cblA, 0.7554, 3.15, 0.202, 356, 257, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
2411, 3bceC, 0.7554, 3.51, 0.169, 286, 261, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2412, 3a99A, 0.7554, 3.04, 0.198, 273, 252, STRUCTURE OF PIM-1 KINASE CRYSTALLIZED IN THE PRESENCE OF P27KIP1 CARBOXY-TERMINAL PEPTIDE
2413, 1zwsC, 0.7554, 3.18, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2414, 6g33A, 0.7553, 3.11, 0.190, 335, 253, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
2415, 2vagA, 0.7553, 3.08, 0.190, 330, 252, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
2416, 2itwA, 0.7553, 3.38, 0.180, 300, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
2417, 4umpB, 0.7552, 2.68, 0.238, 324, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
2418, 4ub7A, 0.7552, 3.28, 0.165, 334, 255, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
2419, 4j99C, 0.7552, 3.12, 0.175, 291, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2420, 4fuxA, 0.7552, 2.77, 0.217, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
2421, 2x7oE, 0.7552, 3.35, 0.211, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
2422, 6g91A, 0.7551, 2.77, 0.217, 344, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2423, 6d8eA, 0.7551, 3.29, 0.181, 304, 259, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
2424, 5ukkA, 0.7551, 3.28, 0.199, 613, 261, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2425, 5cwzB, 0.7551, 3.02, 0.181, 284, 254, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2426, 3uixA, 0.7551, 2.81, 0.201, 266, 249, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2427, 3f5uA, 0.7551, 3.09, 0.194, 279, 253, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
2428, 6glbB, 0.7550, 3.32, 0.210, 288, 262, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
2429, 5y9mA, 0.7550, 2.95, 0.183, 320, 252, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
2430, 4iirA, 0.7550, 2.73, 0.165, 325, 248, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
2431, 4c61B, 0.7550, 3.23, 0.202, 274, 257, INHIBITORS OF JAK2 KINASE DOMAIN
2432, 3f5gA, 0.7550, 3.09, 0.194, 279, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
2433, 3comA, 0.7550, 3.03, 0.191, 264, 256, CRYSTAL STRUCTURE OF MST1 KINASE
2434, 6glaB, 0.7549, 3.25, 0.207, 286, 261, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
2435, 5uy6A, 0.7549, 2.73, 0.206, 282, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
2436, 5ebzE, 0.7549, 3.60, 0.199, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
2437, 5ebzD, 0.7549, 3.73, 0.182, 655, 269, CRYSTAL STRUCTURE OF HUMAN IKK1
2438, 5e8yA, 0.7549, 3.26, 0.163, 298, 257, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
2439, 4yo4A, 0.7549, 3.16, 0.193, 280, 254, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
2440, 4y85B, 0.7549, 2.88, 0.213, 306, 253, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
2441, 4xp2A, 0.7549, 2.76, 0.217, 337, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2442, 3gqiA, 0.7549, 3.25, 0.205, 304, 259, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
2443, 3eh9A, 0.7549, 3.09, 0.194, 278, 253, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
2444, 2x7oD, 0.7549, 3.35, 0.207, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
2445, 1koaA, 0.7549, 3.44, 0.169, 447, 260, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2446, 4zzmA, 0.7548, 2.82, 0.217, 344, 249, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
2447, 4y85A, 0.7548, 2.90, 0.213, 307, 253, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
2448, 4xp3A, 0.7548, 2.77, 0.217, 339, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2449, 3tjdB, 0.7548, 3.42, 0.198, 287, 262, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 19
2450, 2c3iB, 0.7548, 2.80, 0.201, 266, 249, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH IMIDAZOPYRIDAZIN I
2451, 1unhA, 0.7548, 2.36, 0.178, 276, 241, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2452, 3ot3A, 0.7547, 2.91, 0.208, 259, 250, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
2453, 1wvwA, 0.7547, 3.01, 0.186, 275, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2454, 1rw8A, 0.7547, 3.30, 0.217, 301, 258, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
2455, 1erkA, 0.7547, 2.86, 0.220, 357, 250, STRUCTURE OF SIGNAL-REGULATED KINASE
2456, 4xj0B, 0.7546, 2.85, 0.221, 338, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
2457, 2e9uA, 0.7546, 3.01, 0.219, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
2458, 2e9oA, 0.7546, 3.05, 0.214, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
2459, 1m2rA, 0.7546, 3.27, 0.163, 327, 258, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
2460, 5oq6A, 0.7545, 2.86, 0.221, 257, 249, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
2461, 5o0yA, 0.7545, 3.25, 0.176, 288, 256, TLK2 KINASE DOMAIN FROM HUMAN 
2462, 4zznA, 0.7545, 2.78, 0.217, 338, 249, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
2463, 2x7oB, 0.7545, 3.36, 0.211, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
2464, 6cmjA, 0.7544, 2.96, 0.201, 285, 249, HUMAN CAMKK2 WITH GSK650393
2465, 5ebzK, 0.7544, 3.69, 0.191, 655, 267, CRYSTAL STRUCTURE OF HUMAN IKK1
2466, 4s34A, 0.7544, 2.81, 0.216, 343, 250, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
2467, 4f70A, 0.7544, 2.98, 0.147, 327, 252, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
2468, 2x2lA, 0.7544, 3.09, 0.169, 287, 254, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
2469, 2qhmA, 0.7544, 2.92, 0.212, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
2470, 6cmjB, 0.7543, 3.03, 0.192, 284, 250, HUMAN CAMKK2 WITH GSK650393
2471, 5umoA, 0.7543, 2.82, 0.220, 347, 250, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
2472, 5op4A, 0.7543, 2.84, 0.213, 259, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
2473, 5mzlA, 0.7543, 2.85, 0.185, 269, 249, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
2474, 4ypdA, 0.7543, 3.17, 0.193, 281, 254, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
2475, 4l3jA, 0.7543, 3.08, 0.190, 291, 252, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
2476, 3bhhD, 0.7543, 3.08, 0.181, 286, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2477, 2ivvA, 0.7543, 3.02, 0.170, 282, 253, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR PP1
2478, 6g9nA, 0.7542, 2.80, 0.221, 344, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2479, 6g9mA, 0.7542, 2.80, 0.221, 341, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2480, 5ebzG, 0.7542, 3.55, 0.196, 655, 265, CRYSTAL STRUCTURE OF HUMAN IKK1
2481, 4zp5A, 0.7542, 3.14, 0.196, 284, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
2482, 4riyB, 0.7542, 3.37, 0.182, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
2483, 4ic7A, 0.7542, 3.02, 0.225, 355, 253, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2484, 4g3fA, 0.7542, 3.22, 0.196, 312, 260, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 2-(AMINOTHIAZOLY)PHENOL (CMP2)
2485, 4f6sA, 0.7542, 3.11, 0.150, 328, 254, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
2486, 4erkA, 0.7542, 2.84, 0.220, 350, 250, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
2487, 4enxA, 0.7542, 2.92, 0.196, 266, 250, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH INHIBITOR (2E5Z)-2- (2-CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-NITROBENZYLIDENE)THIAZOLIDIN-4- ONE
2488, 3bceA, 0.7542, 3.48, 0.169, 285, 260, CRYSTAL STRUCTURE OF THE ERBB4 KINASE
2489, 2pk9A, 0.7542, 2.84, 0.190, 287, 247, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
2490, 5oszA, 0.7541, 3.12, 0.176, 327, 256, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
2491, 3vjoA, 0.7541, 3.40, 0.173, 298, 260, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
2492, 3ug2A, 0.7541, 3.42, 0.172, 299, 261, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
2493, 3comB, 0.7541, 3.07, 0.179, 279, 257, CRYSTAL STRUCTURE OF MST1 KINASE
2494, 1tvoA, 0.7541, 2.84, 0.220, 350, 250, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
2495, 4fv1A, 0.7540, 2.79, 0.221, 342, 249, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
2496, 3vjnA, 0.7540, 3.27, 0.174, 297, 258, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
2497, 2x7oC, 0.7540, 3.36, 0.211, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
2498, 2w4jA, 0.7540, 3.19, 0.193, 276, 254, X-RAY STRUCTURE OF A DAP-KINASE 2-277
2499, 5yf9X, 0.7539, 2.81, 0.182, 319, 247, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
2500, 4s33A, 0.7539, 2.81, 0.220, 347, 250, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
2501, 1unhB, 0.7539, 2.36, 0.178, 276, 241, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
2502, 5hq0A, 0.7538, 2.78, 0.198, 292, 247, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
2503, 4y72A, 0.7538, 2.78, 0.198, 292, 247, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
2504, 3nyxA, 0.7538, 3.33, 0.218, 287, 262, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
2505, 3eqpB, 0.7538, 3.20, 0.233, 270, 257, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2506, 3tkhA, 0.7537, 3.00, 0.223, 269, 251, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S01
2507, 3kcfB, 0.7537, 3.21, 0.209, 324, 258, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2508, 2ywpA, 0.7537, 3.06, 0.214, 269, 252, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
2509, 6ge0A, 0.7536, 2.77, 0.222, 343, 248, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2510, 5tr6A, 0.7536, 3.34, 0.181, 272, 260, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2511, 2wouA, 0.7536, 3.20, 0.215, 299, 256, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
2512, 2e9nA, 0.7536, 3.08, 0.218, 269, 252, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
2513, 1zwsE, 0.7536, 3.21, 0.191, 278, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2514, 5y9mX, 0.7535, 2.92, 0.183, 319, 251, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
2515, 5lcjA, 0.7535, 2.79, 0.217, 345, 249, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
2516, 4wnpD, 0.7535, 3.01, 0.235, 272, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2517, 4qp3B, 0.7535, 2.80, 0.222, 331, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
2518, 3bhyA, 0.7535, 3.10, 0.187, 268, 252, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2519, 1golA, 0.7535, 2.90, 0.216, 357, 250, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
2520, 6g9dA, 0.7534, 2.81, 0.221, 345, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2521, 5oprA, 0.7534, 2.86, 0.213, 258, 249, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIDINE LRRK2 INHIBITOR
2522, 5ar2B, 0.7534, 3.27, 0.166, 285, 259, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
2523, 4rixB, 0.7534, 3.35, 0.178, 293, 258, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
2524, 4g3gA, 0.7534, 3.23, 0.196, 312, 260, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) V408L BOUND TO A 2-(AMINOTHIAZOLYL)PHENOL (CMP3)
2525, 2pwlA, 0.7534, 3.06, 0.192, 284, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549H MUTATION RESPONSIBLE FOR CROUZON SYNDROME.
2526, 5av3A, 0.7533, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
2527, 4j95C, 0.7533, 3.09, 0.176, 281, 256, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
2528, 4f9aC, 0.7533, 3.33, 0.216, 317, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
2529, 3qywA, 0.7533, 2.78, 0.217, 340, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2530, 4jr7A, 0.7532, 3.15, 0.153, 367, 255, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
2531, 4iirB, 0.7532, 2.69, 0.166, 327, 247, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
2532, 2xa4A, 0.7532, 3.05, 0.201, 276, 254, INHIBITORS OF JAK2 KINASE DOMAIN
2533, 5vubB, 0.7531, 2.87, 0.197, 269, 249, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2534, 5owlA, 0.7531, 3.30, 0.179, 331, 257, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
2535, 3we4A, 0.7531, 3.15, 0.194, 286, 252, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
2536, 1iasC, 0.7531, 3.35, 0.208, 330, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2537, 5j1vC, 0.7530, 3.11, 0.190, 314, 252, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
2538, 5ebzB, 0.7530, 3.71, 0.191, 655, 267, CRYSTAL STRUCTURE OF HUMAN IKK1
2539, 4d1sA, 0.7530, 3.11, 0.199, 280, 256, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
2540, 3zmmB, 0.7530, 3.25, 0.202, 274, 257, INHIBITORS OF JAK2 KINASE DOMAIN
2541, 3faaB, 0.7530, 3.32, 0.208, 324, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
2542, 6brcB, 0.7529, 2.78, 0.206, 260, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2543, 4wnpB, 0.7529, 2.98, 0.231, 272, 251, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2544, 4fsyA, 0.7529, 3.04, 0.207, 267, 251, CRYSTAL STRUCTURE OF THE CHK1
2545, 2yerA, 0.7529, 2.95, 0.211, 268, 251, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
2546, 1iasE, 0.7529, 3.21, 0.209, 330, 258, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2547, 5ugaA, 0.7528, 3.42, 0.181, 283, 260, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
2548, 5oq7A, 0.7528, 2.90, 0.224, 259, 250, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2549, 5o11A, 0.7528, 2.95, 0.180, 268, 250, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2550, 4s2zA, 0.7528, 2.83, 0.220, 346, 250, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
2551, 4gfgA, 0.7528, 3.16, 0.194, 277, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
2552, 4ftjA, 0.7528, 2.93, 0.225, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
2553, 4ft0A, 0.7528, 2.98, 0.216, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
2554, 3nczB, 0.7528, 3.10, 0.196, 379, 255, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2555, 1iasD, 0.7528, 3.40, 0.211, 330, 261, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2556, 5ebzF, 0.7527, 3.68, 0.192, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
2557, 4s32A, 0.7527, 2.82, 0.220, 346, 250, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
2558, 4pf4A, 0.7527, 3.17, 0.193, 278, 254, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
2559, 4iz5D, 0.7527, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2560, 4iz5C, 0.7527, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2561, 4g6oA, 0.7527, 2.72, 0.219, 339, 247, CRYSTAL STRUCTURE OF THE ERK2
2562, 4f9bA, 0.7527, 3.49, 0.213, 318, 258, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
2563, 4ae9B, 0.7527, 3.05, 0.187, 321, 252, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2564, 2psqA, 0.7527, 3.17, 0.183, 287, 257, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2565, 6brcA, 0.7526, 2.78, 0.206, 265, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
2566, 5uhnA, 0.7526, 3.18, 0.175, 282, 257, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
2567, 5j79B, 0.7526, 3.12, 0.164, 277, 256, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE COMPOUND 3 COMPLEX
2568, 4iz5B, 0.7526, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2569, 4iz5A, 0.7526, 2.86, 0.221, 347, 249, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
2570, 4g5jA, 0.7526, 3.24, 0.172, 307, 256, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
2571, 3ri1A, 0.7526, 3.17, 0.183, 285, 257, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2572, 3pjcA, 0.7526, 3.64, 0.228, 286, 263, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
2573, 3nizA, 0.7526, 3.25, 0.179, 288, 252, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
2574, 2z7lA, 0.7526, 2.73, 0.219, 329, 247, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
2575, 2wtkF, 0.7525, 2.99, 0.188, 268, 250, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
2576, 2c30A, 0.7525, 3.21, 0.185, 289, 259, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
2577, 5y5uA, 0.7524, 3.11, 0.200, 266, 255, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
2578, 5n51A, 0.7524, 2.82, 0.177, 268, 248, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
2579, 5j9yA, 0.7524, 3.48, 0.181, 300, 260, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
2580, 2r2pA, 0.7524, 3.29, 0.154, 283, 260, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
2581, 2r0uA, 0.7524, 3.00, 0.211, 269, 251, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
2582, 5u94A, 0.7523, 2.42, 0.216, 263, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2583, 4umpD, 0.7523, 2.76, 0.237, 321, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
2584, 4p7eB, 0.7523, 3.49, 0.198, 285, 262, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
2585, 4lrmE, 0.7523, 3.41, 0.180, 290, 261, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
2586, 3kcfC, 0.7523, 3.35, 0.208, 330, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2587, 5y9tA, 0.7522, 3.33, 0.185, 300, 260, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
2588, 5f20A, 0.7522, 3.12, 0.231, 274, 255, STRUCTURE OF TYK2 WITH INHIBITOR 4: 3-AZANYL-5-(2-METHYLPHENYL)-7-(1- METHYLPYRAZOL-3-YL)-1~{H}-PYRAZOLO[43-C]PYRIDIN-4-ONE
2589, 5auvA, 0.7522, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
2590, 4fsuA, 0.7522, 3.04, 0.207, 260, 251, CRYSTAL STRUCTURE OF THE CHK1
2591, 3tzmA, 0.7522, 3.21, 0.208, 295, 255, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
2592, 3ha6A, 0.7522, 2.72, 0.194, 263, 248, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
2593, 3cd3A, 0.7522, 3.15, 0.207, 352, 256, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
2594, 2qhnA, 0.7522, 2.95, 0.212, 268, 250, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
2595, 4qp1A, 0.7521, 2.83, 0.221, 342, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
2596, 4j98A, 0.7521, 3.21, 0.174, 304, 258, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
2597, 4g6nA, 0.7521, 2.80, 0.221, 341, 249, CRYSTAL STRUCTURE OF THE ERK2
2598, 4enyA, 0.7521, 2.90, 0.193, 261, 249, CRYSTAL STRUCTURE OF PIM-1 KINASE IN COMPLEX WITH (2E5Z)-2-(2- CHLOROPHENYLIMINO)-5-(4-HYDROXY-3-METHOXYBENZYLIDENE)THIAZOLIDIN-4- ONE
2599, 3ug1A, 0.7521, 3.27, 0.175, 296, 257, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
2600, 2pmoX, 0.7521, 3.29, 0.196, 340, 260, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
2601, 5av2A, 0.7520, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2602, 5ar3A, 0.7520, 3.09, 0.164, 279, 256, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
2603, 4i0sA, 0.7520, 3.04, 0.201, 267, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(6- CHLORO-1-METHYL-1H-INDAZOL-3-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID ISOPROPYLAMIDE
2604, 3dlsD, 0.7520, 3.08, 0.179, 284, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2605, 5vucB, 0.7519, 2.89, 0.197, 269, 249, PIM1 KINASE IN COMPLEX WITH A BENZOFURANONE INHIBITOR
2606, 5tt7A, 0.7519, 3.17, 0.184, 274, 256, DISCOVERY OF TAK-659 AN ORALLY AVAILABLE INVESTIGATIONAL INHIBITOR OF SPLEEN TYROSINE KINASE (SYK)
2607, 5auyA, 0.7519, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2608, 4xj0A, 0.7519, 2.88, 0.221, 345, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
2609, 4wkqA, 0.7519, 3.26, 0.175, 296, 257, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
2610, 4s31A, 0.7519, 2.84, 0.220, 347, 250, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
2611, 5av1A, 0.7518, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
2612, 4aguB, 0.7518, 2.33, 0.209, 276, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
2613, 3uodA, 0.7518, 2.90, 0.195, 266, 251, AURORA A IN COMPLEX WITH RPM1693
2614, 3r63A, 0.7518, 2.84, 0.220, 347, 250, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
2615, 1xbcA, 0.7518, 3.22, 0.198, 268, 258, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
2616, 5yf9B, 0.7517, 2.90, 0.180, 319, 250, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
2617, 5x2kA, 0.7517, 3.39, 0.182, 314, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
2618, 5cshB, 0.7517, 2.96, 0.183, 323, 251, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
2619, 2bfyA, 0.7517, 2.75, 0.157, 270, 249, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2620, 1py5A, 0.7517, 3.36, 0.212, 301, 259, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
2621, 5auxA, 0.7516, 3.13, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
2622, 4rx7A, 0.7516, 3.19, 0.183, 272, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR
2623, 4j97B, 0.7516, 3.06, 0.181, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2624, 3up2A, 0.7516, 2.83, 0.196, 266, 250, AURORA A IN COMPLEX WITH RPM1686
2625, 3socA, 0.7516, 3.14, 0.188, 307, 255, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
2626, 6cd6A, 0.7515, 2.73, 0.211, 264, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
2627, 5hg7A, 0.7515, 3.42, 0.181, 280, 260, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-{(3R4R)-3-[5-CHLORO-2- (1-METHYL-1H-PYRAZOL-4-YLAMINO)-7H-PYRROLO[23-D]PYRIMIDIN-4- YLOXYMETHYL]-4-METHOXY-PYRROLIDIN-1-YL}PROPENONE (PF-06459988)
2628, 4y85C, 0.7515, 2.93, 0.209, 303, 253, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
2629, 4g3eA, 0.7515, 3.18, 0.190, 314, 258, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO A 6-ALKYNYLINDOLINE (CMP1)
2630, 4aguC, 0.7515, 2.37, 0.209, 278, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
2631, 3kcfE, 0.7515, 3.39, 0.207, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2632, 3faaC, 0.7515, 3.43, 0.203, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
2633, 3dlsA, 0.7515, 3.07, 0.179, 285, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2634, 2aypA, 0.7515, 2.97, 0.223, 268, 251, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
2635, 5up3A, 0.7514, 2.64, 0.225, 258, 244, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2636, 5ebzI, 0.7514, 3.70, 0.188, 655, 266, CRYSTAL STRUCTURE OF HUMAN IKK1
2637, 4qp2B, 0.7514, 2.83, 0.222, 329, 248, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
2638, 4f9aA, 0.7514, 3.30, 0.220, 315, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
2639, 1szmB, 0.7514, 2.97, 0.183, 320, 251, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2640, 6gdmA, 0.7513, 2.79, 0.222, 341, 248, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2641, 5ebzH, 0.7513, 3.76, 0.187, 655, 267, CRYSTAL STRUCTURE OF HUMAN IKK1
2642, 4wnmA, 0.7513, 3.24, 0.194, 273, 258, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT TRIAZOLOPYRIDINE INHIBITOR
2643, 3lpbA, 0.7513, 3.34, 0.205, 278, 258, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
2644, 3faaE, 0.7513, 3.38, 0.212, 330, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
2645, 1iasA, 0.7513, 3.35, 0.208, 330, 260, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
2646, 3ri1B, 0.7511, 3.24, 0.182, 283, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
2647, 5oryA, 0.7510, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2648, 5hx8A, 0.7510, 3.38, 0.205, 291, 259, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
2649, 5av0A, 0.7510, 3.14, 0.194, 275, 253, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
2650, 4aguA, 0.7510, 2.38, 0.209, 277, 239, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
2651, 3zu7A, 0.7510, 3.00, 0.216, 344, 250, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
2652, 3umwA, 0.7510, 2.86, 0.202, 264, 248, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDAZOL-3-YL)METHYLENE]-6-METHOXY-7-(PIPERAZIN-1-YLMETHYL)BENZOFURAN- 3(2H)-ONE
2653, 2pvfA, 0.7510, 3.15, 0.176, 285, 256, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
2654, 6fckA, 0.7509, 3.01, 0.210, 269, 252, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2655, 5vjaD, 0.7509, 2.96, 0.185, 261, 249, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2656, 5v24B, 0.7509, 2.73, 0.216, 263, 245, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2657, 6bbvA, 0.7508, 3.61, 0.192, 289, 265, CRYSTAL STRUCTURE OF JAK2 IN COMPLEX WITH COMPOUND 25
2658, 5v19B, 0.7508, 2.83, 0.220, 260, 246, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
2659, 5hg9A, 0.7508, 3.54, 0.184, 280, 261, EGFR (L858R T790M V948R) IN COMPLEX WITH 1-[(3R4R)-3-[({2-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY) METHYL]-4-(TRIFLUOROMETHYL)PYRROLIDIN-1-YL]PROP-2-EN-1-ONE
2660, 4qp6B, 0.7508, 2.83, 0.222, 334, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
2661, 4hvhA, 0.7508, 3.23, 0.226, 278, 257, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
2662, 3uo5A, 0.7508, 2.99, 0.194, 267, 252, AURORA A IN COMPLEX WITH YL1-038-31
2663, 3u9nA, 0.7508, 2.86, 0.218, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
2664, 3rgfA, 0.7508, 3.14, 0.142, 321, 254, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
2665, 6bqpA, 0.7507, 2.78, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
2666, 5ortA, 0.7507, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2667, 5orrA, 0.7507, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2668, 5dt3A, 0.7507, 2.89, 0.195, 263, 251, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
2669, 4nzwB, 0.7507, 2.77, 0.219, 266, 247, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
2670, 4fttA, 0.7507, 3.03, 0.204, 266, 250, CRYSTAL STRUCTURE OF THE CHK1
2671, 4f9bC, 0.7507, 3.45, 0.215, 316, 256, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
2672, 3q4tA, 0.7507, 3.07, 0.194, 305, 253, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
2673, 6bleA, 0.7506, 2.79, 0.211, 265, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
2674, 4xozA, 0.7506, 2.86, 0.217, 341, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2675, 1xbaA, 0.7506, 3.24, 0.194, 266, 258, CRYSTAL STRUCTURE OF APO SYK TYROSINE KINASE DOMAIN
2676, 6g92A, 0.7505, 2.85, 0.221, 343, 249, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2677, 4rioA, 0.7505, 3.45, 0.223, 285, 260, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
2678, 4i6qA, 0.7505, 3.24, 0.226, 277, 257, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
2679, 2x8eA, 0.7505, 2.80, 0.223, 259, 247, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
2680, 5lckA, 0.7504, 2.79, 0.218, 345, 248, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
2681, 4riwB, 0.7504, 3.49, 0.185, 293, 259, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
2682, 4g5pA, 0.7504, 3.34, 0.181, 299, 260, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
2683, 4fyoA, 0.7504, 3.05, 0.201, 267, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH N-{(S)-1- [7-(34-DIMETHOXY-PHENYLAMINO)-THIAZOLO[54-D]PYRIMIDIN-5-YL]- PYRROLIDIN-3-YL}-TEREPHTHALAMIC ACID
2684, 2psqB, 0.7504, 3.27, 0.181, 286, 259, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
2685, 2brgA, 0.7504, 2.90, 0.213, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2686, 6fc8A, 0.7503, 3.01, 0.210, 269, 252, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
2687, 5orwA, 0.7503, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2688, 5lqfA, 0.7503, 2.72, 0.201, 287, 244, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2689, 4gt3A, 0.7503, 2.86, 0.221, 347, 249, ATP-BOUND FORM OF THE ERK2 KINASE
2690, 2fumB, 0.7503, 2.37, 0.217, 262, 240, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2691, 2b54A, 0.7503, 3.02, 0.176, 298, 250, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
2692, 1kobB, 0.7503, 3.60, 0.174, 352, 259, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2693, 6g9kA, 0.7502, 2.81, 0.222, 343, 248, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2694, 5uglA, 0.7502, 3.15, 0.179, 285, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
2695, 5osdA, 0.7502, 2.97, 0.195, 266, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2696, 5orxA, 0.7502, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2697, 5dnrA, 0.7502, 2.87, 0.192, 264, 250, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
2698, 4k33A, 0.7502, 3.22, 0.195, 293, 257, CRYSTAL STRUCTURE OF FGF RECEPTOR 3 (FGFR3) KINASE DOMAIN HARBORING THE K650E MUTATION A GAIN-OF-FUNCTION MUTATION RESPONSIBLE FOR THANATOPHORIC DYSPLASIA TYPE II AND SPERMATOCYTIC SEMINOMA
2699, 2f4jA, 0.7502, 3.55, 0.202, 287, 262, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
2700, 5otlA, 0.7501, 2.92, 0.184, 320, 250, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
2701, 5n52A, 0.7501, 2.80, 0.182, 268, 247, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
2702, 4fmqA, 0.7501, 2.98, 0.220, 350, 250, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2703, 3faaD, 0.7501, 3.44, 0.211, 330, 261, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
2704, 2itxA, 0.7501, 3.42, 0.181, 307, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
2705, 2ghgA, 0.7501, 2.97, 0.216, 269, 250, H-CHK1 COMPLEXED WITH A431994
2706, 5uoxA, 0.7500, 2.74, 0.216, 263, 245, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2707, 5ug9A, 0.7500, 3.53, 0.184, 280, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
2708, 5oroA, 0.7500, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2709, 5e1eA, 0.7500, 3.38, 0.202, 279, 258, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
2710, 3dlsE, 0.7500, 3.13, 0.174, 282, 253, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2711, 2c3jA, 0.7500, 2.83, 0.214, 257, 248, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
2712, 1u4dB, 0.7500, 2.97, 0.236, 262, 250, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
2713, 5ug8A, 0.7499, 3.53, 0.184, 280, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(1- METHYL-1H-PYRAZOL-4-YL)AMINO]-9-(PROPAN-2-YL)-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
2714, 5orzA, 0.7499, 2.97, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2715, 5orvA, 0.7499, 2.93, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2716, 5autA, 0.7499, 3.11, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
2717, 3ztxA, 0.7499, 2.89, 0.187, 269, 251, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2718, 5e1eB, 0.7498, 3.42, 0.205, 280, 259, HUMAN JAK1 KINASE IN COMPLEX WITH COMPOUND 30 AT 2.30 ANGSTROMS RESOLUTION
2719, 4ic7D, 0.7498, 3.01, 0.226, 353, 252, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
2720, 2bujB, 0.7498, 3.00, 0.191, 286, 251, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2721, 5osfA, 0.7497, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2722, 5oq7B, 0.7497, 2.83, 0.227, 256, 247, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
2723, 5e91A, 0.7497, 3.27, 0.172, 297, 256, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4- (MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE
2724, 5dn3A, 0.7497, 2.75, 0.194, 264, 248, AURORA A IN COMPLEX WITH ATP AND AA35.
2725, 5cxzA, 0.7497, 3.29, 0.198, 269, 257, SYK CATALYTIC DOMAIN COMPLEXED WITH NAPHTHYRIDINE INHIBITOR
2726, 4l42A, 0.7497, 2.99, 0.198, 299, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
2727, 3ue4A, 0.7497, 3.27, 0.205, 270, 258, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2728, 3faaA, 0.7497, 3.40, 0.208, 328, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
2729, 2clqA, 0.7497, 2.80, 0.223, 263, 247, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
2730, 2bzkB, 0.7497, 2.81, 0.182, 268, 247, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
2731, 5tozA, 0.7496, 3.36, 0.229, 278, 258, JAK3 WITH COVALENT INHIBITOR PF-06651600
2732, 4s30A, 0.7496, 2.83, 0.217, 342, 249, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
2733, 5orpA, 0.7495, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2734, 5iu2B, 0.7495, 2.93, 0.207, 313, 251, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
2735, 4b8mA, 0.7495, 2.89, 0.187, 270, 251, AURORA B KINASE IN COMPLEX WITH VX-680
2736, 3qyzA, 0.7495, 2.87, 0.221, 339, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2737, 2y7jD, 0.7495, 2.88, 0.193, 281, 249, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2738, 2jitA, 0.7495, 3.34, 0.165, 299, 260, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
2739, 1ol5A, 0.7495, 2.69, 0.194, 263, 247, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
2740, 1kobA, 0.7495, 3.67, 0.173, 352, 260, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2741, 6ccfB, 0.7494, 2.82, 0.206, 262, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
2742, 5wo4A, 0.7494, 3.41, 0.205, 292, 259, JAK1 COMPLEXED WITH COMPOUND 28
2743, 5os1A, 0.7494, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2744, 5ornA, 0.7494, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2745, 5ar3B, 0.7494, 3.20, 0.163, 276, 257, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
2746, 3pj8A, 0.7494, 3.12, 0.171, 288, 251, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
2747, 3mdyA, 0.7494, 3.22, 0.199, 320, 256, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
2748, 3kk9A, 0.7494, 2.96, 0.196, 275, 250, CAMKII SUBSTRATE COMPLEX B
2749, 5os5A, 0.7493, 2.98, 0.195, 267, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2750, 4j97A, 0.7493, 3.12, 0.173, 282, 255, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2751, 4f99A, 0.7493, 3.35, 0.220, 312, 255, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
2752, 3vbwA, 0.7493, 2.80, 0.186, 264, 247, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
2753, 3r83A, 0.7493, 3.09, 0.171, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
2754, 3qziA, 0.7493, 3.29, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
2755, 2fumA, 0.7493, 2.46, 0.216, 263, 241, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2756, 1ykrA, 0.7493, 3.01, 0.172, 298, 250, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
2757, 5oseA, 0.7492, 2.99, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2758, 4fuyA, 0.7492, 2.90, 0.218, 329, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
2759, 3zewA, 0.7492, 3.00, 0.143, 269, 252, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
2760, 3vf8A, 0.7492, 3.23, 0.198, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH PYRAZOLYLBENZIMIDAZOLE INHIBITOR 416
2761, 3dlsC, 0.7492, 2.99, 0.171, 281, 251, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2762, 2py3B, 0.7492, 3.10, 0.173, 284, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2763, 5os3A, 0.7491, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2764, 5os0A, 0.7491, 2.99, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2765, 5k3yB, 0.7491, 2.78, 0.149, 277, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2766, 5d9lA, 0.7491, 2.98, 0.189, 299, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2767, 5auzA, 0.7491, 3.13, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
2768, 5ar5B, 0.7491, 3.01, 0.170, 279, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
2769, 4uxlA, 0.7491, 3.25, 0.172, 288, 256, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
2770, 4gh2A, 0.7491, 3.00, 0.213, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
2771, 3eqpA, 0.7491, 3.23, 0.219, 268, 256, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
2772, 3dlsF, 0.7491, 3.12, 0.179, 281, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2773, 1y57A, 0.7491, 3.18, 0.207, 452, 256, STRUCTURE OF UNPHOSPHORYLATED C-SRC IN COMPLEX WITH AN INHIBITOR
2774, 5iu2A, 0.7490, 3.00, 0.202, 312, 252, DISCOVERY OF IMIDAZOQUINOLINES AS A NOVEL CLASS OF POTENT SELECTIVE AND IN VIVO EFFICACIOUS COT KINASE INHIBITORS
2775, 4xrjA, 0.7490, 2.88, 0.217, 344, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2776, 4wnoA, 0.7490, 3.08, 0.231, 272, 251, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
2777, 4e20A, 0.7490, 3.27, 0.230, 282, 257, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
2778, 3ppzA, 0.7490, 2.83, 0.217, 264, 249, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2779, 2b53A, 0.7490, 3.04, 0.171, 294, 252, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
2780, 5orsA, 0.7489, 2.98, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2781, 5k3yA, 0.7489, 2.78, 0.157, 267, 249, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2782, 5c26A, 0.7489, 3.17, 0.195, 272, 256, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
2783, 4rx8A, 0.7489, 3.23, 0.194, 269, 258, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT TRIAZINE INHIBITOR2
2784, 4qt1A, 0.7489, 3.18, 0.230, 277, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
2785, 4ft5A, 0.7489, 3.01, 0.197, 265, 249, CRYSTAL STRUCTURE OF THE CHK1
2786, 3qrtA, 0.7489, 3.05, 0.182, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
2787, 3qqlA, 0.7489, 3.27, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L3
2788, 2vgoB, 0.7489, 2.90, 0.175, 277, 252, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2789, 2vgoA, 0.7489, 2.91, 0.187, 268, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2790, 5av4A, 0.7488, 3.03, 0.196, 274, 250, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
2791, 4bicB, 0.7488, 2.71, 0.233, 259, 245, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2792, 3uo4A, 0.7488, 2.81, 0.197, 266, 249, AURORA A IN COMPLEX WITH RPM1680
2793, 3kcfD, 0.7488, 3.34, 0.208, 330, 259, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2794, 6bbuA, 0.7487, 3.45, 0.196, 279, 260, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH COMPOUND 25
2795, 4j97C, 0.7487, 3.10, 0.185, 283, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
2796, 2j0lA, 0.7487, 3.12, 0.200, 274, 255, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
2797, 5gtzA, 0.7486, 3.45, 0.186, 317, 258, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
2798, 4qpaA, 0.7486, 2.87, 0.222, 331, 248, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2799, 2r7iC, 0.7486, 2.96, 0.174, 321, 247, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2800, 2g2fA, 0.7486, 3.34, 0.201, 275, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2801, 2e9vB, 0.7486, 2.97, 0.224, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2802, 5w5oM, 0.7485, 3.19, 0.167, 276, 257, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2803, 5os6A, 0.7485, 2.99, 0.199, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2804, 5o12A, 0.7485, 2.83, 0.174, 264, 247, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH SMALL-MOLECULE INHIBITOR
2805, 5g15A, 0.7485, 2.79, 0.161, 265, 248, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
2806, 5ci7A, 0.7485, 3.00, 0.232, 276, 250, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
2807, 3r1qA, 0.7485, 3.26, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
2808, 3kcfA, 0.7485, 3.42, 0.208, 328, 260, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A PYRAZOLONE INHIBITOR
2809, 2bfyB, 0.7485, 2.85, 0.144, 278, 250, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2810, 2bfxA, 0.7485, 2.92, 0.187, 269, 251, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2811, 5wngB, 0.7484, 2.85, 0.201, 365, 249, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2812, 5ng0B, 0.7484, 3.01, 0.163, 282, 252, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
2813, 5auuA, 0.7484, 3.14, 0.194, 274, 252, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
2814, 4deeA, 0.7484, 2.98, 0.195, 271, 251, AURORA A IN COMPLEX WITH ADP
2815, 3r28A, 0.7484, 3.37, 0.160, 294, 257, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
2816, 2z60A, 0.7484, 3.50, 0.203, 281, 261, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
2817, 2e9vA, 0.7484, 2.97, 0.224, 268, 250, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
2818, 2a0cX, 0.7484, 3.14, 0.170, 294, 253, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
2819, 6g9jA, 0.7483, 2.79, 0.223, 347, 247, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
2820, 6c7yA, 0.7483, 3.44, 0.209, 273, 258, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS1 IN COMPLEX WITH JAK1 KINASE DOMAIN 
2821, 5jznA, 0.7483, 2.84, 0.202, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2822, 4o0sA, 0.7483, 2.94, 0.196, 265, 250, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
2823, 3dqwD, 0.7483, 3.20, 0.203, 276, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2824, 3bhhC, 0.7483, 3.11, 0.177, 285, 254, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2825, 2bvaB, 0.7483, 2.93, 0.167, 274, 252, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
2826, 5uorB, 0.7482, 2.64, 0.230, 262, 243, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
2827, 4xg6A, 0.7482, 3.14, 0.180, 271, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2828, 4e5wA, 0.7482, 3.44, 0.201, 292, 259, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
2829, 3dlsB, 0.7482, 3.15, 0.179, 280, 252, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
2830, 2fysA, 0.7482, 3.02, 0.217, 348, 249, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
2831, 5f4nA, 0.7481, 2.95, 0.209, 258, 249, MULTI-PARAMETER LEAD OPTIMIZATION TO GIVE AN ORAL CHK1 INHIBITOR CLINICAL CANDIDATE: (R)-5-((4-((MORPHOLIN-2-YLMETHYL)AMINO)-5- (TRIFLUOROMETHYL)PYRIDIN-2-YL)AMINO)PYRAZINE-2-CARBONITRILE (CCT245737)
2832, 4rvlA, 0.7481, 2.97, 0.206, 258, 248, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
2833, 4lrmD, 0.7481, 3.46, 0.172, 289, 261, EGFR D770_N771INSNPG IN COMPLEX WITH PD168393
2834, 4fv0A, 0.7481, 2.82, 0.222, 341, 248, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
2835, 4bibB, 0.7481, 2.60, 0.222, 258, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2836, 3rniA, 0.7481, 3.15, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
2837, 2py3A, 0.7481, 3.13, 0.173, 282, 254, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565G MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2838, 1pmeA, 0.7481, 2.74, 0.220, 333, 246, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
2839, 5w5oO, 0.7480, 3.17, 0.168, 276, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2840, 5os4A, 0.7480, 3.00, 0.195, 264, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2841, 5auwA, 0.7480, 3.04, 0.196, 274, 250, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
2842, 3vf9A, 0.7480, 3.26, 0.198, 265, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE SYK CATALYTIC DOMAIN WITH THIENOPYRAZOLYLINDOLE INHIBITOR 027
2843, 3dqwA, 0.7480, 3.18, 0.207, 278, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2844, 5w5oL, 0.7479, 3.14, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2845, 5ugcA, 0.7479, 3.54, 0.184, 280, 261, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH A COVALENT INHIBITOR N-[(3R4R)-4-FLUORO-1-{6-[(3- METHOXY-1-METHYL-1H-PYRAZOL-4-YL)AMINO]-9-METHYL-9H-PURIN-2- YL}PYRROLIDIN-3-YL]PROPANAMIDE
2846, 5clpA, 0.7479, 2.96, 0.184, 322, 250, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
2847, 4xp0A, 0.7479, 2.78, 0.219, 336, 247, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
2848, 4mygA, 0.7479, 2.71, 0.218, 335, 243, MAPK13 ACTIVE FORM
2849, 4debA, 0.7479, 2.92, 0.196, 264, 250, AURORA A IN COMPLEX WITH RK2-17-01
2850, 4deaA, 0.7479, 2.94, 0.195, 266, 251, AURORA A IN COMPLEX WITH YL1-038-18
2851, 3f69B, 0.7479, 3.11, 0.214, 282, 252, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
2852, 1m52B, 0.7479, 3.40, 0.208, 272, 259, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2853, 4qpaB, 0.7478, 2.89, 0.221, 345, 249, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
2854, 4j99D, 0.7478, 3.01, 0.183, 281, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
2855, 4ix5B, 0.7478, 3.60, 0.166, 350, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
2856, 4fsmA, 0.7478, 3.01, 0.205, 265, 249, CRYSTAL STRUCTURE OF THE CHK1
2857, 4c2wA, 0.7478, 2.82, 0.153, 268, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2858, 3dqwC, 0.7478, 3.19, 0.199, 275, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2859, 4l45A, 0.7477, 3.10, 0.190, 317, 248, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
2860, 3r1sA, 0.7477, 3.30, 0.169, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
2861, 1wzyA, 0.7477, 2.96, 0.216, 350, 250, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
2862, 1oplA, 0.7477, 3.34, 0.201, 451, 259, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2863, 5e92A, 0.7476, 3.24, 0.160, 298, 256, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH AMPPNP
2864, 5dr2A, 0.7476, 2.98, 0.195, 264, 251, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
2865, 4hvdA, 0.7476, 3.24, 0.230, 276, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
2866, 4h3qA, 0.7476, 2.90, 0.225, 352, 249, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
2867, 2w1cA, 0.7476, 2.74, 0.198, 261, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
2868, 5m44A, 0.7475, 3.12, 0.171, 329, 252, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
2869, 4z16B, 0.7475, 3.28, 0.223, 276, 256, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
2870, 4izaA, 0.7475, 2.97, 0.225, 346, 249, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
2871, 3dqwB, 0.7475, 3.19, 0.203, 278, 256, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
2872, 2z8cA, 0.7475, 3.07, 0.202, 297, 253, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
2873, 6bqqA, 0.7474, 2.85, 0.206, 271, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
2874, 5lqfD, 0.7474, 2.85, 0.201, 285, 244, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
2875, 5khwB, 0.7474, 3.47, 0.205, 276, 259, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
2876, 5khwA, 0.7474, 3.45, 0.205, 276, 259, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH ADP
2877, 4ix6B, 0.7474, 3.60, 0.166, 350, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
2878, 4ix4B, 0.7474, 3.60, 0.158, 350, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
2879, 5w5oJ, 0.7473, 3.17, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2880, 5hgiA, 0.7473, 3.23, 0.168, 395, 256, CRYSTAL STRUCTURE OF APO HUMAN IRE1 ALPHA
2881, 5ghvB, 0.7473, 3.04, 0.194, 265, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2882, 5aneA, 0.7473, 3.02, 0.172, 294, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
2883, 4l46A, 0.7473, 3.13, 0.184, 317, 250, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
2884, 4ftcA, 0.7473, 3.02, 0.205, 266, 249, CRYSTAL STRUCTURE OF THE CHK1
2885, 3pxrA, 0.7473, 3.20, 0.169, 294, 254, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
2886, 3b2tB, 0.7473, 3.10, 0.174, 287, 253, STRUCTURE OF PHOSPHOTRANSFERASE
2887, 2r7iD, 0.7473, 3.06, 0.175, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2888, 4l44A, 0.7472, 3.08, 0.192, 321, 250, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
2889, 4g3cA, 0.7472, 3.24, 0.186, 315, 258, CRYSTAL STRUCTURE OF APO MURINE NF-KAPPAB INDUCING KINASE (NIK)
2890, 4bn1A, 0.7472, 2.78, 0.198, 261, 248, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
2891, 4bidB, 0.7472, 2.68, 0.217, 258, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2892, 3raiA, 0.7472, 3.30, 0.165, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
2893, 3qzhA, 0.7472, 3.32, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
2894, 3qxoA, 0.7472, 3.19, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
2895, 2r7iB, 0.7472, 3.07, 0.175, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2896, 2clxA, 0.7472, 3.15, 0.170, 293, 253, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
2897, 1wvyA, 0.7472, 3.11, 0.194, 273, 253, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
2898, 4ix6A, 0.7471, 3.65, 0.166, 346, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
2899, 4bicA, 0.7471, 2.84, 0.228, 260, 246, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2900, 3lfqA, 0.7471, 3.05, 0.173, 289, 249, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
2901, 2r7iA, 0.7471, 3.06, 0.179, 322, 251, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
2902, 5feqA, 0.7470, 3.45, 0.183, 290, 257, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
2903, 3r6xA, 0.7470, 3.24, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
2904, 3mdyC, 0.7470, 3.32, 0.207, 320, 256, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (BMPR1B) IN COMPLEX WITH FKBP12 AND LDN- 193189
2905, 2vrxA, 0.7470, 2.92, 0.187, 268, 251, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2906, 1jktA, 0.7470, 3.25, 0.185, 276, 254, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2907, 5jznB, 0.7469, 2.81, 0.203, 266, 246, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2908, 4k77A, 0.7469, 3.36, 0.195, 282, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
2909, 4ix5A, 0.7469, 3.65, 0.166, 346, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
2910, 4fl1A, 0.7469, 3.21, 0.195, 268, 257, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
2911, 3qx2A, 0.7469, 3.21, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
2912, 3lxlA, 0.7469, 3.47, 0.233, 281, 258, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
2913, 5x28A, 0.7468, 3.34, 0.176, 310, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
2914, 5w5oH, 0.7468, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2915, 5ghvA, 0.7468, 3.04, 0.194, 265, 253, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2916, 5cwzC, 0.7468, 2.75, 0.202, 271, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
2917, 4j8nC, 0.7468, 2.97, 0.195, 266, 251, AURORA A KINASE APO
2918, 5amnA, 0.7467, 3.15, 0.170, 287, 253, THE DISCOVERY OF 2-SUBSTITUTED PHENOL QUINAZOLINES AS POTENT AND SELECTIVE RET KINASE INHIBITORS
2919, 3lfsA, 0.7467, 3.15, 0.172, 290, 250, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
2920, 3e3pA, 0.7467, 3.27, 0.177, 337, 254, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
2921, 4j8nB, 0.7466, 2.97, 0.195, 266, 251, AURORA A KINASE APO
2922, 4ivbA, 0.7466, 3.40, 0.205, 291, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
2923, 5x27A, 0.7465, 3.43, 0.179, 302, 257, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
2924, 5mjbB, 0.7465, 3.24, 0.148, 278, 257, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
2925, 5eykB, 0.7465, 2.82, 0.153, 275, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2926, 4j8nD, 0.7465, 2.97, 0.195, 265, 251, AURORA A KINASE APO
2927, 3rk9A, 0.7465, 3.20, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
2928, 3qx4A, 0.7465, 3.24, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
2929, 2brhA, 0.7465, 2.99, 0.213, 257, 249, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
2930, 5x26A, 0.7464, 3.36, 0.180, 302, 256, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
2931, 5orlA, 0.7464, 2.91, 0.197, 264, 249, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
2932, 4rssA, 0.7464, 3.19, 0.191, 269, 257, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE SYK WITH AN INHIBITOR
2933, 4j8nA, 0.7464, 2.98, 0.195, 266, 251, AURORA A KINASE APO
2934, 3pa3A, 0.7464, 2.95, 0.217, 259, 249, X-RAY CRYSTAL STRUCTURE OF COMPOUND 70 BOUND TO HUMAN CHK1 KINASE DOMAIN
2935, 3g2fA, 0.7464, 3.35, 0.171, 302, 257, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
2936, 6ccfA, 0.7463, 2.85, 0.206, 260, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
2937, 5w5oP, 0.7463, 3.17, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2938, 5w5oD, 0.7463, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2939, 4bhnB, 0.7463, 2.69, 0.217, 257, 244, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2940, 3royA, 0.7463, 3.36, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
2941, 3r7eA, 0.7463, 3.21, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
2942, 3hmmA, 0.7463, 3.15, 0.202, 293, 253, STRUCTURE OF ALK5 + GW855857
2943, 2g2hB, 0.7463, 3.46, 0.201, 272, 259, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
2944, 2evaA, 0.7463, 2.97, 0.196, 295, 250, STRUCTURAL BASIS FOR THE INTERACTION OF TAK1 KINASE WITH ITS ACTIVATING PROTEIN TAB1
2945, 4utdA, 0.7462, 3.11, 0.194, 266, 252, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2946, 4cegA, 0.7462, 2.96, 0.196, 264, 250, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
2947, 4bieB, 0.7462, 2.67, 0.226, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
2948, 3r73A, 0.7462, 3.37, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
2949, 2gmxA, 0.7462, 2.96, 0.212, 357, 250, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
2950, 1opkA, 0.7462, 3.37, 0.205, 449, 259, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2951, 1ol7A, 0.7462, 2.85, 0.197, 261, 249, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
2952, 1b6cD, 0.7462, 3.42, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
2953, 6dcgA, 0.7461, 2.78, 0.211, 326, 246, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
2954, 3r8pA, 0.7461, 3.15, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
2955, 3qwkA, 0.7461, 3.08, 0.190, 294, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
2956, 3qwjA, 0.7461, 3.22, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
2957, 4ix4A, 0.7460, 3.66, 0.158, 346, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
2958, 4ftrA, 0.7460, 2.94, 0.215, 258, 247, CRYSTAL STRUCTURE OF THE CHK1
2959, 3qtwA, 0.7460, 3.38, 0.171, 294, 257, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
2960, 3fqeA, 0.7460, 3.12, 0.196, 269, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH YM193306
2961, 2v7aA, 0.7460, 3.26, 0.210, 269, 257, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
2962, 1m52A, 0.7460, 3.34, 0.210, 271, 257, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
2963, 5w5oC, 0.7459, 3.18, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2964, 4dedA, 0.7459, 2.89, 0.197, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
2965, 3wf8A, 0.7459, 3.18, 0.192, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
2966, 5w5oE, 0.7458, 3.18, 0.165, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2967, 5dlsA, 0.7458, 2.87, 0.227, 257, 247, IDENTIFICATION OF NOVEL IN VIVO ACTIVE CHK1 INHIBITORS UTILIZING STRUCTURE GUIDED DRUG DESIGN
2968, 4u41A, 0.7458, 3.22, 0.198, 275, 253, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
2969, 4nifE, 0.7458, 2.98, 0.222, 348, 248, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2970, 4nifB, 0.7458, 2.98, 0.222, 349, 248, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
2971, 3rm6A, 0.7458, 3.24, 0.181, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
2972, 3nrmA, 0.7458, 2.93, 0.197, 263, 249, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
2973, 3ma3A, 0.7458, 2.89, 0.182, 266, 247, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A NAPHTHO-DIFURAN LIGAND
2974, 5c27A, 0.7457, 3.22, 0.191, 272, 256, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
2975, 4xg4A, 0.7457, 3.06, 0.198, 264, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
2976, 4c62A, 0.7457, 3.07, 0.198, 273, 252, INHIBITORS OF JAK2 KINASE DOMAIN
2977, 3r1yA, 0.7457, 3.27, 0.169, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
2978, 3qqkA, 0.7457, 3.23, 0.173, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L4
2979, 3pp0A, 0.7457, 3.39, 0.181, 286, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN HER2 (ERBB2).
2980, 3kxxC, 0.7457, 3.11, 0.205, 286, 254, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
2981, 2q0bB, 0.7457, 3.11, 0.170, 282, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
2982, 4fswA, 0.7456, 2.96, 0.206, 265, 248, CRYSTAL STRUCTURE OF THE CHK1
2983, 4ez7A, 0.7456, 2.99, 0.198, 302, 248, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
2984, 3qtzA, 0.7456, 3.30, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
2985, 2ds1A, 0.7456, 3.07, 0.173, 290, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
2986, 1pw2A, 0.7456, 3.07, 0.176, 294, 250, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
2987, 4oliA, 0.7455, 3.32, 0.230, 539, 256, THE PSEUDOKINASE/KINASE PROTEIN FROM JAK-FAMILY MEMBER TYK2
2988, 4i5cB, 0.7455, 3.43, 0.205, 291, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
2989, 3wf9A, 0.7455, 3.20, 0.192, 287, 250, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
2990, 1hckA, 0.7455, 3.19, 0.170, 294, 253, HUMAN CYCLIN-DEPENDENT KINASE 2
2991, 5w5oK, 0.7454, 3.22, 0.168, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
2992, 4pv0A, 0.7454, 3.27, 0.195, 268, 257, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH AN IMIDAZOPYRAZINE INHIBITOR
2993, 4k77B, 0.7454, 3.40, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 6
2994, 4ix3B, 0.7454, 3.63, 0.162, 350, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
2995, 4ivdB, 0.7454, 3.41, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
2996, 4hviA, 0.7454, 3.29, 0.223, 274, 256, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-1-METHYL-2-OXO-2-PIPERIDIN-1-YL- ETHYL)-AMIDE
2997, 4ez3A, 0.7454, 3.10, 0.187, 294, 252, CDK2 IN COMPLEX WITH NSC 134199
2998, 3ue4B, 0.7454, 3.20, 0.204, 268, 255, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
2999, 3fqsA, 0.7454, 3.17, 0.200, 268, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R406
3000, 5w5oI, 0.7453, 3.15, 0.169, 275, 254, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3001, 5ttvA, 0.7453, 3.49, 0.221, 280, 258, JAK3 WITH COVALENT INHIBITOR 6
3002, 4lynA, 0.7453, 3.01, 0.189, 287, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
3003, 4c62B, 0.7453, 3.22, 0.197, 271, 254, INHIBITORS OF JAK2 KINASE DOMAIN
3004, 3rk7A, 0.7453, 3.34, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
3005, 3jvrA, 0.7453, 2.93, 0.215, 258, 246, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3006, 2qohB, 0.7453, 3.54, 0.203, 281, 261, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3007, 4ivbB, 0.7452, 3.41, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXANECARBONITRILE
3008, 3kxxD, 0.7452, 3.16, 0.208, 288, 255, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
3009, 2y9qA, 0.7452, 2.92, 0.226, 349, 248, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3010, 1f5qC, 0.7452, 3.04, 0.185, 288, 249, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
3011, 5tq6A, 0.7451, 3.28, 0.203, 274, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3012, 4kd1A, 0.7451, 3.18, 0.170, 298, 253, CDK2 IN COMPLEX WITH DINACICLIB
3013, 3umxA, 0.7451, 2.83, 0.203, 261, 246, CRYSTAL STRUCTURE OF PIM1 KINASE IN COMPLEX WITH INHIBITOR (Z)-2-[(1H- INDOL-3-YL)METHYLENE]-7-(AZEPAN-1-YLMETHYL)-6-HYDROXYBENZOFURAN- 3(2H)-ONE
3014, 3lfnA, 0.7451, 2.98, 0.172, 285, 250, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
3015, 3kf4A, 0.7451, 3.59, 0.211, 281, 261, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3016, 2clqB, 0.7451, 2.77, 0.220, 259, 245, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3017, 5tq7A, 0.7450, 3.39, 0.202, 275, 257, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3018, 4dfnA, 0.7450, 3.28, 0.190, 269, 258, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH AN ADAMANTYLPYRAZINE INHIBITOR
3019, 2ydkA, 0.7450, 3.07, 0.214, 263, 252, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3020, 5hx8B, 0.7449, 3.43, 0.190, 279, 258, JAK1 COMPLEX WITH 4-[(4-AMINOCYCLOHEXYL)AMINO]-3-(1H-BENZIMIDAZOL-2- YL)-1H-PYRIDIN-2-ONE
3021, 4erwA, 0.7449, 2.97, 0.188, 292, 250, CDK2 IN COMPLEX WITH STAUROSPORINE
3022, 4e4nA, 0.7449, 3.41, 0.195, 291, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3023, 3vuhA, 0.7449, 2.75, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
3024, 3up7A, 0.7449, 2.89, 0.193, 264, 249, AURORA A IN COMPLEX WITH YL1-038-09
3025, 3clyA, 0.7449, 3.50, 0.170, 289, 259, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAINS TRAPPED IN TRANS-PHOSPHORYLATION REACTION
3026, 1hclA, 0.7449, 3.20, 0.170, 294, 253, HUMAN CYCLIN-DEPENDENT KINASE 2
3027, 5w5oA, 0.7448, 3.14, 0.169, 275, 254, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3028, 4twpB, 0.7448, 3.25, 0.211, 271, 256, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3029, 4ix3A, 0.7448, 3.68, 0.162, 346, 259, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
3030, 4e4nB, 0.7448, 3.42, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 49
3031, 3vugA, 0.7448, 2.77, 0.221, 356, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3032, 3qtxA, 0.7448, 3.27, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
3033, 6bl8A, 0.7447, 3.35, 0.209, 270, 258, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3034, 5jgaA, 0.7447, 3.06, 0.203, 296, 251, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 11C
3035, 4ixpA, 0.7447, 3.00, 0.222, 334, 248, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
3036, 4fynA, 0.7447, 3.09, 0.198, 267, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 3-(8-{4- [ETHYL-(2-HYDROXY-ETHYL)-AMINO]-PHENYLAMINO}-IMIDAZO[12-A]PYRAZIN-5- YL)-PHENOL
3037, 4bieA, 0.7447, 2.71, 0.222, 257, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3038, 3vuiA, 0.7447, 2.76, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
3039, 3r7vA, 0.7447, 3.22, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
3040, 2xmyA, 0.7447, 3.27, 0.161, 295, 254, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3041, 1qpjA, 0.7447, 3.08, 0.202, 265, 253, CRYSTAL STRUCTURE OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH STAUROSPORINE.
3042, 5w5oF, 0.7446, 3.20, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3043, 4zy5B, 0.7446, 3.26, 0.226, 287, 252, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
3044, 4oboA, 0.7446, 3.37, 0.200, 275, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
3045, 3uztA, 0.7446, 3.11, 0.204, 586, 250, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
3046, 3rjcA, 0.7446, 3.25, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR L4-12
3047, 3qu0A, 0.7446, 3.30, 0.172, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
3048, 3e3pB, 0.7446, 3.33, 0.176, 337, 255, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
3049, 5w5oB, 0.7445, 3.20, 0.169, 275, 255, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3050, 5ar4B, 0.7445, 3.12, 0.157, 279, 254, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3051, 4obqA, 0.7445, 3.16, 0.199, 275, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
3052, 4ivcB, 0.7445, 3.42, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3053, 4gvaA, 0.7445, 2.90, 0.217, 345, 249, ADP-BOUND FORM OF THE ERK2 KINASE
3054, 3qruA, 0.7445, 3.22, 0.185, 295, 254, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
3055, 3qqfA, 0.7445, 3.22, 0.174, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L1
3056, 3pa4A, 0.7445, 2.94, 0.218, 257, 248, X-RAY CRYSTAL STRUCTURE OF COMPOUND 2A BOUND TO HUMAN CHK1 KINASE DOMAIN
3057, 2vgpA, 0.7445, 2.81, 0.181, 265, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3058, 2v7aB, 0.7445, 3.24, 0.210, 268, 257, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3059, 1b6cB, 0.7445, 3.45, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3060, 4zogB, 0.7444, 3.31, 0.207, 268, 256, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3061, 4lgdD, 0.7444, 3.42, 0.183, 338, 257, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3062, 3sa0A, 0.7444, 2.85, 0.222, 354, 248, COMPLEX OF ERK2 WITH NORATHYRIOL
3063, 3rpvA, 0.7444, 3.27, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
3064, 3pxfA, 0.7444, 3.17, 0.196, 302, 250, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3065, 1b6cF, 0.7444, 3.43, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3066, 4lqmA, 0.7443, 3.52, 0.162, 305, 259, EGFR L858R IN COMPLEX WITH PD168393
3067, 4c61A, 0.7443, 3.05, 0.199, 272, 251, INHIBITORS OF JAK2 KINASE DOMAIN
3068, 3zmmA, 0.7443, 3.09, 0.198, 273, 252, INHIBITORS OF JAK2 KINASE DOMAIN
3069, 5wo4B, 0.7442, 3.45, 0.202, 280, 258, JAK1 COMPLEXED WITH COMPOUND 28
3070, 5w5oG, 0.7442, 3.25, 0.168, 275, 256, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3071, 4ftaA, 0.7442, 3.02, 0.206, 264, 248, CRYSTAL STRUCTURE OF THE CHK1
3072, 3rpoA, 0.7442, 3.25, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
3073, 4l43A, 0.7441, 2.94, 0.195, 316, 246, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
3074, 4iz7A, 0.7441, 2.78, 0.224, 344, 246, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3075, 3zepA, 0.7441, 3.20, 0.226, 274, 252, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3076, 3r7yA, 0.7441, 3.20, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
3077, 3kulB, 0.7441, 3.20, 0.165, 271, 255, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3078, 2exmA, 0.7441, 3.18, 0.170, 298, 253, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
3079, 1y91A, 0.7441, 3.10, 0.187, 286, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3080, 5os2A, 0.7440, 2.89, 0.198, 261, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3081, 5byyA, 0.7440, 2.87, 0.231, 338, 247, ERK5 IN COMPLEX WITH SMALL MOLECULE
3082, 4bgqA, 0.7440, 2.77, 0.199, 276, 246, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
3083, 3wf6A, 0.7440, 3.14, 0.197, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3084, 3rm7A, 0.7440, 3.19, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
3085, 3r9dA, 0.7440, 3.26, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
3086, 2gmxB, 0.7440, 2.93, 0.217, 357, 249, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
3087, 2e9pA, 0.7440, 3.12, 0.215, 269, 251, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3088, 1pxiA, 0.7440, 3.19, 0.170, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
3089, 4n0sA, 0.7439, 2.87, 0.222, 348, 248, COMPLEX OF ERK2 WITH CAFFEIC ACID
3090, 4b8mB, 0.7439, 3.13, 0.175, 279, 252, AURORA B KINASE IN COMPLEX WITH VX-680
3091, 3wf5A, 0.7439, 3.16, 0.197, 277, 249, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
3092, 3vudA, 0.7439, 2.78, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
3093, 1b6cH, 0.7439, 3.46, 0.208, 326, 259, CRYSTAL STRUCTURE OF THE CYTOPLASMIC DOMAIN OF THE TYPE I TGF-BETA RECEPTOR IN COMPLEX WITH FKBP12
3094, 4jajA, 0.7438, 3.06, 0.195, 265, 251, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3095, 4ivcA, 0.7438, 3.44, 0.198, 291, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR (TRANS-4-{2- [(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(6H)- YL}CYCLOHEXYL)ACETONITRILE
3096, 4c2vB, 0.7438, 3.02, 0.175, 280, 251, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
3097, 3pxqA, 0.7438, 3.14, 0.197, 298, 249, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
3098, 3c51B, 0.7438, 2.95, 0.194, 461, 247, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
3099, 3ad6A, 0.7438, 3.14, 0.201, 272, 254, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3100, 4jikA, 0.7437, 2.85, 0.215, 256, 246, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22A (R)-2-(4-CHLOROPHENYL)-8- (PIPERIDIN-3-YLAMINO)IMIDAZO[12-C]PYRIMIDINE-5-CARBOXAMIDE BOUND TO HUMAN CHK1 KINASE DOMAIN
3101, 3r71A, 0.7437, 3.18, 0.166, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
3102, 2wmrA, 0.7437, 2.80, 0.216, 254, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3103, 2qohA, 0.7437, 3.29, 0.211, 271, 256, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
3104, 5w5oN, 0.7436, 3.05, 0.171, 272, 252, IDENTIFICATION OF POTENT AND SELECTIVE RIPK2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES.
3105, 5gmpA, 0.7436, 3.32, 0.189, 305, 254, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3106, 5dosA, 0.7436, 2.75, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3107, 5ar2A, 0.7436, 3.04, 0.171, 277, 252, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3108, 4rx9A, 0.7436, 3.16, 0.192, 268, 255, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT PYRIMIDINE INHIBITOR
3109, 4gsbA, 0.7436, 2.80, 0.220, 343, 246, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
3110, 3vukA, 0.7436, 2.78, 0.221, 355, 244, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
3111, 5lmbA, 0.7435, 3.21, 0.185, 264, 254, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3112, 4gcjA, 0.7435, 3.20, 0.177, 304, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3113, 2no3A, 0.7435, 2.97, 0.212, 357, 250, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3114, 2fo0A, 0.7435, 3.40, 0.201, 465, 259, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3115, 1jktB, 0.7435, 3.29, 0.189, 276, 254, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3116, 5ttsA, 0.7434, 3.36, 0.227, 274, 256, JAK3 WITH COVALENT INHIBITOR 4
3117, 4wa9B, 0.7434, 3.42, 0.190, 276, 258, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3118, 4ftlA, 0.7434, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
3119, 2z7rA, 0.7434, 2.84, 0.181, 265, 243, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3120, 4ftmA, 0.7433, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
3121, 2itoA, 0.7433, 3.38, 0.180, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
3122, 2bfxB, 0.7433, 2.86, 0.169, 275, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
3123, 1mruA, 0.7433, 2.61, 0.216, 269, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3124, 5jgbA, 0.7432, 3.02, 0.196, 295, 250, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 10
3125, 5dt4A, 0.7432, 2.75, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3126, 5cs6B, 0.7432, 2.70, 0.177, 316, 243, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
3127, 4zy4B, 0.7432, 3.27, 0.226, 292, 252, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3128, 4px6A, 0.7432, 3.11, 0.201, 262, 254, SYK CATALYTIC DOMAIN IN COMPLEX WITH A POTENT PYRIDOPYRIMIDINONE INHIBITOR
3129, 4jboA, 0.7432, 3.12, 0.198, 266, 252, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3130, 5b2lA, 0.7431, 3.13, 0.198, 288, 252, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
3131, 4ivdA, 0.7431, 3.41, 0.202, 290, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 34
3132, 4ehzA, 0.7431, 3.52, 0.200, 290, 260, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3133, 4c2wB, 0.7431, 3.14, 0.179, 277, 252, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
3134, 3ql8A, 0.7431, 3.28, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
3135, 3pxzA, 0.7431, 3.10, 0.197, 302, 249, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
3136, 3kxzA, 0.7431, 3.09, 0.202, 263, 253, THE COMPLEX CRYSTAL STRUCTURE OF LCK WITH A PROBE MOLECULE W259
3137, 3kmmA, 0.7431, 3.12, 0.202, 270, 253, STRUCTURE OF HUMAN LCK KINASE WITH A SMALL MOLECULE INHIBITOR
3138, 3bu6A, 0.7431, 3.17, 0.202, 294, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
3139, 2qluA, 0.7431, 3.15, 0.171, 297, 251, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE II KINASE DOMAIN FROM HUMAN
3140, 2pzrB, 0.7431, 3.10, 0.171, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3141, 2pzpB, 0.7431, 3.11, 0.171, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3142, 2pz5B, 0.7431, 3.16, 0.174, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3143, 5drdA, 0.7430, 2.77, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3144, 4fsqA, 0.7430, 2.96, 0.211, 263, 246, CRYSTAL STRUCTURE OF THE CHK1
3145, 3zepD, 0.7430, 3.14, 0.227, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3146, 3srvB, 0.7430, 3.18, 0.201, 263, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3147, 3rzfA, 0.7430, 3.40, 0.187, 541, 256, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPAB KINASE BETA (I4122)
3148, 3qzfA, 0.7430, 3.22, 0.174, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
3149, 3qtqA, 0.7430, 3.15, 0.178, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
3150, 2pvyD, 0.7430, 3.02, 0.163, 283, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3151, 2b52A, 0.7430, 2.87, 0.177, 283, 248, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
3152, 5tvtA, 0.7429, 2.57, 0.243, 321, 239, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3153, 4j99A, 0.7429, 3.09, 0.178, 280, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
3154, 3vw6A, 0.7429, 2.69, 0.223, 255, 242, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3155, 3qtuA, 0.7429, 3.28, 0.185, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
3156, 1o6yA, 0.7429, 2.43, 0.210, 260, 238, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
3157, 3zc6A, 0.7428, 3.27, 0.220, 277, 254, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
3158, 3r8uA, 0.7428, 3.43, 0.160, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
3159, 3qxpA, 0.7428, 3.08, 0.187, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
3160, 2q0bA, 0.7428, 3.10, 0.171, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC E565A MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3161, 1pxjA, 0.7428, 3.23, 0.157, 294, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
3162, 5objA, 0.7427, 2.89, 0.194, 260, 248, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3163, 5mjbA, 0.7427, 3.18, 0.150, 276, 254, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
3164, 4ei4B, 0.7427, 3.45, 0.202, 280, 258, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3165, 3dk7B, 0.7427, 3.54, 0.205, 268, 259, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3166, 2pvyA, 0.7427, 3.04, 0.163, 288, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3167, 1xbbA, 0.7427, 3.21, 0.200, 268, 255, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH GLEEVEC
3168, 6bl8B, 0.7426, 3.25, 0.204, 268, 255, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3169, 4dhfA, 0.7426, 2.78, 0.195, 258, 246, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3170, 2x6dA, 0.7426, 2.79, 0.195, 255, 246, AURORA-A BOUND TO AN INHIBITOR
3171, 1pxpA, 0.7426, 3.16, 0.166, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
3172, 5tiuA, 0.7425, 3.20, 0.177, 266, 254, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH INHIBITOR
3173, 4dflA, 0.7425, 3.23, 0.188, 263, 255, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A SULFONAMIDOPYRAZINE PIPERIDINE INHIBITOR
3174, 3dk3B, 0.7425, 3.57, 0.204, 269, 260, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3175, 2vgpB, 0.7425, 3.04, 0.175, 277, 251, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
3176, 4zxtA, 0.7424, 2.88, 0.222, 348, 248, COMPLEX OF ERK2 WITH CATECHOL
3177, 4k6zA, 0.7424, 3.42, 0.205, 279, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 37
3178, 4j97D, 0.7424, 3.14, 0.170, 285, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
3179, 4d2pB, 0.7424, 2.77, 0.236, 323, 242, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3180, 3ti1A, 0.7424, 3.21, 0.173, 294, 254, CDK2 IN COMPLEX WITH SUNITINIB
3181, 3rk5A, 0.7424, 3.22, 0.177, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
3182, 5j7bA, 0.7423, 3.11, 0.158, 277, 253, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3183, 4rj3A, 0.7423, 3.09, 0.169, 287, 248, CDK2 WITH EGFR INHIBITOR COMPOUND 8
3184, 4ftkA, 0.7423, 3.01, 0.202, 263, 247, CRYSTAL STRUCTURE OF THE CHK1
3185, 4bhnA, 0.7423, 2.77, 0.222, 256, 243, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3186, 4au8B, 0.7423, 2.67, 0.202, 277, 242, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
3187, 3sqqA, 0.7423, 3.02, 0.175, 288, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
3188, 3o17B, 0.7423, 3.02, 0.212, 357, 250, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3189, 3amyA, 0.7423, 2.87, 0.176, 318, 245, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
3190, 1y8yA, 0.7423, 3.15, 0.175, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
3191, 1oirA, 0.7423, 3.02, 0.170, 286, 247, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
3192, 6gttA, 0.7422, 3.05, 0.202, 282, 248, HUMAN STK10 BOUND TO BIRB-796 
3193, 2zybA, 0.7422, 3.13, 0.202, 270, 253, CRYSTAL STRUCTURE OF PHENYLIMIDAZO PYRAZIN 2 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3194, 2zm3B, 0.7422, 3.10, 0.194, 296, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3195, 2r3hA, 0.7422, 3.17, 0.173, 289, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3196, 5v5nA, 0.7421, 3.05, 0.200, 294, 250, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
3197, 5jzjA, 0.7421, 2.80, 0.204, 271, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3198, 4mygB, 0.7421, 2.75, 0.214, 335, 243, MAPK13 ACTIVE FORM
3199, 4gfoA, 0.7421, 3.26, 0.235, 272, 255, TYK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
3200, 4e4lD, 0.7421, 3.57, 0.196, 281, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3201, 3lcdA, 0.7421, 3.09, 0.203, 290, 251, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3202, 1mruB, 0.7421, 2.61, 0.216, 271, 241, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3203, 4fk6B, 0.7420, 3.53, 0.192, 284, 261, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3204, 4ek5A, 0.7420, 3.15, 0.173, 289, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3205, 3uliA, 0.7420, 3.00, 0.172, 286, 250, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
3206, 3r9hA, 0.7420, 3.17, 0.178, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
3207, 3mtlA, 0.7420, 2.91, 0.198, 294, 247, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
3208, 2vtoA, 0.7420, 3.16, 0.175, 283, 251, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3209, 2dq7X, 0.7420, 2.97, 0.217, 262, 249, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
3210, 3r8zA, 0.7419, 3.09, 0.187, 290, 252, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
3211, 2of4A, 0.7419, 3.17, 0.201, 271, 254, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 1 BOUND TO LCK
3212, 2of2A, 0.7419, 3.17, 0.201, 271, 254, CRYSTAL STRUCTURE OF FURANOPYRIMIDINE 8 BOUND TO LCK
3213, 1mq4A, 0.7419, 2.85, 0.198, 261, 248, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3214, 1fvtA, 0.7419, 3.16, 0.175, 282, 251, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
3215, 4xg9B, 0.7418, 3.11, 0.187, 265, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3216, 4lgdB, 0.7418, 3.31, 0.184, 350, 255, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3217, 4jnwB, 0.7418, 3.38, 0.167, 321, 257, BACTERIALLY EXPRESSED TITIN KINASE
3218, 3lxkA, 0.7418, 3.51, 0.233, 279, 258, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
3219, 3fz1A, 0.7418, 2.98, 0.177, 284, 249, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
3220, 2ym6A, 0.7418, 2.86, 0.212, 253, 245, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3221, 4puzB, 0.7417, 3.14, 0.186, 265, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3222, 4i0tA, 0.7417, 3.19, 0.201, 266, 254, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(5678- TETRAHYDRO-IMIDAZO[15-A]PYRIDIN-1-YL)-5H-PYRROLO[23-B]PYRAZINE-7- CARBOXYLIC ACID TERT-BUTYLAMIDE
3223, 4dhfB, 0.7417, 2.85, 0.194, 258, 247, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3224, 3ad4A, 0.7417, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF METHOXY BENZOFURAN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3225, 3ac5A, 0.7417, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3226, 2xeyA, 0.7417, 2.82, 0.209, 252, 244, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3227, 2ittA, 0.7417, 3.41, 0.180, 302, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
3228, 5vt1A, 0.7416, 2.84, 0.207, 265, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO A BENZAMIDE INHIBITOR
3229, 4zs0A, 0.7416, 2.73, 0.192, 257, 245, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3230, 4zjiB, 0.7416, 3.35, 0.202, 276, 257, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3231, 4jnwA, 0.7416, 3.39, 0.167, 320, 257, BACTERIALLY EXPRESSED TITIN KINASE
3232, 4fkvA, 0.7416, 3.01, 0.188, 282, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3233, 4fkuA, 0.7416, 3.33, 0.189, 293, 254, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3234, 3zc6B, 0.7416, 3.22, 0.221, 276, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
3235, 2x2mB, 0.7416, 3.03, 0.161, 279, 249, CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN WITH INHIBITOR
3236, 2pzpA, 0.7416, 3.06, 0.179, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K526E MUTATION RESPONSIBLE FOR CROUZON SYNDROME
3237, 1h0vA, 0.7416, 3.26, 0.170, 288, 253, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
3238, 6es0B, 0.7415, 3.41, 0.160, 287, 257, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3239, 6b16B, 0.7415, 3.19, 0.229, 281, 249, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3240, 5jq5A, 0.7415, 3.04, 0.174, 287, 247, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
3241, 3tiyA, 0.7415, 3.23, 0.182, 293, 253, CDK2 IN COMPLEX WITH NSC 35676
3242, 3srvA, 0.7415, 3.18, 0.174, 262, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH A DIAMINOPYRIMIDINE CARBOXAMIDE INHIBITOR
3243, 3s00A, 0.7415, 3.34, 0.161, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L4-14
3244, 3hkoA, 0.7415, 3.36, 0.209, 319, 254, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
3245, 3gxlA, 0.7415, 3.18, 0.206, 285, 252, ALK-5 KINASE COMPLEX WITH GW857175
3246, 3ac3A, 0.7415, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3247, 3ac1A, 0.7415, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZIN DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3248, 4qp8B, 0.7414, 2.77, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
3249, 4d2pD, 0.7414, 2.99, 0.237, 317, 245, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3250, 2xnbA, 0.7414, 3.01, 0.181, 296, 249, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
3251, 2j5fA, 0.7414, 3.47, 0.167, 308, 258, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
3252, 1b38A, 0.7414, 3.24, 0.175, 290, 252, HUMAN CYCLIN-DEPENDENT KINASE 2
3253, 5deyB, 0.7413, 3.17, 0.229, 281, 249, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
3254, 5byzA, 0.7413, 3.11, 0.210, 348, 252, ERK5 IN COMPLEX WITH SMALL MOLECULE
3255, 4i5cA, 0.7413, 3.42, 0.202, 279, 257, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3256, 4fk6A, 0.7413, 3.51, 0.192, 285, 260, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
3257, 3wf7A, 0.7413, 3.34, 0.186, 288, 253, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
3258, 3o17A, 0.7413, 2.95, 0.209, 357, 249, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
3259, 3acjA, 0.7413, 3.14, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3260, 2x4fB, 0.7413, 3.38, 0.179, 288, 257, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3261, 5y5tA, 0.7412, 3.12, 0.178, 263, 253, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3262, 3vw6B, 0.7412, 2.56, 0.221, 253, 240, CRYSTAL STRUCTURE OF HUMAN APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) WITH IMIDAZOPYRIDINE INHIBITOR
3263, 3jvsA, 0.7412, 2.85, 0.218, 256, 243, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
3264, 3ackA, 0.7412, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRROLO PYRAZINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3265, 3ac4A, 0.7412, 3.16, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3266, 4xg3B, 0.7411, 3.03, 0.199, 267, 251, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3267, 3iggA, 0.7411, 3.26, 0.175, 290, 252, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
3268, 2pz5A, 0.7411, 3.12, 0.179, 280, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC N549T MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3269, 2c5yA, 0.7411, 3.12, 0.179, 290, 251, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
3270, 1wccA, 0.7411, 3.01, 0.172, 283, 250, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
3271, 1tkiB, 0.7411, 3.39, 0.167, 321, 257, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3272, 1tkiA, 0.7411, 3.39, 0.167, 321, 257, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
3273, 4xg7A, 0.7410, 3.28, 0.184, 266, 255, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3274, 3bymA, 0.7410, 3.14, 0.202, 271, 253, X-RAY CO-CRYSTAL STRUCTURE AMINOBENZIMIDAZOLE TRIAZINE 1 BOUND TO LCK
3275, 1qpcA, 0.7410, 3.15, 0.202, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3276, 1h01A, 0.7410, 3.04, 0.170, 286, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3277, 6cpwA, 0.7409, 2.87, 0.203, 328, 246, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
3278, 4qnyB, 0.7409, 2.92, 0.202, 339, 247, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3279, 3v3vA, 0.7409, 2.75, 0.222, 351, 243, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
3280, 3ad5A, 0.7409, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF TRIAZOLONE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3281, 2x8iA, 0.7409, 3.07, 0.204, 261, 250, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3282, 2wmvA, 0.7409, 2.77, 0.206, 251, 243, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3283, 1pxoA, 0.7409, 3.25, 0.162, 294, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
3284, 6eqiC, 0.7408, 3.77, 0.163, 392, 263, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3285, 3zepC, 0.7408, 3.14, 0.215, 276, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3286, 2zv2A, 0.7408, 2.82, 0.196, 256, 245, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2 BETA CAMKK2 KINASE DOMAIN IN COMPLEX WITH STO-609
3287, 2g2hA, 0.7408, 3.50, 0.204, 272, 260, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3288, 6eixA, 0.7407, 3.50, 0.181, 312, 259, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE Q207E MUTANT OF ACVR1 (ALK2) IN COMPLEX WITH A 2-AMINOPYRIDINE INHIBITOR K02288
3289, 4d2tD, 0.7407, 2.91, 0.238, 319, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3290, 3bu3A, 0.7407, 3.20, 0.202, 294, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
3291, 2r3pA, 0.7407, 3.27, 0.175, 289, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3292, 1pf8A, 0.7407, 2.99, 0.188, 298, 250, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
3293, 1ckpA, 0.7407, 3.12, 0.176, 279, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
3294, 4z16A, 0.7406, 3.22, 0.226, 271, 252, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3295, 4r5sA, 0.7406, 3.41, 0.180, 299, 255, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
3296, 3byoA, 0.7406, 3.16, 0.202, 270, 253, X-RAY CO-CRYSTAL STRUCTURE OF 2-AMINO-6-PHENYLPYRIMIDO[5  4 :56]PYRIMIDO[12-A]BENZIMIDAZOL-5(6H)-ONE 25 BOUND TO LCK
3297, 3a62A, 0.7406, 2.90, 0.201, 263, 244, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
3298, 2qg5A, 0.7406, 3.14, 0.179, 284, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3299, 2pzrA, 0.7406, 3.08, 0.171, 280, 251, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K641R MUTATION RESPONSIBLE FOR PFEIFFER SYNDROME
3300, 2jiuB, 0.7406, 3.70, 0.147, 309, 266, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3301, 1buhA, 0.7406, 3.07, 0.190, 287, 248, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
3302, 4l53A, 0.7405, 3.10, 0.199, 296, 251, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
3303, 4j95A, 0.7405, 3.15, 0.178, 279, 253, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
3304, 2zm1A, 0.7405, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO PYRAZIN 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3305, 2uzoA, 0.7405, 3.30, 0.174, 290, 253, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3306, 2itnA, 0.7405, 3.48, 0.180, 304, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
3307, 1qpeA, 0.7405, 3.16, 0.202, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3308, 1pkgA, 0.7405, 3.24, 0.209, 290, 254, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
3309, 1gz8A, 0.7405, 3.29, 0.174, 290, 253, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
3310, 5khxA, 0.7404, 3.47, 0.191, 276, 257, CRYSTAL STRUCTURE OF JAK1 IN COMPLEX WITH PF-4950736
3311, 5jgdA, 0.7404, 3.10, 0.203, 295, 251, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 12
3312, 5j7bB, 0.7404, 3.25, 0.157, 281, 255, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
3313, 4lg4A, 0.7404, 3.27, 0.170, 289, 253, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3314, 3rkbA, 0.7404, 3.09, 0.179, 294, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
3315, 3ac8A, 0.7404, 3.16, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3316, 3ac2A, 0.7404, 3.15, 0.202, 270, 253, CRYSTAL STRUCTURE OF PYRAZOLO PYRIMIDINE DERIVATIVE BOUND TO THE KINASE DOMAIN OF HUMAN LCK (AUTO-PHOSPHORYLATED ON TYR394)
3317, 2vrxB, 0.7404, 2.86, 0.169, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
3318, 2pmiC, 0.7404, 2.69, 0.187, 285, 241, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
3319, 2no3B, 0.7404, 3.04, 0.216, 357, 250, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
3320, 1qpdA, 0.7404, 3.15, 0.198, 270, 253, STRUCTURAL ANALYSIS OF THE LYMPHOCYTE-SPECIFIC KINASE LCK IN COMPLEX WITH NON-SELECTIVE AND SRC FAMILY SELECTIVE KINASE INHIBITORS
3321, 5wnhB, 0.7403, 2.77, 0.200, 365, 245, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3322, 5tq7B, 0.7403, 3.39, 0.203, 269, 256, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3323, 5t68A, 0.7403, 3.26, 0.196, 266, 255, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3324, 4zauA, 0.7403, 3.23, 0.187, 283, 252, AZD9291 COMPLEX WITH WILD TYPE EGFR
3325, 4xliA, 0.7403, 3.29, 0.208, 264, 255, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3326, 4qp7A, 0.7403, 2.77, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
3327, 3r8lA, 0.7403, 3.24, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR L3-4
3328, 3ppzB, 0.7403, 2.78, 0.200, 264, 245, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3329, 2a4lA, 0.7403, 2.92, 0.176, 286, 245, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
3330, 1u54A, 0.7403, 3.03, 0.204, 262, 250, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3331, 5l8lA, 0.7402, 2.91, 0.185, 263, 249, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3332, 4twpA, 0.7402, 3.46, 0.210, 266, 257, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3333, 4mneB, 0.7402, 3.13, 0.203, 270, 251, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3334, 4i21B, 0.7402, 3.75, 0.177, 302, 266, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
3335, 2vtrA, 0.7402, 3.25, 0.171, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3336, 2vtmA, 0.7402, 3.28, 0.175, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3337, 5lmaA, 0.7401, 3.06, 0.195, 267, 251, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3338, 5k4jA, 0.7401, 3.13, 0.175, 282, 251, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
3339, 5fedA, 0.7401, 3.45, 0.173, 288, 255, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3340, 5anjA, 0.7401, 3.17, 0.171, 291, 251, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3341, 4gs6A, 0.7401, 3.03, 0.197, 294, 249, IRREVERSIBLE INHIBITION OF TAK1 KINASE BY 5Z-7-OXOZEAENOL
3342, 2zm4A, 0.7401, 3.18, 0.202, 270, 253, CRYSTAL STRUCTURE OF IMIDAZO QUINOXALINE 1 BOUND TO THE KINASE DOMAIN OF HUMAN LCK ACTIVATED FORM (AUTO- PHOSPHORYLATED ON TYR394)
3343, 2g01B, 0.7401, 3.12, 0.215, 356, 251, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3344, 1w8cA, 0.7401, 3.30, 0.174, 290, 253, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
3345, 4fkiA, 0.7400, 3.04, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3346, 4e5wB, 0.7400, 3.42, 0.207, 278, 256, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 26
3347, 3sxsA, 0.7400, 3.08, 0.151, 264, 252, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
3348, 2c6iA, 0.7400, 3.21, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3349, 5e8vA, 0.7399, 3.25, 0.161, 296, 254, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A)
3350, 2r3rA, 0.7399, 3.26, 0.175, 290, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3351, 2c6lA, 0.7399, 3.32, 0.174, 291, 253, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3352, 2c6kA, 0.7399, 3.19, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3353, 1aq1A, 0.7399, 2.94, 0.192, 277, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
3354, 5t68B, 0.7398, 3.08, 0.194, 264, 252, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
3355, 4zsjA, 0.7398, 3.03, 0.225, 344, 249, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3356, 4zjjA, 0.7398, 3.25, 0.204, 280, 255, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3357, 3r8vA, 0.7398, 3.26, 0.170, 294, 253, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
3358, 3lckA, 0.7398, 3.17, 0.202, 270, 253, THE KINASE DOMAIN OF HUMAN LYMPHOCYTE KINASE (LCK) ACTIVATED FORM (AUTO-PHOSPHORYLATED ON TYR394)
3359, 2vtlA, 0.7398, 3.27, 0.175, 290, 252, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3360, 2h96A, 0.7398, 3.04, 0.212, 358, 250, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3361, 2c6oA, 0.7398, 3.15, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3362, 2c69A, 0.7398, 3.19, 0.175, 292, 252, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3363, 4zy6B, 0.7397, 3.18, 0.229, 280, 249, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3364, 4qp4A, 0.7397, 2.78, 0.222, 337, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
3365, 4fkqA, 0.7397, 3.11, 0.175, 283, 251, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3366, 4ei4A, 0.7397, 3.47, 0.195, 289, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 20
3367, 1pxlA, 0.7397, 3.25, 0.175, 290, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
3368, 5osmA, 0.7396, 3.24, 0.171, 292, 252, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
3369, 5l8kA, 0.7396, 3.01, 0.192, 266, 250, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
3370, 2v0dA, 0.7396, 3.20, 0.175, 292, 252, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3371, 2itzA, 0.7396, 3.30, 0.177, 302, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
3372, 5ievA, 0.7395, 3.06, 0.176, 284, 250, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
3373, 4f9cA, 0.7395, 3.22, 0.220, 306, 250, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
3374, 4au8A, 0.7395, 2.80, 0.193, 276, 243, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
3375, 2ityA, 0.7395, 3.36, 0.185, 300, 254, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
3376, 4fklA, 0.7394, 3.24, 0.171, 290, 252, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3377, 2ofuA, 0.7394, 3.17, 0.202, 272, 253, X-RAY CRYSTAL STRUCTURE OF 2-AMINOPYRIMIDINE CARBAMATE 43 BOUND TO LCK
3378, 2gqgB, 0.7394, 3.22, 0.206, 276, 253, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3379, 1fvrB, 0.7394, 3.39, 0.175, 300, 257, TIE2 KINASE DOMAIN
3380, 3r7iA, 0.7393, 3.22, 0.171, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
3381, 3qqgA, 0.7393, 3.42, 0.180, 294, 256, CDK2 IN COMPLEX WITH INHIBITOR L2-5
3382, 2qg5B, 0.7393, 3.17, 0.179, 280, 251, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3383, 6fu5A, 0.7392, 2.95, 0.173, 282, 249, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3384, 4zjiA, 0.7392, 3.35, 0.203, 278, 256, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3385, 3ztxB, 0.7392, 2.84, 0.166, 272, 247, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
3386, 1u4dA, 0.7392, 3.05, 0.218, 258, 248, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
3387, 6bqlA, 0.7391, 2.95, 0.202, 278, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
3388, 5gjdA, 0.7391, 3.16, 0.211, 292, 251, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
3389, 4z16C, 0.7391, 3.16, 0.227, 271, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3390, 4l3pA, 0.7391, 3.03, 0.197, 295, 249, CRYSTAL STRUCTURE OF 2-(1-BENZOTHIOPHEN-7-YL)-4-[1-(PIPERIDIN-4-YL)- 1H-PYRAZOL-4-YL]FURO[23-C]PYRIDIN-7-AMINE BOUND TO TAK1-TAB1
3391, 4at3A, 0.7391, 3.23, 0.229, 289, 253, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3392, 2r3oA, 0.7391, 3.18, 0.175, 289, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3393, 4xg3A, 0.7390, 3.15, 0.190, 262, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3394, 4trlA, 0.7390, 3.05, 0.163, 268, 251, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
3395, 4id7A, 0.7390, 3.18, 0.220, 268, 254, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
3396, 3zduA, 0.7390, 3.25, 0.190, 297, 252, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
3397, 2r3fA, 0.7390, 3.16, 0.171, 290, 251, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3398, 2bdwA, 0.7390, 3.46, 0.186, 309, 258, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
3399, 4fz6A, 0.7389, 3.17, 0.198, 266, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH [6-((S)-2- METHYL-PYRROLIDIN-1-YL)-PYRIDIN-2-YL]-(6-PHENYL-IMIDAZO[12- B]PYRIDAZIN-8-YL)-AMINE
3400, 3sdjK, 0.7389, 3.52, 0.210, 422, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3401, 3s0oA, 0.7389, 3.37, 0.165, 293, 254, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
3402, 3g2fB, 0.7389, 3.27, 0.174, 300, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II (BMPR2) AT 2.35 A RESOLUTION
3403, 6b2qB, 0.7388, 2.66, 0.258, 266, 240, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3404, 5mjaB, 0.7388, 3.13, 0.150, 274, 253, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3405, 5ieyA, 0.7388, 3.13, 0.176, 286, 250, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
3406, 4o0rB, 0.7388, 3.20, 0.229, 282, 249, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3407, 4fkrA, 0.7388, 3.11, 0.172, 282, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3408, 4ehzB, 0.7388, 3.47, 0.194, 280, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3409, 4e4lE, 0.7388, 3.45, 0.195, 280, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3410, 3zhpD, 0.7388, 3.12, 0.183, 264, 251, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3411, 3r7uA, 0.7388, 3.29, 0.167, 282, 252, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
3412, 3dk3A, 0.7388, 3.41, 0.206, 266, 257, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3413, 2r64A, 0.7388, 3.06, 0.177, 279, 249, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
3414, 4wrgA, 0.7387, 3.28, 0.175, 289, 252, 1.9 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN
3415, 4ehzC, 0.7387, 3.46, 0.195, 278, 257, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3416, 3sdjD, 0.7387, 3.52, 0.206, 422, 257, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3417, 2zm3D, 0.7387, 3.21, 0.198, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3418, 2wtwA, 0.7387, 2.75, 0.201, 256, 244, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
3419, 2w06A, 0.7387, 3.20, 0.175, 282, 251, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
3420, 1ke7A, 0.7387, 3.12, 0.176, 281, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
3421, 1di8A, 0.7387, 3.11, 0.176, 283, 250, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
3422, 4u5jB, 0.7386, 3.01, 0.209, 267, 249, C-SRC IN COMPLEX WITH RUXOLITINIB
3423, 4e26A, 0.7386, 3.04, 0.217, 270, 249, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3424, 3tizA, 0.7386, 3.42, 0.165, 293, 255, CDK2 IN COMPLEX WITH NSC 111848
3425, 3fbvK, 0.7386, 3.50, 0.206, 422, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3426, 1ke8A, 0.7386, 3.23, 0.175, 282, 251, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
3427, 5w86D, 0.7385, 3.18, 0.231, 272, 251, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3428, 4z16D, 0.7385, 3.24, 0.226, 271, 252, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3429, 3wblA, 0.7385, 2.93, 0.173, 283, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
3430, 3sdjB, 0.7385, 3.49, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3431, 3fbvD, 0.7385, 3.50, 0.206, 422, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3432, 2h96B, 0.7385, 2.96, 0.214, 357, 248, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
3433, 1jowB, 0.7385, 2.58, 0.179, 277, 240, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
3434, 5dt0A, 0.7384, 2.87, 0.195, 259, 246, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3435, 4z7hA, 0.7384, 3.26, 0.175, 385, 252, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
3436, 3sdjF, 0.7384, 3.49, 0.207, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3437, 3qzgA, 0.7384, 3.30, 0.165, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
3438, 3py1A, 0.7384, 3.32, 0.178, 302, 253, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
3439, 1v0oA, 0.7384, 2.76, 0.207, 276, 241, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3440, 1h0wA, 0.7384, 3.14, 0.175, 283, 251, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
3441, 5hcyA, 0.7383, 3.37, 0.169, 302, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-CARBOXAMIDE AZAINDOLE COMPOUND 13
3442, 5casA, 0.7383, 3.34, 0.182, 299, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41A
3443, 4yznA, 0.7383, 3.15, 0.199, 269, 251, HUMANIZED ROCO4 BOUND TO COMPOUND 19
3444, 4puzA, 0.7383, 3.12, 0.187, 263, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE (SYK) IN COMPLEX WITH GS- 9973
3445, 4fz7A, 0.7383, 3.17, 0.198, 265, 253, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 6-((1R2S)- 2-AMINO-CYCLOHEXYLAMINO)-4-(6-ETHYL-PYRIDIN-2-YLAMINO)-PYRIDAZINE-3- CARBOXYLIC ACID AMIDE
3446, 4e4lB, 0.7383, 3.49, 0.195, 279, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3447, 3sdjH, 0.7383, 3.49, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3448, 2itvA, 0.7383, 3.45, 0.180, 303, 255, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
3449, 1b39A, 0.7383, 3.19, 0.175, 290, 251, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
3450, 6cpfA, 0.7382, 2.91, 0.195, 259, 246, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3451, 5canA, 0.7382, 3.28, 0.183, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
3452, 3sdjN, 0.7382, 3.49, 0.207, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3453, 3sdjM, 0.7382, 3.49, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3454, 3s2pA, 0.7382, 3.07, 0.177, 279, 249, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
3455, 1ke5A, 0.7382, 3.14, 0.176, 281, 250, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
3456, 1fvrA, 0.7382, 3.34, 0.176, 299, 256, TIE2 KINASE DOMAIN
3457, 5dr9A, 0.7381, 2.79, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3458, 4v0gB, 0.7381, 3.22, 0.231, 272, 251, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3459, 3sdjE, 0.7381, 3.50, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3460, 3fbvN, 0.7381, 3.47, 0.207, 415, 256, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3461, 2dwbA, 0.7381, 2.82, 0.195, 259, 246, AURORA-A KINASE COMPLEXED WITH AMPPNP
3462, 1oplB, 0.7381, 3.34, 0.200, 365, 255, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3463, 1ke9A, 0.7381, 3.13, 0.176, 281, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
3464, 5iexA, 0.7380, 3.19, 0.171, 285, 252, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
3465, 4lg4C, 0.7380, 3.27, 0.181, 288, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3466, 3sdjG, 0.7380, 3.49, 0.207, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3467, 3sdjA, 0.7380, 3.49, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3468, 3ns9A, 0.7380, 3.16, 0.176, 289, 250, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
3469, 2w1hA, 0.7380, 3.12, 0.187, 283, 251, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
3470, 2vtsA, 0.7380, 2.98, 0.173, 282, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3471, 2r3iA, 0.7380, 3.29, 0.175, 289, 252, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3472, 1u54B, 0.7380, 3.18, 0.207, 261, 251, CRYSTAL STRUCTURES OF THE PHOSPHORYLATED AND UNPHOSPHORYLATED KINASE DOMAINS OF THE CDC42-ASSOCIATED TYROSINE KINASE ACK1 BOUND TO AMP-PCP
3473, 1ke6A, 0.7380, 3.14, 0.176, 280, 250, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
3474, 4xoyA, 0.7379, 3.04, 0.224, 326, 246, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
3475, 3lm0A, 0.7379, 3.25, 0.155, 278, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
3476, 3fbvF, 0.7379, 3.47, 0.207, 415, 256, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3477, 2x4fA, 0.7379, 3.38, 0.180, 289, 255, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3478, 5tq6B, 0.7378, 3.26, 0.206, 271, 253, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
3479, 5hcxA, 0.7378, 3.34, 0.170, 298, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH AZABENZIMIDAZOLE COMPOUND 7
3480, 4xeyA, 0.7378, 3.31, 0.193, 269, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3481, 4fkwA, 0.7378, 3.03, 0.189, 280, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3482, 3sdjC, 0.7378, 3.50, 0.211, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3483, 3ig7A, 0.7378, 3.04, 0.177, 278, 248, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
3484, 5uoxB, 0.7377, 2.62, 0.217, 252, 240, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3485, 5dpvA, 0.7377, 2.76, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3486, 4d2vD, 0.7377, 2.96, 0.238, 318, 244, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3487, 3sdjL, 0.7377, 3.50, 0.207, 415, 256, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3488, 5imeB, 0.7376, 3.23, 0.230, 280, 248, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
3489, 4d2vB, 0.7376, 2.96, 0.235, 322, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3490, 5ar4A, 0.7375, 3.05, 0.156, 274, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3491, 4zjjB, 0.7375, 3.26, 0.205, 277, 254, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
3492, 4h3pA, 0.7375, 2.89, 0.224, 342, 245, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3493, 4ehzD, 0.7375, 3.53, 0.194, 280, 258, THE JAK1 KINASE DOMAIN IN COMPLEX WITH INHIBITOR
3494, 4d2tB, 0.7375, 2.80, 0.232, 323, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3495, 4c8bB, 0.7375, 2.96, 0.146, 281, 247, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
3496, 3zhpC, 0.7375, 3.19, 0.206, 272, 253, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3497, 3qqjA, 0.7375, 3.41, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2
3498, 3o2mB, 0.7375, 2.99, 0.210, 358, 248, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3499, 3fbvM, 0.7375, 3.51, 0.214, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3500, 5mhqA, 0.7374, 3.16, 0.169, 291, 249, CCT068127 IN COMPLEX WITH CDK2
3501, 4fkgA, 0.7374, 3.03, 0.173, 286, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3502, 3kf4B, 0.7374, 3.38, 0.211, 270, 256, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3503, 3fbvG, 0.7374, 3.52, 0.214, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3504, 2c68A, 0.7374, 3.16, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3505, 5dr6A, 0.7373, 2.80, 0.197, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3506, 3sdmG, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3507, 3sdmF, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3508, 3sdmE, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3509, 3sdmD, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3510, 3sdmC, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3511, 3sdmB, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3512, 3sdmA, 0.7373, 3.51, 0.210, 415, 257, STRUCTURE OF OLIGOMERIC KINASE/RNASE IRE1 IN COMPLEX WITH AN OLIGONUCLEOTIDE
3513, 3py0A, 0.7373, 3.36, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR SU9516
3514, 3fbvE, 0.7373, 3.52, 0.214, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3515, 3fbvB, 0.7373, 3.51, 0.210, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3516, 2ituA, 0.7373, 3.44, 0.164, 304, 256, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
3517, 4o91A, 0.7372, 3.02, 0.214, 293, 248, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
3518, 3fbvL, 0.7372, 3.52, 0.214, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3519, 3fbvH, 0.7372, 3.51, 0.210, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3520, 3fbvA, 0.7372, 3.51, 0.210, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3521, 2hziB, 0.7372, 3.39, 0.204, 264, 255, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3522, 5osjA, 0.7371, 3.13, 0.172, 292, 250, CDK2(WT) WITH COVALENT ADDUCT AT C177
3523, 4qnyA, 0.7371, 2.95, 0.207, 333, 246, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
3524, 4ek3A, 0.7371, 3.11, 0.173, 287, 249, CRYSTAL STRUCTURE OF APO CDK2
3525, 3f9nA, 0.7371, 2.91, 0.212, 253, 245, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
3526, 2bvaA, 0.7371, 3.01, 0.173, 272, 249, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3527, 6b2qC, 0.7370, 2.71, 0.257, 264, 241, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3528, 4w9wA, 0.7370, 2.97, 0.182, 306, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
3529, 4u5jA, 0.7370, 3.08, 0.209, 267, 249, C-SRC IN COMPLEX WITH RUXOLITINIB
3530, 4l52A, 0.7370, 2.96, 0.190, 295, 247, CRYSTAL STRUCTURE OF 1-(4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7-YL) FURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}PIPERIDIN-1-YL)ETHAN-1-ONE BOUND TO TAK1-TAB1
3531, 4at5A, 0.7370, 3.25, 0.221, 294, 253, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
3532, 3r9oA, 0.7370, 3.15, 0.192, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
3533, 3dk7A, 0.7370, 3.36, 0.204, 265, 255, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3534, 2hziA, 0.7370, 3.38, 0.200, 268, 255, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3535, 5c8mA, 0.7369, 3.27, 0.183, 302, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
3536, 5ar7B, 0.7369, 3.18, 0.162, 278, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3537, 4i0rA, 0.7369, 3.09, 0.191, 264, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH 2-(345- TRIMETHOXY-PHENYL)-5H-PYRROLO[23-B]PYRAZINE-7-CARBOXYLIC ACID ISOPROPYLAMIDE
3538, 3fqhA, 0.7369, 3.14, 0.167, 262, 251, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3539, 3fbvC, 0.7369, 3.52, 0.210, 415, 257, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3540, 3a4oX, 0.7369, 2.91, 0.187, 259, 246, LYN KINASE DOMAIN
3541, 2xf0A, 0.7369, 2.81, 0.202, 251, 242, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3542, 2vtpA, 0.7369, 3.00, 0.177, 281, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3543, 2r3gA, 0.7369, 3.14, 0.173, 287, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3544, 1pxmA, 0.7369, 3.47, 0.173, 290, 254, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
3545, 5wp1A, 0.7368, 2.92, 0.223, 340, 247, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
3546, 5ttuA, 0.7368, 3.29, 0.222, 271, 252, JAK3 WITH COVALENT INHIBITOR 7
3547, 5te0A, 0.7368, 3.04, 0.177, 316, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
3548, 3eqfA, 0.7368, 3.26, 0.193, 314, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
3549, 2c6mA, 0.7368, 3.19, 0.175, 290, 251, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
3550, 1h07A, 0.7368, 2.99, 0.194, 285, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3551, 4ek6A, 0.7367, 2.98, 0.174, 278, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3552, 3zc6C, 0.7367, 3.32, 0.221, 275, 253, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
3553, 2vthA, 0.7367, 3.03, 0.173, 278, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
3554, 4lgdA, 0.7366, 3.34, 0.176, 350, 255, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3555, 1giiA, 0.7366, 3.13, 0.173, 279, 249, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3556, 5hczA, 0.7365, 3.43, 0.169, 300, 254, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
3557, 5buiA, 0.7365, 2.75, 0.223, 338, 242, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
3558, 4zsgA, 0.7365, 3.08, 0.221, 347, 249, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3559, 4qpsC, 0.7365, 3.43, 0.215, 276, 256, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3560, 3ckwA, 0.7365, 2.64, 0.191, 255, 241, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
3561, 1jsvA, 0.7365, 3.15, 0.173, 287, 249, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
3562, 5caqA, 0.7364, 3.31, 0.183, 301, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
3563, 4qp3A, 0.7364, 2.80, 0.226, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
3564, 4fkjA, 0.7364, 3.05, 0.173, 278, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3565, 1e1xA, 0.7364, 3.32, 0.175, 290, 252, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
3566, 4tthB, 0.7363, 2.63, 0.172, 256, 239, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
3567, 4bf2B, 0.7363, 2.64, 0.222, 252, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3568, 5y90A, 0.7362, 3.21, 0.198, 304, 252, MAP2K7 MUTANT -C218S
3569, 5xp5A, 0.7362, 3.10, 0.217, 267, 249, C-SRC IN COMPLEX WITH ATP-CHF
3570, 4yjoA, 0.7362, 3.09, 0.195, 267, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
3571, 4ek4A, 0.7362, 3.12, 0.173, 287, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
3572, 1g5sA, 0.7362, 2.87, 0.184, 275, 245, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
3573, 2r3mA, 0.7361, 2.99, 0.194, 278, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3574, 2g2fB, 0.7361, 3.27, 0.194, 264, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3575, 4e4lA, 0.7360, 3.51, 0.195, 277, 257, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3576, 6b2pA, 0.7359, 2.35, 0.209, 255, 234, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3577, 4zogA, 0.7359, 3.44, 0.206, 269, 257, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3578, 4y83B, 0.7359, 2.95, 0.205, 302, 249, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3579, 2xynA, 0.7359, 3.33, 0.205, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3580, 2gqgA, 0.7359, 3.28, 0.209, 277, 254, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3581, 5ng0A, 0.7358, 2.86, 0.156, 274, 244, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3582, 4w9xA, 0.7358, 2.97, 0.174, 300, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
3583, 4mkcA, 0.7358, 3.59, 0.175, 303, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
3584, 4c02A, 0.7358, 3.43, 0.173, 313, 255, CRYSTAL STRUCTURE OF HUMAN ACVR1 (ALK2) IN COMPLEX WITH FKBP12.6 AND DORSOMORPHIN
3585, 6fu5B, 0.7357, 3.16, 0.159, 286, 252, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
3586, 6fdyU, 0.7357, 2.83, 0.201, 261, 244, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH BOSUTINIB 
3587, 5aniA, 0.7357, 3.02, 0.173, 280, 248, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3588, 5a14A, 0.7357, 3.07, 0.191, 284, 246, HUMAN CDK2 WITH TYPE II INHIBITOR
3589, 3lm5A, 0.7357, 3.28, 0.159, 274, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
3590, 3ggfA, 0.7357, 3.09, 0.199, 275, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
3591, 2zm3A, 0.7357, 3.27, 0.197, 300, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3592, 2r3qA, 0.7357, 3.16, 0.173, 286, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3593, 2jfmA, 0.7357, 3.27, 0.175, 287, 251, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE (UNLIGANDED FORM)
3594, 2hz4A, 0.7357, 3.19, 0.203, 262, 251, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3595, 1rqqB, 0.7357, 3.28, 0.185, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3596, 1jsuA, 0.7357, 2.99, 0.180, 285, 244, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
3597, 5capA, 0.7356, 3.28, 0.183, 303, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
3598, 4xliB, 0.7356, 3.15, 0.207, 264, 251, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3599, 3py3A, 0.7356, 2.94, 0.204, 355, 245, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
3600, 2vtaA, 0.7356, 3.04, 0.173, 278, 248, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3601, 2jitB, 0.7356, 3.81, 0.148, 312, 264, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
3602, 5oo0A, 0.7355, 3.19, 0.176, 288, 250, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
3603, 4wsqA, 0.7355, 2.98, 0.173, 317, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3604, 1pxkA, 0.7355, 3.16, 0.172, 290, 250, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
3605, 5o7iA, 0.7354, 2.97, 0.220, 340, 246, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
3606, 5c8nA, 0.7354, 3.33, 0.183, 300, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
3607, 2vv9A, 0.7354, 2.98, 0.194, 279, 248, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
3608, 1v0oB, 0.7354, 2.68, 0.209, 274, 239, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
3609, 5hicA, 0.7353, 3.36, 0.170, 302, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH A IMIDAZOPYRIDINYL- AMINOPYRIMIDINE INHIBITOR
3610, 3unkA, 0.7353, 3.37, 0.180, 295, 255, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
3611, 1w0xC, 0.7353, 3.15, 0.192, 280, 250, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
3612, 1e1vA, 0.7353, 3.27, 0.175, 290, 251, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
3613, 4ftqA, 0.7352, 2.87, 0.231, 254, 242, CRYSTAL STRUCTURE OF THE CHK1
3614, 4bidA, 0.7352, 2.82, 0.216, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3615, 3pxyA, 0.7351, 3.38, 0.176, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR JWS648
3616, 3f69A, 0.7351, 2.69, 0.220, 270, 241, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3617, 2xynB, 0.7351, 3.30, 0.205, 264, 254, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3618, 1p4fA, 0.7351, 2.99, 0.199, 269, 246, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
3619, 4rj4A, 0.7350, 3.37, 0.187, 299, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
3620, 4fkpA, 0.7350, 3.06, 0.173, 279, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3621, 3eqhA, 0.7350, 3.43, 0.187, 314, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
3622, 2vtiA, 0.7350, 3.12, 0.177, 280, 249, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3623, 4xg2A, 0.7349, 3.02, 0.190, 259, 248, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
3624, 4u40B, 0.7349, 3.39, 0.185, 299, 259, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
3625, 4ek8A, 0.7349, 2.98, 0.174, 280, 247, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3626, 3qtrA, 0.7349, 3.20, 0.192, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
3627, 5i3oB, 0.7348, 2.93, 0.179, 302, 246, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3628, 4rj8A, 0.7347, 3.35, 0.183, 298, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
3629, 4fkoA, 0.7347, 3.17, 0.180, 291, 250, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3630, 3rahA, 0.7347, 3.19, 0.172, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
3631, 3o2mA, 0.7347, 3.03, 0.210, 358, 248, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
3632, 3my0M, 0.7347, 3.47, 0.184, 298, 256, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3633, 2qg5D, 0.7347, 3.18, 0.184, 283, 250, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3634, 5twlA, 0.7346, 2.58, 0.241, 319, 237, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3635, 5eykA, 0.7346, 2.81, 0.155, 263, 245, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
3636, 5em7A, 0.7346, 3.34, 0.183, 300, 252, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3637, 5bx0A, 0.7346, 3.37, 0.187, 315, 256, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
3638, 4lg4F, 0.7346, 2.96, 0.186, 276, 247, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3639, 3r9nA, 0.7346, 3.27, 0.171, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
3640, 5y5uB, 0.7345, 2.88, 0.200, 257, 245, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
3641, 3qqhA, 0.7345, 3.41, 0.180, 294, 255, CDK2 IN COMPLEX WITH INHIBITOR L2-2
3642, 5ar8B, 0.7344, 3.28, 0.158, 274, 253, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIPHENYLSULFONAMIDE
3643, 4d2wD, 0.7344, 2.89, 0.210, 326, 243, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3644, 3sw7A, 0.7344, 3.02, 0.181, 278, 248, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3645, 5ih9A, 0.7343, 2.64, 0.239, 308, 238, MELK IN COMPLEX WITH NVS-MELK8A
3646, 4qp9A, 0.7343, 2.87, 0.222, 335, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
3647, 4byiA, 0.7343, 2.59, 0.201, 254, 239, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3648, 2uznA, 0.7343, 2.97, 0.174, 279, 247, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
3649, 1h08A, 0.7343, 3.04, 0.177, 283, 248, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3650, 5ugxB, 0.7342, 2.99, 0.178, 282, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A E565A/D650V DOUBLE GAIN-OF-FUNCTION MUTATION
3651, 5hvkA, 0.7342, 3.31, 0.179, 297, 252, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3652, 5cauA, 0.7342, 3.40, 0.170, 297, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
3653, 3qtsA, 0.7342, 3.25, 0.187, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
3654, 2w17A, 0.7342, 2.90, 0.175, 278, 246, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
3655, 2btsA, 0.7342, 2.97, 0.183, 274, 246, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
3656, 4nj3A, 0.7341, 3.04, 0.190, 277, 247, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
3657, 4fktA, 0.7341, 2.93, 0.175, 278, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3658, 4cqgA, 0.7341, 2.43, 0.235, 313, 234, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
3659, 3rprA, 0.7341, 3.25, 0.187, 282, 251, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
3660, 5mahA, 0.7340, 2.63, 0.241, 316, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3661, 5calA, 0.7340, 3.29, 0.183, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
3662, 2r3kA, 0.7340, 3.04, 0.194, 277, 248, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3663, 2np8A, 0.7340, 2.65, 0.198, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
3664, 2ivsB, 0.7340, 3.00, 0.175, 277, 246, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED RET TYROSINE KINASE DOMAIN
3665, 1pxnA, 0.7340, 3.47, 0.156, 294, 256, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
3666, 5twuA, 0.7339, 2.73, 0.230, 318, 239, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
3667, 3ezvA, 0.7339, 3.02, 0.190, 277, 247, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
3668, 3dj7A, 0.7339, 2.73, 0.189, 257, 243, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
3669, 2b9iA, 0.7339, 2.96, 0.217, 338, 244, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
3670, 1v1kA, 0.7339, 2.95, 0.190, 277, 247, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3671, 3rmfA, 0.7338, 3.05, 0.181, 278, 248, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
3672, 3le6A, 0.7338, 3.07, 0.176, 283, 244, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
3673, 2yiyA, 0.7338, 3.02, 0.219, 293, 247, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
3674, 6cpeA, 0.7337, 2.83, 0.193, 256, 244, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
3675, 5em6A, 0.7337, 3.45, 0.186, 301, 253, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
3676, 4cnhB, 0.7337, 3.52, 0.180, 293, 255, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3677, 2g01A, 0.7337, 3.06, 0.213, 355, 249, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
3678, 6gipA, 0.7336, 3.44, 0.188, 296, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 2; 5-DIMETHYL CORE. 
3679, 5v19A, 0.7336, 2.52, 0.224, 250, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3680, 4v0gA, 0.7336, 3.21, 0.233, 267, 249, JAK3 IN COMPLEX WITH A COVALENT EGFR INHIBITOR
3681, 4f4pA, 0.7336, 3.30, 0.198, 262, 253, SYK IN COMPLEX WITH LIGAND LASW836
3682, 2xynC, 0.7336, 3.29, 0.206, 262, 253, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
3683, 1dm2A, 0.7336, 2.91, 0.180, 274, 245, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
3684, 5ar7A, 0.7335, 3.15, 0.164, 278, 250, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
3685, 4bf2A, 0.7335, 2.71, 0.222, 253, 239, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3686, 3ppkB, 0.7335, 2.83, 0.221, 264, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3687, 3lvpC, 0.7335, 3.32, 0.200, 293, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3688, 3d14A, 0.7335, 2.80, 0.189, 262, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
3689, 2r3jA, 0.7335, 3.14, 0.193, 278, 249, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3690, 2jflA, 0.7335, 3.26, 0.172, 286, 250, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE ( DIPHOSPHORYLATED FORM) BOUND TO 5- AMINO-3-((4-( AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-12 4-TRIAZOLE-1-CARBOTHIOAMIDE
3691, 5xp5B, 0.7334, 3.13, 0.205, 267, 249, C-SRC IN COMPLEX WITH ATP-CHF
3692, 5c8kA, 0.7334, 3.32, 0.183, 300, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
3693, 4bibA, 0.7334, 2.81, 0.220, 254, 241, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3694, 2j51A, 0.7334, 3.30, 0.171, 288, 251, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 5- AMINO-3-((4-(AMINOSULFONYL)PHENYL)AMINO)-N-(26- DIFLUOROPHENYL)-1H-124-TRIAZOLE-1-CARBOTHIOAMIDE
3695, 5feeA, 0.7333, 3.47, 0.174, 287, 253, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
3696, 5dewB, 0.7333, 3.11, 0.231, 281, 247, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
3697, 3kl8C, 0.7333, 3.16, 0.189, 256, 249, CAMKIINTIDE INHIBITOR COMPLEX
3698, 1rqqA, 0.7333, 3.31, 0.185, 294, 254, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3699, 5wfjA, 0.7332, 3.35, 0.222, 265, 252, THE JAK3 KINASE DOMAIN IN COMPLEX WITH A COVALENT INHIBITOR
3700, 5w86C, 0.7332, 3.23, 0.233, 273, 249, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
3701, 5anoA, 0.7331, 2.94, 0.175, 277, 246, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
3702, 4yc8B, 0.7331, 3.20, 0.199, 264, 251, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3703, 4hzrA, 0.7331, 3.10, 0.225, 261, 249, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3704, 3f6xD, 0.7331, 3.01, 0.206, 267, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3705, 2vtjA, 0.7331, 2.98, 0.190, 276, 247, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3706, 6b2qA, 0.7330, 2.52, 0.263, 261, 236, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3707, 4qp6A, 0.7330, 2.85, 0.226, 339, 243, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
3708, 4bfmA, 0.7330, 2.43, 0.235, 313, 234, THE CRYSTAL STRUCTURE OF MOUSE PK38
3709, 5mafA, 0.7329, 2.65, 0.241, 315, 237, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3710, 5hvkC, 0.7329, 3.28, 0.179, 291, 251, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3711, 4yc6C, 0.7329, 2.82, 0.179, 285, 240, CDK1/CKS1
3712, 4rj7A, 0.7329, 3.38, 0.183, 295, 252, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 1
3713, 2j9mA, 0.7329, 2.92, 0.183, 275, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
3714, 1u46B, 0.7329, 3.01, 0.211, 257, 246, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
3715, 5ng2B, 0.7328, 3.01, 0.150, 278, 246, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3716, 4fksA, 0.7328, 2.96, 0.191, 275, 246, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
3717, 3q4uB, 0.7328, 3.37, 0.181, 300, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3718, 3kulA, 0.7328, 3.18, 0.167, 267, 251, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3719, 2zm3C, 0.7328, 3.30, 0.197, 296, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3720, 2fvdA, 0.7328, 2.87, 0.180, 284, 244, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
3721, 5k00A, 0.7327, 2.59, 0.233, 311, 236, MELK IN COMPLEX WITH NVS-MELK5
3722, 5ew8A, 0.7327, 3.24, 0.196, 291, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3723, 4yc6E, 0.7327, 2.86, 0.183, 285, 240, CDK1/CKS1
3724, 3psdB, 0.7327, 2.86, 0.224, 264, 245, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3725, 1vyzA, 0.7327, 3.08, 0.174, 279, 247, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
3726, 5vndB, 0.7326, 3.34, 0.210, 295, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3727, 3zbfA, 0.7326, 3.23, 0.169, 281, 249, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
3728, 3pa5A, 0.7326, 2.86, 0.223, 255, 242, X-RAY CRYSTAL STRUCTURE OF COMPOUND 1 BOUND TO HUMAN CHK1 KINASE DOMAIN
3729, 2uv2A, 0.7326, 3.11, 0.170, 286, 247, CRYSTAL STRUCTURE OF HUMAN STE20-LIKE KINASE BOUND TO 4-(4-( 5-CYCLOPROPYL-1H-PYRAZOL-3-YLAMINO)-QUINAZOLIN-2-YLAMINO)- PHENYL)-ACETONITRILE
3730, 5v24A, 0.7325, 2.54, 0.224, 249, 237, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3731, 4fstA, 0.7325, 2.83, 0.212, 253, 241, CRYSTAL STRUCTURE OF THE CHK1
3732, 3nieA, 0.7325, 3.07, 0.215, 369, 247, CRYSTAL STRUCTURE OF PF11_0147
3733, 3n9xB, 0.7325, 3.17, 0.189, 374, 249, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3734, 3g6hA, 0.7325, 3.00, 0.206, 266, 247, SRC THR338ILE INHIBITED IN THE DFG-ASP-OUT CONFORMATION
3735, 2vu3A, 0.7325, 2.96, 0.184, 285, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3736, 5wnfB, 0.7324, 2.75, 0.202, 358, 242, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3737, 4rj6A, 0.7324, 3.33, 0.183, 297, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 4
3738, 4ftnA, 0.7324, 3.00, 0.206, 253, 243, CRYSTAL STRUCTURE OF THE CHK1
3739, 4acmA, 0.7324, 3.12, 0.194, 277, 248, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
3740, 3zepB, 0.7324, 2.97, 0.224, 268, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
3741, 3sdjI, 0.7324, 3.52, 0.212, 413, 255, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3742, 5vndA, 0.7323, 3.24, 0.212, 302, 250, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
3743, 5m5aA, 0.7323, 2.62, 0.237, 315, 236, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
3744, 4zslA, 0.7323, 3.06, 0.219, 341, 247, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
3745, 4kikA, 0.7323, 3.43, 0.183, 618, 252, HUMAN IKB KINASE BETA
3746, 3zm4A, 0.7323, 3.30, 0.190, 309, 253, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 1
3747, 3dk6A, 0.7323, 3.37, 0.213, 262, 254, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
3748, 4zjvA, 0.7322, 3.69, 0.176, 282, 261, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
3749, 4qp2A, 0.7322, 2.86, 0.226, 336, 243, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
3750, 4p90A, 0.7322, 3.08, 0.202, 272, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3751, 4d2pC, 0.7322, 2.75, 0.244, 316, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3752, 3ppjB, 0.7322, 2.85, 0.221, 264, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3753, 4f1oA, 0.7321, 3.18, 0.187, 276, 251, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
3754, 4d2tA, 0.7321, 2.83, 0.238, 316, 239, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3755, 4an2A, 0.7321, 3.35, 0.180, 282, 256, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3756, 6es0A, 0.7320, 3.22, 0.175, 288, 251, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3757, 5i3rB, 0.7320, 3.04, 0.178, 302, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3758, 4e93A, 0.7320, 2.81, 0.218, 361, 243, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
3759, 3ot8A, 0.7320, 2.99, 0.202, 251, 243, X-RAY CRYSTAL STRUCTURE OF COMPOUND 17R BOUND TO HUMAN CHK1 KINASE DOMAIN
3760, 2xezA, 0.7320, 2.75, 0.208, 249, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3761, 2b9hA, 0.7320, 2.96, 0.218, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
3762, 5jzjB, 0.7319, 2.91, 0.210, 261, 243, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3763, 5j7hA, 0.7319, 3.42, 0.178, 291, 253, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
3764, 4z55A, 0.7319, 3.53, 0.176, 294, 255, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
3765, 4bbmA, 0.7319, 3.42, 0.185, 314, 248, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
3766, 3s1hA, 0.7319, 3.02, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
3767, 2b4sB, 0.7319, 3.26, 0.203, 294, 251, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3768, 5ng2A, 0.7318, 2.92, 0.152, 274, 244, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3769, 4qpsA, 0.7318, 3.27, 0.219, 270, 251, CRYSTAL STRUCTURE OF JAK3 COMPLEXED TO N-[3-(6-PHENYLAMINO-PYRAZIN-2- YL)-3H-BENZOIMIDAZOL-5-YL]-ACRYLAMIDE
3770, 4lmnA, 0.7318, 3.49, 0.174, 292, 258, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3771, 4arkA, 0.7318, 3.50, 0.174, 291, 258, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3772, 3zlsA, 0.7318, 3.60, 0.190, 315, 258, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
3773, 3fbvI, 0.7318, 3.52, 0.216, 413, 255, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3774, 2w05A, 0.7318, 2.90, 0.184, 276, 245, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
3775, 4wsqB, 0.7317, 3.02, 0.177, 310, 248, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3776, 3sdjJ, 0.7317, 3.54, 0.212, 413, 255, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3777, 3fbvJ, 0.7317, 3.52, 0.216, 413, 255, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3778, 3emgA, 0.7317, 3.07, 0.206, 255, 248, DISCOVERY AND SAR OF NOVEL 4-THIAZOLYL-2- PHENYLAMINOPYRIMIDINES AS POTENT INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)
3779, 2bheA, 0.7317, 2.92, 0.184, 274, 245, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
3780, 1s9iA, 0.7317, 3.41, 0.169, 303, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
3781, 4yc6A, 0.7316, 2.84, 0.179, 285, 240, CDK1/CKS1
3782, 4u44B, 0.7316, 3.44, 0.198, 296, 257, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
3783, 4e3cC, 0.7316, 3.45, 0.197, 624, 254, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3784, 4bl1A, 0.7316, 2.62, 0.242, 312, 236, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
3785, 3teiA, 0.7316, 2.87, 0.230, 339, 243, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
3786, 3js2A, 0.7316, 3.34, 0.210, 295, 252, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
3787, 2w1gA, 0.7316, 2.65, 0.200, 254, 240, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3788, 2b9jA, 0.7316, 2.95, 0.218, 337, 243, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
3789, 4e3cD, 0.7315, 3.39, 0.198, 624, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3790, 5vcwB, 0.7314, 3.09, 0.178, 285, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
3791, 4cd0A, 0.7314, 3.51, 0.181, 295, 254, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3792, 4z7hB, 0.7313, 3.27, 0.177, 388, 249, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC KINASE-RNASE REGION - COMPLEX WITH IMIDAZOPYRIDINE COMPOUND 3
3793, 3eqgA, 0.7313, 3.41, 0.187, 314, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
3794, 3d15A, 0.7313, 2.82, 0.189, 256, 243, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
3795, 4e26B, 0.7312, 3.05, 0.223, 264, 247, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3796, 2r3lA, 0.7312, 3.03, 0.194, 275, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3797, 1yi6B, 0.7312, 3.39, 0.213, 274, 254, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3798, 4iz7C, 0.7311, 2.88, 0.226, 340, 243, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
3799, 3q4uC, 0.7311, 3.45, 0.184, 296, 255, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
3800, 3bqrA, 0.7311, 3.33, 0.183, 275, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH AN IMIDAZO-PYRIDAZINE LIGAND
3801, 5ikwA, 0.7310, 3.02, 0.174, 297, 247, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3802, 4uwbB, 0.7310, 3.23, 0.212, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3803, 3rzbA, 0.7310, 3.27, 0.188, 282, 250, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
3804, 3ralA, 0.7310, 3.08, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
3805, 3qa8H, 0.7310, 3.39, 0.194, 541, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3806, 3pp1A, 0.7310, 3.58, 0.185, 291, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3807, 3lctA, 0.7310, 3.78, 0.174, 308, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3808, 3lcsA, 0.7310, 3.74, 0.178, 304, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3809, 1yi6A, 0.7310, 3.62, 0.202, 274, 257, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
3810, 5lmbB, 0.7309, 2.91, 0.204, 261, 245, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
3811, 5caoA, 0.7309, 3.31, 0.180, 300, 250, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
3812, 4zsaA, 0.7309, 3.36, 0.210, 289, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
3813, 3qa8A, 0.7309, 3.43, 0.197, 622, 254, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3814, 3my0L, 0.7309, 3.48, 0.184, 296, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3815, 2ym5A, 0.7309, 2.79, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3816, 2b55A, 0.7309, 2.95, 0.184, 276, 245, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
3817, 1h00A, 0.7309, 3.00, 0.175, 278, 246, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
3818, 4xlvA, 0.7308, 3.33, 0.185, 307, 254, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
3819, 3psbB, 0.7308, 2.88, 0.224, 264, 245, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
3820, 3oomA, 0.7308, 3.57, 0.191, 297, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00507
3821, 2ydjA, 0.7308, 2.91, 0.222, 252, 243, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3822, 2hk5A, 0.7308, 3.07, 0.193, 269, 249, HCK KINASE IN COMPLEX WITH LCK TARGETTED INHIBITOR PG-1009247
3823, 2eb3A, 0.7308, 3.20, 0.181, 294, 249, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
3824, 5ajqB, 0.7307, 3.27, 0.188, 267, 250, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3825, 4neuA, 0.7307, 3.53, 0.169, 286, 255, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
3826, 4at4A, 0.7307, 3.32, 0.222, 292, 252, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3827, 3qa8B, 0.7307, 3.39, 0.194, 622, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3828, 3q4cA, 0.7307, 2.91, 0.217, 264, 244, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3829, 3kl8G, 0.7307, 3.15, 0.190, 259, 248, CAMKIINTIDE INHIBITOR COMPLEX
3830, 3f6xC, 0.7307, 3.08, 0.206, 265, 247, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3831, 2vtqA, 0.7307, 2.98, 0.184, 274, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3832, 1gihA, 0.7307, 3.06, 0.190, 276, 247, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3833, 5jq8A, 0.7306, 3.04, 0.175, 278, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
3834, 5g6vA, 0.7306, 3.13, 0.203, 308, 246, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
3835, 4xg8A, 0.7306, 3.26, 0.194, 258, 252, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3836, 4fodA, 0.7306, 3.64, 0.176, 308, 256, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
3837, 4bzdA, 0.7306, 2.97, 0.187, 277, 246, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
3838, 3w55A, 0.7306, 2.77, 0.225, 335, 240, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
3839, 3sw4A, 0.7306, 3.22, 0.173, 279, 249, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
3840, 3e8nA, 0.7306, 3.57, 0.185, 291, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3841, 3d2iA, 0.7306, 2.69, 0.191, 255, 241, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
3842, 2duvA, 0.7306, 2.81, 0.193, 272, 243, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
3843, 4mxxA, 0.7305, 3.01, 0.207, 266, 246, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3844, 4f1mA, 0.7305, 3.21, 0.187, 278, 251, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
3845, 3qa8D, 0.7305, 3.39, 0.194, 622, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3846, 3dqxB, 0.7305, 3.23, 0.212, 268, 250, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3847, 3d4qB, 0.7305, 2.85, 0.218, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3848, 2xngA, 0.7305, 2.67, 0.196, 253, 240, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
3849, 5a46B, 0.7304, 3.35, 0.211, 297, 251, FGFR1 IN COMPLEX WITH DOVITINIB
3850, 4yjtA, 0.7304, 3.13, 0.189, 268, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233
3851, 3rpyA, 0.7304, 3.04, 0.186, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
3852, 3qa8E, 0.7304, 3.39, 0.194, 622, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3853, 3bu5A, 0.7304, 3.22, 0.192, 291, 250, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
3854, 5ew8B, 0.7303, 3.30, 0.211, 290, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
3855, 4pdpB, 0.7303, 3.17, 0.191, 265, 246, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
3856, 4i21A, 0.7303, 3.59, 0.188, 290, 260, CRYSTAL STRUCTURE OF L858R + T790M EGFR KINASE DOMAIN IN COMPLEX WITH MIG6 PEPTIDE
3857, 4eutA, 0.7303, 3.74, 0.160, 384, 256, STRUCTURE OF BX-795 COMPLEXED WITH UNPHOSPHORYLATED HUMAN TBK1 KINASE- ULD DOMAIN
3858, 4fobA, 0.7302, 3.54, 0.176, 295, 255, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
3859, 4d2wB, 0.7302, 2.92, 0.207, 323, 241, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3860, 3unjA, 0.7302, 3.34, 0.181, 294, 254, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
3861, 3eqcA, 0.7302, 3.49, 0.187, 312, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
3862, 1r78A, 0.7302, 2.91, 0.180, 273, 244, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
3863, 6ginA, 0.7301, 3.46, 0.188, 296, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
3864, 5o49A, 0.7301, 3.37, 0.210, 289, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
3865, 4yc6G, 0.7301, 2.85, 0.179, 285, 240, CDK1/CKS1
3866, 4ux9A, 0.7301, 2.83, 0.228, 343, 241, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
3867, 4focA, 0.7301, 3.48, 0.177, 296, 254, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
3868, 3rakA, 0.7301, 3.06, 0.182, 277, 247, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
3869, 3o71A, 0.7301, 3.10, 0.223, 340, 247, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
3870, 3n9xA, 0.7301, 3.21, 0.194, 374, 248, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
3871, 3eqiA, 0.7301, 3.34, 0.193, 315, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
3872, 2wmtA, 0.7301, 2.80, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3873, 1k3aA, 0.7301, 3.35, 0.197, 288, 254, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
3874, 4uwbA, 0.7300, 3.27, 0.212, 299, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
3875, 4n4sA, 0.7300, 2.95, 0.220, 342, 245, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
3876, 3zlwA, 0.7300, 3.33, 0.189, 312, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
3877, 3r8mA, 0.7300, 3.28, 0.187, 286, 252, CDK2 IN COMPLEX WITH INHIBITOR L3-3
3878, 3qa8G, 0.7300, 3.40, 0.194, 541, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3879, 3nieB, 0.7300, 3.16, 0.219, 367, 247, CRYSTAL STRUCTURE OF PF11_0147
3880, 3my0A, 0.7300, 3.50, 0.184, 296, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3881, 3eqdA, 0.7300, 3.31, 0.193, 315, 254, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
3882, 5g6vB, 0.7299, 3.11, 0.199, 302, 246, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
3883, 4uwcA, 0.7299, 3.26, 0.212, 300, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3884, 4useA, 0.7299, 3.63, 0.183, 286, 252, HUMAN STK10 (LOK) WITH SB-633825
3885, 3qa8C, 0.7299, 3.40, 0.194, 622, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3886, 3fqhB, 0.7299, 3.05, 0.194, 258, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH A 2-SUBSTITUTED 7-AZAINDOLE
3887, 3c9wA, 0.7299, 2.74, 0.230, 336, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3888, 2r3nA, 0.7299, 3.08, 0.186, 275, 247, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
3889, 5hznE, 0.7298, 3.31, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3890, 5hznA, 0.7298, 3.30, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3891, 5ftoA, 0.7298, 3.56, 0.176, 298, 256, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
3892, 4jbqA, 0.7298, 2.88, 0.193, 257, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3893, 3my0B, 0.7298, 3.49, 0.188, 295, 255, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3894, 3mblA, 0.7298, 3.60, 0.185, 290, 259, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3895, 2wmxA, 0.7298, 2.74, 0.213, 248, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3896, 2f49A, 0.7298, 2.91, 0.218, 335, 243, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
3897, 4xg9A, 0.7297, 3.09, 0.210, 259, 248, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
3898, 4xeyB, 0.7297, 3.48, 0.193, 359, 254, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3899, 4u7zA, 0.7297, 3.59, 0.189, 291, 259, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
3900, 4h58B, 0.7297, 3.02, 0.224, 262, 245, BRAF IN COMPLEX WITH COMPOUND 3
3901, 3mtfB, 0.7297, 3.59, 0.191, 298, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3902, 3kl8I, 0.7297, 3.10, 0.194, 254, 247, CAMKIINTIDE INHIBITOR COMPLEX
3903, 3gc0A, 0.7297, 3.12, 0.180, 278, 245, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
3904, 2bhhA, 0.7297, 2.95, 0.188, 274, 245, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
3905, 5xp7B, 0.7296, 3.03, 0.207, 267, 246, C-SRC IN COMPLEX WITH ATP-CHCL
3906, 5es1A, 0.7296, 2.73, 0.239, 304, 238, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3907, 4hzrB, 0.7296, 3.22, 0.209, 258, 249, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN
3908, 3i60A, 0.7296, 2.64, 0.228, 335, 237, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
3909, 5w5qB, 0.7295, 3.43, 0.195, 297, 257, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3910, 4uwcB, 0.7295, 3.26, 0.212, 301, 250, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
3911, 4o0tB, 0.7295, 3.35, 0.230, 280, 248, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3912, 4f1tA, 0.7295, 3.28, 0.187, 269, 251, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
3913, 4d2vC, 0.7295, 2.76, 0.244, 316, 238, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3914, 3my0N, 0.7295, 3.47, 0.189, 300, 254, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
3915, 2btrA, 0.7295, 2.98, 0.192, 275, 245, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
3916, 2b4sD, 0.7295, 3.31, 0.195, 294, 251, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
3917, 5l2qC, 0.7294, 2.84, 0.161, 282, 242, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3918, 4zjvB, 0.7294, 3.49, 0.183, 273, 257, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH MITOGEN- INDUCIBLE GENE 6 PROTEIN
3919, 4umpC, 0.7294, 2.51, 0.239, 311, 234, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3920, 4o0wA, 0.7294, 2.77, 0.199, 259, 241, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3921, 4e3cB, 0.7294, 3.42, 0.186, 632, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3922, 3prfB, 0.7294, 2.81, 0.211, 262, 242, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
3923, 3c4fB, 0.7294, 3.46, 0.209, 290, 253, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3924, 2g2iA, 0.7294, 3.27, 0.207, 271, 251, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3925, 1gijA, 0.7294, 2.97, 0.188, 273, 245, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
3926, 5hznH, 0.7293, 3.31, 0.176, 303, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3927, 4un0D, 0.7293, 2.73, 0.242, 276, 240, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
3928, 4umpA, 0.7293, 2.60, 0.242, 313, 236, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
3929, 4bggB, 0.7293, 3.44, 0.185, 293, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3930, 3dqxA, 0.7293, 3.19, 0.213, 267, 249, CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH ATPGS
3931, 2j0jA, 0.7293, 3.16, 0.206, 611, 247, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3932, 5hznD, 0.7292, 3.32, 0.176, 304, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3933, 3qa8F, 0.7292, 3.41, 0.194, 622, 253, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
3934, 3c9wB, 0.7292, 2.77, 0.230, 336, 239, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
3935, 3c4fA, 0.7292, 3.40, 0.210, 290, 252, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
3936, 2fysB, 0.7292, 2.92, 0.225, 338, 244, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
3937, 5hznG, 0.7291, 3.35, 0.192, 296, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3938, 5hznC, 0.7291, 3.35, 0.192, 296, 250, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3939, 4y83A, 0.7291, 2.99, 0.215, 299, 247, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
3940, 4uy9A, 0.7291, 3.40, 0.211, 313, 251, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3941, 4mxoA, 0.7291, 3.03, 0.207, 266, 246, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
3942, 4e3cF, 0.7291, 3.43, 0.189, 624, 254, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3943, 3f6xA, 0.7291, 3.01, 0.215, 264, 246, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3944, 2ym4A, 0.7291, 2.92, 0.207, 251, 241, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3945, 5mjaA, 0.7290, 3.06, 0.153, 271, 248, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3946, 5aafA, 0.7290, 2.66, 0.197, 254, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
3947, 4yjpA, 0.7290, 3.18, 0.195, 263, 251, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223
3948, 4iwqA, 0.7290, 3.48, 0.167, 626, 252, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3949, 4f0fA, 0.7290, 3.22, 0.191, 276, 251, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
3950, 6ginB, 0.7289, 3.50, 0.188, 296, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH AN QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 4-MORPHOLINOPHENYL SOLVENT ACCESSIBLE GROUP. 
3951, 5vcyA, 0.7289, 3.29, 0.173, 296, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
3952, 5l6wL, 0.7289, 3.29, 0.180, 290, 250, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
3953, 4mxzA, 0.7289, 3.01, 0.215, 266, 246, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3954, 4mxyA, 0.7289, 3.01, 0.215, 266, 246, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
3955, 3zlxA, 0.7289, 3.34, 0.193, 312, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
3956, 3r22A, 0.7289, 2.76, 0.195, 255, 241, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3957, 3hmiA, 0.7289, 3.45, 0.200, 268, 255, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3958, 2vttA, 0.7289, 2.97, 0.180, 272, 244, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3959, 5vd1A, 0.7288, 3.22, 0.174, 295, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
3960, 5hznF, 0.7288, 3.32, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3961, 4bggA, 0.7288, 3.45, 0.185, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
3962, 3l8vA, 0.7288, 3.39, 0.168, 293, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
3963, 3kl8E, 0.7288, 3.18, 0.190, 256, 248, CAMKIINTIDE INHIBITOR COMPLEX
3964, 3f6xB, 0.7288, 2.97, 0.204, 267, 245, C-SRC KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
3965, 3ezrA, 0.7288, 2.92, 0.184, 273, 244, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
3966, 2z7sA, 0.7288, 2.74, 0.181, 256, 237, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
3967, 2ym7A, 0.7288, 2.83, 0.204, 248, 240, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3968, 6gi6A, 0.7287, 3.49, 0.192, 298, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH A QUINAZOLINONE BASED ALK2 INHIBITOR WITH A 5-METHYL CORE. 
3969, 5aagA, 0.7287, 2.69, 0.200, 253, 240, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
3970, 4iwoA, 0.7287, 3.64, 0.168, 629, 256, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
3971, 4e3cA, 0.7287, 3.44, 0.194, 624, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3972, 2w1fA, 0.7287, 2.66, 0.201, 253, 239, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3973, 2p55A, 0.7287, 3.48, 0.187, 289, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
3974, 3rhxA, 0.7286, 3.32, 0.211, 289, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
3975, 3r21A, 0.7286, 2.73, 0.200, 254, 240, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3976, 3ndmC, 0.7286, 3.03, 0.213, 371, 244, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
3977, 2ym3A, 0.7286, 2.79, 0.209, 247, 239, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
3978, 1k2pA, 0.7286, 3.16, 0.164, 258, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
3979, 5vczA, 0.7285, 3.20, 0.174, 294, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
3980, 5hznB, 0.7285, 3.31, 0.193, 296, 249, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
3981, 3m11A, 0.7285, 2.85, 0.198, 256, 242, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3982, 3d4qA, 0.7285, 2.89, 0.218, 264, 243, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3983, 2i6lA, 0.7285, 2.72, 0.211, 292, 237, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
3984, 4b99A, 0.7284, 3.10, 0.233, 335, 245, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
3985, 2fa2A, 0.7284, 2.90, 0.214, 333, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
3986, 5ajqA, 0.7283, 3.41, 0.190, 280, 252, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3987, 4u81A, 0.7283, 3.47, 0.187, 289, 257, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
3988, 3q4cB, 0.7283, 2.96, 0.217, 264, 244, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3989, 3mtfA, 0.7283, 3.47, 0.189, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH A 2- AMINOPYRIDINE INHIBITOR
3990, 2vtnA, 0.7283, 2.98, 0.180, 274, 245, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
3991, 2pvyC, 0.7283, 3.07, 0.166, 285, 247, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
3992, 2b9fA, 0.7283, 2.97, 0.218, 337, 243, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
3993, 1cm8B, 0.7283, 2.83, 0.183, 327, 240, PHOSPHORYLATED MAP KINASE P38-GAMMA
3994, 1cm8A, 0.7283, 2.83, 0.183, 327, 240, PHOSPHORYLATED MAP KINASE P38-GAMMA
3995, 5fm3A, 0.7282, 3.29, 0.173, 276, 249, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
3996, 4bkyA, 0.7282, 2.64, 0.238, 311, 235, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
3997, 3ppjA, 0.7282, 2.82, 0.219, 262, 242, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3998, 5oxgB, 0.7281, 3.45, 0.185, 296, 254, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
3999, 5nzzE, 0.7281, 2.81, 0.192, 343, 240, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4000, 5fm2A, 0.7281, 3.29, 0.173, 273, 249, CRYSTAL STRUCTURE OF HYPER-PHOSPHORYLATED RET KINASE DOMAIN WITH (PROXIMAL) JUXTAMEMBRANE SEGMENT
4001, 4yzcA, 0.7281, 3.01, 0.193, 382, 244, CRYSTAL STRUCTURE OF PIRE1ALPHA IN COMPLEX WITH STAUROSPORINE
4002, 4h58A, 0.7281, 2.94, 0.224, 263, 245, BRAF IN COMPLEX WITH COMPOUND 3
4003, 3l9pA, 0.7281, 3.76, 0.174, 303, 259, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4004, 5aadA, 0.7280, 2.67, 0.197, 252, 239, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4005, 4rvtB, 0.7280, 3.56, 0.186, 297, 258, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4006, 3priA, 0.7280, 3.05, 0.228, 264, 246, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4007, 3eqbA, 0.7280, 3.46, 0.187, 289, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4008, 5o49B, 0.7279, 3.21, 0.210, 286, 248, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4009, 4yjuA, 0.7279, 2.99, 0.191, 262, 246, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249
4010, 4e3cE, 0.7279, 3.47, 0.190, 624, 253, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4011, 4anbA, 0.7279, 3.42, 0.180, 282, 256, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4012, 3priB, 0.7279, 3.11, 0.227, 264, 247, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4013, 3dv3A, 0.7279, 3.51, 0.187, 288, 257, MEK1 WITH PF-04622664 BOUND
4014, 2hz4B, 0.7279, 3.18, 0.202, 261, 248, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4015, 5obrA, 0.7278, 2.78, 0.199, 255, 241, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
4016, 5i3oA, 0.7278, 2.95, 0.180, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4017, 4h3pD, 0.7278, 2.84, 0.228, 338, 241, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
4018, 3v04A, 0.7278, 3.48, 0.187, 289, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4019, 3s95B, 0.7278, 3.18, 0.182, 290, 247, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4020, 3od6X, 0.7278, 2.95, 0.177, 344, 243, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
4021, 3js2B, 0.7278, 3.27, 0.197, 291, 249, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
4022, 2g2iB, 0.7278, 3.21, 0.201, 265, 249, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4023, 6fcfA, 0.7277, 2.93, 0.223, 251, 242, CHK1 KINASE IN COMPLEX WITH COMPOUND 44
4024, 5o4aA, 0.7277, 3.43, 0.210, 290, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4025, 5andA, 0.7277, 3.00, 0.176, 273, 244, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4026, 4nifD, 0.7277, 3.69, 0.197, 313, 254, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4027, 4d2wC, 0.7277, 2.79, 0.245, 313, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4028, 3my0C, 0.7276, 3.47, 0.190, 299, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4029, 2qkrA, 0.7276, 2.91, 0.172, 273, 238, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
4030, 5xdlA, 0.7275, 3.23, 0.190, 292, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4031, 5edrA, 0.7275, 3.33, 0.181, 299, 249, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
4032, 4u80A, 0.7275, 3.49, 0.187, 286, 257, MEK 1 KINASE BOUND TO G799
4033, 4lg4B, 0.7275, 3.22, 0.177, 284, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4034, 5vcwA, 0.7274, 3.07, 0.176, 285, 244, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
4035, 5oxgD, 0.7274, 3.50, 0.184, 293, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4036, 5oxgA, 0.7274, 3.46, 0.185, 293, 254, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4037, 4c8bA, 0.7274, 3.08, 0.158, 279, 247, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4038, 3tt0A, 0.7274, 3.31, 0.211, 305, 251, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
4039, 3oz6A, 0.7274, 3.14, 0.195, 343, 246, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4040, 3f5pT, 0.7274, 3.34, 0.197, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4041, 2oiqB, 0.7274, 3.04, 0.211, 265, 246, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4042, 5y25A, 0.7273, 3.15, 0.182, 292, 247, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4043, 5oxgC, 0.7273, 3.50, 0.188, 301, 255, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH LDN- 212854
4044, 4d9tA, 0.7273, 3.45, 0.190, 299, 252, RSK2 C-TERMINAL KINASE DOMAIN WITH INHIBITOR (E)-METHYL 3-(4-AMINO-7- (3-HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4045, 3sxrA, 0.7273, 3.09, 0.137, 260, 248, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4046, 3ornA, 0.7273, 3.64, 0.181, 280, 259, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
4047, 3l8pA, 0.7273, 3.29, 0.176, 292, 250, CRYSTAL STRUCTURE OF CYTOPLASMIC KINASE DOMAIN OF TIE2 COMPLEXED WITH INHIBITOR CEP11207
4048, 1gagA, 0.7273, 3.32, 0.202, 300, 253, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
4049, 5magA, 0.7271, 2.68, 0.233, 314, 236, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4050, 5fp6A, 0.7271, 2.89, 0.185, 278, 243, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
4051, 4d2tC, 0.7271, 2.81, 0.245, 313, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4052, 3q4uD, 0.7271, 3.60, 0.187, 299, 257, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4053, 3ggfB, 0.7271, 3.16, 0.204, 270, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE MST4 IN COMPLEX WITH AN QUINAZOLIN
4054, 2pvyB, 0.7271, 3.07, 0.163, 286, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME.
4055, 1k9aE, 0.7271, 3.18, 0.202, 440, 248, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4056, 4fv6A, 0.7270, 2.65, 0.229, 332, 236, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
4057, 4ftoA, 0.7270, 2.97, 0.203, 252, 241, CRYSTAL STRUCTURE OF THE CHK1
4058, 4d55A, 0.7270, 2.89, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4059, 3a61A, 0.7270, 2.70, 0.211, 254, 237, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM II)
4060, 3gqlA, 0.7269, 3.50, 0.215, 287, 251, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4061, 5vo6A, 0.7268, 3.34, 0.228, 271, 250, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4062, 5uhnB, 0.7268, 2.99, 0.176, 269, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING A N549H/E565A DOUBLE GAIN-OF-FUNCTION MUTATION
4063, 4bc6A, 0.7268, 3.55, 0.184, 285, 250, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4064, 3zzeA, 0.7268, 3.16, 0.182, 286, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
4065, 3zlyA, 0.7268, 3.43, 0.193, 310, 254, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
4066, 3zfxA, 0.7268, 3.14, 0.146, 267, 247, CRYSTAL STRUCTURE OF EPHB1
4067, 3psdA, 0.7268, 2.86, 0.222, 262, 243, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
4068, 3f5pA, 0.7268, 3.26, 0.194, 299, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4069, 1ungB, 0.7268, 2.44, 0.159, 268, 233, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
4070, 5ih8A, 0.7267, 2.61, 0.234, 306, 235, MELK IN COMPLEX WITH NVS-MELK1
4071, 4yc8A, 0.7267, 3.31, 0.199, 259, 251, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4072, 4rwiA, 0.7267, 3.27, 0.216, 305, 250, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4073, 3zfxD, 0.7267, 3.11, 0.146, 265, 246, CRYSTAL STRUCTURE OF EPHB1
4074, 3my0E, 0.7267, 3.46, 0.186, 294, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4075, 3dk6B, 0.7267, 3.42, 0.203, 259, 251, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4076, 5am7A, 0.7266, 3.25, 0.210, 294, 248, FGFR1 MUTANT WITH AN INHIBITOR
4077, 4ux9C, 0.7266, 2.77, 0.230, 333, 239, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4078, 4rwkA, 0.7266, 3.36, 0.215, 308, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4079, 4mxcA, 0.7266, 3.02, 0.180, 290, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4080, 4jg8A, 0.7266, 3.51, 0.194, 300, 253, STRUCTURE OF RSK2 T493M CTD MUTANT BOUND TO 2-CYANO-N-(1-HYDROXY-2- METHYLPROPAN-2-YL)-3-(3-(345-TRIMETHOXYPHENYL)-1H-INDAZOL-5-YL) ACRYLAMIDE
4081, 3ncgA, 0.7266, 3.40, 0.213, 426, 249, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
4082, 2c6eA, 0.7266, 2.64, 0.207, 251, 237, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4083, 5nzzF, 0.7265, 2.74, 0.193, 341, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4084, 4uy9B, 0.7265, 3.43, 0.211, 315, 251, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
4085, 3d7uC, 0.7265, 3.11, 0.203, 257, 246, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4086, 3d7uA, 0.7265, 3.11, 0.203, 257, 246, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4087, 2f49B, 0.7265, 2.94, 0.214, 337, 243, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
4088, 4y83C, 0.7264, 2.92, 0.200, 293, 245, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4089, 3hgkA, 0.7264, 3.47, 0.186, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4090, 3en4B, 0.7264, 3.06, 0.207, 266, 246, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4091, 2j7tA, 0.7264, 3.68, 0.187, 285, 252, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO SU11274
4092, 4iwpA, 0.7263, 3.67, 0.168, 628, 256, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4093, 3psbA, 0.7263, 2.99, 0.224, 262, 245, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4094, 3my0U, 0.7263, 3.47, 0.186, 285, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4095, 2wmwA, 0.7263, 2.75, 0.214, 247, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4096, 1s9jA, 0.7263, 3.48, 0.187, 289, 257, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4097, 1ir3A, 0.7263, 3.38, 0.185, 300, 254, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
4098, 5ankA, 0.7262, 2.97, 0.177, 273, 243, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4099, 5am6A, 0.7262, 3.32, 0.197, 295, 249, NATIVE FGFR1 WITH AN INHIBITOR
4100, 4zk5B, 0.7262, 3.37, 0.189, 294, 254, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4101, 4aszA, 0.7262, 3.31, 0.224, 289, 250, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
4102, 3v01A, 0.7262, 3.50, 0.187, 289, 257, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4103, 5vd3A, 0.7260, 3.19, 0.179, 293, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
4104, 5nzzG, 0.7260, 2.77, 0.197, 342, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4105, 5j95B, 0.7260, 3.43, 0.192, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
4106, 3uqgA, 0.7260, 3.00, 0.213, 263, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4107, 3prfA, 0.7260, 2.93, 0.217, 262, 244, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4108, 4yzcB, 0.7259, 3.00, 0.193, 381, 243, CRYSTAL STRUCTURE OF PIRE1ALPHA IN COMPLEX WITH STAUROSPORINE
4109, 4mxzB, 0.7258, 3.06, 0.212, 264, 245, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4110, 4mxyB, 0.7258, 3.06, 0.212, 264, 245, SRC M314L T338M DOUBLE MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4111, 4an3A, 0.7258, 3.54, 0.183, 280, 257, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4112, 3f5pS, 0.7258, 3.27, 0.194, 295, 252, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4113, 3a4pA, 0.7258, 3.46, 0.168, 285, 250, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
4114, 2ydjB, 0.7258, 2.87, 0.232, 251, 241, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
4115, 5t0pB, 0.7257, 3.01, 0.205, 263, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4116, 4cmoA, 0.7257, 3.54, 0.178, 295, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
4117, 5ihaA, 0.7256, 2.59, 0.235, 303, 234, MELK IN COMPLEX WITH NVS-MELK8F
4118, 5i3rA, 0.7256, 3.00, 0.171, 302, 245, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4119, 5di1B, 0.7256, 3.43, 0.188, 300, 255, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4120, 5aaaA, 0.7256, 3.68, 0.173, 294, 255, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4121, 4qrcA, 0.7256, 3.12, 0.199, 297, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
4122, 4nk9B, 0.7256, 3.26, 0.202, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4123, 3k5uA, 0.7256, 2.87, 0.194, 260, 242, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
4124, 2w1eA, 0.7256, 2.65, 0.202, 252, 238, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4125, 1k9aA, 0.7256, 3.18, 0.202, 439, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4126, 5edqA, 0.7255, 3.42, 0.167, 298, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
4127, 5edpA, 0.7255, 3.43, 0.179, 295, 251, EGFR KINASE (T790M/L858R) APO
4128, 5a46A, 0.7255, 3.31, 0.213, 289, 249, FGFR1 IN COMPLEX WITH DOVITINIB
4129, 4im0A, 0.7255, 3.53, 0.163, 619, 251, STRUCTURE OF TANK-BINDING KINASE 1
4130, 3vvhC, 0.7255, 3.67, 0.173, 283, 260, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4131, 3ppkA, 0.7255, 2.93, 0.225, 262, 244, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4132, 5i9vA, 0.7254, 3.11, 0.166, 279, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
4133, 5htiA, 0.7254, 3.01, 0.184, 290, 244, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
4134, 4bggD, 0.7254, 3.43, 0.187, 286, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4135, 3my0G, 0.7254, 3.49, 0.190, 294, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4136, 2z7qA, 0.7254, 2.73, 0.182, 255, 236, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4137, 2pmiA, 0.7254, 2.80, 0.186, 284, 237, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
4138, 5uorA, 0.7253, 2.48, 0.223, 249, 233, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4139, 5iuiA, 0.7253, 3.72, 0.167, 303, 257, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4140, 4o6eA, 0.7253, 2.82, 0.234, 328, 239, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
4141, 3zclA, 0.7253, 3.23, 0.182, 289, 247, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
4142, 3my0D, 0.7253, 3.45, 0.190, 298, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4143, 2wmuA, 0.7253, 2.79, 0.206, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4144, 2fumD, 0.7253, 2.44, 0.215, 258, 233, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4145, 5w86A, 0.7252, 3.16, 0.228, 269, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4146, 4im2A, 0.7252, 3.53, 0.163, 618, 251, STRUCTURE OF TANK-BINDING KINASE 1
4147, 4d9uA, 0.7252, 3.45, 0.190, 307, 252, RSK2 C-TERMINAL KINASE DOMAIN (E)-TERT-BUTYL 3-(4-AMINO-7-(3- HYDROXYPROPYL)-5-P-TOLYL-7H-PYRROLO[23-D]PYRIMIDIN-6-YL)-2- CYANOACRYLATE
4148, 3zfxI, 0.7252, 3.12, 0.146, 263, 246, CRYSTAL STRUCTURE OF EPHB1
4149, 3my0F, 0.7252, 3.50, 0.186, 294, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4150, 3hgkD, 0.7252, 3.49, 0.186, 286, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4151, 2xruA, 0.7252, 2.71, 0.205, 253, 239, AURORA-A T288E COMPLEXED WITH PHA-828300
4152, 2etmB, 0.7252, 3.05, 0.208, 263, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4153, 2bdfB, 0.7252, 3.07, 0.211, 265, 247, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4154, 1urwA, 0.7252, 3.02, 0.172, 274, 244, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
4155, 5j8iA, 0.7251, 2.99, 0.210, 288, 243, CRYSTAL STRUCTURE OF TL11-113 BOUND TO TAK1-TAB1
4156, 5a4cB, 0.7251, 3.31, 0.213, 286, 249, FGFR1 LIGAND COMPLEX
4157, 4qqjA, 0.7251, 3.17, 0.175, 282, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
4158, 4j95D, 0.7251, 3.04, 0.180, 271, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4159, 4bghA, 0.7251, 3.08, 0.191, 275, 246, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
4160, 3q4zB, 0.7251, 3.30, 0.222, 279, 248, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
4161, 5j9zA, 0.7250, 3.22, 0.198, 291, 247, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4162, 4zp5B, 0.7250, 3.44, 0.188, 300, 255, MAP4K4 IN COMPLEX WITH INHIBITOR
4163, 3f5pC, 0.7250, 3.37, 0.197, 301, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4164, 2ym8A, 0.7250, 2.80, 0.206, 246, 238, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4165, 1k9aB, 0.7250, 3.19, 0.202, 441, 247, CRYSTAL STRUCTURE ANALYSIS OF FULL-LENGTH CARBOXYL-TERMINAL SRC KINASE AT 2.5 A RESOLUTION
4166, 4rwlB, 0.7249, 3.20, 0.211, 285, 247, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4167, 3f5pB, 0.7249, 3.37, 0.197, 298, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4168, 1u46A, 0.7249, 3.12, 0.208, 255, 245, CRYSTAL STRUCTURE OF THE UNPHOSPHORYLATED KINASE DOMAIN OF THE TYROSINE KINASE ACK1
4169, 5hezD, 0.7248, 3.46, 0.215, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4170, 5gjfA, 0.7248, 3.36, 0.212, 298, 250, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
4171, 4qtaA, 0.7248, 2.75, 0.231, 335, 238, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
4172, 4cljA, 0.7248, 3.65, 0.180, 295, 255, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4173, 3q4uA, 0.7248, 3.52, 0.188, 298, 255, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4174, 3my0Q, 0.7248, 3.49, 0.190, 294, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4175, 3f5pI, 0.7248, 3.37, 0.197, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4176, 3dbfA, 0.7248, 2.69, 0.219, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 562
4177, 2xb7A, 0.7248, 3.37, 0.181, 286, 249, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH NVP- TAE684
4178, 2j0mB, 0.7248, 2.84, 0.207, 257, 241, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
4179, 5nkeA, 0.7247, 3.68, 0.160, 292, 256, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
4180, 4rj5A, 0.7247, 3.49, 0.183, 296, 251, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4181, 4lg4E, 0.7247, 3.25, 0.165, 275, 249, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4182, 3my0R, 0.7247, 3.48, 0.186, 294, 253, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4183, 1mqbB, 0.7247, 2.93, 0.168, 265, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4184, 5k4iA, 0.7246, 2.77, 0.231, 336, 238, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
4185, 3zfxH, 0.7246, 3.21, 0.146, 266, 247, CRYSTAL STRUCTURE OF EPHB1
4186, 3f5pD, 0.7246, 3.37, 0.197, 297, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4187, 2j0kB, 0.7246, 2.96, 0.206, 612, 243, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4188, 1k2pB, 0.7246, 3.22, 0.164, 258, 250, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4189, 5larA, 0.7245, 3.26, 0.198, 350, 247, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
4190, 4u0iA, 0.7245, 3.21, 0.215, 297, 247, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
4191, 4gu6A, 0.7245, 3.15, 0.204, 271, 245, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4192, 4ccbA, 0.7245, 3.42, 0.180, 287, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 3-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(5-METHYL-1H-PYRAZOL-4-YL)PYRIDIN-2-AMINE
4193, 3fxxA, 0.7245, 3.16, 0.161, 288, 249, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
4194, 2zvaA, 0.7245, 3.00, 0.193, 261, 244, LYN TYROSINE KINASE DOMAIN-DASATINIB COMPLEX
4195, 5w86B, 0.7244, 3.23, 0.220, 267, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 46-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7)
4196, 4maoA, 0.7244, 3.54, 0.194, 298, 253, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH RMM58
4197, 4fg7A, 0.7244, 2.92, 0.200, 250, 240, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4198, 4bggC, 0.7244, 3.34, 0.184, 279, 250, CRYSTAL STRUCTURE OF THE ACVR1 KINASE IN COMPLEX WITH LDN-213844
4199, 3plsA, 0.7244, 3.51, 0.142, 298, 254, RON IN COMPLEX WITH LIGAND AMP-PNP
4200, 3omvB, 0.7244, 3.08, 0.240, 264, 246, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4201, 3f5pG, 0.7244, 3.38, 0.197, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4202, 2wgjA, 0.7244, 3.24, 0.182, 289, 247, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
4203, 1p2aA, 0.7244, 2.86, 0.182, 271, 242, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
4204, 6eimB, 0.7243, 3.43, 0.184, 295, 250, HUMAN STK10 BOUND TO GW683134A
4205, 5vd0A, 0.7243, 3.28, 0.178, 293, 247, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
4206, 4nifA, 0.7243, 3.56, 0.198, 313, 252, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
4207, 4jbpA, 0.7243, 2.87, 0.199, 255, 241, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4208, 3omvA, 0.7243, 3.08, 0.240, 264, 246, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
4209, 3my0S, 0.7243, 3.47, 0.187, 294, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4210, 3hgkC, 0.7243, 3.47, 0.186, 284, 253, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4211, 3hgkB, 0.7243, 3.51, 0.185, 286, 254, CRYSTAL STRUCTURE OF EFFECT PROTEIN AVRPTOB COMPLEXED WITH KINASE PTO
4212, 3geqB, 0.7243, 3.00, 0.217, 273, 244, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4213, 2fb8A, 0.7243, 2.86, 0.227, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4214, 1fgiA, 0.7243, 3.35, 0.212, 283, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4215, 3zc6D, 0.7242, 3.30, 0.230, 267, 248, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH AN INDAZOLE SUBSTITUTED PYRROLOPYRAZINE INHIBITOR
4216, 3vvhA, 0.7242, 3.50, 0.184, 287, 256, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4217, 2y4iC, 0.7242, 3.53, 0.174, 313, 253, KSR2-MEK1 HETERODIMER
4218, 2r5tA, 0.7242, 3.37, 0.207, 284, 246, CRYSTAL STRUCTURE OF INACTIVE SERUM AND GLUCOCORTICOID- REGULATED KINASE 1 IN COMPLEX WITH AMP-PNP
4219, 4xcuA, 0.7241, 3.20, 0.178, 288, 247, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
4220, 4kipB, 0.7241, 2.83, 0.211, 338, 237, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4221, 4aotA, 0.7241, 3.17, 0.194, 278, 247, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4222, 3f5pH, 0.7241, 3.37, 0.197, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4223, 3dbdA, 0.7241, 2.67, 0.220, 261, 236, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 094
4224, 4v05A, 0.7240, 3.33, 0.212, 287, 250, FGFR1 IN COMPLEX WITH AZD4547.
4225, 4u3yB, 0.7240, 3.61, 0.190, 300, 258, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4226, 2rf9A, 0.7240, 3.69, 0.178, 280, 259, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4227, 5o4aB, 0.7239, 3.14, 0.211, 291, 246, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
4228, 4ux9B, 0.7239, 2.74, 0.224, 327, 237, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4229, 4rwjA, 0.7239, 3.30, 0.212, 307, 250, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
4230, 3fy2A, 0.7239, 3.19, 0.160, 285, 250, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
4231, 3zxzA, 0.7238, 3.25, 0.182, 289, 247, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
4232, 3gbzA, 0.7238, 2.88, 0.183, 274, 241, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
4233, 1oitA, 0.7238, 2.89, 0.178, 273, 242, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
4234, 5t0pA, 0.7237, 3.02, 0.205, 264, 244, C-SRC KINASE DOMAIN IN COMPLEX WITH RAO-IV-151
4235, 4nk9A, 0.7237, 3.24, 0.202, 281, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
4236, 4mxoB, 0.7237, 3.08, 0.212, 264, 245, HUMAN SRC KINASE BOUND TO KINASE INHIBITOR BOSUTINIB
4237, 4ap7A, 0.7237, 3.24, 0.182, 289, 247, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
4238, 5vcxA, 0.7236, 3.21, 0.184, 287, 245, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
4239, 4umqA, 0.7236, 2.76, 0.241, 314, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4240, 4qp8A, 0.7236, 2.90, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
4241, 3s95A, 0.7236, 3.21, 0.183, 290, 246, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4242, 3fdnA, 0.7236, 2.99, 0.193, 261, 244, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
4243, 2x9fA, 0.7236, 3.13, 0.150, 265, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4244, 2hz4C, 0.7236, 3.25, 0.201, 259, 249, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4245, 4o2pB, 0.7235, 2.99, 0.209, 265, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4246, 4m8tA, 0.7235, 3.52, 0.194, 303, 253, RSK2 T493M C-TERMINAL KINASE DOMAIN IN COMPLEX WITH 3-(3-(1H-PYRAZOL- 4-YL)PHENYL)-2-CYANOACRYLAMIDE
4247, 4cliA, 0.7235, 3.71, 0.176, 294, 255, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4248, 4v05B, 0.7234, 3.27, 0.210, 286, 248, FGFR1 IN COMPLEX WITH AZD4547.
4249, 4nkaB, 0.7234, 3.21, 0.203, 287, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4250, 4d2pA, 0.7234, 2.72, 0.243, 313, 235, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4251, 3zbxA, 0.7234, 3.17, 0.183, 282, 246, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
4252, 3qd2B, 0.7234, 3.03, 0.202, 271, 243, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4253, 5nkhA, 0.7233, 3.57, 0.161, 295, 254, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
4254, 5kz0A, 0.7233, 3.48, 0.179, 293, 252, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
4255, 4yhtB, 0.7233, 2.93, 0.226, 258, 243, BRAF COMPLEXED WITH AN INHIBITOR
4256, 4mneC, 0.7233, 2.98, 0.206, 260, 243, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4257, 4aoiA, 0.7233, 3.18, 0.183, 289, 246, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
4258, 3txoA, 0.7233, 3.37, 0.193, 317, 244, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
4259, 2j4zB, 0.7233, 2.97, 0.207, 269, 242, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4260, 5imxA, 0.7232, 3.35, 0.181, 266, 249, ANAPLASTIC LYMPHOMA KINASE (ALK) CATALYTIC DOMAIN COMPLEXED WITH NOVEL INHIBITOR 3-SULFONYLPYRAZOL-4-AMINO PYRIMIDINE
4261, 4d2wA, 0.7232, 2.87, 0.241, 314, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4262, 3q6uA, 0.7232, 3.15, 0.175, 287, 246, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4263, 3oriB, 0.7232, 2.85, 0.213, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4264, 3my0I, 0.7232, 3.47, 0.190, 293, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4265, 3my0H, 0.7232, 3.48, 0.187, 294, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4266, 5j5tA, 0.7231, 3.49, 0.206, 297, 248, GLK CO-CRYSTAL STRUCTURE WITH AMINOPYRROLOPYRIMIDINE INHIBITOR
4267, 4u45B, 0.7231, 3.52, 0.196, 295, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4268, 4o0uA, 0.7231, 2.93, 0.198, 259, 242, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
4269, 4j8mA, 0.7231, 3.04, 0.204, 265, 240, AURORA A IN COMPLEX WITH CD532
4270, 4g3dD, 0.7231, 3.03, 0.196, 290, 245, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK)
4271, 2j4zA, 0.7231, 2.76, 0.209, 263, 239, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
4272, 5oy6D, 0.7230, 3.41, 0.179, 292, 251, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4273, 5ftqA, 0.7230, 3.51, 0.179, 293, 252, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4274, 3mygA, 0.7230, 2.70, 0.197, 252, 238, AURORA A KINASE COMPLEXED WITH SCH 1473759
4275, 3hdnA, 0.7230, 3.40, 0.203, 280, 246, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 2
4276, 3f5pE, 0.7230, 3.39, 0.197, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4277, 5kbqB, 0.7229, 3.15, 0.223, 273, 242, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
4278, 4ueuA, 0.7229, 2.91, 0.231, 256, 242, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
4279, 4equB, 0.7229, 3.44, 0.185, 282, 248, HUMAN STK-10 (LOK) KINASE DOMAIN IN DFG-OUT CONFORMATION WITH INHIBITOR DSA-7
4280, 4an9A, 0.7229, 3.55, 0.183, 281, 257, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4281, 3twjB, 0.7229, 3.55, 0.190, 395, 253, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
4282, 3mwuA, 0.7229, 3.42, 0.214, 447, 248, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
4283, 3ky2A, 0.7229, 3.28, 0.197, 307, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4284, 3f5pK, 0.7229, 3.36, 0.198, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4285, 5ce3B, 0.7228, 3.58, 0.142, 598, 253, THE YERSINIA YOPO - ACTIN COMPLEX WITH MGADP
4286, 5aaeA, 0.7228, 2.64, 0.203, 252, 237, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4287, 4zloB, 0.7228, 3.03, 0.210, 263, 243, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4288, 4yjqA, 0.7228, 3.09, 0.179, 264, 246, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000224
4289, 4u41B, 0.7228, 3.55, 0.187, 297, 256, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4290, 4dymA, 0.7228, 3.48, 0.187, 293, 252, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH THE IMIDAZO[12-B]PYRIDAZINE INHIBITOR K00135
4291, 4cmuA, 0.7228, 3.56, 0.178, 294, 253, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4292, 3lj1A, 0.7228, 3.11, 0.205, 404, 244, IRE1 COMPLEXED WITH CDK1/2 INHIBITOR III
4293, 3fzrA, 0.7228, 3.01, 0.173, 261, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
4294, 3dbcA, 0.7228, 2.73, 0.219, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 257
4295, 5oneA, 0.7227, 2.83, 0.202, 257, 238, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
4296, 4u3zB, 0.7227, 3.37, 0.177, 294, 254, APO MAP4K4 T181E PHOSPHOMIMETIC MUTANT
4297, 3vvhB, 0.7227, 3.65, 0.178, 290, 259, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4298, 3et7A, 0.7227, 3.01, 0.173, 261, 243, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
4299, 5aa9A, 0.7226, 3.65, 0.173, 295, 254, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4300, 3oriA, 0.7226, 2.86, 0.213, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4301, 3lj1B, 0.7226, 3.11, 0.205, 404, 244, IRE1 COMPLEXED WITH CDK1/2 INHIBITOR III
4302, 2qkwB, 0.7226, 3.60, 0.180, 290, 255, STRUCTURAL BASIS FOR ACTIVATION OF PLANT IMMUNITY BY BACTERIAL EFFECTOR PROTEIN AVRPTO
4303, 4oboB, 0.7225, 3.56, 0.191, 297, 256, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4304, 3my0P, 0.7225, 3.49, 0.190, 290, 252, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4305, 4usdA, 0.7224, 3.16, 0.194, 268, 248, HUMAN STK10 (LOK) WITH SB-633825
4306, 4mneG, 0.7224, 2.92, 0.207, 259, 242, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4307, 4mcvB, 0.7224, 3.08, 0.207, 265, 246, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4308, 4lgdC, 0.7224, 3.13, 0.171, 349, 246, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
4309, 4fv8A, 0.7224, 2.72, 0.229, 333, 236, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
4310, 3zc5A, 0.7224, 3.26, 0.182, 289, 247, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
4311, 3uzsA, 0.7224, 2.94, 0.211, 609, 242, STRUCTURE OF THE C13.28 RNA APTAMER BOUND TO THE G PROTEIN-COUPLED RECEPTOR KINASE 2-HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNIT COMPLEX
4312, 3lvpD, 0.7224, 3.19, 0.205, 282, 249, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4313, 3db8A, 0.7224, 2.74, 0.219, 261, 237, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 041
4314, 2iwiB, 0.7224, 2.56, 0.201, 249, 234, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4315, 5ce3D, 0.7223, 3.60, 0.142, 598, 253, THE YERSINIA YOPO - ACTIN COMPLEX WITH MGADP
4316, 5aabA, 0.7223, 3.62, 0.171, 293, 252, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4317, 4obqB, 0.7223, 3.38, 0.190, 293, 253, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4318, 3my0O, 0.7223, 3.45, 0.191, 297, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4319, 6fnhB, 0.7222, 3.44, 0.163, 271, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4320, 5k9iB, 0.7222, 2.99, 0.209, 262, 244, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH A COVALENT LYSINE PROBE
4321, 3f5pL, 0.7222, 3.37, 0.198, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4322, 3f5pF, 0.7222, 3.40, 0.197, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4323, 2wkmA, 0.7222, 3.32, 0.177, 286, 248, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
4324, 2qr8A, 0.7222, 3.59, 0.190, 298, 253, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2 (RSK2)
4325, 2xneA, 0.7221, 2.63, 0.194, 246, 237, STRUCTURE OF AURORA-A BOUND TO AN IMIDAZOPYRAZINE INHIBITOR
4326, 6cnhA, 0.7220, 2.74, 0.177, 321, 237, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
4327, 5xp7A, 0.7220, 3.09, 0.208, 265, 245, C-SRC IN COMPLEX WITH ATP-CHCL
4328, 5dg5B, 0.7220, 3.03, 0.181, 297, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4329, 5d12A, 0.7220, 3.05, 0.209, 260, 244, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL40
4330, 4tt7A, 0.7220, 3.63, 0.171, 291, 252, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
4331, 3vn9A, 0.7220, 3.66, 0.166, 291, 259, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
4332, 4ztrA, 0.7218, 2.54, 0.196, 249, 235, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
4333, 4y5qA, 0.7218, 3.45, 0.213, 449, 249, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
4334, 3sxrB, 0.7218, 3.08, 0.130, 258, 246, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4335, 3h0zA, 0.7218, 2.56, 0.200, 248, 235, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4336, 1vzoA, 0.7218, 3.47, 0.153, 319, 248, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
4337, 3o0gB, 0.7217, 2.50, 0.164, 264, 232, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
4338, 3f5pM, 0.7217, 3.40, 0.197, 295, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4339, 5up3B, 0.7216, 2.52, 0.223, 243, 233, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4340, 5gjgA, 0.7216, 3.26, 0.193, 289, 249, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 4
4341, 5eakA, 0.7216, 3.03, 0.233, 305, 240, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4342, 5am6B, 0.7216, 2.99, 0.219, 280, 242, NATIVE FGFR1 WITH AN INHIBITOR
4343, 1ua2C, 0.7216, 3.11, 0.164, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
4344, 5kvtA, 0.7215, 3.29, 0.202, 287, 248, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
4345, 4pmmA, 0.7215, 3.29, 0.203, 285, 246, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
4346, 4m66A, 0.7215, 3.16, 0.158, 268, 247, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
4347, 3zosB, 0.7215, 3.31, 0.200, 303, 245, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
4348, 3twjD, 0.7215, 3.56, 0.190, 395, 253, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
4349, 4pmsA, 0.7214, 3.14, 0.208, 283, 245, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
4350, 3geqA, 0.7214, 3.01, 0.218, 272, 243, STRUCTURAL BASIS FOR THE CHEMICAL RESCUE OF SRC KINASE ACTIVITY
4351, 3f5pR, 0.7214, 3.41, 0.197, 294, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4352, 4qp7B, 0.7213, 2.92, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
4353, 4k8aB, 0.7213, 2.93, 0.211, 258, 242, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
4354, 4ccuA, 0.7213, 3.49, 0.172, 292, 250, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
4355, 3slsB, 0.7213, 3.67, 0.178, 294, 258, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4356, 3my0T, 0.7213, 3.48, 0.187, 292, 251, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4357, 3mvlB, 0.7213, 2.77, 0.211, 339, 237, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4358, 3beaA, 0.7213, 3.40, 0.209, 310, 249, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
4359, 1t46A, 0.7213, 3.24, 0.215, 297, 247, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
4360, 4mcvA, 0.7212, 3.12, 0.203, 267, 246, STAR 12 BOUND TO ANALOG-SENSITIVE SRC KINASE
4361, 3ma6B, 0.7212, 3.31, 0.233, 266, 245, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4362, 3kl8A, 0.7212, 3.11, 0.197, 256, 244, CAMKIINTIDE INHIBITOR COMPLEX
4363, 1ol6A, 0.7212, 2.62, 0.186, 245, 236, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4364, 5vcvA, 0.7211, 3.31, 0.175, 287, 246, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
4365, 5hezB, 0.7211, 3.86, 0.189, 289, 259, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4366, 3zfxE, 0.7211, 3.14, 0.143, 262, 245, CRYSTAL STRUCTURE OF EPHB1
4367, 2dylA, 0.7211, 2.91, 0.183, 272, 240, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
4368, 5grnA, 0.7210, 3.24, 0.232, 285, 246, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
4369, 4d1xA, 0.7210, 3.04, 0.193, 274, 244, CDK2 IN COMPLEX WITH LUCIFERIN
4370, 3lj2B, 0.7210, 3.10, 0.205, 404, 244, IRE1 COMPLEXED WITH JAK INHIBITOR I
4371, 5nk5A, 0.7209, 3.49, 0.159, 287, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
4372, 3f5pJ, 0.7209, 3.39, 0.198, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
4373, 3cthA, 0.7209, 3.46, 0.172, 295, 250, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4374, 1s9iB, 0.7209, 3.62, 0.173, 291, 255, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4375, 5jh6A, 0.7208, 3.03, 0.206, 288, 243, CRYSTAL STRUCTURE OF TL10-92 BOUND TO TAK1-TAB1
4376, 5am7B, 0.7208, 3.12, 0.213, 287, 244, FGFR1 MUTANT WITH AN INHIBITOR
4377, 4dfyE, 0.7208, 3.31, 0.206, 312, 247, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4378, 4deiA, 0.7208, 3.34, 0.173, 287, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
4379, 3d7tB, 0.7208, 3.11, 0.191, 265, 246, STRUCTURAL BASIS FOR THE RECOGNITION OF C-SRC BY ITS INACTIVATOR CSK
4380, 2f9gA, 0.7208, 2.79, 0.223, 332, 238, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
4381, 2bdfA, 0.7208, 2.99, 0.205, 261, 244, SRC KINASE IN COMPLEX WITH INHIBITOR AP23451
4382, 5zv2A, 0.7207, 3.25, 0.215, 284, 247, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4383, 5em5A, 0.7207, 3.55, 0.183, 298, 251, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4384, 3wigA, 0.7207, 3.62, 0.176, 278, 256, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
4385, 3os3A, 0.7207, 3.53, 0.173, 272, 255, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
4386, 1ua2B, 0.7207, 3.10, 0.160, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
4387, 5lw1H, 0.7206, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4388, 4u42B, 0.7206, 3.11, 0.193, 265, 244, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
4389, 3lj2A, 0.7206, 3.11, 0.205, 404, 244, IRE1 COMPLEXED WITH JAK INHIBITOR I
4390, 2w1dA, 0.7206, 2.68, 0.203, 251, 237, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4391, 2jkmA, 0.7206, 3.10, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4392, 1t45A, 0.7206, 3.43, 0.208, 331, 250, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
4393, 5uglB, 0.7205, 3.13, 0.179, 271, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 TYROSINE KINASE DOMAIN HARBORING THE D650V ACTIVATING MUTATION
4394, 4u43B, 0.7205, 3.45, 0.188, 302, 255, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4395, 4c3rA, 0.7205, 2.69, 0.197, 252, 238, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4396, 3hdmA, 0.7205, 3.48, 0.206, 285, 247, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
4397, 4mnfB, 0.7204, 2.77, 0.222, 257, 239, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4398, 3oz6B, 0.7204, 3.04, 0.222, 341, 243, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
4399, 2qocA, 0.7204, 3.04, 0.163, 283, 246, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
4400, 6dkiA, 0.7203, 3.05, 0.206, 279, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
4401, 4looA, 0.7203, 3.01, 0.203, 349, 241, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
4402, 4gk4A, 0.7203, 3.05, 0.167, 275, 245, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
4403, 2wd1A, 0.7203, 3.20, 0.183, 289, 246, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
4404, 2bdjA, 0.7203, 2.88, 0.216, 254, 241, SRC KINASE IN COMPLEX WITH INHIBITOR AP23464
4405, 5yu9D, 0.7202, 3.40, 0.172, 300, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
4406, 5i9uA, 0.7202, 3.30, 0.165, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4407, 4yjvA, 0.7202, 3.09, 0.180, 263, 245, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250
4408, 4gk3A, 0.7202, 2.95, 0.165, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
4409, 3f66B, 0.7202, 3.28, 0.183, 269, 246, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4410, 3d5vA, 0.7202, 2.71, 0.220, 260, 236, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
4411, 5wneB, 0.7201, 2.84, 0.201, 352, 239, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4412, 4ztsA, 0.7201, 2.61, 0.199, 249, 236, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
4413, 4qp4B, 0.7201, 2.94, 0.224, 335, 241, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
4414, 4ansA, 0.7201, 3.68, 0.178, 293, 253, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4415, 4anqA, 0.7201, 3.68, 0.174, 293, 253, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4416, 3zosA, 0.7201, 3.21, 0.210, 301, 243, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
4417, 3qlgB, 0.7201, 3.03, 0.218, 260, 243, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4418, 2fb8B, 0.7201, 2.93, 0.227, 259, 242, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4419, 2fa2B, 0.7201, 3.06, 0.218, 332, 243, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
4420, 5xy1A, 0.7200, 2.85, 0.196, 253, 240, CRYSTAL STRUCTURE OF LYN KINASE DOMAIN IN COMPLEX WITH N-(1H-INDAZOL- 6-YL)-8-(PIPERIDIN-4-YLOXY)-6-PROPYLQUINAZOLIN-2-AMINE
4421, 5xgnB, 0.7200, 3.93, 0.142, 308, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
4422, 5maiA, 0.7200, 2.59, 0.224, 312, 232, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
4423, 5hezC, 0.7200, 3.54, 0.219, 289, 251, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4424, 5dg5A, 0.7200, 3.06, 0.177, 297, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
4425, 5a4cA, 0.7200, 3.20, 0.208, 294, 245, FGFR1 LIGAND COMPLEX
4426, 4rwlA, 0.7200, 3.18, 0.204, 282, 245, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
4427, 3uo6B, 0.7200, 2.71, 0.203, 264, 236, AURORA A IN COMPLEX WITH YL5-083
4428, 3u6iA, 0.7200, 3.08, 0.164, 281, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4429, 5zv2B, 0.7199, 3.22, 0.211, 282, 246, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
4430, 5uwdA, 0.7199, 3.46, 0.185, 271, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
4431, 5lw1E, 0.7199, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4432, 5ax3A, 0.7199, 2.96, 0.221, 329, 240, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
4433, 4prjA, 0.7199, 2.68, 0.198, 251, 237, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
4434, 4kiqA, 0.7199, 2.75, 0.212, 338, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
4435, 3uo6A, 0.7199, 2.71, 0.203, 264, 236, AURORA A IN COMPLEX WITH YL5-083
4436, 3slsA, 0.7199, 3.50, 0.188, 292, 255, CRYSTAL STRUCTURE OF HUMAN MEK-1 KINASE IN COMPLEX WITH UCB1353770 AND AMPPNP
4437, 3el8B, 0.7199, 2.97, 0.219, 259, 242, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4438, 2yjrA, 0.7199, 3.32, 0.178, 278, 247, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
4439, 5lw1B, 0.7198, 2.99, 0.217, 355, 240, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
4440, 4yhtA, 0.7198, 2.89, 0.228, 256, 241, BRAF COMPLEXED WITH AN INHIBITOR
4441, 4pdpA, 0.7198, 3.12, 0.186, 261, 242, CRYSTAL STRUCTURE OF RAD53 KINASE DOMAIN AND SCD2
4442, 4f0iB, 0.7198, 3.17, 0.209, 294, 244, CRYSTAL STRUCTURE OF APO TRKA
4443, 3h3cA, 0.7198, 3.07, 0.169, 263, 243, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
4444, 2j0kA, 0.7198, 2.97, 0.211, 598, 242, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
4445, 2fumC, 0.7198, 2.39, 0.212, 254, 231, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
4446, 5twuB, 0.7197, 2.65, 0.235, 315, 234, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4447, 5nkgA, 0.7197, 3.33, 0.165, 292, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
4448, 4pmpA, 0.7197, 3.25, 0.203, 280, 246, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
4449, 4m69A, 0.7197, 3.61, 0.156, 284, 256, CRYSTAL STRUCTURE OF THE MOUSE RIP3-MLKL COMPLEX
4450, 4usdB, 0.7196, 3.17, 0.190, 267, 247, HUMAN STK10 (LOK) WITH SB-633825
4451, 4mnfA, 0.7196, 2.87, 0.225, 257, 240, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4452, 4aaaA, 0.7196, 3.42, 0.180, 295, 245, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
4453, 3uohB, 0.7196, 2.84, 0.202, 264, 238, AURORA A IN COMPLEX WITH RPM1722
4454, 3uohA, 0.7196, 2.84, 0.202, 264, 238, AURORA A IN COMPLEX WITH RPM1722
4455, 3lvpB, 0.7196, 3.50, 0.178, 295, 253, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4456, 5nkfA, 0.7195, 3.34, 0.165, 291, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
4457, 4mneE, 0.7195, 3.57, 0.184, 286, 256, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4458, 3igoA, 0.7195, 3.38, 0.211, 446, 247, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
4459, 3gqlB, 0.7195, 3.12, 0.216, 276, 245, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4460, 2i1mA, 0.7195, 3.38, 0.209, 311, 249, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
4461, 5odtA, 0.7194, 3.15, 0.202, 258, 242, AURORA-A IN COMPLEX WITH TACC3
4462, 5nzzH, 0.7194, 2.88, 0.180, 335, 239, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
4463, 3uojB, 0.7194, 2.82, 0.202, 263, 238, AURORA A IN COMPLEX WITH RPM1715
4464, 1ua2D, 0.7194, 3.11, 0.160, 286, 244, CRYSTAL STRUCTURE OF HUMAN CDK7
4465, 3uojA, 0.7193, 2.82, 0.202, 263, 238, AURORA A IN COMPLEX WITH RPM1715
4466, 3ikaB, 0.7193, 3.90, 0.142, 310, 261, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
4467, 3ce3A, 0.7193, 3.42, 0.169, 293, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
4468, 2wmqA, 0.7193, 2.82, 0.215, 246, 237, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4469, 1x8bA, 0.7193, 2.94, 0.175, 259, 240, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
4470, 4xg8C, 0.7192, 3.02, 0.206, 254, 243, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4471, 3ormA, 0.7192, 2.91, 0.209, 266, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN D76A MUTANT
4472, 5eydA, 0.7191, 3.29, 0.170, 289, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
4473, 4v04B, 0.7191, 3.29, 0.199, 287, 246, FGFR1 IN COMPLEX WITH PONATINIB.
4474, 4izaC, 0.7191, 2.84, 0.234, 335, 239, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
4475, 3p1aA, 0.7191, 3.07, 0.182, 281, 242, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
4476, 5vdkA, 0.7190, 3.13, 0.173, 260, 243, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
4477, 4ow8A, 0.7190, 3.33, 0.221, 276, 249, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PKNA FROM MTB
4478, 4o2pA, 0.7190, 3.21, 0.196, 265, 245, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
4479, 3el8A, 0.7190, 3.09, 0.217, 263, 244, CRYSTAL STRUCTURE OF C-SRC IN COMPLEX WITH PYRAZOLOPYRIMIDINE 5
4480, 6d20A, 0.7189, 3.20, 0.204, 296, 245, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
4481, 4yjrA, 0.7189, 3.10, 0.171, 263, 245, SYK KINASE DOMAIN IN COMPLEX WITH INHIBITOR GTC000225
4482, 4g5pB, 0.7189, 3.74, 0.136, 303, 257, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4483, 2ijmB, 0.7189, 3.06, 0.213, 261, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4484, 5vd4A, 0.7188, 3.15, 0.176, 261, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
4485, 4yjsA, 0.7188, 3.29, 0.189, 257, 249, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226
4486, 4xyfA, 0.7188, 3.27, 0.174, 290, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4487, 4mneF, 0.7188, 2.91, 0.207, 258, 241, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4488, 4fnwA, 0.7188, 3.66, 0.171, 304, 252, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4489, 3unzB, 0.7188, 2.84, 0.206, 263, 238, AURORA A IN COMPLEX WITH RPM1679
4490, 3unzA, 0.7188, 2.84, 0.206, 263, 238, AURORA A IN COMPLEX WITH RPM1679
4491, 5jfsA, 0.7187, 2.91, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4492, 5b7vA, 0.7187, 3.14, 0.205, 282, 244, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4493, 4hzsD, 0.7187, 3.54, 0.211, 319, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
4494, 4hzsB, 0.7187, 3.54, 0.211, 319, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
4495, 2xvdA, 0.7187, 3.36, 0.149, 270, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4496, 2vx0A, 0.7187, 3.28, 0.153, 273, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4497, 5hvjA, 0.7186, 3.16, 0.180, 283, 244, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4498, 4umrA, 0.7186, 2.85, 0.241, 313, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4499, 4hzsA, 0.7186, 3.54, 0.211, 319, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
4500, 4eutB, 0.7186, 3.57, 0.160, 379, 250, STRUCTURE OF BX-795 COMPLEXED WITH UNPHOSPHORYLATED HUMAN TBK1 KINASE- ULD DOMAIN
4501, 3uolB, 0.7186, 2.83, 0.202, 263, 238, AURORA A IN COMPLEX WITH SO2-162
4502, 3uolA, 0.7186, 2.83, 0.202, 263, 238, AURORA A IN COMPLEX WITH SO2-162
4503, 3pxkB, 0.7186, 2.98, 0.211, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH PYRROLO[23- D]THIAZOLE
4504, 3kfaB, 0.7186, 3.57, 0.211, 284, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4505, 3kfaA, 0.7186, 3.57, 0.211, 284, 251, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4506, 2z2wA, 0.7186, 3.09, 0.178, 260, 242, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
4507, 2jboA, 0.7186, 3.55, 0.169, 295, 248, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-1 SOAKING)
4508, 4hzsC, 0.7185, 3.54, 0.211, 319, 251, CRYSTAL STRUCTURE OF ACK1 KINASE DOMAIN WITH C-TERMINAL SH3 DOMAIN
4509, 3rhxB, 0.7185, 3.19, 0.217, 275, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
4510, 6d1zA, 0.7184, 3.15, 0.205, 290, 244, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
4511, 5m57A, 0.7184, 2.95, 0.176, 261, 238, NEK2 BOUND TO ARYLAMINOPURINE 6
4512, 4ctbA, 0.7184, 3.63, 0.175, 292, 251, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
4513, 5ia2A, 0.7183, 3.33, 0.165, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
4514, 5eobA, 0.7183, 3.23, 0.183, 288, 246, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4515, 3ik3A, 0.7183, 3.50, 0.208, 280, 250, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4516, 1zz2A, 0.7183, 2.79, 0.212, 337, 236, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
4517, 3u6jA, 0.7182, 3.48, 0.204, 308, 250, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4518, 3lj0A, 0.7182, 3.17, 0.209, 404, 244, IRE1 COMPLEXED WITH ADP AND QUERCETIN
4519, 4fv4A, 0.7181, 2.64, 0.227, 329, 233, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
4520, 2rfeA, 0.7181, 3.63, 0.166, 286, 253, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4521, 2oiqA, 0.7181, 3.16, 0.205, 265, 244, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4522, 6dkgA, 0.7180, 3.08, 0.206, 276, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
4523, 5nk6A, 0.7180, 3.37, 0.166, 284, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
4524, 5kbrA, 0.7180, 2.92, 0.213, 259, 239, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
4525, 4qqtA, 0.7180, 3.10, 0.193, 283, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
4526, 4kipA, 0.7180, 2.81, 0.212, 337, 236, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
4527, 3kc3F, 0.7180, 3.33, 0.176, 293, 245, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4528, 2vwyA, 0.7180, 3.30, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4529, 6fnhA, 0.7179, 3.17, 0.167, 277, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4530, 5eycA, 0.7179, 3.25, 0.175, 288, 246, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4531, 3mvlA, 0.7179, 2.83, 0.211, 339, 237, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
4532, 5vd7A, 0.7178, 3.15, 0.176, 261, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
4533, 5kmjA, 0.7178, 3.25, 0.204, 300, 245, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
4534, 3ugcA, 0.7178, 3.25, 0.204, 274, 245, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
4535, 3cc6A, 0.7178, 3.34, 0.178, 269, 247, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
4536, 2in6A, 0.7178, 2.96, 0.175, 256, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4537, 5oatE, 0.7177, 3.90, 0.154, 359, 259, PINK1 STRUCTURE
4538, 5kmnA, 0.7177, 3.32, 0.207, 296, 246, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4539, 5hzeA, 0.7177, 3.48, 0.190, 305, 253, MEK1 ADOPTS DFG-OUT CONFORMATION WHEN BOUND TO AN ANALOG OF E6201.
4540, 4zseB, 0.7177, 3.36, 0.172, 313, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4541, 4yneA, 0.7177, 3.10, 0.209, 281, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4542, 3gokB, 0.7177, 3.23, 0.177, 290, 243, BINDING SITE MAPPING OF PROTEIN LIGANDS
4543, 3aoxA, 0.7177, 3.58, 0.164, 298, 250, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
4544, 1v0bA, 0.7177, 3.04, 0.205, 286, 239, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
4545, 5v5yA, 0.7176, 3.07, 0.178, 259, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4546, 5oatB, 0.7176, 3.94, 0.146, 359, 260, PINK1 STRUCTURE
4547, 5j9lA, 0.7176, 3.06, 0.202, 286, 242, CRYSTAL STRUCTURE OF CPT1691 BOUND TO TAK1-TAB1
4548, 4onaA, 0.7176, 3.54, 0.207, 465, 251, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
4549, 4fv9A, 0.7176, 2.71, 0.231, 331, 234, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
4550, 3gokK, 0.7176, 3.23, 0.177, 290, 243, BINDING SITE MAPPING OF PROTEIN LIGANDS
4551, 2jbpH, 0.7176, 3.23, 0.177, 282, 243, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4552, 4mxaA, 0.7175, 3.47, 0.204, 459, 250, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
4553, 2yfxA, 0.7175, 3.56, 0.179, 292, 251, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4554, 2vx1A, 0.7175, 3.31, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4555, 5kmoA, 0.7174, 3.16, 0.209, 291, 244, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
4556, 5a9uA, 0.7174, 3.69, 0.171, 292, 252, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4557, 4neuB, 0.7174, 3.31, 0.181, 268, 248, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
4558, 4mneA, 0.7174, 3.64, 0.183, 286, 257, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4559, 4aa4A, 0.7174, 3.15, 0.203, 347, 241, P38ALPHA MAP KINASE BOUND TO CMPD 22
4560, 3uokB, 0.7174, 2.86, 0.202, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
4561, 3uokA, 0.7174, 2.86, 0.202, 265, 238, AURORA A IN COMPLEX WITH YL5-81-1
4562, 3ik3B, 0.7174, 3.60, 0.211, 286, 251, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
4563, 3gokG, 0.7174, 3.29, 0.177, 286, 243, BINDING SITE MAPPING OF PROTEIN LIGANDS
4564, 2jbpG, 0.7174, 3.18, 0.178, 287, 242, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4565, 5oy6B, 0.7173, 3.42, 0.184, 292, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4566, 5jfxA, 0.7173, 2.91, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4567, 4obpB, 0.7173, 3.37, 0.187, 290, 251, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
4568, 3is5F, 0.7173, 3.30, 0.233, 266, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4569, 3gokH, 0.7173, 3.23, 0.177, 290, 243, BINDING SITE MAPPING OF PROTEIN LIGANDS
4570, 2xp2A, 0.7173, 3.55, 0.177, 285, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB (PF-02341066)
4571, 4wg5A, 0.7172, 3.44, 0.212, 464, 250, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
4572, 4eqmF, 0.7172, 3.04, 0.228, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4573, 3lj0B, 0.7172, 3.14, 0.210, 399, 243, IRE1 COMPLEXED WITH ADP AND QUERCETIN
4574, 3gokE, 0.7172, 3.24, 0.177, 290, 243, BINDING SITE MAPPING OF PROTEIN LIGANDS
4575, 6eimA, 0.7171, 3.31, 0.180, 286, 244, HUMAN STK10 BOUND TO GW683134A
4576, 5jfwA, 0.7171, 2.93, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4577, 4d2vA, 0.7171, 2.86, 0.243, 313, 235, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4578, 2zv8A, 0.7171, 2.97, 0.199, 257, 241, LYN TYROSINE KINASE DOMAIN-AMP-PNP COMPLEX
4579, 2vwzA, 0.7171, 3.31, 0.149, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4580, 1opjB, 0.7171, 3.45, 0.226, 288, 248, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4581, 5oatA, 0.7170, 3.96, 0.158, 359, 259, PINK1 STRUCTURE
4582, 4mx9A, 0.7170, 3.49, 0.204, 459, 250, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
4583, 3u6hA, 0.7170, 3.07, 0.165, 280, 243, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 26
4584, 6bfaA, 0.7169, 3.54, 0.211, 464, 251, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
4585, 5owrA, 0.7169, 3.62, 0.181, 282, 248, HUMAN STK10 BOUND TO DASATINIB
4586, 5oatD, 0.7169, 3.95, 0.158, 359, 259, PINK1 STRUCTURE
4587, 4x7qB, 0.7169, 2.54, 0.193, 243, 233, PIM2 KINASE IN COMPLEX WITH COMPOUND 1S
4588, 4gt5A, 0.7169, 3.21, 0.209, 290, 244, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
4589, 4f64B, 0.7169, 3.16, 0.218, 272, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4590, 4eqmE, 0.7169, 3.05, 0.228, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4591, 2fgiB, 0.7169, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4592, 1ua2A, 0.7169, 3.24, 0.154, 286, 247, CRYSTAL STRUCTURE OF HUMAN CDK7
4593, 5oatF, 0.7168, 3.98, 0.146, 359, 260, PINK1 STRUCTURE
4594, 5aacA, 0.7168, 3.69, 0.171, 292, 252, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4595, 4rwkB, 0.7168, 3.20, 0.220, 282, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
4596, 4fv5A, 0.7168, 2.72, 0.235, 330, 234, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
4597, 3oy3B, 0.7168, 3.58, 0.211, 284, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4598, 3gokJ, 0.7168, 3.21, 0.178, 283, 242, BINDING SITE MAPPING OF PROTEIN LIGANDS
4599, 2wntB, 0.7168, 3.49, 0.190, 285, 248, CRYSTAL STRUCTURE OF THE HUMAN RIBOSOMAL PROTEIN S6 KINASE
4600, 2r4bA, 0.7168, 3.52, 0.155, 292, 252, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4601, 6d22A, 0.7167, 3.28, 0.208, 299, 245, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
4602, 5oatC, 0.7167, 3.97, 0.146, 359, 260, PINK1 STRUCTURE
4603, 5cenA, 0.7167, 3.14, 0.184, 281, 244, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4604, 5bvdA, 0.7167, 2.66, 0.232, 330, 233, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4605, 5aa8A, 0.7167, 3.62, 0.171, 292, 251, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4606, 4r1vA, 0.7167, 3.24, 0.183, 289, 246, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
4607, 4nksB, 0.7167, 3.16, 0.214, 271, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
4608, 4eqmD, 0.7167, 3.07, 0.224, 268, 241, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4609, 5jfvA, 0.7166, 2.93, 0.212, 277, 240, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4610, 5ci6B, 0.7166, 2.90, 0.205, 350, 239, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
4611, 4zloA, 0.7166, 3.41, 0.219, 277, 247, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
4612, 5vc4A, 0.7165, 3.25, 0.167, 261, 245, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4613, 4kabB, 0.7165, 3.07, 0.210, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4614, 3oy3A, 0.7165, 3.60, 0.211, 284, 251, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
4615, 3i5zA, 0.7165, 2.71, 0.235, 331, 234, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
4616, 3h9rA, 0.7165, 3.24, 0.184, 312, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TYPE I ACTIVIN RECEPTOR (ACVR1) IN COMPLEX WITH FKBP12 AND DORSOMORPHIN
4617, 3f82A, 0.7165, 3.13, 0.178, 278, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH N- (4-(2-AMINO-3-CHLOROPYRIDIN-4-YLOXY)-3-FLUOROPHENYL)-4- ETHOXY-1-(4-FLUOROPHENYL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4618, 2zv9A, 0.7165, 2.96, 0.199, 256, 241, LYN TYROSINE KINASE DOMAIN-PP2 COMPLEX
4619, 1pkgB, 0.7165, 3.10, 0.210, 277, 243, STRUCTURE OF A C-KIT KINASE PRODUCT COMPLEX
4620, 5nk9A, 0.7164, 3.40, 0.166, 285, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
4621, 4g2fA, 0.7164, 3.03, 0.169, 275, 243, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4622, 3eknA, 0.7164, 3.35, 0.202, 297, 248, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
4623, 2vwxA, 0.7164, 3.30, 0.153, 274, 249, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4624, 1v0pA, 0.7164, 2.93, 0.218, 277, 238, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
4625, 6b2qD, 0.7163, 2.93, 0.248, 259, 238, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
4626, 4fnyA, 0.7163, 3.36, 0.163, 273, 245, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4627, 4cmtA, 0.7163, 3.57, 0.173, 284, 249, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)-5-(3-(METHYLSULFONYL)PHENYL)PYRIDIN-2-AMINE
4628, 4bb4A, 0.7163, 3.17, 0.150, 265, 246, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4629, 3vntA, 0.7163, 3.36, 0.206, 301, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
4630, 3f3tB, 0.7163, 2.97, 0.207, 259, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL38 (TYPE III)
4631, 3cqeA, 0.7163, 3.11, 0.178, 258, 242, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4632, 2qr7A, 0.7163, 3.43, 0.193, 292, 249, 2.0A X-RAY STRUCTURE OF C-TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2: SE-MET DERIVATIVE
4633, 1agwB, 0.7163, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4634, 4zsaB, 0.7162, 3.18, 0.213, 282, 244, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
4635, 3gokD, 0.7162, 3.21, 0.178, 283, 242, BINDING SITE MAPPING OF PROTEIN LIGANDS
4636, 1fgkB, 0.7162, 3.18, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4637, 6fnmA, 0.7161, 3.42, 0.144, 270, 250, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
4638, 5nkbA, 0.7161, 3.40, 0.166, 285, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
4639, 4anlA, 0.7161, 3.56, 0.175, 292, 251, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
4640, 3gokA, 0.7161, 3.21, 0.178, 285, 242, BINDING SITE MAPPING OF PROTEIN LIGANDS
4641, 2hz0A, 0.7161, 3.19, 0.208, 265, 245, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4642, 6dkbA, 0.7160, 3.10, 0.206, 272, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
4643, 4m84A, 0.7160, 3.55, 0.207, 464, 251, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
4644, 4jrnA, 0.7160, 3.37, 0.174, 349, 247, ROP18 KINASE DOMAIN IN COMPLEX WITH AMP-PNP AND SUCROSE
4645, 4aojA, 0.7160, 2.87, 0.204, 260, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4646, 3svvA, 0.7160, 2.99, 0.199, 261, 241, CRYSTAL STRUCTURE OF T338C C-SRC COVALENTLY BOUND TO VINYLSULFONAMIDE- PYRAZOLOPYRIMIDINE 9
4647, 3kc3E, 0.7160, 3.30, 0.172, 287, 244, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4648, 3hl7A, 0.7160, 2.82, 0.212, 336, 236, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
4649, 3fzpA, 0.7160, 3.08, 0.169, 259, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
4650, 5ihcA, 0.7159, 2.59, 0.221, 305, 231, MELK IN COMPLEX WITH NVS-MELK12B
4651, 3g5dB, 0.7159, 2.99, 0.207, 257, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4652, 3g5dA, 0.7159, 2.96, 0.200, 256, 240, KINASE DOMAIN OF CSRC IN COMPLEX WITH DASATINIB
4653, 2weiA, 0.7159, 3.25, 0.199, 278, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
4654, 2etmA, 0.7159, 3.26, 0.207, 262, 246, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
4655, 2auhA, 0.7159, 3.50, 0.182, 297, 253, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
4656, 4ejnA, 0.7158, 3.18, 0.215, 376, 242, CRYSTAL STRUCTURE OF AUTOINHIBITED FORM OF AKT1 IN COMPLEX WITH N-(4- (5-(3-ACETAMIDOPHENYL)-2-(2-AMINOPYRIDIN-3-YL)-3H-IMIDAZO[45- B]PYRIDIN-3-YL)BENZYL)-3-FLUOROBENZAMIDE
4657, 4c7tA, 0.7158, 3.14, 0.206, 259, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
4658, 4aotB, 0.7158, 3.40, 0.198, 279, 248, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4659, 6fnkA, 0.7157, 3.25, 0.149, 274, 248, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4660, 5nk1A, 0.7157, 3.31, 0.163, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
4661, 4ux9D, 0.7157, 3.06, 0.198, 344, 242, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
4662, 5vd9A, 0.7156, 3.25, 0.176, 261, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
4663, 4jg7A, 0.7156, 3.59, 0.187, 307, 251, STRUCTURE OF RSK2 CTD BOUND TO 3-(3-(1H-PYRROLO[23-B]PYRIDINE-3- CARBONYL)PHENYL)-2-CYANOACRYLAMIDE
4664, 3nwwA, 0.7156, 2.85, 0.211, 339, 237, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
4665, 3g51A, 0.7156, 3.10, 0.166, 280, 241, STRUCTURAL DIVERSITY OF THE ACTIVE CONFORMATION OF THE N- TERMINAL KINASE DOMAIN OF P90 RIBOSOMAL S6 KINASE 2
4666, 3bi6A, 0.7156, 3.03, 0.174, 258, 241, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
4667, 2r4bB, 0.7156, 3.66, 0.158, 291, 253, ERBB4 KINASE DOMAIN COMPLEXED WITH A THIENOPYRIMIDINE INHIBITOR
4668, 6d1yA, 0.7155, 3.23, 0.201, 300, 244, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
4669, 5xgmA, 0.7155, 3.27, 0.188, 288, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4670, 4uynA, 0.7155, 2.68, 0.201, 249, 234, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
4671, 4ihpA, 0.7155, 3.49, 0.208, 454, 250, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
4672, 6eq9A, 0.7154, 3.15, 0.207, 350, 242, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
4673, 4v01B, 0.7154, 3.10, 0.195, 275, 241, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4674, 4h1jA, 0.7154, 3.16, 0.171, 263, 245, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
4675, 3g6gB, 0.7154, 3.06, 0.194, 263, 242, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4676, 3fklA, 0.7154, 2.98, 0.210, 344, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
4677, 2qo9A, 0.7154, 3.04, 0.164, 277, 244, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
4678, 2balA, 0.7154, 2.78, 0.209, 337, 235, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
4679, 5wr7A, 0.7153, 3.23, 0.209, 301, 244, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
4680, 5w8rA, 0.7153, 3.48, 0.208, 456, 250, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR 3CIB-PPI
4681, 5vc5A, 0.7153, 3.20, 0.172, 261, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
4682, 5oy6C, 0.7153, 3.46, 0.184, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4683, 5kmlA, 0.7153, 3.27, 0.208, 296, 245, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
4684, 4bkzA, 0.7153, 2.68, 0.233, 309, 232, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH A BENZODIPYRAZOLE INHIBITOR
4685, 3dkcA, 0.7153, 3.65, 0.146, 312, 254, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
4686, 5vc6A, 0.7152, 3.21, 0.173, 259, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4687, 4dfyA, 0.7152, 3.31, 0.204, 310, 245, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
4688, 2yhvA, 0.7152, 3.62, 0.175, 291, 251, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
4689, 5nk7A, 0.7151, 3.32, 0.163, 284, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
4690, 5nk3A, 0.7151, 3.41, 0.169, 281, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
4691, 2jbpA, 0.7151, 3.22, 0.178, 283, 242, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4692, 2a19B, 0.7151, 3.04, 0.224, 263, 241, PKR KINASE DOMAIN- EIF2ALPHA- AMP-PNP COMPLEX.
4693, 5x2fC, 0.7150, 3.52, 0.171, 302, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
4694, 5kmiA, 0.7150, 3.29, 0.204, 300, 245, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
4695, 5b7vB, 0.7150, 3.20, 0.210, 277, 243, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
4696, 4fk3B, 0.7150, 3.18, 0.230, 257, 243, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4697, 4aojC, 0.7150, 2.93, 0.207, 261, 241, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4698, 3w2rA, 0.7150, 3.28, 0.179, 297, 246, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 4
4699, 3fmeA, 0.7150, 3.48, 0.174, 268, 247, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (MEK6) ACTIVATED MUTANT (S207D T211D)
4700, 3e7oA, 0.7150, 3.30, 0.221, 342, 244, CRYSTAL STRUCTURE OF JNK2
4701, 1fgkA, 0.7150, 3.09, 0.207, 278, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
4702, 5dbxB, 0.7149, 3.72, 0.198, 282, 253, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4703, 4lqpA, 0.7149, 3.78, 0.198, 383, 253, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM A
4704, 4f0iA, 0.7149, 3.26, 0.204, 284, 245, CRYSTAL STRUCTURE OF APO TRKA
4705, 3g6gA, 0.7149, 3.10, 0.207, 264, 242, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4706, 3fmhA, 0.7149, 3.05, 0.210, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4707, 5vd5A, 0.7148, 3.24, 0.172, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
4708, 5m51A, 0.7148, 2.95, 0.177, 260, 237, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
4709, 5kmkA, 0.7148, 3.29, 0.208, 304, 245, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
4710, 4ctcA, 0.7148, 3.47, 0.173, 288, 248, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4711, 3oriD, 0.7148, 2.92, 0.209, 267, 239, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4712, 2jkqA, 0.7148, 3.06, 0.211, 258, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4713, 5wnoA, 0.7147, 3.80, 0.172, 302, 256, CRYSTAL STRUCTURE OF C. ELEGANS LET-23 KINASE DOMAIN COMPLEXED WITH AMP-PNP
4714, 5kkrC, 0.7147, 3.68, 0.180, 309, 255, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4715, 4f63B, 0.7147, 3.14, 0.215, 271, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4716, 4asdA, 0.7147, 3.38, 0.206, 305, 247, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
4717, 3uqgB, 0.7147, 2.91, 0.205, 257, 239, C-SRC KINASE DOMAIN IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4718, 2c6dA, 0.7147, 2.93, 0.202, 254, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
4719, 5i9xA, 0.7146, 3.35, 0.167, 284, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
4720, 4ll0A, 0.7146, 3.49, 0.184, 291, 250, EGFR L858R/T790M IN COMPLEX WITH PD168393
4721, 5nk2A, 0.7145, 3.36, 0.167, 290, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
4722, 5i9zA, 0.7145, 3.22, 0.164, 273, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
4723, 4mxxB, 0.7145, 3.07, 0.203, 260, 241, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4724, 4f64A, 0.7145, 3.18, 0.206, 278, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
4725, 3oriC, 0.7145, 2.87, 0.218, 267, 238, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 1)
4726, 2ijmA, 0.7145, 3.17, 0.209, 260, 244, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4727, 1agwA, 0.7145, 3.22, 0.205, 278, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
4728, 5ur1A, 0.7144, 3.17, 0.206, 278, 243, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4729, 4dehA, 0.7144, 3.29, 0.171, 286, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4730, 2wmsA, 0.7144, 2.82, 0.209, 243, 235, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4731, 5oy6A, 0.7143, 3.46, 0.184, 291, 250, CRYSTAL STRUCTURE OF THE ACVR1 (ALK2) KINASE IN COMPLEX WITH CYCLICAL INHIBITOR OD36.
4732, 4m97A, 0.7143, 3.45, 0.205, 465, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
4733, 4aseA, 0.7143, 3.46, 0.206, 305, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
4734, 3w2sA, 0.7143, 3.59, 0.185, 307, 254, EGFR KINASE DOMAIN WITH COMPOUND4
4735, 3rocA, 0.7143, 2.81, 0.209, 337, 235, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
4736, 3flyA, 0.7143, 3.06, 0.202, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
4737, 2jbpB, 0.7143, 3.25, 0.177, 290, 243, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4738, 5vd8A, 0.7142, 3.27, 0.176, 260, 244, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
4739, 4lv8A, 0.7142, 3.61, 0.163, 360, 257, MURINE IRGA6 BOUND TO TOXOPLASMA ROP5C A PSEUDOKINASE GDI
4740, 4gg7A, 0.7142, 3.34, 0.183, 278, 246, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4741, 2x6eA, 0.7142, 2.69, 0.200, 249, 235, AURORA-A BOUND TO AN INHIBITOR
4742, 2jbpD, 0.7142, 3.24, 0.178, 286, 242, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4743, 4y95A, 0.7141, 3.11, 0.159, 266, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4744, 4f63A, 0.7141, 3.11, 0.207, 278, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
4745, 3kc3B, 0.7141, 3.31, 0.177, 290, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4746, 4y95D, 0.7140, 3.11, 0.159, 265, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4747, 4otrA, 0.7140, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
4748, 4f65A, 0.7140, 3.18, 0.198, 279, 243, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4749, 3g0fB, 0.7140, 3.36, 0.207, 293, 246, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4750, 5x2aB, 0.7139, 3.58, 0.171, 322, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
4751, 5w80A, 0.7139, 3.45, 0.209, 453, 249, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-237
4752, 3kc3A, 0.7139, 3.28, 0.173, 288, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4753, 2iwiA, 0.7139, 2.58, 0.203, 244, 232, CRYSTAL STRUCTURE OF THE HUMAN PIM2 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4754, 2fgiA, 0.7139, 3.11, 0.207, 274, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
4755, 5zwjA, 0.7138, 3.08, 0.191, 267, 241, CRYSTAL STRUCTURE OF EGFR 675-1022 T790M/C797S/V948R IN COMPLEX WITH EAI045 
4756, 5nk4A, 0.7138, 3.34, 0.167, 290, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
4757, 4p90B, 0.7138, 3.15, 0.227, 262, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
4758, 3kc3I, 0.7138, 3.34, 0.172, 295, 244, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4759, 3f66A, 0.7138, 3.41, 0.186, 288, 247, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4760, 3c1xA, 0.7138, 3.32, 0.168, 290, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4761, 1ob3A, 0.7138, 3.10, 0.212, 277, 240, STRUCTURE OF P. FALCIPARUM PFPK5
4762, 5k5xA, 0.7137, 3.50, 0.229, 345, 249, CRYSTAL STRUCTURE OF HUMAN PDGFRA
4763, 5ia0B, 0.7137, 3.03, 0.169, 266, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4764, 4rfyA, 0.7137, 3.19, 0.159, 263, 246, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
4765, 4jbvA, 0.7137, 3.48, 0.205, 458, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1268
4766, 4g9cA, 0.7137, 3.15, 0.222, 265, 243, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4767, 4f65B, 0.7137, 3.24, 0.204, 279, 245, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
4768, 4ehgA, 0.7137, 3.08, 0.226, 262, 243, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
4769, 4ag8A, 0.7137, 3.39, 0.206, 296, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
4770, 3n51A, 0.7137, 3.48, 0.201, 448, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
4771, 3a60A, 0.7137, 3.14, 0.193, 263, 238, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM I)
4772, 2xirA, 0.7137, 3.39, 0.206, 296, 247, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
4773, 2qu5A, 0.7137, 3.27, 0.215, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4774, 1fgiB, 0.7137, 3.19, 0.218, 272, 243, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
4775, 4y95C, 0.7136, 3.15, 0.154, 266, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4776, 4y95B, 0.7136, 3.11, 0.159, 266, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
4777, 4tyiA, 0.7136, 3.17, 0.202, 277, 243, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
4778, 4otqA, 0.7136, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
4779, 4dceA, 0.7136, 3.40, 0.166, 288, 247, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4780, 3h10A, 0.7136, 3.09, 0.202, 268, 242, AURORA A INHIBITOR COMPLEX
4781, 3efkA, 0.7136, 3.17, 0.173, 276, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4782, 2helA, 0.7136, 3.07, 0.156, 256, 244, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4783, 5kmmA, 0.7135, 3.33, 0.204, 301, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
4784, 5gtyH, 0.7135, 3.62, 0.155, 300, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH LXX-6-26
4785, 4rg0A, 0.7135, 3.13, 0.156, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
4786, 4jaiA, 0.7135, 2.66, 0.197, 249, 234, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
4787, 4i20A, 0.7135, 3.91, 0.176, 287, 262, CRYSTAL STRUCTURE OF MONOMERIC (V948R) PRIMARY ONCOGENIC MUTANT L858R EGFR KINASE DOMAIN
4788, 4gu9B, 0.7135, 3.07, 0.211, 255, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
4789, 4agcA, 0.7135, 3.40, 0.206, 304, 247, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
4790, 3rcdB, 0.7135, 3.29, 0.176, 271, 244, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
4791, 3k5vB, 0.7135, 3.50, 0.230, 283, 248, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4792, 3dkfA, 0.7135, 3.44, 0.183, 294, 246, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4793, 5x2cA, 0.7134, 3.51, 0.167, 304, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(5)
4794, 4gu6B, 0.7134, 3.11, 0.206, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4795, 4d4vA, 0.7134, 2.97, 0.207, 256, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4796, 4bkjB, 0.7134, 3.32, 0.201, 297, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4797, 3vw8A, 0.7134, 3.28, 0.181, 303, 243, CRYSTAL STRUCTURE OF HUMAN C-MET KINASE DOMAIN WITH ITS INHIBITOR
4798, 3uqfA, 0.7134, 3.04, 0.212, 260, 241, C-SRC KINASE DOMAIN IN COMPLEX WITH BKI RM-1-89
4799, 3skcB, 0.7134, 3.31, 0.227, 276, 247, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
4800, 3rcdD, 0.7134, 3.29, 0.176, 271, 244, HER2 KINASE DOMAIN COMPLEXED WITH TAK-285
4801, 3flzA, 0.7134, 3.06, 0.202, 347, 238, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
4802, 3b2wA, 0.7134, 3.32, 0.203, 261, 246, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
4803, 2p2iA, 0.7134, 3.29, 0.204, 289, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4804, 5hezA, 0.7133, 3.83, 0.188, 287, 255, JAK2 KINASE (JH1 DOMAIN) MUTANT P1057A IN COMPLEX WITH TG101209
4805, 4zseC, 0.7133, 3.50, 0.168, 301, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4806, 4tzrA, 0.7133, 3.50, 0.217, 461, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1561
4807, 4rfzA, 0.7133, 3.09, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
4808, 3lvpA, 0.7133, 3.44, 0.180, 289, 250, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
4809, 1oukA, 0.7133, 3.20, 0.204, 348, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
4810, 5p9fA, 0.7132, 3.13, 0.159, 266, 245, BTK IN COMPLEX WITH GDC-0834
4811, 5eakB, 0.7132, 2.91, 0.237, 300, 236, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
4812, 3d94A, 0.7132, 3.15, 0.198, 288, 242, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
4813, 1uwjA, 0.7132, 3.20, 0.213, 264, 244, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
4814, 5vamB, 0.7131, 3.12, 0.212, 260, 241, BRAF IN COMPLEX WITH RAF709
4815, 4ymjB, 0.7131, 3.19, 0.214, 275, 243, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4816, 4wg4A, 0.7131, 3.44, 0.210, 454, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1613
4817, 4kinD, 0.7131, 2.84, 0.200, 339, 235, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4818, 3zewB, 0.7131, 2.84, 0.152, 252, 237, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4819, 3ku2A, 0.7131, 3.41, 0.210, 457, 248, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
4820, 3h0yA, 0.7131, 2.72, 0.195, 250, 236, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4821, 3cr0A, 0.7131, 3.05, 0.162, 257, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
4822, 5ia0C, 0.7130, 3.09, 0.169, 269, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4823, 4m66B, 0.7130, 3.10, 0.149, 265, 242, CRYSTAL STRUCTURE OF THE MOUSE RIP3 KINASE DOMAIN
4824, 3tz8B, 0.7130, 3.14, 0.202, 263, 242, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4825, 3gqlC, 0.7130, 3.29, 0.215, 275, 246, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4826, 2zv7A, 0.7130, 3.11, 0.194, 257, 242, LYN TYROSINE KINASE DOMAIN APO FORM
4827, 2jkkA, 0.7130, 3.04, 0.207, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4828, 6dkwA, 0.7129, 3.01, 0.217, 284, 240, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
4829, 5vdaA, 0.7129, 3.24, 0.173, 259, 243, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 101 A MK1775 ANALOGUE
4830, 5fp5A, 0.7129, 2.79, 0.195, 264, 236, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
4831, 4eheB, 0.7129, 3.30, 0.228, 276, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
4832, 3ctqA, 0.7129, 2.83, 0.209, 336, 234, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
4833, 5vamA, 0.7128, 3.38, 0.211, 269, 247, BRAF IN COMPLEX WITH RAF709
4834, 5ia3A, 0.7128, 3.25, 0.165, 275, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
4835, 4zseA, 0.7128, 3.52, 0.175, 297, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4836, 4xmoA, 0.7128, 3.27, 0.176, 289, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4837, 4wg3A, 0.7128, 3.42, 0.210, 460, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1610
4838, 4usfB, 0.7128, 3.37, 0.170, 285, 247, HUMAN SLK WITH SB-440719
4839, 4nkaA, 0.7128, 3.18, 0.194, 279, 242, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
4840, 4fnzA, 0.7128, 3.34, 0.167, 287, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4841, 5vfiA, 0.7127, 3.17, 0.154, 271, 246, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
4842, 5cnnB, 0.7127, 3.59, 0.167, 304, 252, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN MUTANT I682Q
4843, 3zfxB, 0.7127, 2.95, 0.146, 254, 239, CRYSTAL STRUCTURE OF EPHB1
4844, 3vo3A, 0.7127, 3.40, 0.206, 303, 247, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
4845, 3sxfA, 0.7127, 3.45, 0.206, 452, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-89
4846, 3ocgA, 0.7127, 2.78, 0.209, 336, 234, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
4847, 3i79A, 0.7127, 3.51, 0.208, 455, 250, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1)
4848, 5x2aC, 0.7126, 3.50, 0.172, 303, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
4849, 5iugA, 0.7126, 3.59, 0.173, 285, 248, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
4850, 5d1jA, 0.7126, 2.89, 0.177, 265, 237, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
4851, 5angA, 0.7126, 2.90, 0.189, 268, 238, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
4852, 5x2aD, 0.7125, 3.70, 0.170, 297, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
4853, 5dbxA, 0.7125, 3.43, 0.198, 284, 247, CRYSTAL STRUCTURE OF MURINE SPAK(T243D) IN COMPLEX WITH AMPPNP
4854, 4v04A, 0.7125, 3.19, 0.194, 290, 242, FGFR1 IN COMPLEX WITH PONATINIB.
4855, 4dceB, 0.7125, 3.39, 0.163, 284, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4856, 4d58B, 0.7125, 3.11, 0.207, 261, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4857, 3v5tA, 0.7125, 3.42, 0.210, 460, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1299
4858, 3t3uA, 0.7125, 3.50, 0.205, 452, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-130
4859, 3lauA, 0.7125, 2.69, 0.197, 251, 233, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
4860, 3kc3L, 0.7125, 3.31, 0.177, 291, 243, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4861, 6gt1B, 0.7124, 3.05, 0.227, 269, 242, NEK7 BOUND TO PURINE INHIBITOR 
4862, 5w9eA, 0.7124, 3.44, 0.206, 451, 248, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-186
4863, 4rwiB, 0.7124, 3.30, 0.212, 280, 245, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
4864, 3wzeA, 0.7124, 3.30, 0.212, 298, 245, KDR IN COMPLEX WITH LIGAND SORAFENIB
4865, 3v51A, 0.7124, 3.42, 0.206, 459, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR RM-1-176
4866, 3t3vA, 0.7124, 3.42, 0.210, 453, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-87
4867, 4yjnA, 0.7123, 3.45, 0.210, 460, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1639
4868, 4eevA, 0.7122, 3.08, 0.178, 283, 241, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
4869, 3zfxF, 0.7122, 2.81, 0.148, 254, 236, CRYSTAL STRUCTURE OF EPHB1
4870, 3vheA, 0.7122, 3.31, 0.207, 303, 246, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
4871, 3i7bA, 0.7122, 3.50, 0.209, 459, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
4872, 1di9A, 0.7122, 3.22, 0.204, 348, 240, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
4873, 6gt1A, 0.7121, 2.98, 0.232, 267, 241, NEK7 BOUND TO PURINE INHIBITOR 
4874, 5u6cA, 0.7121, 3.07, 0.156, 272, 243, CRYSTAL STRUCTURE OF THE MER KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4875, 4zseD, 0.7121, 3.64, 0.171, 297, 252, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R CRYSTAL FORM II
4876, 4uxqA, 0.7121, 3.20, 0.197, 286, 244, FGFR4 IN COMPLEX WITH PONATINIB
4877, 4kaoB, 0.7121, 2.95, 0.204, 254, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4878, 4eqmB, 0.7121, 3.18, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4879, 4d4sB, 0.7121, 3.11, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4880, 3hllA, 0.7121, 2.83, 0.209, 337, 235, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
4881, 2wtvD, 0.7121, 2.86, 0.207, 262, 237, AURORA-A INHIBITOR STRUCTURE
4882, 2wtvA, 0.7121, 2.86, 0.207, 262, 237, AURORA-A INHIBITOR STRUCTURE
4883, 1blxA, 0.7121, 3.29, 0.168, 305, 244, P19INK4D/CDK6 COMPLEX
4884, 5j87A, 0.7120, 3.10, 0.160, 263, 244, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
4885, 5iuhA, 0.7120, 3.54, 0.170, 285, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4886, 5a6nA, 0.7120, 3.16, 0.183, 271, 240, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH COMPOUND 2
4887, 4wunA, 0.7120, 3.15, 0.214, 282, 243, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4888, 4bkjA, 0.7120, 3.33, 0.201, 295, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
4889, 3h10B, 0.7120, 3.07, 0.203, 267, 241, AURORA A INHIBITOR COMPLEX
4890, 2wntA, 0.7120, 3.38, 0.196, 281, 245, CRYSTAL STRUCTURE OF THE HUMAN RIBOSOMAL PROTEIN S6 KINASE
4891, 5nkcA, 0.7119, 3.38, 0.167, 286, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
4892, 5i4nA, 0.7119, 3.41, 0.170, 275, 247, CRYSTAL STRUCTURE OF THE E596A V617F MUTANT JAK2 PSEUDOKINASE DOMAIN BOUND TO MG-ATP
4893, 5bveA, 0.7119, 2.89, 0.228, 330, 237, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
4894, 3ky2B, 0.7119, 3.28, 0.209, 280, 244, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
4895, 3cohB, 0.7119, 2.75, 0.201, 247, 234, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4896, 2x7fE, 0.7119, 2.63, 0.189, 251, 233, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
4897, 1uwhA, 0.7119, 3.20, 0.231, 264, 242, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
4898, 4kinB, 0.7118, 3.00, 0.210, 341, 238, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
4899, 4g9rA, 0.7118, 3.13, 0.215, 262, 242, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
4900, 4b0gA, 0.7118, 2.73, 0.191, 247, 235, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4901, 3h10D, 0.7118, 2.69, 0.205, 255, 234, AURORA A INHIBITOR COMPLEX
4902, 3efkB, 0.7118, 3.24, 0.160, 272, 243, STRUCTURE OF C-MET WITH PYRIMIDONE INHIBITOR 50
4903, 1lewA, 0.7118, 2.97, 0.203, 341, 237, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
4904, 5hieC, 0.7117, 3.00, 0.228, 253, 241, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4905, 4ot6A, 0.7117, 3.11, 0.160, 265, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4906, 4g9cB, 0.7117, 3.28, 0.225, 264, 244, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
4907, 4eheA, 0.7117, 3.22, 0.224, 266, 245, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
4908, 3tv6A, 0.7117, 3.22, 0.224, 268, 245, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
4909, 3mptA, 0.7117, 3.15, 0.201, 347, 239, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
4910, 3dt1A, 0.7117, 3.19, 0.204, 356, 240, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
4911, 2g1tC, 0.7117, 3.54, 0.198, 276, 252, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4912, 5w9rA, 0.7116, 3.44, 0.206, 445, 248, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LJQ138
4913, 5hesA, 0.7116, 3.32, 0.205, 287, 244, HUMAN LEUCINE ZIPPER- AND STERILE ALPHA MOTIF-CONTAINING KINASE (ZAK MLT HCCS-4 MRK AZK MLTK) IN COMPLEX WITH VEMURAFENIB
4914, 5bpyA, 0.7116, 3.07, 0.160, 263, 243, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4915, 4mbjB, 0.7116, 3.33, 0.220, 276, 246, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
4916, 4mbjA, 0.7116, 3.23, 0.229, 269, 245, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
4917, 3vhkA, 0.7116, 3.34, 0.207, 297, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
4918, 3my0V, 0.7116, 3.43, 0.194, 282, 247, CRYSTAL STRUCTURE OF THE ACVRL1 (ALK1) KINASE DOMAIN BOUND TO LDN- 193189
4919, 3gokC, 0.7116, 3.20, 0.179, 285, 240, BINDING SITE MAPPING OF PROTEIN LIGANDS
4920, 5wnlA, 0.7115, 2.91, 0.202, 262, 238, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
4921, 4lopD, 0.7115, 3.17, 0.191, 351, 241, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4922, 4ifgA, 0.7115, 3.51, 0.209, 452, 249, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
4923, 3kc3H, 0.7115, 3.29, 0.178, 290, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4924, 3cohA, 0.7115, 2.75, 0.201, 247, 234, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
4925, 3bz3A, 0.7115, 3.24, 0.204, 259, 245, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4926, 2jbpF, 0.7115, 3.26, 0.174, 287, 241, PROTEIN KINASE MK2 IN COMPLEX WITH AN INHIBITOR (CRYSTAL FORM-2 CO-CRYSTALLIZATION)
4927, 2c6eB, 0.7115, 2.59, 0.198, 246, 232, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
4928, 5x2fD, 0.7114, 3.67, 0.170, 309, 253, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(6)
4929, 4l7sA, 0.7114, 2.96, 0.197, 250, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4930, 4i1zA, 0.7114, 3.87, 0.188, 287, 260, CRYSTAL STRUCTURE OF THE MONOMERIC (V948R) FORM OF THE GEFITINIB/ERLOTINIB RESISTANT EGFR KINASE DOMAIN L858R+T790M
4931, 3og7B, 0.7114, 3.09, 0.232, 254, 241, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
4932, 3en4A, 0.7114, 3.03, 0.212, 257, 240, TARGETED POLYPHARMACOLOGY: CRYSTAL STRUCTURE OF THE C-SRC KINASE DOMAIN IN COMPLEX WITH PP121 A MULTITARGETED KINASE INHIBITOR
4933, 5njzA, 0.7113, 3.17, 0.165, 273, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
4934, 5hieB, 0.7113, 3.25, 0.230, 259, 244, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4935, 4hvsA, 0.7113, 3.33, 0.212, 326, 245, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
4936, 4aacA, 0.7113, 3.18, 0.204, 350, 240, P38ALPHA MAP KINASE BOUND TO CMPD 29
4937, 3tv4B, 0.7113, 3.26, 0.228, 276, 246, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
4938, 3qlgA, 0.7113, 3.03, 0.204, 259, 240, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH DASATINIB
4939, 3f3vB, 0.7113, 3.10, 0.203, 262, 241, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4940, 2pzyB, 0.7113, 3.24, 0.175, 283, 240, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4941, 2okrA, 0.7113, 2.99, 0.203, 339, 237, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4942, 5yu9C, 0.7112, 3.61, 0.175, 306, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH IBRUTINIB
4943, 5t3qA, 0.7112, 3.06, 0.162, 278, 241, CRYSTAL STRUCTURE OF THE C-MET KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
4944, 5bujA, 0.7112, 2.84, 0.228, 331, 237, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
4945, 4v01A, 0.7112, 3.19, 0.195, 273, 241, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
4946, 4knbA, 0.7112, 3.32, 0.184, 273, 244, C-MET IN COMPLEX WITH OSI LIGAND
4947, 4eqmC, 0.7112, 3.20, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4948, 4eqmA, 0.7112, 3.19, 0.202, 269, 243, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
4949, 4d4yB, 0.7112, 3.13, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4950, 3sx9A, 0.7112, 3.50, 0.209, 457, 249, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-132
4951, 3oezA, 0.7112, 3.12, 0.207, 261, 241, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4952, 3kc3J, 0.7112, 3.28, 0.178, 288, 242, MK2 COMPLEXED TO INHIBITOR N4-(7-(BENZOFURAN-2-YL)-1H-INDAZOL-5-YL) PYRIMIDINE-24-DIAMINE
4953, 2pzyA, 0.7112, 3.32, 0.174, 291, 242, STRUCTURE OF MK2 COMPLEXED WITH COMPOUND 76
4954, 5p9gA, 0.7111, 3.12, 0.160, 265, 244, STRUCTURE OF BTK WITH RN486
4955, 4kioC, 0.7111, 3.02, 0.196, 251, 240, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH A COVALENTLY-BINDING INHIBITOR
4956, 3is5B, 0.7111, 3.13, 0.237, 260, 240, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
4957, 3fzoA, 0.7111, 3.26, 0.180, 262, 244, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
4958, 5twyA, 0.7110, 2.82, 0.239, 313, 234, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
4959, 4n4sB, 0.7110, 2.97, 0.217, 337, 240, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
4960, 4mneH, 0.7110, 3.61, 0.189, 275, 254, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4961, 4fnxA, 0.7110, 3.71, 0.163, 292, 251, CRYSTAL STRUCTURE OF THE APO R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4962, 3v6rA, 0.7110, 3.18, 0.202, 349, 242, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
4963, 3tv6B, 0.7110, 3.27, 0.228, 276, 246, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
4964, 2yjsA, 0.7110, 3.59, 0.169, 286, 248, STRUCTURE OF C1156Y MUTANT ANAPLASTIC LYMPHOMA KINASE
4965, 5xyyA, 0.7109, 3.25, 0.204, 350, 240, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
4966, 5hieA, 0.7109, 3.21, 0.230, 258, 243, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4967, 4yzmB, 0.7109, 3.27, 0.207, 262, 242, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4968, 4uwyA, 0.7109, 3.24, 0.197, 296, 244, FGFR1 APO STRUCTURE
4969, 4umtA, 0.7109, 3.06, 0.236, 316, 237, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
4970, 4ot5A, 0.7109, 3.12, 0.160, 263, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
4971, 4lopC, 0.7109, 3.02, 0.188, 341, 239, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
4972, 3v5pA, 0.7109, 3.46, 0.210, 450, 248, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1288
4973, 3g0fA, 0.7109, 3.27, 0.213, 291, 244, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
4974, 3bx5A, 0.7109, 3.01, 0.211, 338, 237, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
4975, 2wtvC, 0.7109, 2.81, 0.211, 261, 237, AURORA-A INHIBITOR STRUCTURE
4976, 2wtvB, 0.7109, 2.81, 0.211, 261, 237, AURORA-A INHIBITOR STRUCTURE
4977, 2onlB, 0.7109, 3.00, 0.203, 339, 237, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
4978, 4yzmA, 0.7108, 3.09, 0.204, 260, 240, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4979, 4yhfB, 0.7108, 3.14, 0.160, 269, 244, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4980, 4l7sB, 0.7108, 2.98, 0.197, 250, 239, KINASE DOMAIN MUTANT OF HUMAN ITK IN COMPLEX WITH AN AMINOBENZOTHIAZOLE INHIBITOR
4981, 4ckrA, 0.7108, 3.34, 0.201, 295, 244, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
4982, 4agdA, 0.7108, 3.51, 0.206, 303, 248, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
4983, 3w32A, 0.7108, 4.03, 0.165, 317, 260, EGFR KINASE DOMAIN COMPLEXED WITH COMPOUND 20A
4984, 3oroA, 0.7108, 3.31, 0.209, 272, 244, MYCOBACTERIUM TUBERCULOSIS PKNB KINASE DOMAIN L33D MUTANT (CRYSTAL FORM 4)
4985, 3k5vA, 0.7108, 3.43, 0.231, 286, 247, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
4986, 5w91A, 0.7107, 3.46, 0.210, 451, 248, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LZH118
4987, 5tehA, 0.7107, 3.04, 0.200, 261, 240, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4988, 5nkdA, 0.7107, 3.37, 0.167, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
4989, 5kz8A, 0.7107, 3.01, 0.241, 302, 237, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
4990, 5hvjB, 0.7107, 3.28, 0.181, 284, 243, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
4991, 4ewqA, 0.7107, 3.12, 0.197, 346, 239, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
4992, 5xfjA, 0.7106, 2.99, 0.201, 266, 239, CRYSTAL STRUCTURE OF LY2874455 IN COMPLEX OF FGFR4 GATEKEEPER MUTATION (V550M) 
4993, 4uwyB, 0.7106, 3.03, 0.212, 273, 240, FGFR1 APO STRUCTURE
4994, 4i5hA, 0.7106, 2.92, 0.226, 335, 235, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
4995, 4d5hB, 0.7106, 3.13, 0.207, 260, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4996, 3flwA, 0.7106, 2.97, 0.195, 345, 236, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
4997, 3f3wA, 0.7106, 3.10, 0.207, 261, 241, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4998, 3b8qA, 0.7106, 3.15, 0.202, 292, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4999, 5i9yA, 0.7105, 3.39, 0.167, 287, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
5000, 2g15A, 0.7105, 3.62, 0.152, 301, 250, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
